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This study developed a GC-MS method for the simultaneous detection of piperazines and 
congeners in street samples of amphetamine type stimulants. This research investigated the 
clandestine routes of synthesis and chemical profiles of phenylpiperazines, represented by 1-
(4-fluorophenyl)piperazine (4-FPP) and 1-(3-trifluoromethylphenyl)piperazine (3-TFMPP). 
These drugs are part of the increasingly prevalent illicit new psychoactive substances. The 
presence of (2, 3, 4) FPP and (2, 3, 4) TFMPP positional isomers has been identified by other 
researchers as a limitation due to their similar chemical profiles.  
 
The method was optimized and confirmed as compliant with the International Conference on 
Harmonisation and the Center for Drug Evaluation and Research guidelines on validation. 4-
FPP and 3-TFMPP were synthesised using potential routes for clandestine laboratories. 
Simple extraction and analysis of 11 street samples was conducted using the method 
developed. Furthermore, the stability of 22 drugs during analysis was investigated. 
 
Limits of detection were in the range 5 – 1.95ng/mL free base on column. The synthesised 
samples were identified as 4-FPP and 3-TFMPP. Several impurities were observed in the 
synthesised samples, which were identified and categorised as residual reactants, isomers of 
4-FPP and of 3-TFMPP and by-products of synthesis. The percentage yields of the 
synthesised samples obtained were up to 82.4% 4-FPP and 78.7% 3-TFMPP.  
The street samples were found to contain MDMA, 3-TFMPP, BZP, caffeine, ephedrine and 
other impurities. 
 
The analytical method simultaneously separates 19 of the most common drugs found in 
piperazine samples and achieves for the first time the GC-MS separation of (i) 2-FPP, 3-FPP 
and 4-FPP and (ii) 2-TFMPP, 3-TFMPP and 4-TFMPP at the same time from a sample 
matrix containing all the 19 compounds. This method provides operational laboratories with 
a more effective method for the chemical characterisation of street samples of piperazines 
and also provides novel stability data. 
 
Keywords: piperazines, method, charaterisation, street drugs, stability. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 AN OVERVIEW OF DRUGS OF ABUSE 
 
Drugs of abuse regardless of their origin have a complex profile containing not only the 
active substances but also impurities such as potential by-products of synthesis, solvents 
and degradation products (UN, 2001; Inoue et al., 2008). In addition, cutting agents and 
adulterants are added along the distribution chain mainly so as to increase the volume so 
that more doses can be sold, e.g. starch, flour, sugar, caffeine (Andreasen et al., 2009). This 
effectively increases the profits for the drug seller. An adulterant unlike a cutting agent is 
pharmacologically active; it is stimulating and as such it normally enhances the 
psychoactive effects of the drug (adulterants are further discussed in section 1.2.2.1). The 
type and amount of adulterant or cutting agent depends on the illicit drug, the market and 
the desired effects (UN, 2001; Cole et al., 2011; Elliot, 2011). In some cases more than one 
is added, thereby further increasing the complexity of the drug profile.  
 
Theoretically, investigation of all the components of a sample provides a complete 
“history” of the sample and is of use in characterising samples. According to the United 
Nations (UN, 2001) studies on characterisation/impurity profiling of seized drugs can 
provide insight into diverse law enforcement investigative issues, ranging from dealer-user 
relationships, drug source, distribution networks, and trafficking routes to manufacturing 
methods and precursors used. Such information may also be used to identify and control 
precursors and other chemicals by regulatory authorities. To evaluate the profile of a drug 
through analytical investigation involves identification, quantification, chemical 
characterisation and profiling (Bartos and Gorog, 2008; Inoue et al., 2008). These are 
therefore further discussed in section 1.8. 
 
According to the UN (2001) and DEA (2011) drugs of abuse can be classified by origin and 
pharmacological effects. Categorisation by origin is useful in gaining insight into how the 
drug arises and evaluation of the similarities of their origin. This is of use in 
characterisation and profiling of a substance (UN, 2001; Aalberg et al., 2005a; Bartos and 
Gorog, 2008). Whilst categorisation by pharmacological effects gives an understanding of 
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the psychoactive effects of the substance, both sought by the user and the associated 
adverse effects. These can have a socio-economic impact, e.g. health risks. Consequently, 
these categories are discussed further. Categorisation by pharmacological effects is variable 
however they are mainly classified into depressants, stimulants and hallucinogens (DEA, 
2011; Dargan and Wood, 2013). This is further discussed in the section 1.5 on 
pharmacological effects. 
 
 Table 1.1 gives an over view of the classes by origin. As shown in the table illicit drugs 
can be classified by origin into natural, semi-synthetic and synthetic substances. The 
natural group has been in existence the longest, e.g. cocaine is reported to have been in use 
since circa 470 – 370 B.C (Brick and Erickson, 2013; Seymour and Smith, 2011). The 
semi-synthetics arose in the late 1800s when Bayer Laboratories discovered a new pain 
reliever, diacetylmorphine (heroin). A compound derived from morphine by the addition of 
two acetyl groups. The drug had a high potential for abuse as it was 2 to 3 times more 
potent than morphine and was a stronger psychoactive substance. The emergence of the 
synthetic group started with amphetamine which was intended as a medical drug in the late 
1920s (Dargan and Wood, 2013). Its “success” as an illict drug saw the development of its 
derivatives and other synthetic drugs (Shulgin and Shulgin, 1991). 
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Table 1.1 Classification/categories of drugs by origin (Arbo et al., 2012; Brick and Erickson, 2013; Dargan and Wood, 2013; DEA, 2011; King, 
2009; Seymour and Smith, 2011; Shulgin and Shulgin, 1991; Winstock and Wilkins, 2011). 
Drug category Definition  Origin  Examples 
Natural 
 
Substances that are only 
produced naturally without 
chemical alteration.  
Plants  
 
 
 
 
 
 
Fungi  
• Cocaine: derived from the coca plant, 
Erythroxylum coca and Erythrxylum 
novogranatense.  
• Cannabis: derived from the leaves of 
various species of Cannabis. 
• Natural opiates e.g. morphine, codeine. 
• Khat (Catha edulis) and kratom. 
Magic mushrooms: various mushroom 
species of Psilocybe. 
Semi-synthetic 
 
These are drugs that are 
derived by synthesis from a 
natural psychoactive drug. 
Made by derivation from natural opiates such as 
morphine, codeine and thebaine. These substances 
were initially derived for use as pharmaceuticals.   
Heroin  
Oxycodone 
Synthetic These are a relatively new 
generation of drugs, 
completely man made and 
are derived wholly from 
chemical synthesis.  
They are mainly made by modification of another drug 
molecule, commonly a pharmaceutical drug or a 
controlled psychoactive drug with the aim of 
circumventing legal controls.  
 
 
• Amphetamines e.g amphetamine, 
methamphetamine, MDMA. 
• Piperazines (BZP, 3-TFMPP, 4-FPP).  
• Tryptamines (LSD). 
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A general review of the trends in the history of drugs of abuse (King, 2009; King and 
Kicman, 2011; Dargan and Wood, 2013; UNODC, 2013a) confirmed that in the early years 
the natural class accounted for all the abused substances. However, from the 1940s the drug 
scene changed due to the emergence of synthetic and semi-synthetic drugs. This can be 
seen in the trends in substances under legal control (Fig 1.1).  
 
 
Figure 1.1 Trend in substances controlled by the UN, showing changes in the type and 
number of substances (data from UNODC, 2013a). 
 
Figure 1.1 shows that globally there has been an increase over the years in the number of 
drugs of abuse controlled by the UN in the period 1912 - 2012. With this increase synthetic 
drugs have increased exponentially since the 1940s (UNODC, 2013a) by 2012 accounting 
for 84% (196 substances) of all the substances controlled by the UN. In comparison the 
natural class accounted for 16% (UNODC, 2013a). The marked increase in 1948 can be 
attributed to the emergence of phenethylamines (Shulgin and Shulgin, 1991; Dargan and 
Wood, 2013). The increasingly large discrepancy in the drug types with time is due to the 
emergence of a larger variety in the types of synthetic relative to the natural drugs.  
 
It has been recently reported by the UNODC (2013a) that for the first time the international 
drug control system is floundering under the speed, creativity and unfailing regularity of 
appearance of new psychoactive substances (NPS). Furthermore, for the first time the 
number of NPS actually exceeds the total number of substances under international control 
4 7
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(234). Currently 250 NPS are listed (UNODC, 2013b; EMCDDA-Europol; 2012). 
Furthermore, it was reported in the UNODC Global Smart program (UNODC, 2014) that 
synthetic drugs pose a threat and a significant drug problem globally. The report stated that 
“after cannabis, amphetamine-type stimulants (ATS) are the second most widely used 
drugs across the globe”. Further to this is the exponential increase highlighted above. This 
shows that there is need to keep up with investigation of these newly developing substances 
as a way of gaining information, increasing regulations, reducing risk, potential health 
issues and prevalence. This study will investigate a new psychoactive substances; 
phenylpiperazines with a focus on 1-(4-fluorophenyl)piperazine (4-FPP) and 1-(3-
trifluoromethylphenyl)piperazine (3-TFMPP). 
 
1.2 PROPERTIES OF 4-FPP AND 3-TFMPP 
 
The properties of a class of synthetic drugs of abuse, i.e., piperazines will be reviewed so as 
to gain an insight into their characteristics.  
 
1.2.1 PHYSICAL  AND CHEMICAL PROPERTIES 
 
4-FPP and 3-TFMPP are isomeric, exhibiting (2, 3 and 4) positional isomers. The 
structures, CAS numbers (chemical identity numbers), molecular mass, boiling points and 
characteristic mass spectral ions are shown in Figure 1 and Table 1.2. These properties are 
characteristic of these compounds and as such are of use in their identification (de Boer et 
al., 2001; Takahashi et al., 2009; UNODC, 2013b). 
 
NHNF3CNHN
F3C
NHN
CF3
NHNFNHN
F
NHN
F
1-(2-fluorophenyl)piperazine 1-(3-fluorophenyl)piperazine 1-(4-fluorophenyl)piperazine
1-(2-trifluoromethyl)phenyl]piperazine 1-(3-trifluoromethyl)phenyl]piperazine 1-(4-trifluoromethyl)phenyl]piperazine
 
Figure 1.2 Chemical structures of selected piperazine based psychoactive drugs; the main 
drugs of focus for this research.   
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Table 1.2 Properties of FPP and TFMPP compounds (UNODC 2013c; NIST, 2014; Takahashi et al., 2009; de Boer et al., 2001; RSC 
Chemspider, 2013) 
Compound Common 
name 
CAS No. Molecular mass 
(g/mol) 
Boiling point 
(oC)[1] 
Characteristic mass 
spectral ions m/z[2] 
1-(2-fluorophenyl)piperazine 2-FPP 1011-15-0 180.22 398.35 –401.84 138(100), 180(M+), 122, 56 
1-(3-fluorophenyl)piperazine 3-FPP 3801-89-6 180.22 358.33 –372.97 138(100), 180(M+), 122, 56 
1-(4-fluorophenyl)piperazine 4-FPP 2252-63-3 180.22 440.24 138(100), 180(M+), 122, 56 
1-(2-trifluoromethylphenyl)piperazine 2-TFMPP 63854-31-9 230.23 344.27 – 350.91 188(100), 230(M+), 172, 145 
1-(3-trifluoromethylphenyl)piperazine 3-TFMPP 15532-75-9 230.23 190.92 – 198.95 188(100), 230(M+), 172, 145 
1-(4-trifluoromethylphenyl)piperazine 4-TFMPP 30459-17-7 230.23 309.10 188(100), 230(M+), 172, 145 
[1] At (oC/760mmHg). [2] A discussion of the ions and mass spectra is conducted Chapter 7 (Validation).  
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1.2.2   PHYSICAL PROPERTIES OF PIPERAZINE (4-FPP AND 3-TFMPP) STREET DRUGS 
ON THE MARKET 
 
In street drugs, 4-FPP and 3-TFMPP exist in the free base or salt form, such as the 
hydrochloride salt (Nikolova and Danchev, 2008; Kenyon et al., 2010; Kelleher et al., 
2011). These drugs are sold as powders, liquids, tablets and capusules (Vorce et al., 2008; 
Nikolva and Danchev, 2008), however they have been reported mostly as tablets and 
capsules (Nikolva and Danchev, 2008; DEA, 2009a, b; Kenyon et al., 2010; Kuleya et al., 
2014; Yuk, 2010). Piperazine drugs are easily available in pubs, clubs and herbal shops. 
The internet has also been widely reported to be the main source of new psychoactive 
substances (ACMD, 2011; Arbo et al., 2012; Baron et al., 2011; EMCDA – Europol, 2013). 
Figure 1.3 shows images of some of the different clandestine drugs containing 4-FPP and 
3-TFMPP encountered in illegal drugs marketed under a variety of names.  
 
 (I) (II) (III) (IV)   
(V)  (VI)    (VII)   
Figure 1.3 Images of some the different clandestine drugs containing 4-FPP and 3-TFMPP; 
Majik tablets (I), Exotic tablets (II, III), 3-TFMPP powder (IV, VI), Obama logo tablets 
(VI) and Playboy bunny tablets (VII) (DEA, 2009a; Yuk, 2010; EMCDDA, 2011; 
UNODC, 2013b).  
 
According to EMCDDA (2011) and DEA (2011) they often carry logos similar to those 
seen on ecstasy (Figure 1.3). For example, 4-FPP was reported in seized Playboy bunny 
shaped ‘ecstasy’ tablets. This is likely so as to mislead the user into thinking they are a 
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form of ecstasy. Table 1.3 gives examples of some of the street drugs that have been 
reported as containing piperazines.  
 
Table 1.3 Examples of steet drugs containing piperazines (DEA, 2010; Yeap et al., 2010; 
Yuk, 2010; Kelleher et al., 2011; Arbo et al., 2012; ECDD, 2012) 
Street name Composition 
Exotic, A2, Charge, Nemesis, 
Legal X  
BZP 50 - 200mg 
3-TFMPP 5 - 225mg 
Altitude BZP 45mg 
3-TFMPP 15mg 
Vitamins, minerals 
Super E[1] 4-FPP 
3-TFMPP 
Caffeine 
E-XTC “Not for human consumption” dicalcium 
phosphate, ketones and magnesium stearate but 
was actually found to contain TFMPP 
“ecstasy”[1] 4-FPP 
[1]
 Dosages not given 
 
Piperazine drugs have been reported to exist as drug cocktails and that they are rarely found 
as the only active ingredient present (Davies et al, 2010; Kenyon et al., 2010; Yeap et al., 
2010; Kelleher et al., 2011; Winstock and Wilkins, 2011). This is evidenced by the 
composition of the street samples given in Table 1.3. The most common combination was 
found to be BZP and TFMPP (DEA, 2009a, 2010; Kenyon et al., 2010; Yuk, 2010; 
Kelleher et al., 2011). According to a DEA report (2009a, 2009b) caffeine and 
nicotinamide are routinely found as adulterants in most piperazine drug cocktails. 
Furthermore, other drugs such as dapoxetine, dextromethorphan, diazepam and cocaine 
have also been reported to exist with these drugs (Staack, 2007; Nikolova and Danchev, 
2008; DEA, 2009 a, b). Table 1.4 shows the list of congeners found in street samples 
containing 4-FPP and 3-TFMPP and Figure 1.4 shows their chemical structures. Congeners 
can be defined as other chemical components which together with the main drug aid in give 
it its distinctive character or physiological effects. 
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Table 1.4 Congeners found with 4-FPP and 3-TFMPP drugs of abuse on the street (Staack, 
2007; Nikolova and Danchev, 2008; Vorce et al., 2008; Kenyon et al., 2010; Kelleher et al., 
2011; UNODC, 2013a). 
Substance (chemical name) Common name 
1-benzylpiperazine BZP 
1,4-dibenzylpiperazine DBZP 
1-(4-methylbenzyl)piperazine MBZP 
1-(3-chlorophenyl)piperazine CPP 
1-(4-methylphenyl)piperazine MePP 
 (2S)-1-phenylpropan-2-amine (+)-Amphetamine 
 (2S)-N-methyl-1-phenylpropan-2-amine (+)-Methamphetamine 
methyl (3S,4R)-3-benzoyloxy-8-methyl-8-
azabicyclo[3.2.1]octane-4-carboxylate 
Cocaine 
1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-
amine 
Dapoxetine 
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one Diazepam 
Dextromethorphan: d-methorphan Dextromethorphan 
(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol Ephedrine 
1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione 3,7-dihydro-
1,3,7-trimethyl-1H-purine-2,6-dione 
Caffeine 
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one Nicotinamide 
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Figure 1.4 Drugs and other substances found in street samples containing 4-FPP and 3-
TFMPP.  
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The dosages for the drugs vary and are often not reported on the label (Kelleher et al., 
2011). Doses for BZP, 3-TFMPP, CPP and caffeine have been routinely reported by many 
researchers (LTG, 2006; Kenyon et al., 2010; Kelleher et al, 2011; Yeap et al., 2010; 
EMCDDA, 2011). The stated doses ranged between 50 - 200mg BZP and 5 - 75mg TFMPP 
and 90 - 110mg 3-CPP (EMCDDA, 2011; Kenyon et al., 2010; Kelleher et al., 2011). 
However, dosages for 4-FPP or any of the other drugs have not yet been reported. This 
could be due to the fact that research on 4-FPP is very limited in comparison to the 
previously stated piperazines. This can be attributed to the fact that it is relatively newer on 
the market as a drug of abuse than either BZP or 3-TFMPP (section 1.3).  
 
Furthermore, the drugs are often not labelled with safety data or ingredients (Yuk, 2010; 
Elliot, 2011). Where this is present it is often misleading, e.g. the drugs are labelled as 
containing research chemicals (ACMD, 2011; Baron et al., 2011). In some cases tablets 
said to be piperazines were found to contain caffeine and in some cases ‘ecstasy’ tablets 
actually contained piperazines (Davies et al, 2010; DEA, 2009a). The implication is that the 
composition, dose and purity and potential adverse effects of the drug are unknown to the 
user. This puts users at risk of potential health problems. Consequently, this study 
investigates and provides information on the characterisation of piperazine street samples. 
This will beuseful to other researchers and might also be of use to law enforcement 
agencies 
 
1.2.2.1 Why adulterate? 
It is evident from section 1.2.2 that piperazine drugs of abuse are highly adulterated. A 
considerable number of congeners were identified (Table 1.2) as present in 4-FPP and 3-
TFMPP street samples. The aims of adding adulterants are to add bulk, to enhance or 
mimic and to facilitate administration of the drug (Cole et al., 2011). Adulterants are also 
used to reduce the effect of adverse reactions. Consequently, this gives rise to the presence 
of the congeners in 4-FPP and 3-TFMPP street samples. The adulterants have been 
categorised according as; 
 
1.2.2.1.1 True adulterants (such as caffeine, nicotine, nicotinamide) 
These are non-psychoactive but pharmacologically active drugs. Their purpose is mainly to 
add bulk and enhance the effect of the psychoactive substances as a result of their own 
pharmacological properties (DEA, 2011; Barceloux, 2012) These substances have been 
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widely reported in drugs of abuse (Davies et al., 2010; Kenyon et al., 2010; Kelleher et al., 
2011).  Caffeine is one of the most common adulterants found in cocaine, amphetamine, 
methamphetamine, ecstasy and piperazine street drugs (LTG, 2006; Davies et al., 2010; 
Cole et al., 2011). The stimulant properties of caffeine can create similar, although usually 
milder effects to the primary drug (Davies et al., 2012). Nicotinamide also known as 
niacinamide is a water-soluble B-complex vitamin (B3) used in the treatment of vitamin B3 
deficiency and is also commonly used as an adulterant (DEA, 2011). In some cases they are 
also used due to the fact that they facilitate drug administration (Cole et al., 2011; Davies et 
al., 2012) such as caffeine when is smoked with heroin. Huizer (1987) showed that due to 
its physiochemical effects, caffeine lowers the sublimation temperature of heroin, resulting 
in it vaporising at a lower temperature. This slightly increases its recovery and decreases its 
pyrolitic decomposition. Consequently, when heroin is smoked with caffeine there is a 
slightly increased efficiency (Andreasen et al., 2009).  
 
1.2.2.1.2 Use of other drugs of abuse as adulterants 
Piperazines such as BZP, DBZP, MBZP, MePP and CPP are psychoactive illicit drugs used 
to adulterate each other with the purpose of mimicking ecstasy. In combination the drugs 
have a synergistic effect and it has been reported that the BZP and 3-TMPPP combination 
is synergistic such that the effect is similar to ecstasy (Elliot, 2011). Piperazines are also 
reported as adulterants in other non-piperazine based illicit substances such amphetamine, 
methamphetamine, MDMA and cocaine (Arbo et al., 2012). The use of 4-FPP and 3-
TFMPP as adulterants is mainly due to the following: a) their psychoactive effects can 
mask the fact that a reduced amount of the drug is present, b) they are cheaper 
(section1.4.2) and, c) they are more easily available as the legal controls on them are less 
extensive (Davies et al., 2012; Cole et al., 2011). Consequently, besides 4-FPP and 3-
TFMPP other piperazine drugs are increasingly reported as adulterants (Yeap et al., 2010; 
Kelleher et al., 2010, Dargan et al., 2013). 
 
1.2.2.1.3 The use of pharmaceuticals with anti-depressant or pain relieving properties 
The use of these substances as adulterants has been widely reported (Cole et al., 2011; 
DEA, 2011; Arbo et al., 2012). The adulterants are mainly common pharmaceuticals such 
as diazepam, paracetamol and lidocaine. Their prevalent use as adulterants can be attributed 
to their physiological effects. This type of adulterants have sedative and analgesic effects 
and as such they appear to enhance the psychoactive effect of the drug, as they give 
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feelings of relaxation, for example diazepam. They have been found in illicit drugs such as 
piperazines, amphetamines, cocaine, heroin (Nikolova and Danchev, 2008; DEA, 2009a; 
King and Kicman, 2011). Andreasen et al. (2009) reported paracetamol as being widely 
present in amphetamine street samples. Furthermore, the UNODC (2013b) stated that their 
use has been “commonly observed among users of heroin who use benzodiazepines to 
enhance its effects”. In addition, it has been reported that they also facilitate administration 
of the drug for example procaine relieves pain in cocaine intake (Cole et al., 2011). 
 
1.3 HISTORY OF PIPERAZINE DRUGS OF ABUSE 
 
Piperazines are derived by taking advantage of, or remodelling of piperazine based 
pharmacological drugs (Nikolova and Danchev, 2008; Lecompte et al., 2008; Yeap et al., 
2010; Arbo et al., 2012; Dargan and Wood, 2013). The skeleton structure of all these drugs 
is the piperazine moiety (Figure 1.5).   
 
N
H
N
H
N
H
piperazine piperidine
 
Figure 1.5 Chemical structures of piperazine and piperidine 
 
The presence of two reactive amine groups on the piperazine ring makes it amenable to 
chemical derivatisation (for example as shown in Figure 1.16 for the synthesis of 3-
TFMPP). The synthesised drugs structurally are 1-arylpiperazines and benzylpiperazines 
and as such are psychoactive, the degree of which is dependent on the substituent (Staack, 
2007; Kenyon et al., 2010; Yeap et al., 2010). According to King (2009) and UNODC 
(2013a) there are at least 12 substituted piperazines drugs on the clandestine drug market 
(Table 1.5). In addition to these, thienylmethylpiperazines have been reported to a lesser 
extent (Arbo et al., 2012). 
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Table 1.5 Piperazine based psychoactive drugs currently found on market (UNODC, 
2013a). 
Common name  Abbreviation  
1-Benzylpiperazine BZP  
1-Benzyl-4-methylpiperazine MBZP 
1,4-Dibenzylpiperazine DBZP 
3,4-Methylenedioxy-1-benzylpiperazine MDBZP 
1-(4-Bromo-2,5-dimethoxybenzyl)piperazine  2C-B BZP 
1-Phenylpiperazine N/A 
1-(3-Chlorophenyl)piperazine 3-CPP  
1-(3-Chlorophenyl)-4-(3-chloropropyl)piperazine  3-CPCPP 
1-(4-Fluorophenyl)piperazine 4-FPP 
4-Methylphenylpiperazine  4-MePP 
1-(4-Methoxyphenyl)piperazine  4-MeOPP 
1-(3-Trifluoromethylphenyl)piperazine  3-TFMPP 
 
The structures of piperazine drugs not previously shown in Figures 1.2 and 1.3 are given in 
Figure 1.6 
NH
N
O
O
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1-(4-bromo-2,5-dimethoxybenzyl)piperazine
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N
O
1-(4-methoxyphenyl)piperazine
NN
Cl Cl
1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine
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O
3,4-methylenedioxy-1-benzylpiperazine
NHN
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Figure 1.6 Structures of illicit piperazine drugs MDBZP, 2C-B BZP, phenylpiperazine, 3-
CPCPP and 4-MeOPP. 
 
In 1943 the Wellcome Research Laboratories introduced BZP as an antihelmintic agent 
(Staack and Maurer, 2005; Elliot and Smith, 2008; King and Kicman, 2011; Barceloux, 
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2012). This was followed by research into its pharmacological use as an anti-depressant 
(Staack, 2007) and in the 1970s indications were that it induced psychoactive behaviour 
and had addictive properties similar to amphetamines (Staack and Maurer, 2005). This led 
to a discontinuation of the study trials due to perceived potential for abuse (Yeap et al., 
2010). It can therefore be extrapolated that drug users took advantage of this information 
and furthermore that abuse of piperazine drugs started with 1-benzylpiperazine (BZP).  The 
1990s saw the use of BZP for recreational purposes as a rave drug marketed extensively 
over the internet. The drug was sold as a “herbal high”, a term coined due to its similarity 
to piperidine (Figure 1.5) in black pepper (King, 2009; Dargan and Wood, 2013).  
 
According to Arbo et al., (2012) the first documented abuse of BZP was in 1996 in the 
USA. In 2002 BZP was marketed as a legal alternative to methylamphetamine in New 
Zealand (Winstock and Ramsey, 2010) and its use became widespread. With the success of 
BZP as an illicit substance, a variety of other benzylpiperazines also came onto the illicit 
drug market such as 3,4-methylenedioxy-1-benzylpiperazine. The 2000s saw the 
emergence of phenylpiperazines (Staack, 2007; ACMD, 2011; King and Kicman, 2011). 
The most commonly used were reported as 3-CPP and 3-TFMPP. In 2004, 3-CPP was 
reported to be used in 26 member states of the EU (King 2009; Arbo et al., 2012).  
 
3-TFMPP is a drug normally used as a pharmacological probe in animal drug trials (Elliot, 
2011; Staack et al., 2003). Abuse of 3-TFMPP together with BZP was first reported in the 
late 1990s in the USA and Scandinavia (ECDD, 2012).  In the 2000s its use became 
widespread in New Zealand, Australia, Europe, Japan and Bulgaria (Inoue et al., 2008; 
Nikolova and Danchev, 2008; Yuk, 2010; ACMD, 2011).  Second to BZP, 3-TFMPP is the 
most abused piperazine drug (Staack et al., 2003; Staack, 2007; Yeap et al., 2010).  
 
4-FPP was discovered as a metabolite of the pharmaceutical drug Niaprazine (Figure 1.7), 
an antihistamine with psychoactive properties (Kelleher et al., 2011). This could be the 
reason it has found use as a drug of abuse. 4-FPP was initially encountered in New Zealand 
during 1982 in party pills and its use increased in 2003 (Inoue et al., 2008; Vorce et al., 
2008; Dargan and Wood, 2013). Comparatively, use of 3-TFMPP is more widespread than 
4-FPP.  This could be attributed to the fact that 3-TFMPP is found commonly in drugs 
containing BZP and it has been reported that BZP is one of the two most commonly used 
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piperazines. In addition, 4-FPP emerged relatively later on the market; as such the users are 
not as familiar with the drug. 
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Figure 1.7 Structure of niaprazine 
 
Currently, use of piperazines is reported to be spreading globally and increasing in many 
countries. (Takahashi et al., 2009; Kenyon et al. 2010; Yeap et al., 2010; Arbo et al., 2012; 
UNODC, 2013b; EMCDDA, 2014). As such, to gain an insight into the prevalence of 
piperazines, a review of the trends in abuse of these drugs is presented.  
 
1.4 TRENDS IN USE AND ABUSE OF PHENYLPIPERAZINES 
 
1.4.1 GLOBAL PERSPECTIVES 
 
The use of new psychoactive substances has been widely reported globally including 
Australia, New Zealand, EU, and the USA. To obtain a more global perspective, in 2012 
the UNODC carried out a survey on the global spread of NPS, in 80 countries in Europe, 
Asia, the Americas, Africa and Oceania.  The results indicated that all the NPSs were 
widespread with 70 countries reporting the presence of NPSs. Europe had the highest rate 
of prevalence with 31 countries in the EU reporting the presence of an NPS (UNODC, 
2013a). The global distribution of NPS by region is shown in Figure 1.8. 
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Figure 1.8 Global emergences of NPS by region, showing the number of countries 
reporting the presence of NPS by 2012, a total 70 countries (UNODC, 2013a). 
 
Trends in drugs of abuse can be attributed to any of the following; 
a) Easy availability to the end user, due to the internet and clubs.  
b) Legislative controls 
c) Cost of the street drug 
d) Knowledge of the drug and/or its perception 
e) Technology 
f) Production 
g) History of illicit drug use 
 
Consequently, these are contributing factors to the global distribution observed in Figure 
1.8. Historically, Europe has a high rate of illicit drug use (UNODC, 2013a; EMCDDA, 
2013a; EMCDDA-Europol, 2012). whilst most developing countries, e.g. in Africa are 
emerging as drug users. Cost limitations and low technology could all be contributors. 
Furthermore, lack of information regarding use of illicit drugs in countries such as India, 
China and in Africa might mean the data is not exact. However, it has been reported that 
generally rates of drug abuse (consumption and production) are generally higher in Europe 
than in these countries, which confirms the trend in NPS in Figure 1.8. All the different 
types of NPSs were reported in all the regions except Africa (which at the present time had 
Africa, 7
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Asia, 19
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no record of synthetic cannabinoids and phenethylamines). The global prevalence by the 
type of drug is shown in Figure 1.9.  
 
 
Figure 1.9 Global emergence of new psychoactive substance by type, showing the number 
of countries reporting the substance to UNODC up to 2012, also shown as a percentage of 
the countries studied (UNODC, 2013a).  
 
Ketamine and plant-based substances were found to have the highest prevalence, each 
being found in 44 countries, (83% of the countries studied). The most common were 
kratom, khat and Salvia divinorum. Piperazines accounted for 77%, synthetic cannabinoids 
75% and phenethylamines had the lowest at 60%.  The implication of the results is that all 
the groups of NPS have become globally widespread. Furthermore, they confirm earlier 
reports that use and abuse of piperazines and other NPS has spread to several countries 
(Nikolav and Danchev, 2008; Takahashi et al., 2009; Elliot, 2011; EMCDDA, 2011). It is 
therefore suggested that the high spread of NPSs is largely attributed to their easy 
availability over the internet (Davies et al., 2010; King and Kicman, 2011) and also the 
aggressive and often misleading marketing of these substances. They are often marketed as 
legal and herbal highs. Furthermore, currently there is lack of adequate information on their 
adverse effects. 
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The lower prevalence of phenethylaminess can be attributed to the fact that legislation on 
MDMA and other amphetamines is more extensive. Amphetamine, methamphetamine and 
MDMA are listed in Schedule I of the United Nations 1971 Convention on Psychotropic 
Substance. Whilst cannabis and THC are controlled, none of the synthetic cannabinoids are 
under international control (Coulson and Caulkins, 2012; UNODC, 2014). This is likely the 
reason for their high prevalence. Furthermore, for the tryptamines only magic mushrooms; 
psilocin, psilocybin, DET, DMT, and etryptamine are under international control (UNODC, 
2013c). None of the piperazines are under international control (legislation of piperazines 
will further be discussed in section 1.6).  In, addition national controls on amphetamine and 
MDMA are more widespread than for the other drugs (Dargan and Wood, 2013; UNODC, 
2013b).  It has been reported that users view plant based substances as being herbal and 
therefore harmless (Dargan and Wood, 2013). Such perceptions are likely to have an 
impact on prevalence of these substances. Synthetic cathinones, cannabinoids and plant-
based substances are also the latest in emerging NPS, consequently regulations and other 
pertinent information such as health risks and adverse reactions are still very scarce.  
 
From previous discussions it can be seen that piperazines constitute a relatively significant 
share of the global NPS market. The question therefore arises as to which of the piperazines 
are mostly abused and whether 3-TFMPP and 4-FPP the drugs of focus in this study are a 
pertinent problem. Most regions reported the emergence of piperazines before 2012 
(UNODC, 2013a). Figure 1.10 shows the global distribution of the top 5 most commonly 
reported piperazines in drugs of abuse seizures reported to the UNODC as per the 2012 
survey (UNODC, 2013a).  
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Figure 1.10 The top five piperazines reported to the UNODC up to 2012 (UNODC, 2013a). 
 
3-CPP was the most commonly reported piperazine. It has been reported that by 2006 
almost 10% of illicit pills sold in the European Union contained 3-CPP to mimic illicit 
ecstasy (Staack, 2007; King, 2009; EMCDDA, 2011). The data in Figure 1.10 is consistent 
with this view. The graph also shows that 3-TFMPP and 4-FPP the main drugs of focus for 
this research are a significant part of the piperazine based illicit drug market.  
 
1.4.2 EU PERSPECTIVES 
 
In the previous discussion, Europe was identified as having the highest prevalence of NPS 
globally. It has been reported that the United Kingdom is the country that identified the 
most NPS in the European Union accounting for 30 per cent of the total during the 2005 - 
2010 period (EMCDDA-Europol, 2012; UNODC, 2013a). The situation in the UK is 
further shown Figure 1.11 for the number of substances by seizures analysed in the UK for 
phenethylamines (MDMA) and piperazines.  
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Figure 1.11 Number of seizure records for Forensic Science Services (Seizure date July 
2005 - March 2010) (data from UK Focal point, 2012). 
 
Figure 1.11 shows there was a general decrease in MDMA seizures from 2007 to 2009, 
comparatively piperazines increased from 2007 to 2009 then decreased thereafter. Data 
thereafter was not available. However reports for 2012 and 2013 have shown a re-
emergence of piperazines; most countries such as UK, Belgium and Denmark reported ≥ 
20% piperazines in the tablets they analysed (UK Focal Point, 2012, 2013; EMCDDA, 
2014). Furthermore, the UK Focal point (2012) reported there was a resurgence of MDMA 
in 2011 with the decrease in other NPS. The trends shown in Figure 1.11, are also linked to 
the trends in other NPS such as cathinones. Whilst not shown in Figure 1.11 according to 
the EMCDDA (2011), prior to 2009 cathinone seizures were not significant but increased 
from 2009 such that by 2010 cathinone seizures were higher than those of piperazines and 
MDMA. The observed trends can mainly be attributed to legal controls on MDMA having 
resulted in the upsurge in piperazines. Thereafter, legal controls on piperazines in 
December 2009 (King and Kicman 2011), resulted in a drop in their prevalence. This 
created a market for other NPS as evidenced by the rise in cathinones and the resurgence of 
MDMA. 
 
It has been discussed that prevalence of use or distribution is linked to street prices of the 
drugs (UK Focal Point, 2013). To try and evaluate whether the trends observed above are 
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linked to cost of the drugs, the street prices of new psychoactive substances in the UK are 
shown in Table 1.6. 
 
Table 1.6 Prices of new psychoactive substances in the UK (2010 – 2013). 
Drug  Price per capsule or tablet Source 
Amphetamines £10 per gram UK Focal point (2013) 
Ecstasy £4.00 per tablet 
£36 per gram (in 2010) 
UK Focal point (2013) 
Ketamine £21 per gram UK Focal point (2013) 
Cathinones £5.50  per tablet Davies et al. (2010) 
Piperazines £3.30 – £5.85 per tablet Davies et al. (2010) 
Caffeine/ephedrine (no 
psychoactive drug present) 
£2.50 – £3.40 per tablet Davies et al. (2010) 
 
The table shows that piperazines are cheaper than the other psychoactive drugs available. 
Considering they are marketed as ecstasy, this could be a contributing factor to their rise in 
use in the face of a decline of ecstasy. Cannabinoids and cathinones are relatively more 
expensive, however this could be because they are relatively newer on the market hence 
their high price and high prevalence.  
 
The discussions above show that the use of piperazines in the UK is prevalent and growing. 
Hence, there is a need to keep up with not only their analytical investigation but also to 
gain an insight into their psychoactive properties due to their pharmacological effects. 
 
1.5 PHARMACOLOGICAL EFFECTS  OF PIPERAZINE DRUGS OF ABUSE 
 
The perceived biological and bio-behavioural action of a drug determines how a drug is 
defined. Its pharmacological effects are the physiological and biochemical changes that it 
produces in the body. Psychoactive drugs are those drugs that modify our physiological 
traits such as behaviour and cognition (Brick and Erickson, 2013). Psychoactive substances 
are taken for their perceived stimulating effect; because they promote a sense of well-being 
and alertness among others. For example, amphetamine is associated with ‘feelings of 
increased confidence, sociability and energy (Barceloux, 2012). 
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The site of action of psychoactive substances is the Central Nervous System (CNS) and 
Peripheral Nervous System (PNS) in the brain, mainly the medial forebrain bundle known 
as the mesolimbic dopamine system (MDS) in the CNS (Elliot, 2011; Barceloux, 2012; Gee 
and Schep, 2013). Neurochemicals known as neurotransmitters naturally found in the brain 
cells (neurons) located in the MDS are stimulated and/or released during metabolism of 
drugs. These are released or inhibited as a natural part of the nervous system, to regulate 
the various bodily functions such as sleep, feeling and movement. Psychoactive drugs 
produce their effect by altering the activity of neurotransmitters in the brain. It is then the 
presence of the neurochemicals that promote feelings of well-being, craving, alertness etc. 
perceived with the drug (Barceloux, 2012; Brick and Erickson, 2013).  
 
1.5.1 MECHANISM OF ACTION 
 
In the pharmacology of drugs of abuse the most common neurotransmitters are dopamine, 
serotonin, norepinephrine (noradrenaline) and Gamma-aminobutyric acid (GABA). 
Dopamine is the neurotransmitter most affected by psychoactive drugs (Arbo et al., 2012; 
Elliot, 2011; Staack, 2007). Neurotransmitters are either inhibitory (-) (decrease), or 
excitatory (+) (increase) the probability of an action potential in the neuron. A drug may 
influence the activity of a neurotransmitter through the following mechanisms; (Staack and 
Maurer, 2005; Barceloux, 2012; Dargan and Wood, 2013);  
• increase the release of a neurotransmitter. 
• directly activate or block the neurotransmitter receptors. 
• inhibit reuptake (transport) of the transmitter into the neuron, consequently keeping. 
it in the synapse where it is free to interact with receptors again. 
• inhibit enzymes in, or near the neuron that would breakdown the neurotransmitter. 
 
Drugs that directly activate receptors are agonists and those that block are antagonists.  
Figure 1.12 below shows a general mechanism of action of a neuron in response to a 
psychoactive drug.  
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Figure 1.12 Schematic diagram of neurotransmitter mechanism in response to a 
psychoactive drug. The processes occur sequentially as numbered (1 – 5).  
 
The concentration of the neurotransmitter in the synapse influences the degree of effects 
felt on the body’s functions. Psychoactive drugs increase the concentration of 
neurotransmitters in the synapse, thereby deriving the associated functional effects of that 
neurotransmitter, such as increased alertness for noradrenaline. As shown in Figure 1.12; in 
the pre-synaptic neuron synthesis of the neurotransmitter (NT), e.g. dopamine, serotonin 
occurs. This is followed by uptake of the neurotransmitters into vesicles for transportation 
to the membrane. The vesicles fuse with the pre-synaptic membrane and release the 
neurotransmitters into the synapse. In the synapse, the neurotransmitter then a) diffuses to 
the post-synaptic membrane and binds to the post-synaptic receptors (e.g. 5-HT2A for 
serotonin). This activates the receptors and consequently modulates the body’s functions 
regulated by that neurotransmitter, resulting in the perceived psychoactive effects, such as 
an increased feeling of happiness b) the neurotransmitters in the synapse diffuse back to the 
pre-synaptic membrane for re-uptake or enzymatic degradation. This process is inhibited by 
antagonist drugs as they attach to the receptors, thereby blocking access to the 
neurotransmitter and consequently resulting in a build-up of neurotransmitters in the 
synapse (Dargan and Wood, 2013; Gee and Schep, 2013). 
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Therefore, different drugs of abuse produce different psychological effects, depending on 
the neurotransmitter they act upon. Drugs that act on adrenaline are adrenergic and those 
that work on serotonin are serotogernic, whilst dopaminergic drugs act on the dopamine 
pathway. However, they are drugs which due to their structural similarity to 
neurotransmitters mimic the actions of the neurotransmitter as they are able to bind to the 
neurotransmitter’s receptors. Such drugs are sympathomimietic (Gee et al, 2005, DEA, 
2011). Hence, drugs can be categorised (section 1.1) according to their pharmacological 
effects into stimulants, hallucinogens and depressants, e.g. piperazines, LSD and diazepam, 
respectively (Dargan and Wood, 2013; DEA, 2011; EMCDDA, 2013a). The 
pharmacological actions of selected drugs will be discussed below.  
 
1.5.2 PHARMACOLOGICAL ACTIVITY OF SELECTED DRUGS 
 
The pharmacological effects of selected psychoactive drugs of abuse and the responsible 
neurotransmitter functional activity are described in Table 1.7. Piperazines, amphetamines, 
cocaine and generally most of the drugs under study exhibit dopanergic, serotogernic and 
adregernic effects (Elliot, 2011; Dargan and Wood, 2013).  
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Table 1.7 Pharmacological effects of selected psychoactive drugs showing drug categories, the responsible neurotransmitter functional activity 
and drug effects (Arbo et al., 2012; Brick and Erickson, 2013; Elliot, 2011; Dargan and Wood, 2013). 
Category/ definition Examples of selected drugs[1] Main neurotransmitter/ Functions Affected Drug Effects (sought by users) 
Stimulants 
Substances that increase the 
activity of the brain CNS and 
body processes 
Most psychoactive drugs e.g. 
Amphetamine 
Methamphetamine 
MDMA 
Cocaine 
Benzylpiperazines e.g. BZP 
 
Dopamine (+) or (-) 
Reward pathways, cognition  
(Mainly dopamine, lesser extent 
norepinephrine and serotonin). 
 
 
Norepinephrine(-)  
Fight or flight response, sensory processing, 
movement, sleep, mood, memory 
Well-being, pleasure, euphoria, 
forgetfulness, stimulation, mental 
alertness, loss of reality, weight 
loss. 
 
 
 
Alertness, energy rush, 
hyperactivity, anxiety 
Most psychoactive drugs e.g. 
phenylpiperazines e.g  4-FPP 
Serotonin(±) 
Mood regulation, sleep, sexual desire, appetite 
Suppressed appetite, euphoria, 
arousal 
Hallucinogens 
Substances that cause 
distortions in perceptions of 
reality 
MDMA 
LSD 
Ketamine 
Communication in the neural system is 
disrupted on various neurotransmitters that 
affect any of the body functions, e.g. sensory 
perception, sleep, hunger and muscle control 
Distortion of the senses often with 
visual images, disorientation, 
intense mood swings 
Depressants 
Substances that slow down 
brain activity, anxiety, 
memory, anesthesia 
Benzodiazepines e.g. diazepam 
Barbiturates 
Opiods e.g. morphine 
Gamma-aminobutyric acid (GABA), (-) 
Brain neural activity is slowed down 
 
Relaxation, drowsiness, lethargy, 
pain relief, sedative effects 
[1]
 Drugs that are part of/or impact on this research. 
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Amphetamines are mainly dopaminergic and are sympathomimetic; in addition they also 
potentiate the release of small amounts of norepinephrine and serotonin. Dopamine acts to 
regulate the body’s reward pathways, cognition, movement, attention, memory (Brick and 
Erickson, 2013). An increase in dopamine is often associated with intense feelings of 
pleasure (Barceloux, 2012; Gee and Schep, 2013). Amphetamine is less potent than 
methamphetamine, but in uncontrolled situations the effects are almost indistinguishable 
(Barceloux, 2012; Brick and Erickson, 2013; Elliot, 2011). The reason why amphetamines 
are sympathomimetic is shown in Figure 1.13.  
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Figure 1.13 Structures of selected neurotransmitters comparative to some of the 
psychoactive drugs to determine similaties in structure to a neurotransmitter resulting in 
sympathomimetic traits (adapted from Gee et al., 2005; Barceloux, 2012). 
 
It can be seen from the structures in Figure 1.13 that amphetamines, e.g. amphetamine, 
methamphetamine and MDMA contain in their structure the phenylethanamine moiety, 
which is present in catecholamines such as dopamine, epinephrine and noradrenaline. 
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Hence, they are structurally similar. However, cocaine acts in a different manner; it inhibits 
the re-uptake of dopamine. The mechanism of inhibition was shown Figure 1.12). This 
leads to an increase in dopamine. Since the dopamine remains in the synapse, it continues 
to exert its effect. The difference in its action in comparison with amphetamines may be 
due to the difference in structural similarity in comparison to the neurotransmitters 
mentioned above. Whilst cocaine does not contain the phenyethanamine moiety, it contains 
the benzyl group which is also present in these neurotransmitters. Consequently, these 
drugs are mainly dopanergic, they mimic the actions of nervous system that runs on the 
neurotransmitter epinephrine (Gee et al., 2005; Staack and Maurer 2005; Arbo et al., 2012) 
and the drug users experience the effects they seek (Table 1.7), e.g. increased alertness. 
 
In comparison, piperazines are predominantly serotoninergic agonists (Elliot, 2011; Staack 
and Maurer, 2005; Gee and Schep, 2013). The use of piperazines as recreational drugs 
arises from their chemical properties as 1-arylpiperazines which give them the ability to 
bind to serotonin receptors in the human nervous system (Staack et al, 2003; Kenyon et al., 
2010; Yeap et al., 2010; Gee and Schep, 2013). Serotonin (5-hydroxytryptamine) is also 
known as 5-HT. It has both inhibitory and excitatory (±) effects. Agonistic psychoactive 
substances such as piperazines and tryptamines potentiate the release of serotonin as per the 
mechanism described in Fig 1.12. The effects of the increase in serotonin (Table 1.7) are a 
distortion of the senses, arousal, disorientation, suppressed appetite, euphoria (Arbo et al., 
2012; Barceloux, 2012). Piperazines to a slighter extent also increase dopamine thereby 
creating stimulating feelings of euphoria, alertness and social activeness. These properties 
give piperazines status as party pills (Yeap et al., 2010). However, they exhibit less potent 
properties than amphetamine (Elliot, 2011).   
 
Animal studies have demonstrated that BZP unlike most piperazines is mainly 
sympathomimetic and dopaminergic. It stimulates the release and inhibits the reuptake of 
dopamine.  However, to a lesser extent it also potentiates the release of serotonin and 
noradrenaline (Staack and Maurer, 2005; Elliot, 2011). BZP has 10% the potency of 
amphetamine. Active doses of BZP are 50 - 100mg (Nikolova and Danchev, 2008). Higher 
doses of BZP were found to increase pulse rate, blood pressure (systolic and diastolic) and 
pupillary dilation (Elliot, 2011; Arbo et al., 2012; Gee and Schep, 2013).  
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3-TFMPP it is a non-selective agonist at the 5-HT2A, 5-HT1B, and 5- HT2C serotonin 
receptors in the brain (Elliot and Smith, 2008). Consequently, it potentiates an increase in 
serotonin levels. On its own it produces mild hallucinogenic and stimulus effects (Vorce et 
al., 2008, Staak, 2007, Barceloux, 2012). It has no dopaminergic effects and this might be 
the reason it exerts milder psychoactive effects when compared to BZP and amphetamines. 
 
The psychoactive effects of 4-FPP are derived from its ability to raise serotonin and 
dopamine levels.  In vitro studies (Nikolova and Danchev, 2008) have indicated that 4-FPP 
acts mainly as a 5-HT1A serotonin receptor agonist. In addition, it also inhibits the reuptake 
of serotonin and norepinephrine. As a drug of abuse it produces very mild psychoactive 
effects. It is slightly stimulating, producing mildly hallucinogenic and euphoric effects. 
This may explain why it is commonly used in combination with other drugs, such as 
‘ecstasy’.  The active 4-FPP doses are between 20mg - 150mg, higher doses cause a range 
of side effects including migraine headaches, muscle aches, anxiety, nausea and vomiting 
(Nikolova and Danchev, 2008, Elliot and Smith, 2008). 
 
Caffeine an adulterant exerts sympathomimetic effects, however unlike amphetamines or 
piperazines it acts by antagonizing adenosine phosphate receptors in the brain, and may 
also inhibit the enzyme that breaks down cyclic Adenosine monophosphate (cAMP), 
consequently increasing cAMP and thereby phosphorylation of proteins and subsequent 
membrane activity of the neuron. Caffeine increases energy metabolism through the brain, 
hence the perceived alertness with caffeine use. However, it also decreases cerebral blood 
flow inducing brain hypo-perfusion, which may result in its analgesic effects. Nicotine 
stimulates 2 subtypes of the receptor for the neurotransmitter acetylcholine (Seymour et al., 
2011; Barceloux, 2012; Brick and Erickson, 2013). 
 
The effects of 3-CPP and MDMA are somewhat comparable, but unlike MDMA and BZP, 
3-CPP has little effect on the dopaminergic system (EMCDDA, 2009). It can therefore be 
suggested that the ability of BZP to raise dopamine unlike the phenylpiperazines 3-TFMPP 
and 4-FPP is linked to its structural similarity to phenylethylamine (Figure 1.13), a 
structural moiety found in dopamine as is the case with amphetamines and cocaine. It can 
be seen in Figure 1.13 that BZP like cocaine contains the benzyl group which is absent in 
phenypiperazines. The benzyl group is present in the neurotransmitters  dopamine, 
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serotonin and noradrenaline. It is therefore suggested that this structural similarity results in 
its dopaminergic properties. 
 
It has been discussed that clandestine drugs are commonly found in combination in street 
samples as is the case with 4-FPP and 3-TFMPP (Section 1.2.2 above). As such, there is 
possibility of pharmacological drug-drug interactions. Drug-drug interactions can be 
(Elliot, 2011; Arbo et al., 2012; Dargan and Wood, 2013) a) Additive- the drug 
combination exhibits an effect equal to the sum effect of each drug, b) Synergistic 
(potentiation) - drug combination exhibits an effect greater to the sum effect of each drug. 
For example, the combination of BZP and 3-TFMPP is synergistic, giving it its enhanced 
effects not felt with either drug individually. Hence, the combination is perceived to mimic 
the psychoactive effects of ‘ecstasy’. This is due to the fact that BZP is dopaminergic 
whereas 3-TFMPP is mainly serotonergic, therefore in combination there is an increase in 
serotonin and dopamine levels. According to Vorce et al., (2008), clandestine laboratories 
have exploited this synergy in such a way that both 3-TFMPP and 4-FPP are now 
commonly encountered in illicit drugs combined with other psychoactive substances such 
as BZP or cocaine, and c) antagonistic- drug combination exhibits an effect less than the 
sum effect or individual effect of each drug; one drug competitively blocks another by 
occupying the receptors. 
 
1.5.3 METABOLISM OF PIPERAZINE DRUGS OF ABUSE 
 
Metabolism of piperazines is by cytochrome P450 (CYP) and its isoenzymes which results 
in glucuronidation and/or sulfation (Elliot, 2011, Barceloux, 2012). The metabolism of 3-
TFMPP was studied by Staack, et al. (2003) and showed that TFMPP was extensively 
metabolized mostly by CYP2D6 and to a minor extent by the isoenzymes CYP1A2 and 
CYP3A4 (Figure 1.14). This is through hydroxylation of the aromatic ring and degradation 
of the piperazine moiety to mostly the metabolites N-(hydroxy-3-
trifluoromethylphenyl)ethylenediamine (IV), N-(3-trifluoromethylphenyl)ethylenediamine 
(III), 3-trifluoromethylaniline (V), and hydroxy-3-trifluoromethylaniline (VI). Similar 
studies on BZP (Arbo et al., 2012; Staack et al., 2003) identified that BZP was metabolised 
by cytochrome P450 and subsequent catechol-O-methyltransferase catalysed methylation to 
N-4-hydroxy-3-methoxy-BZP. Subsequent degradation follows to produce the metabolites 
4-hydroxy-BZP, 3-hydroxy-BZP, piperazine, benzylamine and N-benzylethylenediamine 
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occurs. Comparatively 3-TFMPP is almost exclusively metabolised prior to renal excretion 
(98 – 99%), whilst BZP is excreted mostly un-metabolised. This may have an effect on the 
toxicity of the drug metabolites and also on analytical investigation, since the detection of 
3-TFMPP in subjects is conducted by testing for its metabolites whereas for BZP this is 
conducted through the BZP molecule itself (Elliot, 2011; Gee and Schep, 2013). The 
metabolism of phenylpiperazines is shown in Figure 1.14 for 3-TFMPP as an exemplar 
(Staack and Maurer, 2003; and Barceloux, 2012). The metabolism of 4-FPP has not yet 
been reported. It is therefore proposed that 4-FPP is similarly metabolised to TFMPP since 
studies on BZP and 3-TFMPP (Staack et al., 2003; Staack and Maurer, 2005; Arbo et al., 
2012; Barceloux, 2012) have shown similar routes of metabolism. Furthermore effects of 
the drug whilst mild were similar (section 1.5.2). 
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Figure 1.14 Metabolism of 3-TFMPP (Adapted from Staack and Maurer (2005) and 
Barceloux (2012). 
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1.5.4 EFFECT OF FLUORINATION ON PHARMACOLOGICAL ACTIVITY 
 
The presence of fluorine in a compound alters the binding affinity to receptors and the 
metabolism of the compound. Fluorine has been shown to improve target receptor 
selectivity and or binding properties, metabolic stability, body distribution and excretion of 
phenethylamines (Trachsel, 2012). According to Filler and Saha (2009) fluorine has the 
advantage that it increases lipid solubility, thereby enhancing rates of absorption and 
transport of drugs in vivo. In addition the C-F bonds are stronger than C-H bonds which 
imparts stronger oxidative and thermal stability. It has been reported by Schifano et al. 
(2015) that fluorination of synthetic cannabimimetic compounds may increase the 
lipophilicity of the compound, which enhances their absorption through biological 
membranes/blood brain barrier. This is due to the strongly negative inductive effects of 
fluorine which influences their acidity/basicity. Fluorine substitution increases the acidity 
of drugs which are organic acids and decreases those which are basic such as amines 
including amphetamines and piperazines (Jones 1982, Park et al., 2001). However this is 
also affected by other substituents on the compound. 3-TFMPP unlike 4-FPP contains a 
trifluoromethyl group, which decreases its basicity due to the electron withdrawing 
properties of the methyl group. This affects their binding affinities to the 5-HT2A receptors. 
This could be the reason why 3-TFMPP has stronger psychoactive effects than 4-FPP. 
Trachsel (2012) reported that studies showed indications that 5HT2A receptor affinities 
might be enhanced by the introduction of the methyl group. Furthermore, Filler and Saha 
(2009) reported that the trifluoromethyl group is more lipophilic than the methyl or chloro 
group and this significantly increased its pharmacological activity 
 
1.5.5 ADVERSE EFFECTS OF PIPERAZINE DRUGS OF ABUSE 
 
Adverse effects of drugs of abuse drugs as amphetamines and BZP is a topic that has been 
studied by many researchers (Elliot, 2011; Gee and Schep, 2013; Staack, 2007; Staack and 
Maurer, 2005; Yeap et al., 2010). However, studies pertaining to 3-TFMPP and 4-FPP are 
limited, as these are relatively new psychoactive substances. Furthermore, according to 
Arbo et al. (2012) although in the market piperazine designer drugs have the reputation of 
being safe, several experimental and epidemiological studies indicate risks for humans. 
Adverse reactions to piperazines include vomiting, headache, palpitations, anxiety, 
insomnia, confusion, irritability and tremors (Davies et al., 2010; Yeap et al., 2010; Elliot, 
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2011). They exhibit effects typical of a serotonin syndrome; anxiety, dizziness, confusion, 
shivering, sensitivity to light and noise, fear of losing control, migraine and panic attacks. 
Amphetamine leads to insomnia, users may feel irritable, restless, anxious, depressed and 
lethargic. It has been reported that chronic use of amphetamines may cause such adverse 
toxic effects as psychosis and schizophrenia (Brick and Erickson, 2013). Since piperazines 
have similar pharmacological activity to amphetamines it can be assumed similar chronic 
adverse effects are also realised with their prolonged use.  
 
‘Drug-drug’ interactions (section 1.5.3) can generate adverse effects. The BZP/TFMPP 
combination has been reported to cause a range of side effects including dehydration, 
seizures, jaw-clench, mild to severe nausea, vomiting, toxic psychosis (panic and extreme 
paranoia), high blood pressure, persistent headache, flu-like symptoms, stiff neck, post-trip 
exhaustion, impotence, anxiety, migraine muscle aches, as well as a come-down syndrome’ 
(Nikolova and Danchev, 2008; Elliot, 2011). Adulterants such as caffeine and nicotinamide 
may also cause adverse effects. It has been reported that caffeine causes nervousness, 
diuresis, and insomnia among others. Nicotine results in craving, drowsiness, bad dreams, 
headaches, depression, increased appetite among others (Seymour et al., 2011; Barceloux, 
2012; Brick and Erickson, 2013). Davies et al., (2012) in their study based on the risks 
associated with caffeine in “illegal highs” found there was a risk of significant caffeine 
toxicity related to the high caffeine content of some novel psychoactive substances. The 
authors reported caffeine content in street samples of up to 940mg per tablet. Furthermore, 
it was indicated that doses >200mg can lead to adverse effects such as anxiety and 
agitation. 
 
However, these drugs are marketed as alternatives to MDMA and LSD and are 
misleadingly considered safe, being described as ‘drug harm minimisation solution’ (Yeap 
et al., 2010; Davies et al., 2010). Contrary to this, there have been a reports of deaths where 
have piperazines been implicated in Europe (Elliott and Smith, 2008; EMCDDA, 2009); 
Elliott, 2011). 
 
1.6 LEGISLATIVE CONTROL OF 3-TFMPP AND 4-FPP 
 
Drugs listed under the UN Convention are subject to global controls whilst those not listed 
under any international legislation can be subject to the national controls existing in 
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different countries. These results in different classification and legislative control of drugs, 
hence a drug might be illegal in one country whilst legal in another and as such can be 
easily sourced from these countries. This therefore can have a negative effect on controlling 
the substances. 
 
Currently, there are no international controls for any piperazine based drugs of abuse. None 
of the piperazines are listed in the United Nations 1971 Convention on Psychotropic 
Substances (DEA, 2011; Coulson and Caulkins, 2012; UNODC, 2013a). However, several 
(BZP, TFMPP, 3-CPP, MDBP) were pre-reviewed by the WHO Expert Committee on 
Drug Dependence in 2012 (UNODC, 2013a). This might in the future lead to stricter 
controls internationally.  
 
Not all countries currently control piperazine based drugs. This is potentially a contributing 
factor to the popularity and widespread use of these drugs.  As a result of the increasing 
trend in the use of piperazine drugs, risk assessments were conducted, for example in the 
EU by the EMCDDA in 2008; as a consequence piperazines came under EU-wide control 
after 2008 (UNODC, 2013). BZP is now controlled in the European Union and several 
other countries such as New Zealand and Japan. In New Zealand as of October 2008; BZP, 
TFMPP, 4-FPP, MBZP MeOPP are all Class C controlled drugs (King, 2009; Arbo et al., 
2012). Control of 4-FPP and 3-TFMPP is not widespread (Nikolova and Danchev, 2008; 
ECDD, 2012). However, in most EU countries, 3-TFMPP is controlled including Belgium, 
Denmark (December 2005), Greece, Estonia, Italy, Lithuania, Malta and Sweden (March 
2006). Outside of the EU 3-TFMPP is controlled in Japan (October 2003), Bulgaria, 
Australia and (Nikolova and Danchev, 2008; ACMD, 2011; Coulson and Caulkins, 2012; 
ECDD, 2012; UNODC, 2013a). Legal controls on 4-FPP are even less prevalent than for 3-
TFMPP. 
 
With reference to the UK, in December 2009 piperazines drugs became listed under the 
Misuse of Drugs Act 1971 (Amendment) Order 2009 (Acts of Parliament, 2009; 
EMCDDA, 2013a); BZP and the all other psychoactive piperazine derivatives were listed 
in Part 3 of the Schedule as Class C drugs (Acts of Parliament, 2009; King 2009; ACMD 
2011). In the UK, controlled substances are listed in Schedule 2 of the Misuse of Drugs Act 
and are categorised into three classes according to the severity of perceived potential health 
risks to humans due to the use of the drug. The drugs in class A are those that are high risk, 
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such as cocaine and heroine and class C contains the low risk group. The scheduling of 
NPS in the UK is shown in Table 1.8. 
 
Table 1.8 UK controls of new psychoactive substances, NPS (Acts of Parliament, 2009; 
Dargan and Wood, 2013). 
Substance Year controlled Class 
Cannabinoid agonists 2009 B 
Cannabinols  1971 B 
Cathinones  2010 B 
Fentanyls  1986 A 
Phenethylamines  1977 A 
Phenyl and benzylpiperazine  2009 C 
Tryptamines  1977 A 
 
It can be seen that all piperazine based drugs of abuse are in class C; this includes BZP, 3-
TFMPP and 4-FPP.  However, amphetamines are in class B (Acts of Parliament, 2009; 
ACMD, 2011). It was highlighted in section 1.5 that the whole purpose of manufacture of 
piperazine based drugs is that they mimic the psychoactive effects of amphetamine type 
drugs. In addition, drugs such as 3-TFMPP and 4-FPP are not used alone but in 
combination with other drugs. As such, the following implications can be drawn; the lack 
of more comprehensive controls imparts the sense that the drugs are harmless (Davies et 
al., 2010; Yeap et al., 2010). Furthermore, scheduling piperazine based drugs in lower class 
than amphetamines gives the sense that these are safer than MDMA and other 
amphetamines. This gives the potential for a growth in use and clandestine synthesis of 
piperazine drugs, especially in view of the increasing market for NPS (section 14) and the 
fact that the precursors and chemicals (section 1.7) used in the manufacture of these drugs 
are not controlled. Precursors for the synthesis of amphetamine; 1-phenyl-2-propanone, 
norephedrine and norpseudoephedrine  are controlled, listed in Table I of the United 
Nations 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances (UNODC, 2013). The corresponding EU legislation is set out in Council 
Regulation (EEC) No 3677/90 (as later amended), which governs trade between the EU and 
developing countries. This could have been a major contributing factor in the decrease of 
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phenethylamines on the illicit market. Such controls can also have a similar impact in 
curbing abuse of piperazines if instigated. 
 
The selling, marketing and easy availability of piperazines and other new psychoactive 
substances such as cathinones and tryptamines openly on the internet, is a challenge to 
legislation, as these substances can be sourced from off-shore sources were they might be 
legally available. They may also be purchased from non-UK internet sites and then 
supplied from overseas, both EU and non EU (ACMD, 2011). The likely reason for the 
lack of more comprehensive controls on piperazines globally is because they are relatively 
new substances on the market (section 1.3). As such, there is lack of adequate information 
pertaining to their analytical properties including their safety. This can be seen by the case 
of 3-TFMPP in the USA where it was scheduled in 2002 and then later unscheduled in 
2004 due to inadequate foreseen risk to users, such that it is currently uncontrolled in the 
USA (Coulson and Caulkins, 2012). 
 
1.7 SYNTHESIS OF 4-FPP AND 3-TFMPP DRUGS OF ABUSE 
 
It is discussed in sections 1.1 and 1.8.3 that information on routes of synthesis, precursors 
and impurities can provide an insight into links between illicit drug samples. This has been 
identified as pertinent to characterisation of street drugs (UN, 2001). Since this research 
will characterise street samples, it is therefore imperative to identify potentially viable 
routes for clandestine synthesis of phenylpiperazine drugs of abuse using 4-FPP and 3-
TFMPP as their representatives. Sources of literature on clandestine methods of synthesis 
were found to be both scientific (peer reviewed literature) and the informal (the internet 
websites not peer reviewed). According to the UNODC (2013c) and EMCDDA (2009) no 
clandestine synthesis of piperazines has been reported. A review of literature on piperazines 
confirmed this observation. However, according to ACMD (2011) chemists responsible for 
the development of new illicit drugs have a sophisticated knowledge of the 
chemical/pharmacological scientific literature. As such both the scientific and informal 
literature were reviewed as potential sources of methods for the illicit manufacture of 4-
FPP and 3-TFMPP.  
 
Early studies (Baltzly et al., 1944) on synthesis of piperazines concentrated on BZP and its 
derivatives. The study detailed the preparation of mono-substitued piperazines in moderate 
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yields by reaction of piperazine with acylating or alkylating agents and has become a 
foundation for current research on other piperazines such as that published by Cymerman 
and Young (1962) on the synthesis of BZP from piperazine and benzoyl chloride. In 
addition, some of the routes of clandestine synthesis of piperazines were found to be similar 
to those of Baltzly et al., (1944). For example, the EMCDDA (2009) and UNODC (2013c) 
reported that clandestine synthesis of BZP involved the reaction of piperazine 
monohydrochloride with benzyl chloride. In addition, the reaction also formed another 
psychoactive substance 1,4-dibenzylpiperazine (DBZP) as a side-product. The precursors 
were readily available, or could be easily manufactured from commercially available 
chemicals. In the same reports another piperazine, 3-CPP is also stated as being 
manufactured from piperazine with m-dichlorobenzene. These routes of synthesis can be 
extrapolated for the synthesis of other benzyl and phenylpiperazine drugs. 
 
Several studies have been reported on the synthesis of phenylpiperazines, the focus of 
which was on synthesis of the drugs as pharmaceutical intermediates (Pollard and Wicker, 
1954; Kiritsy et al., 1978; Mishani et al., 1996; Liu and Robichaud, 2005). These methods 
mainly included acylation, alkylation, and cyclisation and were found to vary both in the 
complexity of reaction methods and reagents used. Common precursors were identified as 
piperazine, anilines, benzene and haloamines (Figures 1.15 – 1.17). It is worth noting that 
of the few published scientific methods for the preparation of 3-TFMPP and 4-FPP, most of 
these were for 3-TFMPP (Kiritsy et al.; 1978; Liu and Robichaud; 2005; Mishani et al., 
1996). Taking into consideration the complexity of these methods, availability and cost of 
the precursors it can be deduced that it is most likely some of these methods of synthesis 
can be extrapolated for clandestine synthesis. Below is a further review of these methods.  
 Mishani et al., (1996) described the synthesis of the phenylpiperazine ring by the reaction 
of aniline derivatives with (2-bromoethyl)-N-(alkyl) amine on an aluminium solid support. 
The reaction is shown in Figure 1.15.  
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NH2 N
CH2CHBr
CH2CHBr
R'+
R
N N R'
R
solid support
40min. 150oC
for 3-TFMPP: R = CF3, R' = H
I = a fluoroaniline compound
II  = 2-bromoethyl)-N-(alkyl)amine
phenylpiperazine derivativeI
II
+ 2HBr
 Figure 1.15 Scheme for the synthesis of 1-(3- trifluoromethylphenyl)piperazine (Mishani 
et al., 1996). 
 
The method is described as rapid and the yield high. The authors stated 80% yield of 3-
TFMPP. Whilst the reaction scheme is shown for 3-TFMPP the authors reported that the 
route of synthesis can be used for any phenylpiperazines. As such, it can be used to 
manufacture other psychoactive drugs such as 3-CPP, 4-MePP and 4-FPP by changing the 
substituent on the aniline (I) in Figure 1.15. 
 
A study by Kiritsy et al. (1978) prepared 3-TFMPP as intermediates during the synthesis of 
pharmaceutical substances using piperazine and a benzene derivative, with comparable 
yields. The authors stated a yield of 81.2% of 3-TFMPP. The same authors also 
investigated the synthesis of 4-FPP from fluoroaniline and bis-2-chloroethylamine. 
However, this method gave low yields and was reported to yield 30% 4-FPP. The reactions 
are shown in Figure 1.16a and 1.17b for 3-TFMPP and 4-FPP respectively. 
 
N
H
N
H
+
Br
CF 3
NHN
F3C
BrH+
II
1-(3-trifluoromethylphenyl)piperazine
I
I = piperazine
II = 3-bromo-1-(trifluoromethyl)benzene
100 oC, 45h, oil bath
  
Figure 1.16a: Scheme for the syntheses of 1-(3-trifluoromethylphenyl)piperazine (Kiritsy et 
al., 1978; Shaman Australis Botanic 2003). 
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I = 4-fluoroaniline
II  = Bis(2-chloroethy)lamine
+
II
I
NH
Cl Cl
base/Na2CO3
100oC, 45h, oil bath
F
NH2
F NHN
1-(4-fluorophenyl)piperazine
+ 2HCl
 
 Figure 1.16b: Scheme for the syntheses of 1-(4-fluorophenyl)piperazine (Kiritsy et al., 
1978; Shaman Australis Botanic, 2003; ECDD, 2012). 
 
In 2005, a general method for the synthesis of N-aryl piperazines from anilines was 
developed by Liu and Robichaud (2005); the reaction is shown in Figure 1.17a and 1.17b 
for 4-FPP and 3-TFMPP respectively below. According to the authors the method gave 
yields of 87% 4-FPP and 67% for 3-TFMPP. 
 
NH
Cl Cl
F
NH2
I
II
NHNFdiethyl glycol monomethyl ether+
1-(4-fluorophenyl)piperazine
+ 2HClI = 4-Fluoroaniline
II = Bis(2-chloroethyl)amine
 
Figure 1.17a: Scheme for the synthesis of 1-(4-fluorophenyl)piperazine piperazine (Liu and 
Robichaud, 2005; EMCDDA, 2009). 
 
NH
Cl Cl
NH2
CF3
NHN
F3C
+ diethyl glycol monomethyl ether
III = 3-trifluoromethylaniline
1-(3-trifluoromethylphenyl)piperazineIII II
+ 2HCl
 
Figure1.17b: Scheme for the synthesis of 1-(3- trifluoromethylphenyl) piperazine (Liu and 
Robichaud, 2005; EMCDDA, 2009). 
 
Comparison of the methods reveals that the studies by Kiritsy et al. (1978) and Liu and 
Robichaud (2005) give high yields. The methodology is relatively easier and cheaper 
compared to that of Mishani et al., (1996) which requires a solid support.  As such, these 
are the most likely methods to be used in clandestine synthesis of these drugs. However, the 
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route of synthesis for 4-FPP by Kiritsy et al. (1978), Figure 1.16b is unlikely to be of use 
due to the low yields (30%) generated. The highest yield encountered by any of the 
methods was 81.2%. This implies that impurities are present in the final product. These 
could be residual precursors and by-products. Consequently, if no further purification of the 
product is conducted it implies that the drug on the street will have impurities in it. This 
could have health implications and as such it is important that these are identified and be of 
use in characterising and profling street drugs. 
 
This review on synthesis also highlights the prevalence of informal sources of literature 
(encountered on the internet) on manufacture of these drugs such as Erowid, Shaman 
Australis and many other drug forums/chartrooms. According to these sources, the drugs 
can be manufactured through several routes; a) the reaction between diethanolamine with 
3-chloroaniline b) the reaction between 3-chloroaniline with bis(2-chloroethyl)amine c) the 
reaction between piperazine with 3-dichlorobenzene (EMCDDA, 2009). According to 
Shaman Australis (2003) all known psychoactive piperazines can generally be derived from 
piperazine and benzyl chloride or a substituted form of benzyl chloride. The precursors 
were identified to be the same as those in the methods published by Kiritsy et al. (1978) 
and Liu and Robichaud (2005), as was highlighted in Figures 1.17a and 1.18 respectively. 
 
The methods of synthesis reported by the EMCDDA (2009) and UNODC (2013c) are a 
distinct possibility in illicit laboratory synthesis, as the materials are easily available and 
the methods are not complex. The EMCDDA further suggests that currently there have 
been no reports of clandestine synthesis of 3-TFMPP and 4-FPP, as currently these drugs 
are available from commercial sources such as chemical suppliers (ECDD, 2012). It was 
found that whilst the UNODC acknowledges that the routes of synthesis are simple and 
product yields high. It shares the same view as the EMCDDA as according to the UNODC 
it is unlikely BZP, 3-CPP or 3-TFMPP found in illicit products have been synthesised 
clandestinely. However, this approach fails to acknowledge the significance of the internet, 
where methods for the preparation are freely available. Furthermore, the impacts of the 
recent regulations controlling these drugs may drive the distributors and users into 
clandestine manufacture. This view is supported by Haroz and Greenberg (2006), who in 
their study state that, ‘‘information accessibility through the internet has facilitated 
accessibility, synthesis and production of substances by individuals’’. In addition, most of 
the designer drugs on the market exist because of synthetic approaches published in the 
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open scientific and medical literature and the exploitation of this research by clandestine 
manufacture of drugs for illicit purposes is drawn (King and Kicman, 2011).  
 
The ECDD (2012) reported a single existence of clandestine laboratory for the manufacture 
of 3-TFMPP. However, no details were available as to the origin of this claim, precursors 
or route of synthesis. The ECDD further indicates that whilst specific information is not 
available, chemical synthesis is likely to involve piperazine. This was found to be similar to 
BZP synthesis (Cymerman and Young, 1962). In addition it indicated that TFMPP is 
available from retail chemical suppliers (ECDD, 2012). Consequently, if the method does 
use the precursors stated then it is similar to that of Kiritsy et al. (1978) (Figure 1.16a). 
 
As such the methods by Kiritsy et al. (1978) (Figure 1.16a) and Liu and Robichaud (2005) 
(Figure 1.17a, b) were identified as potential routes of illicit synthesis. Hence these 
methods were adapted for use in this research.  
 
1.8 REVIEW OF ANALYSIS METHODS AND TECHNIQUES  
 
The analysis drug of abuse is carried out for the purpose of identification, quantitation, 
characterisation and impurity profiling. However in all the cases specific identification of 
the drug is paramount before further testing such as quantification can be carried out. A 
variety of benzylpiperazines and phenylpiperazines have been reported in street samples 
(King, 2009). In addition, isomers may also exist for example the (2, 3, 4) positional 
isomers of CPP, FPP and TFMPP (Takahashi, 2009; UNODC, 2013a; Gee and Schep, 
2013).  This results in a complex sample matrix and this poses a challenge to the 
identification and accurate quantification of these substances. As such, there is need for the 
method of analysis employed to be highly specific so as to selectively analyse for the target 
compound.  
 
Currently, there exists a variety of methods, techniques and tests for the analysis of drugs of 
abuse.  However, studies pertaining to the analysis of 3-TFMPP and 4-FPP are currently 
limited. This is likely to be due to the substances being relatively new on the market as 
previously discussed (section 1.3). Most of the analytical methods published were found to 
be on screening, detection and quantitation of piperazines, based on metabolic and 
toxicological studies of urine and blood samples and not on the drug in its original form 
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(Staack et al., 2003; Elliot and Smith, 2008; Vorce et al., 2008; Elliot, 2011). This further 
implies the need to develop methods not for biological samples but for the analysis of the 
drug as is in street samples. 
 
1.8.1  IDENTIFICATION METHODS 
 
The process of chemical identification often involves the application of two categories of 
qualitative techniques, i.e., preliminary screening tests and confirmatory tests. American 
systems apply two or more independent tests depending on the test used, i.e., use of only 
one confirmatory test would require one or more less conclusive techniques (DEA, 2011). 
Given the diversity of drugs and methods screening tests provide a means of narrowing the 
scope and focusing the direction of the analysis. Hence, further confirmatory tests for the 
unknown substance are more easily identified. According to the UNODC (2013c) a 
screening test is defined as a preliminary test which is used to indicate or eliminate a class 
or group of drugs. For this reason screening tests have become common in routine analysis 
of unknown drugs (Baker and Phillips, 1983; UN, 1994) and have been applied to 
piperazines (Takahashi, 2009; UNODC, 2013b). They entail a) physical tests such as 
appearance, melting and boiling point, b) colour tests and c) thin layer chromatography 
(TLC).  
 
1.8.1.1 Presumptive tests 
Colour tests are used as part of presumptive tests for drugs to distinguish between different 
chemical classes of compounds. They have good sensitivity, with limits of detection in the 
range 1 – 50µg (Takahashi et al., 2009; O’Neal et al., 2010). As such, they provide a guide 
to the identity of a drug. Consequently, these tests will be sensitive enough for use in this 
study as the analytes have been identified to exist in relatively high doses (mg/tablet range) 
in the street samples (Davies et al., 2010; Kenyon et al., 2010).  However, they cannot 
specifically confirm the identity of a particular substance and as such are used in 
conjunction with more confirmatory tests such as Gas chromatograph (GC) or Fourier 
Transform Infrared Spectrometry (FTIR) techniques (section 1.8.1.2).  
 
Even though presumptive analysis is common in analysis of drugs of abuse, it was found 
that studies involving presumptive analysis of piperazines are very few. Of the studies 
found the tests applied were the Marquis, Simon’s reagent and Dragendorff tests. Inoue et 
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al., (2004) in their study applied the Marquis, Simon’s reagent and Dragendorff tests for the 
identification of piperazines. This study set the ground work for presumptive analysis of 
piperazines. It is likely the basis of the presumptive tests recommended by UNODC 
(2013c) for the analysis of piperazine drugs. In the study these tests were able to 
discriminate between amphetamines and piperazines. The UNODC recommends the use of 
Marquis, Simon’s reagent and Dragendorff tests for piperazines. Philip et al., (2013) 
developed a novel presumptive test for piperazines using sodium 1,2-napthoquinone-4-
sulphonate (NQS).  The authors reported that the test can distinguish BZP from its 
analogues and piperazines from most of the analytes tested including amphetamines. This 
gives it an advantage comparative to the other tests. Currently there is no presumptive test 
specific to piperazines and none so highly selective for BZP. However, since the test is 
novel it has not yet had wide application. The concepts and reactions behind the 
presumptive tests that will be applied in this research will be further discussed in the 
chapter for theoretical concepts (Chapter 2 section 2.8.2). 
 
 In contrast to piperazines, preliminary screening of MDMA, other amphetamine drugs and 
cocaine has been more extensive (Cole, 2003; Baker and Phillips, 1983; Dargan and Wood, 
2013). Consequently, since these substances will potentially be present with 4-FPP and 3-
TFMPP the screening tests for amphetamines will thus provide useful comparative data and 
methods for this research.  
 
1.8.1.2 Identification confirmatory tests 
Further confirmatory identification made use of more selective techniques. The techniques 
routinely used were identified as TLC or instrumental techniques such as infra-red 
spectrometry (IR), Ultraviolet–Visible spectrometry (UV-Vis) and chromatographic 
methods, such as high performance liquid chromatography (HPLC) and gas 
chromatography (GC) (Baker and Phillips, 1983; de Boer et al., 2011; Dargan and Wood, 
2013; UNODC, 2013c). In addition, for chemical characterisation and impurity profiling 
where drugs may require synthesis it was found that structural elucidation and 
identification of unknown substances was mainly by infra-red spectrometric methods, FTIR 
and also nuclear magnetic resonance spectroscopy (UN, 2001; Aalberg et al., 2005a; Bartos 
and Gorog, 2008; Inoue et al., 2008). This is due to the techniques providing more highly 
specific structural data. However, for routine analysis tandem methods with mass 
spectrometry (MS) were common such as liquid chromatography-mass spectrometry (LC-
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MS and GC-MS) (Anderson et al., 2007a; Lecompte et al., 2008; Takahashi et al., 2009; 
Schurenkamp, 2010). This can be attributed to the advantage of the mass spectral library. 
Arbo et al. (2012) in a review of piperazine compounds as drugs of abuse identified similar 
analytical approaches for the identification of these drugs. Consequently, in this study 
confirmatory identification will be by UV-Vis, FTIR and GC-MS.  
 
1.8.2 QUANTITATIVE METHODS 
 
In the analysis of drugs of abuse, quantitative analysis is almost exclusively instrumental. 
Common techniques were similar to those for identification, i.e., GC-MS, LC-MS and in 
addition capillary electrophoresis (Baker and Phillips, 1983; Vorce et al., 2008; Kelleher et 
al., 2011; UNODC, 2013c).  It has been discussed (section1.2.2) that 4-FPP, 3-TFMPP or 
other piperazine drugs are often found as a combination of drugs. In addition, impurities 
from synthesis are often present in street samples (UN, 2001; Bartos and Gorog, 2008). 
Hence, consideration is given to issues of selectivity and sensitivity. GC-MS is one such 
technique, as it has the required high selectivity and sensitivity (ng range) (Barwick, 1999; 
Khopkar, 2012). Furthermore, it has been successfully applied in other studies (de Boer et 
al., 2001; LTG, 2006; Maher et al., 2009; Takahashi et al, 2009; Kelleher et al., 2011). Of 
the instrumental techniques, GC and HPLC techniques have found wide application for the 
analysis of drugs of abuse and have been in use since 1970s. The applicability of these 
techniques can be seen by the UNODC recommended methods for the identification and 
analysis of piperazines in seized materials; TLC, GC-FID, GC-MS, GC-IRD, HPLC, 
capillary electrophoresis and FTIR (UNODC, 2013. The use of LC-MS as an alternative to 
GC-MS simplifies sample preparation and eliminates derivatization procedures and in 
addition can be applied to less volatile substances.  However, GC-MS has the advantage of 
a wider application (Bowers et al., 2002; Kronstrand and Jones, 2000) and it has been used 
more extensively for drugs of abuse as such provides more extensive referral material.  
 
Whilst the GC-MS technique has found a wide application in the analysis of drugs of abuse 
in the analysis of piperazine drugs, most of the studies have been on bioanalysis, such as 
toxicological studies not on analysis of street drugs (Staack, and Maurer, 2005; Elliot and 
Smith, 2008). Furthermore, shortcomings were identified in the methods reviewed for 
piperazines drugs and street samples. In a study by Inoue et al. (2004)  to determine BZP, 
MeOPP, TFMPP, FPP and their isomers, a variety of techniques were applied ; colour tests, 
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TLC, IR, GC-MS and LC-MS. However, a limitation of the methods was the inability to 
separate the FPP isomers. These limitations were also encountered in a similar study to 
create a psychoactive drugs database by Takahashi et al. (2009). Isomers possess similar 
chemical and physical properties, resulting in similar analytical profiles and making it 
difficult to distinguish between, for example their chromatographic and spectrometric 
behaviour. Consequently it is often difficult to distinguish between the isomers. In their, 
studies Elliott and Smith (2008) and Vorce et al. (2008) indicated that 3-TFMPP and 4-
TFMPP appear to have identical retention time and identical fragmentation spectra. The 
authors reported that they both exhibited similar principal ions (m/z 230 (M+), 188(100), 
122 and 56. As such, it was impossible to identify the specific isomer by GC/MS. They 
further reported that the resolution of these compounds was achieved by using LC-MS.  In 
these studies it was observed that the researchers highlighted the need for HPLC for the 
separation of isomers, consequently such techniques as LC-MS will likely be appropriate.  
 
Studies have been reported where isomers have been successfully separated, e.g. Maher et 
al. (2009) in a study on regiosomers of TFMPP successfully separated the isomers. 
However, the study whilst successful was qualitative and as such was not applied to street 
samples. A study by (UNOD, 2013c) developed three GC-MS methods for the analysis of 
materials containing piperazine drugs (BZP, MeOPP, FPP, TFMPP). The investigation was 
successful in separating the isomers. The methods by UNODC similarly to that of Maher et 
al. (2009) may face limitations when applied to actual street samples, as they do not take 
into account the congeners present in a street sample. In addition, for purposes of 
characterisation and profiling they may face a further challenge due to the solvent used. 
Whilst the results of drug stability studies with the solvent were not indicated, methanol can 
cause hydrolysis and esterification reactions (sections 2.7.2 and 2.7.3).  
 
Among the instrumental techniques reviewed, GC-MS was chosen for use in this study. 
This was mainly due to its sensitivity, selectivity and diverse application to the 
psychoactive drug investigation (de Boer et al., 2001; Anderson et al, 2007a; Elliot and 
Smith; 2008) and in addition availability. Furthermore, in forensic investigations 
identifying the exact isomer maybe critical and may have legal implications, e.g., it is the 
meta- isomer of TFMPP which is the controlled psychoactive substance in some countries 
such as the USA (Coulson and Caulkins, 2012). In addition, it is the 4-FPP and 3-TFMPP 
isomers that have been reported as pharmacologically active drugs of abuse (Staack, 2007; 
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DEA, 2011; Arbo et al., 2012; Dargan and Wood, 2013), hence it is necessary to identify 
the exact isomer. Consequently, for purposes of conclusive identification more than one 
identifying variable is applied, such as the use of retention indices and retention times in 
addition to the mass spectra and often more than one technique is considered. GC-MS has 
the advantage that it offers all three. It therefore follows that a GC-MS method will be 
developed to overcome the limitations highlighted by the discussions above. 
 
1.8.3 CHEMICAL CHARACTERISATION AND IMPURITY PROFILILNG OF STREET DRUGS 
CONTAINING 4-FPP AND 3-TFMPP 
 
In clandestine production of drugs the main processes are a)  synthesis of the active 
substance (or procurement from commercial sources), b) addition of cutting agents, 
adulterants, lubricants and binders c) mixing of the powders and d)  compression of this 
mixture into tablets using tableting machine with specific settings (UN, 2001; Milliet et al., 
2009). These processes define the physical and chemical characteristics of the finished drug 
and can therefore be used to check for links between samples. Identification of routes of 
synthesis and characterization/impurity profiling of seized drugs studies can provide an 
insight into diverse law enforcement investigative issues; ranging from dealer-user 
relationships, drug source, distribution networks, and trafficking routes to manufacturing 
methods. Drug profiling is made up of characterisation (physical and chemical) and 
impurity profiling (UN, 2001). 
 
Physical characterisation involves a visual inspection of the) physical properties such as 
whether it is a tablet, powder, its colour, dimensions, i.e., generally its appearance and b) 
packaging. Chemical characterisation is the process of establishing a characteristic 
chemical signature of major, minor and trace components of a drug (UN, 2001, Bartos and 
Gorog, 2008). This involves detailed chemical analysis to determine their identity and 
relative concentrations using an appropriate method. In addition, it aids in the identification 
of possible routes of their clandestine synthesis. All this gives a complex chemical profile 
of each drug sample. Comparison of chemical profiles of different drug substances can then 
be carried out. This can be used to establish a) whether or not there is a link between one or 
more drugs, b) links on relationships between, for example distribution networks and, c) 
methods of clandestine synthesis including chemicals used in the manufacture.  
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Impurity profiling is the determination of minor “trace” components in the sample. 
According to King (2009) and EMCDDA, (2013a) impurity profiling is defined as the 
characterisation of naturally occurring or synthetic by-products in a drug to form a 
‘fingerprint’ that maybe characteristic of its origin or manufacture. The aim of which is the 
detection, identification/structure elucidation and quantitative determination of organic and 
inorganic impurities as well as residual solvents (Bartos and Gorog 2008; Verweij, 1992). 
The knowledge of the impurity profile of drugs of abuse in forensic analysis is of great 
importance since the impurities can be characteristic of the synthetic route and starting 
material and hence the origin of the drug (UN, 2001). Verweij (1992) in their study on 
MDA and MDMA reported that it was an established fact that street samples of these 
substances were clandestinely synthesised. The author concluded that establishing the 
presence of contaminations derived from different origins in MDA or MDMA preparations 
can assist in establishing the route of synthesis adopted by the individuals illegally 
producing these amphetamines. As such, a direct comparison of the profiles can provide 
links between different samples seized and also conclusions as to the methods of synthesis 
used. This together with chemical characterisation provides a more holistic picture of the 
drug. This study carried out physical and chemical characterisation; hence the concepts 
behind these processes are further discussed in Chapter 2 (Theoretical concepts).  
 
No chemical characterisation and impurity profiling of 4-FPP and 3-TFMPP has been 
carried out to date. Hence, of studies on other drugs of abuse were reviewed so as to gain 
an insight into the process of characterisation and profiling. A study by Inoue et al. (2008) 
on characterisation and profiling of methamphetamine in seized drugs reviewed methods 
for characterisation and profiling. Both liquid-liquid extraction (LLE) and solid phase 
extraction (SPE) techniques utilising solid phase micro-extraction were found to be 
effective sample treatment techniques for the extraction and isolation of impurities. The 
methods of analysis involved mainly gas chromatography with a flame ionisation detector 
(GC/FID), GC/Thermal desorption, GC-MS and NMR.  Other studies showed a similar 
approach. Andersson et al. (2007b) similarly investigated sample preparation techniques as 
part of their studies on profiling amphetamines. The study concluded that LLE was better 
suited to the extraction of amphetamine impurities than SPE due to lack of information on 
the long-term impact of SPE columns on the stability of the analytes. In a related study 
Andersson et al. (2007a) developed optimised and validated GC-FID and GC-MS methods 
and in addition carried out comprehensive profiling of amphetamine drugs. A study by 
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Dayrit and Dumlao (2004) profiled impurities in seized methamphetamine samples by GC–
MS and GC/FID. These studies confirm the use of GC-MS for this study and that both LLE 
ans SPE can be employed during profiling. However, in this study consideration will be 
given to LLE due to the findings by Andersson et al. (2007b) stated above. Furthermore, 
these studies also highlight that impurities are present in street drugs. As such this confirms 
the fact that 4-FPP and 3-TFMPP drugs synthesised illicitly are most likely to have 
impurities.  
 
Kelleher et al. (2011) in a research for the National Advisory Committee on Drugs of 
Dublin analysed new psychoactive substances by GC-MS.  In the study, street samples 
containing suspected new psychoactive substances were analysed. The results showed that 
street samples do not necessarily contain the substances indicated on the label e.g. ‘E-XTC’ 
was labelled as “not for human consumption” but contained dicalcium phosphate, ketones 
and magnesium stearate and no TFMPP. This is likely for the purpose of circumventing 
legal controls. Also, a variety of drugs are present in street samples (Table 1.3). Baron et al. 
(2011) and the London toxicology group (LTG), (2006) reported similar findings. The LTG 
in their study on analytical profiles of piperazines analysed samples (26) consisting of 
capsules and tablets. These were found to contain mostly a combination of piperazine drugs 
with the most common being BZP and 3-TFMPP. The dosages were in line with the results 
of other researchers and were diverse. Reported dosages were 60 - 200 mg BZP, 4 - 72mg 
3-TFMPP. (The effective dose and physiological effects was in discussed section 1.5). 
Dosages were not stated for the other piperazines found present; 4-FPP, 3-CPP, MePP, 
MBZP and MeOPP. These findings confirm the discussion in section 1.2 where it was 
highlighted that a number of drugs were likely to be present in street samples containing 3-
FPP, 3-TFMPP or any piperazine drug of abuse. 
 
It is evident from the discussion above that the composition and purity of street samples is 
often unclear. Furthermore, it has been highlighted there is lack of information on 
characterisation of piperazine based drugs of abuse, consequently there is need to 
characterise piperazine street drugs. The approach and techniques highlighted in the review 
for other drugs were extrapolated in the characterisation of piperazines in this study.  
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1.9 A REVIEW OF METHOD DEVELOPMENT, OPTIMISATION AND 
VALIDATION 
 
It has been identified in previous discussions (section 1.8) that there are limitations in the 
existing methods for the analysis of piperazines; 4-FPP and 3-TFMPP. Thus this gives rise 
to the need to develop the relevant method(s) for their investigation. A method that will 
therefore be applied for the qualitative and quantitative analysis of street samples 
containing 4-FPP and 3-TFMPP. Further application of the same method will be used for 
the chemical characterisation and impurity profiling of the street samples. In addition the 
method should be able to selectively analyse for 4-FPP and 3-TFMPP in a sample with a 
complex matrix of various drug combinations, impurities and isomers of 4-FPP and 3-
TFMPP. 
 
Several studies on development of methods for drugs of abuse have been reported (Staack 
et al., 2003; Inoue et al; 2004; Andersson et al., 2007a; Elie et al., 2013; Kelleher et al., 
2011; UNODC, 2013c). The review on method development below focused on GC-MS as 
this is the technique to be used. In studies where GC-MS methods were developed, the 
selection of stationary and instrumental parameters, such as flow rate of the mobile phase 
and sensitivity of the detector were identified as paramount to development of the 
preliminary method (Andersson, 2007a; de Boer et al., 2001; Elie et al., 2013; Maher et al., 
2009; Takahashi et al., 2009). In addition, it was also observed that solvents, sample 
preparation techniques and stability of the analytes are also an inherent part of 
development. Furthermore, the method was then review optimised and validated before 
application. 
 
According to ICH guidelines (2005), optimisation ensures that all the variables in the 
method are those that give the best results and validation gives an indication that the 
method is fit for purpose. This process involves manipulating method variables. It was 
found that chromatographic concepts such as Plate theory, van Deemeter equation are often 
employed in determining which variables can be varied so as to optimise chromatographic 
data (Chan et al., 2010; Dijkistra et al., 1996; Horacio et al., 2008; McNair and Miller, 
2009; Khopkar, 2012). Validation is the sequence of events carried out to ensure that the 
method is suitable for its purpose, i.e., it achieves the desired outcome (Eurachem, 1998; 
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ICH, 2005; Horacio et al., 2008; Lavanya et al., 2013). The concepts behind optimisation 
and validation will be discussed in detail in Chapter 2. 
 
In studies where GC-MS methods were developed, it was observed that the following 
method variables were optimised; instrumental parameters such as the detector, mobile 
phase flow rate, injection temperature, oven temperature, ionisation energy and in addition 
sample preparation techniques such as extraction techniques, solvent selection, 
derivatisation methods and stability of samples (Andersson, et al., 2007a; 2007b, Lock at 
al., 2007; Inoue et al., 2008). Different approaches to method validation were found to exist 
showing a wide range of parameters to be validated (Eurachem, 1998; Horacio et al., 2008; 
ICH, 2005; Lavanya et al., 2013; Thompson et al., 2002). The extent of validation was also 
found to depend on use of the method. For example, qualitative methods did not require 
determination of limit of quantitation or linearity (Appendix 4). Lavanya et al. (2013) in a 
review on analytical method validation had similar findings. In addition, the author 
reported the following method variables were basically validated; selectivity/specificity, 
linearity, range, accuracy, precision, method detection limits and robustness. 
 
Byrska et al., (2010) developed and validated a GC-MS method for the determination of 6 
piperazine drugs; 3-MePP, BZP, 3-TFMPP, MBZP, MeOPP and 3-CPP. The approach used 
involved evaluation of different columns and several temperature programs. The column 
selected was HP-5MS comprising of 5%-Phenyl-95%-Dimethylpolysiloxane stationary 
phases. This type of column has been found to be widely used in analysis of drugs of 
abuse.The UNODC (2013c) in its recommended methods for piperazines; Inoue et al. 
(2004) in analysis of benzylpiperazine like substances; Takahashi et al. (2009) in a study on 
creation of a psychoactive library and Andersson et al. (2007a) in developing a GC-MS 
method for the profiling of amphetamines all selected this type of stationary phase for use. 
This implies that this particular stationary phase might be the best suited to analysis of the 
drugs in this study which also contain piperazines and amphetamines (section 1.2.2). 
 
It has been stated above that optimisation of instrument variables can enhance 
chromatographic results. Santali et al., (2011) in their study on developing a method for 
mephedrone and Inoue et al., (2008) in a study on developing a method for profiling 
methamphetamine using GC-MS observed that both efficiency and tailing were 
temperature dependent. Furthermore, in optimising their methods variation of both injector 
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and column temperatures similarly improved efficiency and tailing. It therefore follows that 
in this research optimisation of instrument variables will be investigated so as to enhance 
performance of the preliminary method. In addition, validation will also be conducted so as 
to ascertain suitability of the method for use. The validation will determine the parameters 
selectivity/specificity, linearity, accuracy, precision, method detection limits and 
robustness. 
 
1.10 INVESTIGATION OF THE STABILITY OF DRUGS AND EFFECT OF 
SOLVENTS DURING ANALYSIS 
 
The stability of a drug substance can be defined as its ability to retain its properties (e.g. 
chemical and physical properties) within specified limits throughout its time of usage or 
storage (ICH Q1A(R2), 2003; FDA, 2008). Loss of stability can occur through degradation 
during any of the different stages of a drugs life cycle, such as during formation, 
distribution, storage of the finished product and laboratory investigations. Degradation 
leads to a loss in concentration of the drug and the possibility of degradation products (or 
artefacts) which can suddenly appear in the sample matrix (Yoshioka and Stella, 2000; ICH 
Q1A(R2), 2003). These impact on the quality of analysis results for example degradation 
products in the sample matrix can interfere with the analytes during analysis and as such 
require investigation of stability.  
 
Stability studies on drugs of abuse during laboratory investigations and storage have been 
reported (Aalberg et al., 2005b; Gunnar et al., 2004; Karinen et al., 2011; Moody et al., 
1999; Nowatzke and Woolf, 2007). Karinen et al., (2011) investigated the storage of drugs 
in the refrigerator, freezer and at ambient conditions involving an extensive range of drugs 
in the solvents used methanol, acetonitrile, or a mixture of the two. Loss in concentration (> 
20%) was reported for some of the drugs indicating a loss of stability.  
 
Aalberg et al. (2005b) in a study on profiling of amphetamines investigated the stability of 
impurities of amphetaminmes in organic solvents as a function of time and temperature. 
This study found the impurities were most stable in the solvents iso-octane, toluene and 
ethanol. However, whilst the temeperature effects were not determined, it is a well-known 
fact that temperature affects stability (Yoshioka and Stella, 2000). In other studies; Gunnar 
et al. (2004), Moody et al. (1999) and Nowatzke and Woolf (2007) also similarly found that 
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degradation of drug substances occurs with time. It therefore follows there is need to 
establish the limits during which the drug is stable to enable accurate analytical results. 
 
A review of literature on analytical investigations of drugs of abuse showed that a wide 
variety of solvents are used during analysis. Methanol is the most commonly used solvent 
during drug analysis (de Boer et al., 2001; Staack and Maurer, 2005; Anderson et al., 
2007b; Elliot and Smith, 2008; Takahashi et al., 2009), other solvents commonly used are 
ethyl acetate, ether, ethanol, propanol dichloromethane, chloroform, DMSO and toluene.  
Their use can be attributed to the fact that most drugs of abuse are polar and consequently 
methanol and ethyl acetate are good solvents for such drugs. Both are polar and volatile 
enough for use on the GC-MS. In addition methanol is miscible with aqueous solutions 
hence can be used on the HPLC. Furthermore, ethyl acetate is amenable to use during 
sample derivatisation commonly used in GC-MS analysis. Currently there is very limited 
use of  2-methylpropan-2-ol in analysis of drugs of abuse (de Boer et al., 2001; Inoue et al., 
2004; Staack and Maurer, 2005; Andersson et al., 2007a; Staack 2007; Elliot and Smith, 
2008; Takahashi et al., 2009; Kenyon et al., 2010). However, it has potential for use as 
analytical solvent in analysis of drugs of abuse. It has similar properties to methanol and is 
less reactive as it is a tertiary alcohol (Table 2.3 and section 5.7.1); as such it can be used as 
an alternative solvent in cases where the other solvents prove unsuitable. Its reactivity 
makes it suited to characterisation and profiling. 
 
According to the FDA (2008) it is necessary to establish chemical stability of the drug 
analytes in solution or in the proposed matrix and how stability maybe maintained. 
Consequently, selected solvents will be reviewd further in Chapter 2, so as to evaluate their 
potential reactivity and effect on the stability of the drugs used in this research (Table 4.1).  
 
No literature was found on thermal and chemical stability of 4-FPP and 3-TFMPP or any of 
the piperazines in various solvents either as part of method development or as independent 
investigations. Furthermore, stability studies have focused on storage and none were 
encountered on stability during analysis on the instrument’s autosampler. Analytes can 
spend prolonged periods on the autosampler awaiting the sample to run, in addition the 
temperature on the autosampler maybe above ambient due to the presence of the injector 
and oven. These may influence the stability of the analyte. In addition, literature pertaining 
to metabolic degradation of 3-TFMPP and 4-FPP was evaluated. Studies by Staack (2007) 
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showed that 3-TFMPP is extensively metabolised by hydroxylation at the aromatic ring and 
also by degradation of the piperazine moiety. These results have implication on the stability 
of 3-TFMPP in alcoholic solvents due to the possibility of hydroxylation. It is therefore 
evident there is a lack of adequate information on stability and stability limits to be applied 
for routine laboratory analysis of these drugs, hence this will be investigated in this 
research. 
 
1.11 AIMS AND OBJECTIVES OF THE STUDY 
 
Research on phenylpiperazines drugs is as yet not exhaustive. From the literature review, it 
was identified that there is need to address the lack of research for both the synthesis and 
analysis of 4-FPP and 3-TFMPP for purposes of chemical characterisation and profiling of 
these drugs. In addition, no literature on profiling of piperazines was found. Very few 
analytical investigations have been conducted on 4-FPP, even though it has been identified 
as prevalent in drugs of abuse (UNODC, 2013a). Furthermore, no studies were encountered 
on drug stability of these substances during analytical laboratory conditions and limited 
studies on the other drugs investigated in this study. 
 
Furthermore, it was also identified that research on isomers for psychoactive substances is 
very limited which poses a challenge both on analysis and related toxicity issues. To date 
separation of the positional isomers for TFMPP and FPP has not been achieved in a street 
sample containing other drugs. It has been discussed that the determination of the exact 
isomers is necessary in case work and may have legal implications with regards to 
scheduling status of these drugs (sections 1.6 and 1.8). This study addresses these issues 
and provides novel information.  
 
Currently, there is a lack of information on the stability of piperazines during analysis. In 
addition, no stability studies of the drug whilst on the GC-MS autosampler were 
encountered. The temperature effects of the injector and column oven in close proximity to 
autosamplers and also the duration of stay of the analyte on the autosampler were 
highlighted in section 1.10 as potential causes of degradation thereby raising the need for 
establishing their stability.  
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It has been identified in previous discussions (section 1.4) that new psychoactive 
substances are an emerging and increasing global problem. In addition the complexity of 
the drugs poses health risks (section1.5). The drugs have been reported to exist as 
combinations of two or more drugs and commonly with cutting agents and adulterants 
(Davies, 2010; Kelleher et al., 2011; UNODC, 2013b).  It can therefore be concluded that if 
not investigated to provide scientific data this problem cannot be minimized or halted. This 
is evidenced by the UNODC (2013b) which states that “The increasing number of NPS 
appearing on the market has also become a major public health concern, not only because 
of increasing use but also because of the lack of scientific research and understanding of 
their adverse effects”. Consequently, this research will investigate one group of the NPS, 
i.e., piperazines and develop methods of analysis and also provide research data. As such 
the following aims arise; 
 
a) To develop a method, optimise and validate a GC-MS method for the simultaneous 
analysis of 4-FPP, 3-TFMPP, their positional isomers and their congeners in street 
samples. 
b) To carry out stability studies and establish stability limits  for piperazine drugs of abuse 
and their congeners during laboratory analysis and also determine the solvent in which 
these compounds are most stable during analysis and storage 
c) To synthesise the substituted phenylpiperazine derivatives (3-TFMPP and 4-FPP) and 
thereby determine the viability of the synthesis routes for potential illicit use. 
d) To analyse the synthesised 3-TFMPP and 4-FPP and chemical impurities arising from 
the synthesis (by-products, positional isomers, residual solvents and precursors) using 
the developed GC-MS method, FTIR and UV-Vis to provide analytical data.  
e) To carry out the chemical characterisation and profiling of 3-TFMPP and 4-FPP drugs 
of abuse using the data derived from the synthesis and the developed GC-MS method. 
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CHAPTER 2 
 THEORETICAL CONSIDERATIONS UNDERLYING CONCEPTS 
APPLIED IN THE RESEARCH 
 
2.1 INTRODUCTION TO THE STUDY  
 
This chapter investigates the theoretical concepts underpinning the experimental work for 
this research so as to gain insight into the processes involved. Principles of 
chromatographic processes impacting on this research were discussed (sections 2.1 and 
2.2). In addition, the concepts underpinning optimisation and validation of methods, sample 
treatment and stability studies, including the factors influencing them were reviewed 
(sections 2.3 – 2.5). The aspects behind synthesis, characterisation and profiling of street 
drugs of abuse were also discussed (section 2.8). 
 
2.2 BASIC CONCEPTS OF GC-MS INSTRUMENTATION AND ANALYSIS 
 
Two important aspects arise in the analysis of samples containing more than one analyte or 
an analyte in a sample matrix with detectable elements; a) ability of the system to 
selectively separate the analyte from other components in the sample matrix and b) the 
emission of a signal characteristic of the analyte and its concentration, thereby enabling its 
detection, identification and quantitation. The ability to separate different substances in the 
chromatographic column during analysis lies at the heart of many separation techniques 
such as GC-MS and HPLC. The basic concepts of GC-MS instrumentation are highlighted 
in Figure 2.1.  
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Figure 2.1 Schematic block diagram of a GC-MS instrument. 
 
The types of injection techniques for capillary GC-MS are split, splitless, direct on column, 
thermal desorption and pyrolysis (Grob, 1994). Split and splitless injection were found to 
be common for analysis of street samples of drugs (de Boer et al., 2001; Inoue, 2004; 
Takahashi, 2009; Dargan and Wood; 2013; UNODC, 2013c), will be discussed further. In 
the split mode an aliquot of the sample is passed into the column whilst the rest is vented. 
The amount depends on the split ratio. This has the advantage of avoiding overloading the 
column. However, the limitation is that high sample concentrations are required (>0.01% 
mass/vol) (Barwick, 1999; Grob, 1994; Kaur, 2010).  In addition, the disadvantage is that 
the carrier gas is continuously vented into the laboratory. In splitless mode, the injection 
vent is closed. The sample is first pre-concentrated in the solvent at the top of the column 
before entry into the column and hence is advantageous for trace analysis. The limitation is 
that the boiling points of the analytes have to be 393 - 493oK above the boiling point of the 
solvent so as to facilitate the solvent pre-concentrating the sample (Grob, 1994; Kaur, 2010; 
Miller, 2005). Both injection modes were found applicable to the study, however, the split 
mode was chosen as doses of drugs in street samples are high in the mg/tablet range (Arbo 
et al., 2012; Davies et al., 2010; Kenyon et al., 2010; Kelleher et al., 2011).   
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Mobile phases for GC analysis are inert gases under pressure continuously pumped 
throughout the system, mainly He, H2, N2 and Ar (Kaur; 2010; Kronstrand and Jones, 
2000). The carrier gas moves the analytes through the system thereby facilitating elution 
from the column after injection.  
 
2.2.1 SEPARATION IN THE COLUMN 
 
The sample is injected into the injection chamber (Figure 2.1). Continuous movement of 
the mobile phase carries the sample through the column. The resulting process of 
separation is schematically shown in Figure 2.2. 
 
Figure 2.2 Separation of a sample containing analytes A and B in the column, depicting the 
progression of events sequentially from I – III. The time taken for the analyte to elute is 
shown as tA and tB. 
 
In the column, partition of the analytes between the mobile phase and the stationary phase 
occurs. Compounds show differences in partitioning behaviour depending on their chemical 
properties. Substances with a greater affinity for the stationary phase bond more strongly 
 58 
 
with the stationary phase and are consequently retained longer in the column. This results 
in separation of the analytes into bands (II). Movement of the mobile phase not only moves 
the analytes bands down the column but further separates them. Consequently they elute at 
different rates from the column and are thus separated (III) (Skoog et al., 2007).  
 
 It therefore follows that during method development, selection of column is critical to 
obtaining good results. Furthermore in method development a stationary phase should be 
selected which is suitable to the type of drugs under investigation. It has been found by 
many reseachers that like separates like (Kaur, 2010, Maher et al., 2009). Thus, it follows 
that as the drugs in this study are polar, polar stationary phases were considered so as 
achieve good resolution. This is in line with the other studies conducted on similar drugs, 
such as cocaine, amphetamines and piperazine. In their investigations Andersson et al. 
(2007a), de Boer et al. (2001), Inoue et al. (2004) and UNODC (2013c) employed polar 
columns (mainly 5%-Phenyl-95%-dimethylpolysiloxane). Kaur (2010) suggested the 
following rules of thumb, these will be considered in this research so as to maximise the 
quality of the chromatographic results and are discussed under effect of operational 
variables (section 2.4); 
• A long column gives a longer elution time but high resolution. 
• Small internal diameter gives high efficiency.  
• Film thickness should be thin; about 1µm. thicker films become unstable giving rise 
to pooling and excessive column bleed. 
 
2.2.2 ANALYTE DETECTION 
 
On elution from the column, the mobile phase carries the analytes into the detector. Where 
the GC instrument is coupled to an MS detector, after elution from the column the sample 
first enters the ionisation chamber, where either electron impact ionisation (EI) or chemical 
ionisation (CI) occurs (Khopkar, 2012). This generates charged ions which enter the 
detector and are separated on the basis of mass to charge ratio. The detector determines the 
time of arrival of the analyte into the detector; this is relative to its retention time, t
.
 The 
earlier separation of analytes A, B (Figure 2.2) in the column results in analytes eluting 
from the column and subsequently arriving at the detector at different times. Those that are 
least retained elute first and subsequently have the shortest retention time as shown in 
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Figure 2.2 retention times tA and tB for analytes A and B respectively. Equation 2.1 shows 
calculation of the retention time (Grob and Barry, 2004; Skoog et al., 2007). 
 
Retention time of analyte A = uncorrected retention time – retention time of un-retained 
compound. 
 
t'A = tA – t0 [2.1] 
where: t0 is the retention time of the un-retained compound (minutes) 
tA is the retention time for analyte A (minutes) 
tB is the retention time for analyte B (minutes) 
t'A is the corrected retention time for analyte A (minutes) 
 
In addition, the detector signal is processed and generates a chromatogram with a peak for 
each analyte. Further data processing produces a mass spectrum. The mass spectra and 
retention times can “fingerprint” a compound. Hence, these are useful qualitative tools in 
identification of substances. In the chromatograms generated on analysis the area under a 
peak is relative to the concentration of that analyte. The height of the peak can also be used 
in place of concentration (Kaur, 2010; Khopkar, 2012). This imparts quantitative aspects to 
the technique.  
 
2.3 FACTORS INFLUENCING THE QUALITY OF CHROMATOGRAPHIC 
RESULTS 
 
A good chromatographic peak profile is one with narrow, sharp, symmetrical peaks, i.e., 
the peaks a show a normal distribution pattern, thus are Gaussian shaped. In addition, a 
“clean” baseline is prerequisite. Where more than one analyte is present, the peaks are well 
separated (equation 2.11) with a resolution, Rs > 2 (Huber 1996; ICH, 2005). The quality of 
the chromatogram is influenced by several factors such as the partition coefficient, 
retention (capacity) factor, column efficiency and selectivity. Investigation of these 
parameters aids in determining the performance of the chromatographic system. In this 
study, column efficiency (plate number), tailing, selectivity and resolution is evaluated as 
measures of the quality of the chromatographic peak profiles in order to determine the 
impact of optimisation (Chapter 6). Consequently, these parameters and others which 
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influence them are described below (CDER, 2004; Eurachem, 1998; Thompson et al., 
2002; ICH, 2005; Kaur, 2010; Khopkar, 2012). 
 
The partition coefficient, K is an equilibrium constant which refers to the spatial 
distribution of the analyte between the stationary phase and the mobile phase. K is given by 
the molar concentration of the analyte in the stationary phase relative to the mobile phase at 
equilibrium (equation 2.2). The rate and degree of partition is governed by the analyte’s 
vapour pressure, which is determined by its boiling point, degree of volatility and column 
oven temperature. The partition coefficient is also dependent on the chemical affinity of the 
analyte for stationary phase. It therefore follows that analytes with a larger partition 
coefficients are retained longer in the column and consequently have longer retention times. 
The partition coefficient can be calculated as shown in equation 2.2 (Huber 1996; ICH, 
2005). 
 
K = Cs/Cm  [2.2] 
where: Cs = concentration of analyte in stationary phase (mol/dm-3) 
Cm = concentration of analyte in mobile phase (mol/dm-3) 
 
The capacity factor (retention factor), k describes the migration rate of an analyte in a 
column. This can be calculated by equation 2.3 (CDER, 2004; Skoog et al, 2007). 
 k = t −	tt =	 t 																																																																																																																								2.3 
 
where: t0 is the retention time of the un-retained compound (minutes) 
tr is the gross retention time of the analyte = unadjusted retention time (minutes) 
tr’ =  tr – t0  and is the retention time of the analyte  (minutes) 
 
When an analyte’s capacity factor is less than one, it implies the analyte is not highly 
retained in the column and the elution is very fast. High capacity factors (greater than 20) 
mean that elution takes a very long time. An ideal capacity factor for an analyte is between 
one and five (IUPAC, 2014). The process of separation is also dependent on other factors, 
mainly the type of stationary phase, flow rate and temperature (Barwick, 1999; Khopkar, 
2012; Maher et al., 2009). 
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Plate Column efficiency is measured as plate count (also known as plate number) and plate 
height. Plate number, N is a measure of the ability of a column to produce narrow sharp 
peaks. It shows the resolving power to separate analytes. According to the Plate theory 
(Kaur, 2010; Khopkar, 2012) a chromatographic column is made up of a large number of 
separate layers, called theoretical plates. These plates govern the shapes of the resulting 
peaks in the chromatogram which is also influenced by the flow rate. Complete, separate 
equilibration of the sample between the stationary and mobile phase occur in each of these 
"plates" (equation 2.9). The movement of the mobile phase down the column results in the 
transfer of the equilibrated mobile phase from one plate to the next and with it the analyte. 
The higher the number of theoreticals in a column, generally the sharper (narrower) and 
more intense (higher) the resulting peaks (Figure 2.3).  This results in the better the 
separation from adjacent peaks (equation 2.11). This concept assumes a peak is 
symmetrical, as such shows a normal distribution pattern, i.e., it is Guassian shaped. The 
peak-widths in such a peak are related to the standard deviation (σ) of the peak according to 
Figure 2.3 and the equations 2.4 – 2.8 (Skoog et al, 2007; CDER, 2004; IUPAC, 2014).  
 
Figure 2.3 Schematic representations of determination of plate number and the effect of 
peak shape on it. Showing the effect of an increase in plate number on Analyte A (peak A*) 
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where: W0.5 is  peak width at half height of the peak (seconds) 
Wb is peak width at base of the peak (seconds) 
A* is the analyte peak with a higher value of plate number 
 
In a Gaussian peak 96% of the area is under ±2 and the base peak width is 4σ hence, 
 W = 4σ	  [2.4] W. = 2σ2√2 ln 2 = 2.355σ  [2.5] 
 N =	  [2.6] 
                                                                                      
Deriving σ from equation 2.5 gives 2.6  
 
 σ = 	 !.".#       [2.7] 
 
substituting for σ into equation 2.7 gives 2.8, the formula for calculating N  
N = 5.545 $ tW.% 
 [2.8] 
                       
 Plate height, H is defined as the height equivalent of the theoretical plate (HETP) 
determined by plate number (refer to discussion of column efficiency). It is a measure of 
the length of the column needed for the equilibrium process to proceed. As such it is an 
alternative measure to plate number, N for column efficiency. H is given by equation 2.9 
(IUPAC, 2014). 
 
H = HETP = σN =	 LN																																																																																																															2.9 
                     
where: H is the height equivalent of a theoretical plate (µm) 
L length of column (µm) 
N is plate number 
 
Selectivity, α is a measure of the separating power of a column. It describes the separation 
of analyte 1 and 2 on the column. A selectivity of one or less means compounds cannot be 
separated as they are more or less retained to the same extent (Horacio et al., 2008). If 
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analyte 2 elutes faster than analyte 1, selectivity is greater than 1. This shows that the peaks 
are separated. It can be determined from equation 2.10 (CDER, 2004; IUPAC, 2014). 
 
α = 	 k-k 																																																																																																																																						 	2.10 
      
   
where: α is selectivity  
k1 is capacity factor of the less retained peak (eluting first) 
k2 is capacity factor of the more retained peak (eluting second) 
 
Resolution, Rs is a measure of peak overlap defined by the relative number of peak widths 
between peaks. It aids choice of column and optimisation (CDER, 2004; Horacio et al., 
2008).  Figure 2.4 below shows a schematic diagram of resolution of analytes and equation 
2.11 its calculation.  
 
 
Figure 2.4 Schematic diagram for the determination of resolution of analytes (Adapted 
from CDER, (2004).  
 
where: t2  is the retention time of the more retained peak 
t1 is the retention time of the more retained peak 
 
R1 =	14 $α − 1α % $ kk 2 1%√N																																																																																																	2.11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It can be seen that the equation for resolution, equation 2.11 consists of three terms; (i) 
plate number, ii) selectivity and (iii) capacity factor. Selectivity and capacity factor are a 
measure of retention. Therefore these parameters describe the separation between analytes. 
Consequently, these parameters influence resolution. Hence, increases in plate number and 
selectivity increases resolution whilst an increase in capacity factor reduces resolution. It 
follows that to obtain high resolution, the three terms (efficiency, selectivity and capacity 
factor) must be optimised (the concept is discussed in section 2.4). 
 
Peak broadness and symmetry define the general shape of the peaks. These terms are 
affected by band broadening which in turn is dependent on kinetic variables (these are also 
discussed in section 2.4. 
 
Peak broadness refers to the width of a peak. Good peaks are narrow. This facilitates for 
more accurate triangulation of peak area as such accurate quantification. Also, narrow 
peaks reduce peak overlapping and increases peak separation. In addition, consistent 
retention times and peak areas are obtained (Bowers et al., 2002; Gonzalez and Herrador, 
2007). 
 
Peak asymmetry describes peak shape, as previously highlighted theoretically a peak 
should be Gaussian shaped. However, tailing and fronting can occur when the peak shape 
becomes distorted as shown in Figure 2.5. Peak symmetry is dependent on the adsorption 
isotherm for the distribution of the solute between solid phase and the gas phase. When this 
varies with concentration peak asymmetry occurs. Fronting normally results when the 
amount of sample introduced into the sample is too large. Other factors such use of a 
column with poorly packed stationary phase (inconsistent packing causes voids, which 
affect equilibration of the analyte in the phases).With increase in peak asymmetry and 
tailing, the resolution between peaks decreases (Skoog et al., 2007).  
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Figure 2.5 Schematic diagram showing peak asymmetry.  
 
Peak asymmetry can be used as a measure of peak tailing.  A value of < 1 indicates fronting 
whilst > 1 imples peak tailing (IUPAC, 2014; McNair and Miller, 2009). Tailing can be 
calculated from equation 2.12; 
 
T =	 a 2 b2a 																																																																																																																																	2.12 
 
where: T is the tailing factor  
b is the front half of peak width at 5% height of the peak 
a is the back half of peak width at 5% height of the peak 
 
The parameters that were discussed plate number, selectivity, resolution, peak asymmetry 
and capacity factor are dependent on method operational parameters such as injection 
temperature. In addition, other analytical aspects such as the degree of fragmentation 
observed in mass spectra of an analyte are similarly affected. As such, method operational 
variables can be varied so as to obtain the best chromatographic results. This gives rise to 
the concept of optimising the method (section 2.4 and chapter 6).  
 
 
a b 
5% peak height 
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2.4 EFFECT OF OPERATIONAL VARIABLES AND OPTIMISATION 
 
Operational variables are those aspects of a method that can manipulated, such as 
instrumental parameters, column physical properties, physical and chemical properties of 
the stationary phase, mobile phase, flow rate, detector sensitivity, oven temperatures, 
injector temperature and ionisation energy (where an MS detector is used). Consequently, 
variables which negatively affect peak profiles need to be minimised and those which 
improve performance optimised (Andersson et al., 2007a; Hibbert, 2007; Inoue et al., 
2008). Consequently, these are manipulated so as to;   
 
a) Generally, an improvement in chromatographic peak profile in terms of peak shape, 
broadness, intensity;  
b) Increase column efficiency measured as plate number, N. 
c) Increase selectivity, α,  > 1.0 
d) Increase peak resolution, R >1.5 
e) Decrease peak tailing or peak asymmetry, T < 1.5 
f) Maintain or decrease retention time 
 
The Plate and Rate theories explain the effects of chromatographic variables. They are 
useful tools in deriving variables that can be improved. Consequently, they have found 
wide application in determination of method performance and optimising methods (Moody, 
1982; Kaur, 2010; Khopkar, 2012; IUPAC, 2014). The Rate theory describes the shapes 
and breadths of elution bands. According to the Rate theory, the resulting band shape of a 
chromatographic peak is affected by kinetic variables, i.e., the rate of elution and the 
different paths available to analyte molecules, as they travel between particles of stationary 
phase.  As such, this theory can be used to determine the variables that can improve column 
efficiency.  
 
The van Deemeter equation arises from the Rate theory. It describes some of the 
relationships and effects of the experimental variables that affect band broadening.  
Band broadening is due to 3 main processes in the column; a) multiple path of an analyte 
through the column packing, b) molecular diffusion and c) effect of mass transfer between 
phases. These processes are influenced by variables such as effect of mobile phase flow 
rate. Below is a list of the influencing factors (Hibbert, 2007; Skoog et al., 2007); 
 67 
 
• µ: the linear velocity of the mobile phase (cms-1) 
• dp: the diameter of stationary phase particle size (cm)  
• Dm: diffusion coefficient of analyte in the mobile phase (cm2s-1) 
• Ds: the diffusion coefficient of analyte in the stationary phase (cm2s-1) 
• λ: packing factor related to particle size 
• γ: obstruction factor due to the diffusion restriction by the column  
• df: effective film thickness of liquid phase coating  
• k: capacity factor  
It is evident that these factors are related to the column and analyte properties. Hence, they 
can be manipulated to optimise performance. This is reason it has found wide application in 
determination of optimum values such as flow rate and temperature during optimisation. 
The Van Deemter equation is given by equation 2.13 (Moody, 1982; CDER, 2004; Horacio 
et al., 2008; Kaur, 2010; Khopkar, 2012; IUPAC, 2014). 
HETP = H = A + B /µ + Cµ  [2.13] 
 
where: A refers to Eddy diffusion 
B refers to Longitudinal diffusion 
C refers to Resistance to mass transfer 
 
Eddy diffusion 
A = 2λdp  [2.14] 
This term describes movement of the analyte through the column. The analyte moves 
randomly following different paths through the stationary phase particles. This causes band 
broadening because of differences in paths in lengths. Consequently, the peak shape is 
broadens. As shown in equation 2.14 Eddy diffusion is dependent on particle size. Larger 
particles increase the distance the analyte has to travel and as such increase dispersion 
effects. It is also influenced by particle shape and tightness of packing. 
Longitudinal diffusion 
B/µ = 2γDm  [2.15] 
             µ 
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In the column separation occurs in bands, and the concentration of analyte distribution is 
not homogenous; it is less at the edges of the band than at the centre. Consequently, 
diffusion of analyte molecules from the centre to the edges occurs. This results in band 
broadening. However, if the velocity of the mobile phase is high then the analyte spends 
less time in the column, which decreases the effects of longitudinal diffusion. Molecular 
diffusion in the liquid phase is much lower than that in the gas phase hence this term is 
negligible in HPLC. 
It can be seen from equation 2.15 that longitudinal diffusion is dependent on the mobile 
properties and flow rate. It is also affected by temperature and molecular mass of the 
analyte.  
Resistance to mass transfer 
C = 8 x kdp2 µ [2.16] 
       5  (1+ k)Ds  
The time analyte taken for the analyte to equilibrate between the stationary and mobile 
phase is dependent on the velocity of the mobile phase.  At high flow rates, the mobile 
phase moves ahead of an analyte that has a strong affinity for the stationary phase. This 
results in band broadening. For such analytes band broadening worsens with increasing 
velocity of the mobile phase. Equation 2.16 shows that the C-term decreases with increase 
in velocity whilst it increases with increase in particle size or particle porosity. It is also 
affected by temperature, retention factor. A graphical representation of equation 2.13 is 
shown in (Figure 2.6). 
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Figure 2.6 Van Deemer plot for the determination of optimum conditions (adapted from 
Khopkar, 2012; Moody, 1982; Kaur, 2010) 
Consequently, from the discussion above it follows that reducing eddy diffusion, 
longitudinal diffusion and resistance to mass transfer will reduce HETP (equation 2.13). 
Thus, according to equation 2.9 reducing HETP effectively increases plate number, which 
is desirable so as to obtain optimal separations; sharp sand symmetrical chromatographic 
peaks must be obtained. From the discussion above it has been identified that this can this 
can be achieved through the following; 
a) Column selection 
• Column length (L) - the shorter the column, the higher the efficiency.  
• Particle size- the smaller the particle size the lower the HETP hence the higher the 
value of N. 
• Packing quality- tightly packed column reduces the A term in equation 2.13, 
minimises eddy diffusion. As a result band broadening is minimised. For GC 
analysis capillary columns are therefore more advantageous. As such these will be 
applied to this study. 
b) Mobile phase- increasing the flow rate, µ reduces the B-term in equation 2.13; however 
it also increases the C term. Consequently, there exists an optimum for flow rate which 
is a compromise of the two terms. This can be deduced by graphical van Deemeter 
plots of HETP versus velocity such as Figure 2.6. 
H = A + B /µ + Cµ 
Cµ 
B/µ 
A 
Optimum velocity 
Minimum plate 
  B 
Optimum B/µ  C 
A 
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c) Temperature- in accordance with kinetics, increases in temperature reduces resistance 
to mass transfer. This leads to a decrease in HETP as such an increase in efficiency. 
 
Operational variables therefore have a profound effect on the quality of the results 
generated. Furthermore, it is possible to manipulate these variables and thereby influence 
the underlying chromatographic processes. This can then result in an improvement in the 
results in terms of plate number, selectivity, resolution, peak asymmetry, capacity factor, 
retention time and mass spectra. Consequently the column, injector port and oven 
temperatures, carrier gas flow rate, MS scan rate and MS ionisation energy were be 
investigated in this research (Chapter 7) so as to optimise the methods required to separate 
piperazine compounds from mixtures such as in street drugs. 
 
2.5 CONCEPTS TO METHOD VALIDATION 
 
The need for validation is highlighted in section 1.9. The parameters commonly 
investigated during method validation were identified as selectivity, specificity, linearity, 
linear, range, accuracy, precision limits of detection and quantitation (Eurachem, 1998; 
Thompson et al., 2002; ICH, 2005; Thompson, 2005; Rambla-Alegre et al., 2012; Lavanya 
et al., 2013). These are be investigated in this study and consequently discussed. 
 
2.5.1 FACTORS CHARACTERISTIC OF METHOD VALIDATION 
 
2.5.1.1 Linearity 
2.5.1.1.1 Calibration curves 
Linearity can be defined as the relationship that occurs when detector response (area or 
peak height) is directly proportional to concentration. As such a plot of detector response 
versus concentration gives a linear plot defined by equation 2.17 (similar to equation 3.16). 
  
y = x + c + ε  [2.17] 
where: y = dependent variable (detector response) 
x = independent variable (concentration) 
m = slope 
c = intercept 
ε = random error 
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In validation studies, such plots (calibration plots) are used to investigate linearity and other 
linearity dependent parameters (limits of detection and quantitation). This involves the use 
of statistical analysis such as regression analysis (section 3.11). In this study, calibration 
curves were established by plotting peak area ratio versus concentration. Peak area ratio is 
calculated according to the equation 2.18; 
 
Peak area ratio = peak area of analyte standard  [2.18] 
                            peak area of internal standard 
 
2.5.1.1.2 Testing for linearity 
The linearity of the calibration plot needs to be established so as to ensure accuracy in 
quantitative determinations. Linearity can be determined by several methods among them; 
a) visual inspection of the calibration line plots, b) regression analysis and determination of 
correlation coefficients, c) use of residual plots (Thompson, 2005; Lavanya et al., 2013), d) 
use of other statistical tests such as Fischer-Snedecor test, Lack-of-fit and Mandel’s fitting 
test (Eurachem, 1998; Gonzalez and Herrador, 2007; Rambla-Alegre et al., 2012).  
 
The use of correlation coefficients in establishing linearity is a routine procedure 
commonly used by researchers. If linearity is achieved the linearity plots are visually linear 
with a regression coefficient, R2 > 0.99 and RSD < 2% for repeated injections of the 
calibration solutions (Chan et al., 2010). However, it has been established that use of 
correlation coefficients on their own are inadequate as even a non-linear graph can give a 
high correlation coefficient (Miller, 1991; Rambla-Alegre et al., 2012; Thompson, 2005; 
Van Loco et al., 2002) Consequently linearity should further be established by other 
statistical tests for lack of fit or and or its significance. Analysis of residuals of the 
regression plot was identified as a common test (Thompson, 2005) in evaluating linearity, 
hence it will be applied in this research to confirm wether or not the calibration data 
(Chapter 7) follows a linear trend. 
 
Analyses of the residuals of the regression analysis show the degree of deviations from 
linearity (section 3.2.11 equation 3.20). If there is no lack of fit (linear), deviations are not 
statistically significant, hence a plot of the residuals shows a random distribution with a 
mean of zero and no defined shape as shown in the comparator graph Figure 2.7 (Miller, 
1991; Thompson, 2005).  
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Figure 2.7 Expected shape of standard residual plot for a linear function showing no 
definite shape, i.e., constant variance (adapted from Miller, 1991; Thompson, 2005).  
 
If there is lack of fit (non-linearity), a plot of the residuals shows a defined pattern (non-
random distribution), as shown in the comparator graph Figure 2.8 (Thompson, 2005). 
Furthermore, the standard deviation of the replicates of each point on the plot is reasonably 
less than the systematic deviation of the residuals and hence statistically significant 
(Rambla-Alegre et al., 2012). In addition, as confirmation the randomness of the residuals 
can be statistically evaluated. The Runs test (section 3.2.13) is reported to be applicable to 
such a determination (Sprent and Smeeton, 2007; Chatterjee and Simonoff, 2012). 
 
 
Figure 2.8 Expected shape of standard residual plot for a non-linear function showing a 
bow trend (adapted from Miller, 1991; Thompson, 2005). 
 
Since the detector response is directly proportional to concentration and is employed to 
calculate the concentration of unknown (Crockett, 1986), therefore it follows that linearity 
is desirable, as it makes for accurate determination of unknown substances.  
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2.5.1.2 Range 
For most analytes linearity is observed for a specific concentration range, giving rise to the 
linearity range and working range. The linearity range is the concentration range covering 
the area where the method was confirmed as having acceptable linearity, accuracy and 
precision. The working range defines the target concentration range for analysis. It is 
narrower and encompasses or is above the limit of quantitation (ICH, 2005), (see section 
3.2.11). 
  
2.5.1.3 Limit of detection (LOD) 
According to ICH guidelines, the limit of detection is the minimum level at which the 
analyte can be detected with accuracy and precision. It is dependent on the analytical 
method and instrument sensitivity. The calibration curve of the analyte can be utilised to 
evaluate the LOD, through use of the residual standard deviation of the response and the 
slope. The calculation is given by equation 2.19 (1CH, 2005; IUPAC, 2014). 
 
LOD = 3.3σ  [2.19] 
             S 
  
2.5.1.4 Limit of quantitation (LOQ)  
This is the minimum level at which the analyte can be quantified with acceptable accuracy 
and precision and instrument sensitivity. Similarly to the LOD the LOQ is given by 
equation 2.20 (1CH, 2005; IUPAC, 2014). 
 
LOQ = 10σ  [2.20] 
             S 
 
where: σ is the standard deviation of the response (based on standard deviation of the  
            y-intercepts of the regression line). 
S is the slope of the calibration curve 
 
2.5.1.5 Accuracy 
Accuracy refers to the "the closeness of test results obtained by that method to the true 
value. The criterion for good accuracy is 98 – 102% of the expected amount (Gonzalez and 
Herrador, 2007; Van Loco et al., 2002).  Accuracy can be determined by determining 
analysing a standard of known concentration and calculating the actual amount determined 
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by the method under investigation relative to the known concentration as recovery (%). 
This is given by equation 2.21; 
 
% recovery = amount of substance determined by method x100 [2.21] 
                       actual known amount 
 
2.5.1.6 Precision 
Precision of an analytical method refers to the degree of variability in the results obtained 
between a series of measurements from the same homogenous sample using the same 
method. There are three different levels of precision: 1) repeatability refers to precision 
determined by multiple analyses of the same sample over a short interval of time, 2) 
intermediate precision refers to variability determined over a longer time period, conditions 
may vary such as different analytes or sample, and 3) reproducibility refers to variability 
using different laboratories. Precision is normally expressed as standard deviation or 
relative standard deviation (%RSD) and must be less than 2% for most methods 
(Eurachem, 1998, ICH, 2005; Gonzalez and Herrador, 2007). 
 
2.5.1.7 Specificity/Selectivity 
Specificity and selectivity are an expression of the sensitivity of the method to the analytes 
present in a sample. Specificity is the ability of the method to selectively, unequivocally 
determine the analyte in the presence of other substances in the sample matrix, such as 
impurities and degradants. This is determined through calculating selectivity value and or 
resolution, the higher the resolution between peaks the greater the specificity. Ideally 
selectivity should be > 1 (CDER 2004, Horacio et al., 2008). It is possible for lack of 
specificity to occur, however according to Lavanya et al. (2013) this may be compensated 
by other supporting analytical procedure(s) such as use of selected ion monitoring in GC-
MS.  
 
2.5.1.8 Robustness  
The final part of validation is testing the method for robustness. Robustness refers to the 
ability of the method to withstand small changes in operating conditions (ICH, 2005), such 
as using different instruments, analyst or a similar column but from a different supplier. 
Robustness provides a measure of the reliability of operating the method under normal day 
to day conditions. 
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2.5.2 QUALITY CONTROL 
 
Quality control refers to the processes or checks and standards that are routinely conducted 
in order to ensure that all the work generated is maintained at the required standard of 
quality. Corrective actions to problems are then taken before it affects the quality of the 
work. In laboratory analysis this can be conducted by setting up control charts, such as 
Shewhart charts (ICH, 2005) to monitor, for example, instrument performance and 
temperature. Such approaches have been widely used by researchers (Andersson et al., 
2007a; Hibbert, 2007). System suitability testing has been described as a way of monitoring 
instrument performance (ICH, 2005). Repeated measures are carried out. The standard 
deviation is then determined (Horacio et al., 2008). This can provide a measure of 
consistency of detector performance. This approach is utilised in this study, control charts 
will also be applied as they have good practical application. Peak area ratios will be used as 
a measure of detector response.   
 
It has been highlighted that columns affect the quality of chromatographic results. It is 
therefore critical to monitor their performance so as to check whether the column has 
decomposed.  The general background in a chromatogram might show the presence of 
distinct peaks or an abundance of small peaks. This is a result of contamination due to 
column bleed, hydrocarbons, and phthalate plasticizers (McMaster, 2007; McNair and 
Miller, 2009). The background signal can interfere with analysis scan and decrease the 
sensitivity level for detecting target compounds. Furthermore, specific ions in the 
background can interfere with a single-ion or extracted ion chromatogram.  
 
Columns bleed is the vapourisation of stationary phase coating resulting in the presence of 
peaks in the chromatogram due to the stationary phase. Generally, stationary phases are 
thermally stable, however, due to age or high temperature degradation can occur (McNair 
and Miller, 2009). This needs to be minimised so as to prevent interference with the analyte 
peaks, maintain chromatographic baseline stability, prolong the life of the column and 
prevent any fouling of detector (Barwick, 1999; Kaur, 2010). Contaminant mass ions due to 
column bleed of polysiloxane stationary phases have been reported at m/z 73, 207, 281 and 
327 with the 207 ion being the most abundant followed by 281 (Miller 2005; McMaster, 
2007). Furthermore, it has been identified section 1.8 that polysiloxane columns are 
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routinely applied in analysis of drugs of abuse. Consequently, as this study uses a 
polysiloxane based column the ion at m/z 207 will be monitored.   
 
2.6 SAMPLE TREATMENT: DERIVATISATION 
 
Derivatisation is generally performed to alter reactivity or change a physical property such 
as solubility, boiling point, melting point, thermal stability. It enhances volatility, thereby 
improving resolution and improves peak shape for quantitative analysis (Inuoe et al., 2004; 
Telepchak, 2004; UNODC, 2013c). The process involves altering the functional groups. 
The analyte is tagged with a detector-oriented compound (a compound with high detector 
sensitivity such as pentafluoropropionic anhydride (PFPA), molecular weight 310.05Da, 
boiling point 69 - 70oC and N,O Bis(trimethylsilyl)trifluoroacetamide (BSTFA), molecular 
weight 257.40Da, boiling point 45 - 55oC with trimethylchlorosilane (TMCS) as a catalyst 
(Quirke, 1994; Inoue et al., 2007; Takahashi et al., 2009). The structures of PFPA, BSFTA 
and TMCS are shown in Figure 2.9. 
Si
CH3
CH3CH3
Cl
BSTFA TMCSPFPA
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C
F5C2 O
C
O
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CH3
CH3
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F3C
Si
CH3
CH3CH3
 
Figure 2.9 Structures of derivatising agents. 
BSTFA is a silylation agent, unlike PFPA which acylates. It introduces trimethylsilyl 
(TMS) -Si(CH3)3 or DMS -Si(CH3)2 or N,O-bis(trimethylsilyl) acetamide in place of the 
functional group i.e., substitution of reactive H in polar groups such as -COOH, -OH, - NH 
and -SH to obtain their derivatives. As can be seen from their structures, these compound 
are very reactive and therefore can be used on a wide range of drugs, they also have very 
low boiling points hence are highly volatile hence one of their major functions is to impart 
volatility. These agents can derivatives such compounds amides, secondary amines, 
alcohols and as such will be applicable to the drugs under study (amphetamines, 
piperazines). In this study 4-FPPA will be investigated as an example to determine the 
effect of derivatisation on the analytes under investigation. 
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The generalised derivatisation reaction schemes for compounds containing the functional 
groups NH (e.g. piperazines, tryptamines, MDMA), COO (e.g. cocaine and heroin) and SH 
(e.g. thienylmethylpiperazines) functional groups is shown in Figure 2.10 PFPA.The 
reaction for derivatisation of 4-FPP is also proposed (Figure 2.11). 
 
O
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O
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R X
H O
C
F5C2
X
R
OH
C
O
C2F5
X = O, NH, NR', COO
R, R' = Alkyl, Aryl group
+ +
 
 Figure 2.10 Generalised PFPA derivatisation reaction (adapted from Knapp, 1979; 
Telepchak, 2004; Miller, 2005). 
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Figure 2.11 Proposed PFPA derivatisation reaction for 4-FPP. 
 
2.7 ASPECTS OF SOLVENTS AND STABILITY STUDIES 
 
The presence of degradation in a sample can be demonstrated by variables such as potency 
(concentration of the drug) and degradation products (or artefacts), changes in colour, pH 
and other physical properties (Yoshioka and Stella, 2000; ICH Q1A(R2), 2003). Any of 
these variables can be measured as a test for stability. In studies on drugs of abuse 
concentration is used as a measure of degradation and the presence of degradation products 
also confirms of degradation (Aalberg et al., 2005b; Karinen et al., 2011). Furthermore, 
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degradation products can also give an indication of the degradation pathway that occurred. 
Hence, these will be monitored in this research. 
 
2.7.1 FACTORS INFLUENCING STABILITY 
 
Factors affecting stability can be divided into a) intrinsic factors, such as the molecular 
structure of the drug itself and b) environmental factors- temperature, air, light, humidity, 
solvent effects, additives and excipients (cutting agents). In the molecular structure the 
reaction centres and substituents around the reaction centre affect its degradation, i.e., 
degradation pathway, kinetics and reactivity. For example, steric hinderance or electron 
withdrawing groups next to the reactive centre can make it less reactive thereby imparting a 
greater degree of stability. In solid state properties, such as melting point, crystallinity and 
hygroscopisity are critical and in addition, mechanical forces such as pressure and grinding 
- physical state of the drug may affect solid state and chemical degradation (Yoshioka and 
Stella, 2000; FDA, 2008).  Therefore the stability of substances under analysis is affected 
by the prevailing conditions in the laboratory (environmental and analytical). Often these 
factors can act in combination. Degradation can occur both in the solid-state and more 
commonly in solution. In-solution, factors such as solvent choice critically arise. 
 
2.7.2 EFFECT OF SOLVENTS ON STABILITY 
 
The properties of a solvent, such as boiling point, viscosity, UV absorption, refractive 
index, density, and polarity determine its selection for analytical use. It was reported in 
section 1.10 that solvents influence the stability of drugs. It therefore follows that a good 
solvent is one which not only dissolves the reactants and reagents but whose properties do 
not interfere with the analysis. Hence, it does not affect the outcome or accuracy of the 
results. A good solvent therefore;  
 
• Should have an appropriate boiling point. The boiling point of the solvent should be 
lower than that of the analytes. It is well known that in gas chromatography separation 
is based on their volatility (Khopkar, 2012). Hence, if the solvent and analyte have 
similar boling points the solvent peak will co-elute with the analyte.  
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• Does not contain ions which will interfere with the detector. In gas chromatography 
some detectors are element specific, e.g. acetonitrile will be a poor choice of solvent 
where Nitrogen phosphorous detector (NPD) is used (Barwick, 1999; Kaur, 2010).   
• Should be inert to the reaction conditions so as to prevent degradation of the analytes. 
For example aldehydes or ketones such as acetone are rarely used because they may 
undergo chemical reactions with the analytes. In addition, alcohols such as methanol 
and ethanol may also react with the analytes (Yoshioka and Stella, 2000). 
• Should be thermal stable under routine laboratory conditions.  
 
In this study the solvent selected for use will be applied to all the analytical work in the 
research, identification, quantitative determination of street samples, characterisation and 
profiling. Consequently, the solvent required should not react with the drugs or any 
substances in the street samples as this might generate artefacts which can mask analytes.  
 
This research investigated the solvents shown in Table 2.1. Their use in analysis of drugs of 
abuse was identified in section 1.10. The properties of the solvents (Gokel, 2004), are also 
given in the table. The potential for solvent-drug reactions, which can result in degradation 
were reviewed (Yoshioka and Stella, 2000; Lawrence, 2004; Jones, 1982) so as to gain an 
insight into their influence on chemical stability of the drugs for this research. 
 
Table 2.1 Chemical properties of the solvents investigated (Gokel, 2004). 
 Ethyl acetate Dichloromethane  Methanol 2-methylpropan-2-ol 
Structure 
CH3 O CH3
O
 
 
Cl Cl
 
OH
H H
H
 
OH
CH3 CH3
CH3
 
Dipole  
moment (µ) 
1.84 1.60 1.68 1.67 
Dielectric 
constant (ε) 
6.11 9.14 32.62 10.9 
 
The solvents methanol and 2-methyl-propan-2-ol are alcohols and can undergo reactions 
with analytes characteristic of alcohols depending on the chemical functional groups 
present in the drug analyte, such reactions as esterification with drugs with organic acids 
properties can arise. Oxidation of the solvent can occur, resulting in products which are 
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potentially reactive; oxidation of methanol produces formaldehyde and in excess oxidising 
agent, the formaldehyde is further oxidised to formic acid and then to carbon dioxide and 
water. However, the reaction is very minimal and requires a catalyst. Methylene chloride in 
its pure dry state is a very stable compound. However, as a solvent methylene chloride has 
potential to decompose producing chemicals which can act as degradants (Tanabe and 
Matsuda, 1961). Dichloromethane can undergo atmospheric degradation; on exposure to air 
methylene chloride slowly reacts with photochemically generated hydroxyl radicals. It is 
known that in the presence of moisture methylene chloride has a propensity to undergo 
slow hydrolysis to give formaldehyde and hydrogen chloride and in alkaline solution the 
formaldehyde formed undergoes further reaction with hydroxide ion to give methyl alcohol 
and formic acid. The rate of reaction whilst minimal varies greatly with changes in 
temperature and pH and commercial reagents used for laboratory analysis are stabilised to 
minimise its hydrolysis. Reactions for the hydrolysis are shown in Figure 2.12 below.  
 
CH2Cl2  +  OH- (or H2O) → CH2ClOH+ Cl- (or HCl)        
CH2ClOH  +  H2O → CH2 (OH) 2  +  HCl       
        → CH2O + H2O, 
in alkaline solution 
2CH2O  + OH- →HCO2-  +  CH2OH     
 
Figure 2.12 Hydrolysis of dichloromethane (Tanabe and Matsuda, 1961) 
 
Both formaldehyde and formic acid are reactive species which can affect the stability of 
analytes present in the solution 
 
2.7.3 POTENTIAL CHEMICAL DEGRADATION REACTION PATHWAYS 
 
During analytical investigation drug analytes can undergo different types of chemical 
degradation pathways, such as hydrolysis, oxidation, photochemical degradation, 
esterification and isomerisation. The type of reaction and its likelihood depend on the 
functional group present in the drug and also on the adjacent functional groups which 
influence its reactivity. The compounds (structures in Figure 1.4) under investigation in the 
research are heterocyclic polar compounds, exhibiting a variety of functional groups. They 
can generally be categorised as; 
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• 1-arylpiperazines, benzylpiperazines and amphetamines. These contain the amine and 
fluorine as reaction centres (for fluorinated piperazines such as FPP, CPP and TFMPP). 
• Compounds containing ester bonds; mainly the non–piperazines alkaloid cocaine, 
benzylecgonine, ecgonine methyl ester and dextromethopharn.  
• Compounds containing amides bonds; caffeine (an alkaloid) and diazepam (a 
benzodiazopinone)  
• Other combinations such as dapoxetine and nicotinamide (heteromonocyclic pyridine)  
 
Due to the presence of moisture in the solvents and atmosphere, hydrolysis is the most 
common degradation pathway for most drug compounds. Hydrolysis is often the major 
degradation pathway for substances having ester and amide functional groups due to 
nucleophilic attack of the hydroxide ion or water at the ester (Yoshioka and Stella, 2000; 
Lawrence, 2004) consequently cocaine and diazepam are likely to be subject to hydrolysis. 
Accordingly the degradation of cocaine is well known (Cole, 2003; Yoshioka and Stella, 
2000; Staack and Maurer, 2005), the degradation generally follows the reaction scheme in 
Figure 2.13; shown for the formation of a carboxylic acid ester.  
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Fig. 2.13 General hydrolysis of the drugs containing ester bonds. 
 
Drugs with a reactive nitrogen or amide bonds can also undergo hydrolysis, e.g. diazepam 
can undergo ring opening due to reversible hydrolysis of the amide and azomethine bonds. 
The reaction is generalised in Figure 2.14. 
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Figure 2.14 General hydrolysis of the drugs containing amide bonds.  
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Oxidation reactions are also a potential degradation pathway; in the presence of reactive 
oxygen or other oxidants in the sample matrix or atmosphere (dissolved atmospheric 
oxygen in the sample or solvent) can result in degradation of the drug analytes e.g. amines 
(piperazines) can be oxidised to the respective amine oxide (Jones, 1982). Such a reaction 
usually requires catalysis and elevated temperatures and as such under routine analysis is 
minimal. Esterification of drugs containing carbonyl bond or amine bonds can occur in the 
presence of organic acids, consequently use of ethyl acetate and methanol as solvents gives 
potential to such reactions with the piperazines, cocaine, diazepam and caffeine, such 
reactions generally occurs as shown below in Figure 2.15. 
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Figure 2.15 General esterification reactions of the drugs containing amine bonds.  
 
Furthermore, considering that piperazine drugs of abuse exist as combinations in street 
drugs (Yeap et al., 2010) the likelihood of drug-drug interactions or drug-excipient 
interaction occurring during chemical analysis exists. This has implications of potential 
degradation and hence raises the need to investigate stability during analysis. 
  
2.8 CONCEPTS TO CHARACTERISATION OF STREET SAMPLES  
 
In Chapter 1 (section 1.8.3) physical and chemical characterisation were identified as 
inherent components of drug profiling. In addition, presumptive testing was identified as 
part of chemical characterisation. Hence, the concepts behind physical characterisation and 
the presumptive tests that will be applied in this research are discussed below. The general 
concept behind chemical characterisation was discussed in section 1.8.4.  
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2.8.1 PHYSICAL CHARACTERISATION 
 
Physical features are those features that are present on the tablet after manufacture, i.e., 
“tableting”. These are mainly the shape, logo, colour, dimensions or any other markings 
(Cheng et al., 2003; Makino et al., 2003; Milliet et al., 2009) e.g. Figure 1.3. According to 
Milliet et al. (2009) most physical features (except the logo and colour) are observed to be 
quite persistent in time. As such they can be utilised as a tool to provide links between 
different samples of tablets. For example, tablets produced from the same machine have 
similar features due to the characteristic traits of the tableting machines. A defective tablet 
die machine may even produce a characteristic mark, such as a chipped surface, this can aid 
in identification of its source.  It therefore follows that such samples can be linked 
irrespective of when they were produced. As such, post-tableting links maybe useful 
intelligence tools for law investigation purposes.  
 
In a study by Milliet et al. (2009) on profiling of MDMA, the authors found that generally 
organic impurities confirmed the links highlighted by physical profiling in about half of the 
cases studied (11 out of 19). In other study, also profiling of MDMA by Makino et al. 
(2003) and Zingg (2005) also investigated similar physical characteristic of tablets and 
similarly concluded that physical characteristics produce useful links. It can be extrapolated 
that similar samples from the same source will therefore contain similar chemical profiles, 
thereby confirming the links between them. However, this is not always the case. Cheng et 
al. (2003) in a study also on profiling of several amphetamines that reported that some 
tablets with similar physical appearances had different chemical compositions. 
Furthermore, some manufacturers used several colour dyes and metal dies with different 
shapes, logos, or letters, e.g., rectangular CC, circular 88, and AP were found at a local 
ecstasy tablet-manufacturing scene. The purpose of doing this is most likely to mislead law 
enforcement agents. As such, physical characterisation is not used on its own but in 
complement to chemical analysis. 
 
2.8.2 PRESUMPTIVE TESTS 
 
The concept behind the test is the production of a specific colour change due to a chemical 
reaction between the analyte and the reagent. Hence, these tests provide a visual means of 
identification. Table 2.2, highlights the compounds that give a positive reaction to the 
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presumptive tests used in this research (Marquis and Simon’s test) and the expected colour 
changes.  
 
Table 2.2 Reactions of colour tests used in this investigation (Cole, 2003; Kovar and 
Laudszun, 1989; UNODC, 1994; 2013c)  
Substance Expected colour 
 Marquis reagent Simon’s reagent 
Amphetamine Orange colour changing to brown NR[1] 
Other amphetamine derivatives e.g. 
2,5-dimethoxyamphetamine (DMA)  
 
Yellow to yellowish brown 
 
NR[1] 
Methamphetamine Orange colour changing to brown Blue 
MDMA Black Blue 
Other methamphetamine derivatives 
e.g. 2,5-dimethoxymethamphetamine 
(DMMA) and N-substituted 
derivatives such ethylamphetamine 
Blue Blue 
Piperazines NR[1] Blue 
Piperidine NR[1] Deep blue 
[1] NR is no reaction observed. 
 
The Marquis test is a qualitative test for aromatic compounds. The test is based on the 
reaction of the substance with the Marquis reagent, i.e., a solution of formaldehyde in the 
presence of concentrated sulphuric acid (section 8.2.4.2.1) The reagent can distinguish 
between unsubstituted phenethylamines (amphetamine, methamphetamine) and their ring-
substituted analogues such as MDMA (Kovar and Laudszun, 1989; UNODC, 1994). It can 
be seen in Table 2.2 that the Marquis reagent produces an orange colour with amphetamine 
and methamphetamine whilst a dark blue/black colour is obtained with MDMA. Hence, 
these compounds can visually be distinguished. For this reason it is widely used as a 
presumptive test for ‘ecstasy’ (Cole, 2003; UNODC, 2013c). Piperazines have been 
reported to give no reaction or a faint colouration (UNODC, 2013c). Similarly, the London 
toxicology group (LTG) found that of the piperazines only 2-MeOPP gave a faint pink 
colour with Marquis reagent (LTG, 2006). It can also be applied to other drugs such as 
heroin and codeine.  However, it also produces colour changes with a large number of 
heterocyclic compounds and this is a limitation as it would give ambiguous results if used 
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on sample containg more than one such compound. Figure 2.16 shows the general reaction 
to the Marquis test.  
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Figure 2.16 Reaction of aromatic compounds with Marquis reagent (adapted from Kovar 
and Laudszun, 1989). 
 
In Figure 2.16, formaldehyde in the presence of an acid forms a carbonium ion (I). This 
reacts with the aromatic ring (II) in the presence of sulphuric acid to form a carbenium ion 
(IV). To stabilise the carbenium ion a further reaction with a second aromatic ring occurs 
(V). Oxidation occurs due to traces of heavy metals such as iron in sulphuric acid to give 
(VI). This undergoes hydrolysis in the presence of sulphuric acid to give a carbenium ion 
(VII). This carbenium ion is responsible for the pink colour observed with aromatic 
compounds, however the final colour is dependent on the type of drug. The different 
substituents for R in reaction implies different carbenium ions are formed at the end of the 
reaction resulting in the colours observed (Table 2.2). 
 
Simon’s reagent is comprised of solutions of sodium nitroprusside, acetaldehyde and 
sodium carbonate (UNODC, 2006; Takahashi et al., 2009). Simon’s reagent is used to test 
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for secondary amines on the basis of formation of a blue Simon-Awe complex (Kovar and 
Laudszun, 1989). It can be seen it Table 2.2 that no colour is produced with primary amines 
(e.g. amphetamine) whislt secondary amines produce a blue colour with methamphetamine 
derivatives). In comparison, it has been reported to be less sensitive to piperazine drugs 
(IV) than secondary amines such as methamphetamine or MDMA (UNDOC, 2013c). As 
such, this could prove a limitation to use of the test on its own. The reaction mechanism is 
shown in Figure 2.17. 
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Figure 2.17 Reaction of secondary amine compounds with Simon’s reagent (adapted from 
Kovar and Laudszun, 1989). 
 
Reaction of the secondary amine with formaldehyde results in the formation of an enamine 
intermediate product (VI). This reacts with the sodium nitroprusside anion ([ONFe(CN)5]2-) 
to give the immonium ion (VII) and is subsequently hydrolysed to the Simon-Awe complex 
(VIII), this is responsible for the blue colour change. This is a ferro cyano complex in 
aqueous solution and is characteristically blue. Simon’s test distinguishes between primary 
and secondary amines. Secondary amines give a blue a positive reaction (blue colour) with 
Simon’s reagent (Table 2.2). Hence, the Marquis and Simon’s test will be useful in this 
study as street samples are expected to contain amphetamines such as MDMA and other 
aromatic compounds (such as BZP and other piperazine derivatives, cocaine, diazepam, 
caffeine).  
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Another test that has been reported in the analysis of piperazines is the Dragendorff reagent 
(UNODC, 2013c). The reagent tests for the presence of an alkaloidal base, however tertiary 
amines often show a strong positive result. Piperazines may also give a mildly positive 
result. Whilst reports on presumptive tests are limited, the use of Dragendorff is less than 
that of Marquis and Simon’s reagents. In the UNODC (2013c) study the results for the 
piperazines and amphetamines were orange to orange-red and not easily distinguishable. As 
such, this reagent was not considered for use in this research. 
 
It was identified (section 1.2), that piperazines are often marketed as ‘ecstasy’ and are 
found in combination with other drugs such as methamphetamine, MDMA and adulterants. 
The Marquis test will therefore be a valuable tool in this study in detecting the presence of 
amphetamines. The limitation of presumptive tests is that the reactions are generally 
specific to a class of drugs and not the actual drug substance. For example, it would be 
difficult to specifically identify amphetamine in the presence of MDMA by Marquis 
reagent or methamphetamine if piperidine is present in the sample (Table 2.2). The actual 
colour observed depends on many factors, such as the concentration of the drug and 
whether the drug is a salt or free base form (O’Neal et al., 2000). In addition, the presence 
of impurities in the sample matrix may interfere and mask the colour change (Baker and 
Phillips; 1983; O’Neal et al., 2000). Consequently, more than one colour test is used, this 
gives more discriminating results. Hence, in this study for the analysis of street samples, 
preliminary screenings were carried out using the Marquis and Simon’s tests. 
 
2.8.3 SYNTHESIS (ORGANIC) 
 
Synthesis is the process of chemically reacting compounds so as to produce a desired 
substance. The initial starting materials to a reaction are defined as precursors. The purpose 
of synthesising a drug substance is to obtain the product in the highest yield possible and at 
acceptable purity. This is influenced by several factors. Typically, this is dependent on 
temperature, catalysts, concentration of precursors, reaction time and reaction route and 
furthermore, on the skill of the manufacturer. For example, use of the wrong temperature 
might mean the reaction will not have enough activation energy for the precursors to react. 
If the reaction time is too short the reaction is likely not have had enough time to reach 
completion. If the amount of precursors used are not the reaction’s stoichiometric ratios one 
or more will be in excess. In all these cases the result will be a) poor product yield and b) 
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residual precursors will be present giving poor product quality. Side reactions can occur 
resulting in by-products such the formation of the 2 and 3) positional isomers of 4-FPP and 
(2 and 4) positional isomers of- 3-TFMPP (the reactions would follow a similar mechanism 
to that shown in Figures 1.17a; b for the synthesis of phenylpiperazines. 
 
 In addition, Liu and Robichaud (2005) reported the possibility of a competitive side 
reaction in the reaction of anilines (I) with bis(2-chloroethylamine). The product of the 
reaction 4-FPP or 3-TFMPP and the reactant bis(2-chloroethylamine) occurs the presence 
of a base. The reaction scheme in Figure 2.18 is proposed. However, in the method used the 
author also reported that the use of diethyl glycol monomethyl ether as a solvent minimises 
the competitive side reaction (Liu and Robichaud, 2005). Hence, its occurrence is reduced 
since this was the solvent used. Assuming that the side reaction minimally occurs, products 
(II) and III) could be produced as impurities. This not only gives a poor quality product but 
results in low yields of the product.  
NHNR
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diethyl glycol monomethyl ether
NH
Cl Cl
I
II
N
N
NH
Cl
F
2-chloro-N-{2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl}ethanamine
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N
N
NH
Cl
F3C
III
+ HCl
+ HCl
 
Figure 2.18 Impurities in the synthesis of phenylpiperazines from bis(2-chloroethy1)amine 
hydrochloride and substituted anilines. 
 
In the current study, 4-FPP and 3-TFMPP were synthesized from fluoroanilines according 
to previously published procedures (Liu and Robichaud, 2005) and an adaptation of the 
method for the isomer 4-FMPP for the synthesis of the 3-TFMPP isomer (Kiritsy et al., 
1978; Shaman Australis Botanic 2003). It was recorded the method by Kiritsy et al. for 4-
FPP was similar in reagents to that of Liu and Robichaud, 2005. The schematic diagram for 
 89 
 
the syntheses reactions were shown in Chapter 1, Figures 1.17a,b (Liu and Robichau, 2005) 
and Figures 1.6a,b (Kiritsy et al., 1978; Shaman Australis Botanic 2003). The mechanisms 
for the reactions involved are shown in Figures 2.19 and 2.20 below. Due to 4-FPP having 
electron-donating substituents the mechanism (Figure 2.21) involved ring-closure via 
reaction of bis(2-chloroethy1)amine hydrochloride and the appropriate substituted anilines 
(Kiritsy et al., 1978). For 3-TFMPP the mechanism involved fusion of anhydrous 
piperazine and the corresponding substituted halobenzenes due to the electron-withdrawing 
properties of the (-methyl group) substituent. The intermediate carbocation formed is 
stabilised through resonance (structures IV- VIII). Whilst the main product is 3-TFMPP 
resonance can result in the presence of 2 and 4 (TFMPP) isomers.  The procedure can be 
applied to any other N-(4-substituted pheny1)piperazines.  
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Figure 2.19 Mechanism for the synthesis of phenylpiperazines from bis(2-
chloroethy1)amine hydrochloride and substituted anilines. 
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Figure 2.20 Mechanism for the synthesis of phenylpiperazines from anhydrous piperazine 
and substituted halobenzenes.  
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CHAPTER 3 
STATISTICAL DETERMINATIONS AND OTHER 
CALCULATIONS 
 
3.1 INTRODUCTION TO STATISTICAL EVALUATIONS AND CALCULATIONS 
 
In this chapter the tests applied in testing the validity of the results generated during this 
research are discussed. The mean, standard deviation, relative standard deviation and 
variance are common and useful statistical tests applied in research work and have been 
applied in analysis of drugs of abuse such as Andersson et al. (2007a), Davies et al. (2010) 
and Kelleher et al. (2011). The tests were for descriptive statistical evaluation of research 
data such as the degree of variation and error. Consequently, they were applied in this study 
for similar evaluation. These tests are described in sections 3.2.1 - 3.2.3. Other statistical 
tests used were Pearson’s correlation coefficient; t-test, ANOVA, Chi square, Friedman 
test, Wilcoxon signed-rank test, Gain and loss, linear regression, Mann- Kendal test and 
Runs test for randomness (sections 3.2.4 - 3.2.13). In addition, the calculation of 
identification parameters (relative retention time and relative retention index) and 
quantitative determinations for analytes are described (sections 3.2.14 and 3.2.15). 
 
3.2 TESTS APPLIED 
 
3.2.1 MEAN 
 
The mean or average of a sample 6̅  is given by the sum divided by the sample size. For a 
sample of size n where i = 1, 2, ….,n (Corder and Foreman, 2009). 
 
x9 = 1n:;x<=>?- 																																																																																																																													3.1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3.2.2 STANDARD DEVIATION RELATIVE STANDARD DEVIATION AND VARIANCE 
 
Standard deviation, σ and variance, σ2 are measures of the variation of the data from the 
mean. Standard deviation is given by the square root of the variance. These parameters 
were determined according to equations 3.2 and 3.3 (Sprent and Smeeton, 2007); 
σ = :;(x> −	x9)n − 1=>?- 																																																																																																																	 	3.2 
 
Variance = σ2 [3.3]  
 
The relative standard deviation, %RSD is defined by the equation 3.4 (Sprent and Smeeton, 
2007; Corder and Foreman, 2009). 
 
%RSD = σ ∗ 100%x9 																																																																																																																	3.4	 
 
3.2.3 CONFIDENCE INTERVALS 
 
The interval is a range of values for which there is a specified probability, 100(1-α)% that 
the population mean or parameter lies within it (Corder and Foreman, 2009). For example it 
can be said with 95% confidence (α = 1- 0.95 = 0.05 or 5%) that the mean is defined by this 
value. As such it provides a description of the accuracy of an estimated mean value. The 
interval can be computed using either the normal or t-distribution. In this study, 
computations applied the t-distribution since it is the one applicable to small populations (n 
< 30) and is given by (Corder and Foreman, 2009; Gopal, 2006); 
 x9 	±	$ σ√n% t																																																																																																																																	3.5 
 
Where σ is equivalent to the estimated standard deviation of the sample, t is the t-statistic 
for the t-distribution at 1-α level of confidence (or 1 − α 2G  for a two tailed distribution) and 
n-1 degrees of freedom. It is further discussed in section 3.2.5. 
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3.2.4 PEARSON’S CORRELATION 
 
It is a measure of whether there is a significant relationship, i.e., correlation between two 
variables. Pearson’s correlation coefficient is given by r, where -1< r < +1, the closer to one 
the greater the similarity. A value of 0 indicates there is no relationship, +1 indicates a 
perfect positive correlation and -1 indicates a perfect negative correlation, however it is 
only applicable to continuous data (Gopal, 2006; Sprent and Smeeton, 2007; Corder and 
Foreman, 2009). Pearson’s correlation is given by the equation 3.6 (de Souza and 
Junqueira, 2005; Taverniers et al., 2004; Corder and Foreman, 2009); 
 
Let x and y be the measured variables with sample of size n where i = 1, 2, ….,n 
 
H = ∑ 	(x> −	x9	)(y> −	y9	)=>?-{∑ (x> −	x9)	∑ (y> −	y9)}-=>?-=>?- 																																																											 	3.6 
 
As such in this study this test was applied to compare the data derived from the different 
solvents used in the stability studies. The objective was to statistically determine if different 
solvents produce similar stability profile for the drugs (Chapter 5 on stability studies). In 
addition it was also applied to evaluate if there was correlation between synthesised drugs 
samples and reference standards in the chapter for characterisation of street samples 
(Chapter 8). 
 
3.2.5 T- TEST 
 
T-tests are a basic inferential test used for evaluating the significance of the relationship 
between two sample means (µ0 and µ1), with respect to the variation in the data. This is 
achieved by testing the hypothesis Ho: µo = µ1, i.e., there are no differences between the 
two samples hence their means are equal. The principle behind significance testing is the 
calculation of the test statistic and its comparison to tabulated critical values. In addition, 
the determination of the probability of occurrence (p) by comparison of the p value to the 
level of significance used (α). If p < α, it implies that the means are not equal, hence Ho is 
rejected (Huber, 1996; Sprent and Smeeton, 2007).  There are several types of statistical 
tests that utilises a t-distribution. These are (Gopal, 2006); 
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a) One-sample t-test (uni-variate test): this is a measure of whether a sample mean is 
different from a hypothesized value. This by investigating the value of a single 
sample mean and its comparison of the sample mean with a theoretical value such 
as a known population mean or some other fixed value. 
b) Independent samples t-test : compares two means from different groups 
c) Paired samples t-test: compares two means that are repeated measures of the same 
subject  
The principle assumptions are the population data from which the sample data are drawn 
are normally distributed and that the variances of the populations to be compared are equal 
(Sprent and Smeeton, 2007). In a normally distributed population, the population standard 
deviation, σ is known and the difference between each value of the variable x and the 
population mean, µ is defined by the standard variable, Z where; 
 N = x − μ 																																																																																																																																				 	3.7 
 
Consequently for the sample mean, 6̅ 
 
N = x9 − μσQ 																																																																																																																																				 	3.8 
 
Where σx is the standard error of the mean, σQ = σ √n⁄  . Substituting for σx into equation 
3.8 gives;      
 N = x9 − μσ √T⁄ 																																																																																																																																				3.9 
 
Equation 3.9 has more practical applications than 3.7 and was applied in the calculation of 
the z-statistic in significance tests and in this research. It has been reported that when the 
sample size is small (< 30) and the standard deviation is unknown the sample distribution 
no longer follows a normal distribution pattern, instead it widens and follows a t-
distribution where the t-statistic is defined by the equation 3.10 (Gopal, 2006; Corder and 
Foreman, 2009); 
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U = x9 − μs √T⁄ 																																																																																																																																		 	3.10 
where s is the estimated standard deviation.  
 
Consequently, in this research the following types of t-tests were applied when the 
following conditions existed; for the comparison of two samples (drug A and drug B) 
subjected to the same measure, the independent t-test was be applied. For comparison of 
the drugs in optimisation studies (Chapter 6) such as checking for effects of before and 
after subjection to changes in temperature the paired t-test was applied.  
 
3.2.6 ANALYSIS OF VARIANCE (ANOVA) 
 
ANOVA is a statistical test for heterogeneity of means by analysis of group variances and 
is used to compare the means of two or more groups of data (Huber, 1996). The types of 
ANOVA  are  a) ANOVA One-way; this is applied where there is only one factor (one 
treatment type, one response) and b) two- way which is applied when two factors are 
investigated (2 treatment types or 2 responses). The concept behind ANOVA is the 
calculation of the mean observation and variance within each group. This is followed by 
comparison of the variances among the means to the average variance within each group. 
The hypothesis test is that the observations in the different groups have the same mean, i.e., 
Ho: µ1 = µ2,……, µn. As such the weighted and group variance will be same as the within 
group variance. However, the variance among the means increases if at least one of the 
means is not equal. The significance of the difference between the means is indicated by 
the test statistic, F, where F is the ratio of variance among the means to the average 
variance within the groups (Huber, 1996; Corder and Foreman, 2009). The F statistic has a 
known distribution as such its probability of occurrence can be calculated. 
 
Assumptions of ANOVA are similar to the t-test and the tests are similar. For more than 
two samples it would mean carrying out multiple t-tests since the t-test is for comparison of 
two samples. This would lead to increased errors in the analysis (Sprent and Smeeton, 
2007; Corder and Foreman, 2009), hence the use of ANOVA. As such in this research for 
comparison of more than two samples, ANOVA is one of the tests that were applied. The 
test statistic, F is given by equation 3.11 (Corder and Foreman, 2009) and is determined as 
follows;  
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Let y be the response observed, where y is a random variable with equal variances, 
independent errors and a normal distribution. Let k be the number of groups investigated 
and n the number of observations. For the yij observation; i = 1, 2,…., k and j = 1, 2,…., n. 
The total sum of the squares (SST) is given by sum of the squares when subjected to treat 
(SSA) and the error of the sum of the squares (SSE), i.e., 
 
SST = SSA + SSE 
 
SST = ;;(y>W − yX)=>?-
Y
>?- =;;(y>W)
=
>?-
Y
>?- − ∑ ∑ (y>W)
=>?-Y>?- kn  
 
SSA = 	 1T;;([<\)]<?-
^
<?- − 1_T;;([<\)
]
<?-
^
<?-  
 
SSE = SST – SSA 
 
` = MSAMSE																																																																																																																																			3.11 
 
where: [X is the group mean (mean of means) 
MSA is the mean sum of squares for the treatment  
MSE is the mean error sum of squares 
If p < α reject the null hypothesis, as the deduction is that at least one of the means 
is not same as the others. 
 
3.2.7 CHI SQUARE 
 
Chi square is a goodness-of-fit test used to measure of the deviation of a sample from an 
expected value. It is used to determine whether a sample data are consistent with a 
hypothesised distribution (Gopal, 2006). In stability studies the objective was to determine 
whether the concentration of the analyte remained the same for a period of time i.e., Ho: x1 
= x2 =,…., = xn where x is the concentration of the analyte and N is the sample size (or 
number of determinations). Therefore in this research the chi-square test was one of the 
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tests used in analysis of stability results (Chapter 5). The chi square distribution is the 
distribution of the sum squares of a set of normally distributed random variables. The chi 
square distribution is the distribution of the sum squares of a set of normally distributed 
random variables. The test statistic, chi square, χ2 is given by equation 3.12 (Gopal, 2006; 
Corder and Foreman, 2009). Let the probabilities of various classes in a distribution be p1, 
p2, …, pk 
 
χ = ;(c< − de<)de<
^
<?- 																																																																																																												3.12 
  
Critical values of chi square were used for comparison (Laurencelle and Frangois, 2002).   
 
3.2.8 FRIEDMAN TEST 
 
This is a non-parametric test used to compare more than two related samples. The null 
hypothesis of the test is that when subjects are subjected to different treatments, the 
treatments produce identical effects. The alternative hypothesis is that at least one of the 
treatments tends to yield larger values than the other treatments (Friedman, 1937; Corder 
and Foreman, 2009; Best et al., 2009). The test does not make assumptions that the data is 
normally distributed and uses ranks of data. The objective of the test is it provides a means 
of identifying differences in the distribution under k number of treatments.  
 
Martin et al. (1993) in their study on Friedman tables and Best et al. (2009) in their study 
on non-parametric rank tests reported that the test is an alternative to the F-test for two-way 
analysis of variance when there is reason to believe that the assumptions underlying the 
classical ANOVA are not satisfied by the data. For this reason this test was deemed 
appropriate to use in the study as the data under investigation cannot be assumed to follow 
a normal distribution. In addition, it involves ranking, which was especially useful as the 
data under consideration was very diverse for the different subjects (drugs) which can result 
in swamping of the smaller values. Consequently, ranking gives a clearer picture. The 
descriptive statistics derived from the ranking would also be of use in interpretating the 
pattern between the results, such as the medians and rank sums. Furthermore, Martin et al. 
(1993) reported that it is applicable in situations where multiple correlated measures are 
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obtained on the same subjects. In this research such a situation existed where several 
different instrumental variables, i.e., different column and oven temperatures were applied 
on the subjects. In addition different parameters, i.e., retention time, plate number, 
resolution, selectivity and retention were then determined on the same subjects. As such the 
test was considered ideal for use and was applied in evaluation of optimisation (Chapter 6) 
and validation data (Chapter 7).  
 
The Friedman Test statistic, Fr is calculated by equation 3.13 (Friedman, 1937; Martin et 
al., 1993; Best et al., 2009; Corder and Foreman, 2009).  
 
f` = g	 12T_(_ 2 1);h<2Ti=0 j − 3T(_ 2 1)																																																																											3.13 
 
Corr =  
 
where: Fr is the Friedman test statistic 
n is the number of subjects or cases (= rows) 
k is the number of conditions (= ranks or columns) 
Ri is the sum of the ranks for ranks i     
df is the degrees of freedom = k-1 
Corr is the correction factor for ties 
 
If ties exist on ranking the correction factor, Corr is applied and  
Frcorr  = Fr/ Corr 
 
3.2.9  WILCOXON SIGNED-RANK TEST 
 
The Wilcoxon signed-rank test (Wilcoxon, 1945) a nonparametric test equivalent to the t-
test and similarly is used for the analysis of two samples. It determines the magnitude of 
departures from a hypothetical mean ranks the data and calculates the test statistic 
(Toutenburg, 2002). The assumptions made are that a) the dependent variable is measured 
at the ordinal or interval/ratio level, b) the independent variable consists of two categorical, 
matched pairs, i.e., the same subjects are present in both groups and, c) assumption of 
;;(U#<\	 − 	U<\)/(T_(_2 − 1)^\?-
]
<?-  
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population symmetry. It does not assume normality of data hence can be used when this 
assumption has been violated rendering use of the dependent t-test is inappropriate. When 
participants are subjected to 2 different treatments at different time intervals violation of 
normality assumption can occur (Corder and Foreman, 2009). As such this test was deemed 
appropriate for this study were the drugs were subjected to two different oven temperatures 
and the responses measured through a number of variables (Chapter 6). The Friedman test 
was used for evaluation when more than two temperatures were investigated (Phase 1 of 
the optimisation). 
 
The test is based on the concept that if a true mean or median (θ) exists then there should be 
an equal number of positive and negative ranks. For a data set consisting of N paired 
observations (x1, y1), (x2, y2),...., (xN, yN), where the X and Y random variables are 
correlated. The differences are defined as (Kang and Kvam, 2007); 
Di = xi – yi, i = 1, 2, ..., N 
 
The following assumptions are made about the distribution of the random variables: a) the 
distribution of Di each is symmetric b) the Di’s are mutually independent and c) the Di’s 
have the same median.  As such, the hypothesis tested is Ho: θ1 = θ2 hence θ1 - θ2 = 0 
meaning; Ho: There is no difference between the two treatments. H1: There is a difference 
between the two treatments.  The Wilcoxon signed-rank test statistic is given by T, 
equation 3.14 (Kang and Kvam, 2007; Sprent and Smeeton, 2007; Toutenburg, 2002). 
 
T = min n;R<(D< > 0),;R(D< < 0)=>?
=
>? r																																																												3.14 
 
Mean = E(t) =;r</2=>?  
 
Variance = 	σ;r</4=>?  
The standardised test statistic,  N = 	 wxy(w)z  
 
where: σ is the standard deviation 
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ri is the ranks for ranks i 
Ri is the sum of the ranks for ranks i  
 
The criteria for the test are that for sample sizes, n ≤ 20 by comparison to literature 
Wilcoxon tables. For sample sizes, n > 20 the normal distribution Z score tables are used. 
 
3.2.10 GAIN AND LOSS ANALYSIS 
 
Gain and loss graphs are one of the many types of existing control charts. They are used in 
change analysis. They are used to monitor deviations or variability from a target value. 
They are useful for detection, correction and reduction of process that cause undesirable 
change. According to Cheung et al. (2012) control charts allow for visual distinction 
between meaningful and random change by distribution pattern.  As such, they were found 
useful in this study to enable determination of the changes in the chromatographic profile 
of an analyte caused by variation of experimental variables, such as oven temperature. 
Hence, parameters which caused the highest variations were identified.  This facilitated 
selection of optimum parameters during the optimisation process (Chapter 6). In addition 
they provided easier evaluation of the large experimental data generated.  In the study % 
gain or loss in plate number and tailing was evaluated using this method. With the aim of 
determining which experimental variable (different injector and oven temperatures) caused 
the most increase in N and decrease in T. The % Gain or loss (or % change) is given by 
equation 3.15; 
 
% G or L = Parameter experimental value  - parameter value in control x 100%  [3.15] 
      parameter value in control 
 
Where % G or L is % gain or loss respectively, this is then plotted to give a graphical 
depiction of the changes (Bersimis and Parakis, 2007; Kang and Kvam, 2007; Cheung 
et al., 2012).  
 
3.2.11 SIMPLE LINEAR REGRESSION ANALYSIS 
 
Regression analysis is a method for investigating the relationship between two or more 
variables. Various types of regression analysis exist; however for routine analysis ordinary 
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least squares (OLS) regression analysis is applied (de Souza and Junqueira, 2005; Miller, 
1991; Tavernier et al., 2004). OLS investigates the relationship between one independent 
variable (x) and one dependent variable (y). The OLS model is typically given by equation 
3.1 (Taverniers et al., 2004), for n measurements, i = 1, 2,……., n.  
 y> = β 2 β-x> 2 ε>																																																																																																																		3.16 
 
where: yi is the detector response 
xi is the concentration 
β1 is the slope slope 
β0 is the intercept 
εi is the random error (or residual) 
 
OLS works on the principle of finding the best-fit straight line (ŷ) for the given data. This is 
also known as the predicted or expected line. This it does by determining estimates of the 
intercept (β0) and the slope (β1) such that the predicted (or expected) line plot minimises the 
sum of the squared differences between the actual line plot (y) and the predicted plot (ŷ). 
The concept behind this is that there is a variance between the observed y values and the 
predicted y values due to random errors. Residuals (ε) are the differences between the 
observed value of y and the expected or predicted y value. This is schematically shown in 
Figure 3.1. 
 
 
Figure 3.1 Schematic diagram of ordinary least squares linear regression plot 
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The predicted linear regression model is given by equation 3.17, for n measurements, i = 1, 
2,……., n.. 
 y}> = β~-x> 2 β~																																																																																																																										3.17] 
 
where: ŷ is the expected or predicted y value 
xi is the concentration β~- is the slope of the predicted plot β~ is the intercept of the predicted plot 
 
The values for the slope and intercept are estimated using equations 3.18 and 3.19. β = y9 −mx9																																																																																																																													3.18] 
 
β- = ∑ [@6< −	 6̅	A@[< −	[9	A]]<?-∑ [@6< −	6̅	A]<?- =  																																																																													[3.19] 
 
The residual or random error is given by equation 3.20; ε> = [< − [}< 																																																																																																																															[3.20] 
 
The residual sum squares, SSres has n - 2 degrees of dreedom  and can be broken down into 
two terms, that due to pure error which has n-1 degrees of freedom and is given by SSε and 
that due to lack of fit, SSlof. Hence, 
 
SSres =  SSlof + SSε 
SSres =  ∑ @[< −	ŷ<A]<?- 2 
 
Given that SSε = ∑ @[i< − 	ȳA]<?- 2 
where ȳ = -]∑ [<]<?- . Therefore,  
SSlof = SSres - SSε  
 
To test for lack of fit the mean squares are calculated and the ratio of mean squares due to 
lack of fit relative to pure error determined. This gives the variance ratio, F. 
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MSε =  = 	 T − 1 
MSlof	 = 	  = 	T − 2  
 
The variance ratio F is given as (de Souza and Junqueira, 2005; Miller, 1991); 
` =  																																																																																																																														[3.21] 
 
The significance of F can be determined at the desired level of confidence, α and from 
stastical tables of critical values. Ho: there is a lack of fit or non-linearity. H1 there is 
linearity. If calculated p > α then Ho is rejected (Miller, 1991). 
 
To test for linearity or how good a fit are the actual data points to the regression line the 
coefficient of determination R2 is used (Gopal, 2006). It is a measure of the total variance 
in y that is explained by the regression equation. The coefficient of determination R2 is 
given by the squared value of Pearson’s correlation coefficient, r (section 3.2.4). Hence; 
 
R2 = r2  [3.22] 
(Lavanya et al., 2013; Gopal, 2006) 
 
As for the Pearson’s correlation coefficient (section 3.2.4) its values are in the range -1< R2 
< +1. A value of zero indicates no linear relationship, +1 indicates a perfectly linear 
positive relationship and -1 indicates a perfectly linear negative relationship. Hence 
linearity is achieved when R2 is closest to +1 (Gopal, 2006; Sprent and Smeeton, 2007; 
Corder and Foreman, 2009). The concept of testing for linearity was discussed in Chapter 2 
section 2.5.  
 
OLS makes the following assumptions (de Souza and Junqueira, 2005; Miller, 1991; 
Tavernier et al., 2004);  
a) Linearity: the relationship between the dependent variable y and the independent 
variable x is linear. 
b) Independence: values of εi are linearly independent of each other, with a mean sum 
of zero, i.e., E(εi│xi) = 0,  if not autocolleration exists. 
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c) Independence: values of xi are linearly independent of each other, if not 
multicolinearity exists. 
d) Normality: the residuals, εi are normally distributed for all values of yi,xi hence y 
follows a normal distribution pattern. 
e) Homoscedasticity: the variance of ε is constant for all values of xi, i.e., E(εi)2 = σ2, 
if distribution is not constant then heterostadastacity exists.  
If the assumptions are not met it implies there is a lack of fit and the model is not linear. As 
such these assumptions can be tested to evaluate linearity. If the condition of normality is 
met, there variance is constant as such the residual plots can be checked to see if variance is 
constant. Y values are independent indicates that the residuals follow a random distribution 
pattern (for further details refer to Chapter 2 section 2.5.1.2). 
 
Regression analysis is one of the methods specified in validation guidelines to establish the 
performance of a method (Eurachem, 1998; CDER, 2004; ICH, 2005). As such it has been 
widely applied by several researchers in studies of drugs of abuse and other work in 
quantitative analysis (Byrska et al., 2010; Rambla-Alegre et al., 2012; Van Loco et al., 
2002; Vorce et al., 2008). Consequently it was applied in validation of the method 
developed in this research (Chapter 7). 
 
3.2.12 MANN KENDALL TREND TEST 
 
The test is used for trend analysis. It can be applied to investigate the variation of a variable 
with time. Hence, it has found wide application in monitoring environmental trends with 
time (Gibbons and Coleman, 2001). A trend exists if there is variation of the data in a 
specific manner.   Unlike most other researchers Aalberg et al. (2005b) applied the Mann 
Kendall test to evaluate stability studies.  The study investigated the stability of impurities 
in organic solvents. The Mann Kendall was used to evaluate the existence of a trend in the 
stability data at a significance level of 5%. The test was successfully able to determine the 
existence of a trend for some of the analytes e.g. N-formylamphetamine (p = 3.01%).  
 
It has been found that the t-test is more commonly applied than the Mann Kendal in 
monitoring trends (Onoz and Bayazit, 2003). Karinen et al. (2011) applied the t-test as a 
measure of stability in their study on stability of stock solutions of drugs of abuse. 
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However, it has been suggested by Gibbons and Coleman (2001) that the t-test for trend 
detection is based on linear regression, and therefore checks only for a linear trend. Onoz 
and Bayazit (2003) similarly discussed the use of the t-test to monitor trends and reported 
that it gives best results for normally distributed data. However, the authors further reported 
that it can still be successfully applied to moderately skewed data.  It is therefore concluded 
that the t-test is limited in that if a non-linear trend exists it can miss it. It is possible that 
when an analyte becomes unstable degradation can occur in a non-linear manner. There is 
no such restriction for the Mann-Kendall test. Consequently, the Mann-Kendall is more 
versatile and will be able to detect the presence of even non-linear trends. The Spearman's 
rho test is another test that can also be applied however Yue et al. (2002) cited in Gibbons 
and Coleman (2001) showed that it provides results almost identical to those obtained for 
the Mann-Kendall test. Hence, it was not considered in this research for stability testing 
(Chapter 5). It is evident from the discussion above that the Mann Kendall is more 
appropriate than the t-test as such as such this test was applied in this research in addition to 
the chi square test. Furthermore, like the t-test it can be applied to small sample sizes (n < 
40) hence was deemed ideal for this research (n = 21). 
 
To conduct the test the null hypothesis is Ho: the data x1, x2,…., xn in the time series are 
independent, identically distributed and alternative hypothesis is H1: There is a monotonic 
(not necessarily linear) trend.  Where x1, x2,…., xn where xi is the measured value on 
occasion i for the data arranged in order of sampling date (time) and xj is the immediate 
subsequent value in the series. The Mann Kendall test statistic, S (equation 3.23) is 
calculated as follows;  
 
The difference between subsequent measurements is given by xj – xi giving a positive, 
negative or zero value for each difference. The signs of each of the possible differences xj – 
xi are calculated as (Gibbons and Coleman, 2001; Aalberg et al., 2005b);  
Sign (xj – xi) = 1 if xj > xi 
= 0 if xj = xi 
  = -1 if xj < xi 
 
 = ;;iT@6\ − 6<A]\?-
]x-
<?- 																																																																																																				 [3.23] 
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However, it is necessary to compute the probability associated with S and the sample size, 
n so as to statistically quantify the significance of the trend. According to Gibbons and 
Coleman (2001) the variance of S, VAR(S), is calculated by the equation 3.24; 
 
VAR@SA = 	 118 n@n − 1A@2n + 5A −;t@t − 1A@2t + 5A

?- 																																		[3.24] 
 
where: n is the number of data points,  
g is the number of tied groups (a tied group is a set of sample data having the same 
value), and  
tp is the number of data points in the pth group. 
 
For n < 10 the probability is then evaluated from the literature Mann-Kendal tables for S. 
For n > 10 the normalized test statistic Z and its associated probability are applied. The Z 
value is computed as follows (Gibbons and Coleman, 2001); 
 
If	 > 0; 	N =  − 1h@A																																																																																																							[3.25] 
 
If S = 0; Z = 0  [3.26] 
If	S > 0; 	Z = S + 1VAR@SA																																																																																																								 [3.27] 
 
The probability associated with the Z statistic is then computed as;  
@A = 	 125 x  
 
The computed Z values and associated probabilities, p are the compared to tabulated cirtical 
values (Onoz and Bayazit, 2003). The criteria applied to determine the existence of a trend 
is that at a specified probability level of significance (95% typically) a trend exists if 
Zcalculated > Zα/2 or if using probabilities p < α (α = 0.05). In addition, the trend is decreasing 
if Z is negative and increasing Z if is positive. However if the computed probability is less 
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than the level of significance then there is no trend (Gibbons and Coleman, 2001; Onoz and 
Bayazit, 2003).  
 
The strength of a trend can be measured in terms of trend size (Aalberg et al., 2005b).  
  
Trend size (%) = (Final response – initial response) x 100%  [3.28] 
                                            Initial response 
where: 
Initial response is given by the average of the responses for the first three 
measurements at time t0, t1 and t3 and 
Final response is given by the average of the responses for the last three 
measurements at t19, t20 and t21. 
 
3.2.13 RUNS TEST FOR RANDOMNESS 
 
The Runs test evaluates whether the order of a series of events is random. A run is a 
sequence of one or more like observations, i.e., increasing (positive) events or decreasing 
(negative) events (Chatterjee and Simonoff, 2012). A sample with too many or too few runs 
suggests that the sample is not random. The test does not make any assumptions about the 
normality or distribution of the data. As such, it is applicable to the evaluation of residuals 
(Sprent and Smeeton, 2007), hence it was used in the validation study (Chapter 7) to 
evaluate the linearity of the calibration curves by checking the distribution pattern of the 
residuals. It was reported in section (3.3.11 and 2.4.1.1) that if the data follows a random 
distribution the residual term εi has a zero mean, constant variance and is independent. In 
its application in regression analysis the test proceeds by examination of the signs on the 
residuals, i.e., whether they are positive (+) or negative (-) and the distribution pattern of 
the positive and negative residuals.  
  
Let yi be the observed response (section 3.3.11, equation 3.16), i = 1, 2, 3,…., n with yi ≠ ŷi 
and residuals εi. The randomness of εi is evaluated by the Runs the test statistic, R denoting 
the expected number of runs (equation 3.29), the mean and variance of the residuals by 
equations 3.30 and 3.31; 
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h = 	  T@AT@xAT@A +	T@xA + 1																																																																																																									[3.29] 
 
μ = 2T@AT@xAT 	+ 1																																																																																																																	[3.30] 
H@<A = 	 =	T@ATx T@AT@xA − T¡T@T − 1A 																																																																										[3.31] 
(Gopal, 2006; Chatterjee and Simonoff, 2012; Sprent and Smeeton, 2007) 
 
where: n is the number of runs, n = n(+) + n(-) 
n(+) is the number of positive runs 
n(-) is the number of negative runs 
µ is the mean 
Var(εi) is the variance of the residuals 
σ is the standard deviation of the residuals 
The significance of the test is determined from the probability using Z scores for n > 10 (or 
critical values for R (n < 10). If randomness is not achieved, the probability, p < 0.05 
(significance level α/2 = 0.05) (Gopal, 2006; Sprent and Smeeton, 2007). 
 
N = 	h − 	μ 																																																																																																																														 [3.32] 
 
3.2.14 CALCULATION OF IDENTIFICATION PARAMETERS  
 
The relative retention time and Kovats retention index were calculated according to 
equations 3.32 and 3.33 (Kaur, 2010); 
 
Relative	retentiontime	 = retention	time	of	a	compound	retention	time	of	the	internal	standard																							 [3.33] 
 
Relative	retention	index = 100n + 100 $ tQ − t=t=- − t=%																																																		 [3.34] 
where: x is the analyte 
n is the n-alkane eluting directly before analyte 
tx is the retention time of analyte 
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tn is the retention time of preceding n-alkane to the analyte 
tn+1 is the n-alkane eluting directly after analyte 
 
3.2.15 QUANTITATIVE CALCULATIONS 
 
The concentration of analytes was determined through the following equations 3.34 - 3.40 
(Crockett, 1986; Kaur, 2010). All the quantitave analysis was conducted after conversion of 
any analytes existing in salt form to free base using equation 3.37. 
 
The conversion of substances in salt form to free base is given by; 
 Amount	of	substance@mgA	as	a	salt	x	molecular	mass	of	substance	as	free	basemolecular	mass	of	substance	as	salt 		[3.35] 
 
Concentration	of	analyte@mg mL⁄ A = area	of	analyte ∗ conc	of	internal	standard	area	of	Internal	standard	 ∗ 	RRF 	[3.36] 
 
RRF	 = 	 area	of	analyte	standard ∗ conc	of	internal	standard		area	of	Internal	standard	 ∗ 	conc	of	analyte	standard																														 [3.37] 
 
Where RRF is the Relative response factor, the RRF of an analyte is determined by 
analysing a known concentration of its standard and substituting into the equation 3.37. 
 
Hence; Amount	or	mass@mgA = conc	of	analyte@mg mL⁄ Ax	total	dilution	volume@mLA				[3.38] 
 
%	Amount	in	tablet	 = Mass	of	unknown	@mgA	x	100%	mean	tablet	mass	@mgA 																																										 [3.39] 
 
The mass of drug on column (ng) is given by; 
Concentration of the injected solution x injection volume x split ratio [3.40] 
 
The yield for synthesis was calculated according to equation 3.41; 
%	Yield = amount	obtained	@gA							stoichiometric	expected	amount	@gA 	x	100%																																										[3.41] 
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CHAPTER 4   
DEVELOPMENT OF GC-MS METHOD: PRELIMINARY 
METHOD 
 
4.1 INTRODUCTION TO PRELIMINARY INVESTIGATIONS  
 
The need for development of a method for the analysis and characterisation of 4-FPP and 3-
TFMPP street samples was identified in Chapter 1 (section 1.8). The method to be 
developed needed to selectively and simultaneously analyse for these drugs in a complex 
sample matrix containing positional isomers, congeners and any impurities present in street 
samples (Nikolova and Danchev, 2008; Kelleher et al., 2010; UNODC, 2013c). 
Furthermore, analysis of the isomers has been identified as a challenge due to their similar 
chemical characteristics (Inoue et al., 2004; Elliot and Smith, 2008; Takahashi et al., 2009). 
 
The processes that were conducted in developing the method involved; a) theoretical 
considerations, b) development of a preliminary method, c) optimisation, d) validation, and 
e) its application to street samples. This study is therefore second in this sequence of 
events. The preliminary stage establishes the method variables that can then be further 
investigated to improve the method in further studies.  
 
In this study, investigation of sample preparation techniques was conducted by evaluating 
the use of derivatising agents in comparison to non-derivatisation. Derivatisation was 
carried out according to the method by de Boer et al, (2001) using pentafluoropropionic 
anhydride (PFPA) as the derivatising agent (section 2.6). Selection of internal standard 
investigated quinoline and eicosane as potential internal standards. The investigation of 
instrumental parameters was carried out by applying different experimental conditions. 
These were oven temperature, injector port temperature, flow rate, MS interface 
temperature, MS scan rate and MS ionisation energy. This investigation however, was 
limited to capillary columns (30m x 0.25mm x 0.25um). These were deemed suitable as 
they had been successfully applied by other researchers (de Boer et al., 2001; UNODC, 
2013b; Staack, 2007; Takahashi et al., 2009). 
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4.1.1 AIMS OF THE PRELIMINARY STUDY 
 
The overall aim of this chapter was to establish a foundation of experimental conditions for 
development of the method. This study therefore, set out to find an appropriate sample 
preparation technique, column, internal standard and preliminary instrumental variables. As 
such, it will establish a preliminary method for application in stability studies and for 
further development in the optimisation and validation studies (Chapters 6 and 7). 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 CHEMICALS/REAGENTS 
 
1-(2-Methoxylphenyl)piperazine (2-MeOPP), 97%; lot number S33767 21007B2 was 
procured from Fluka. 1-(4-Methoxylphenyl)piperazine (4-MeOPP), 97%, batch number 
871415 was procured from Sigma. The solvents/chemicals: ethyl acetate, methanol, 2-
methyl-propan-2-ol, dichloromethane and pentane were procured from Fischer Chemicals. 
In addition, the drug reference standards used for this study were also used in subsequent 
studies (Chapters 5, 6, 7 and 8) and are shown in Table 4.1. 
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Table 4.1 List of drug standards and standards of other compounds used in the study 
Substance Purity (%) Supplier  Lot/Batch No. 
1-(2-fluorophenyl)piperazine 97 Sigma Aldrich Lot: S39132 
1-(3-fluorophenyl)piperazine 99 Fluorochem  DO8F 
1-(4-fluorophenyl)piperazine 98 Sigma Aldrich  Lot: S47598 
1-(2-trifluoromethylphenyl)piperazine 100 Chemos GMBH AB148036 
1-(3-trifluoromethylphenyl)piperazine 98 Alfa Aesar LO5333 
1-(4-trifluoromethylphenyl)piperazine 98 Fluka 1292205 
21707187 
1-benzylpiperazine 97 Fluka  0130991/1 
40708251 
1-(4-dibenzyl)piperazine 100 Sigma Aldrich S983381 
1-(4-methylbenzyl)piperazine 97 Aldrich 07602DJ 
1-(3-chorophenyl)piperazine 100 Sigma Aldrich  Lot: 40796T7 
1-(4-methylphenyl)piperazine 98 Sigma Aldrich  BCB0996 
(±)3,4-methylenedioxy 
methamphetamine HCl 
100 Fluka 
 
Sigma 
1BCBC4747 
22010P01 
082M4033V 
(+)-Amphetamine SO4 100 Sgma 101K3351 
(+)-Methamphetamine HCl 100 Sigma 31H0454 
Cocaine HCl 100 Sigma 059K1139 
Benzoylecgonine hydrate 100 Sigma 05M4010 
Ecgonine methyl ester HCl hydrate 100 Sigma 050M4011 
Diazepam 100 Sigma 105F0451 
Dapoxetine HCl 100 Sigma 09M4737 
Dextromethorphan HBr 100 Sigma Aldrich 090M1298V 
Caffeine 100 Aldrich 
Fisher Chemicals 
8595 5 
0078218 
Nicotinamide 100 Sigma BCBD 0222V 
Piperazine 98 Fluka 000143817 
Eicosane (internal standard) 99.5 Agros chemicals A0229 559 
Quinoline (internal standard) 98 Aldrich S61686-48 
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4.2.2 INSTRUMENTS 
 
Preliminary studies were conducted using a Perkin Elmer GC-MS, Clarus Turbomass Gold 
500MS fitted with a Zebron, ZB-1 capillary column (30m x 0.25mm x 0.25µm). The 
instrument was equipped with the NIST MS Search Version 2.0 library software. A Perkin 
Elmer 4mm quartz split/splitless (product number N6121001) injector liner was used. The 
injector was set at 250oC with a split ratio of 20:1. The carrier gas was He (g) at a flow rate 
of 1mL/min. The initial oven temperature was set at 50oC with a hold for 1min and ramped 
at 15oC /min to 300oC with a hold for 5min. The MS transfer line was set at 250oC, source 
temperature 230oC, ionisation energy 70eV and scan range at m/z 40 – 500. The total 
analysis run time was 22.67 minutes.   
 
In addition, the following columns were used in the test for investigation of stationary a) 
Phenomenox, Zebron ZB-1 GC capillary column (30m x 0.25mm x 0.25µm), serial number 
164044, b) Phenomenox, Zebron ZB-5 GC capillary column (30m x 0.25mm x 0.25µm), 
serial number 164043), and c) Supelco, Equity-5 GC capillary columns (30m x 0.25mm x 
0.25µm), serial numbers 43734-04 and 169302. A Genevac Mivac was used to evaporate 
the solutions in derivatisation tests. 
 
4.2.3 STATISTICAL SOFTWARE  
 
Analysis of results was carried out using IBM SPSS Version 20 and MS Office Excel 2010. 
 
4.2.4 PREPARATION OF STANDARD SOLUTIONS 
 
4.2.4.1 Preparation of internal standard stock solutions  
Internal standard stock solutions of eicosane and quinoline were individually prepared to a 
concentration of 1.0mg/mL in pentane for eicosane and in methanol for quinoline.  
 
4.2.4.2 Preparation of analyte standard stock solution  
Individually, stock solutions for the drug standards listed section 4.2.1 were prepared to a 
concentration of 2.50mg/mL free base in methanol. The solutions were sonicated for 15 
minutes to dissolve samples where necessary.  
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4.2.4.3 Preparation of analyte standard working solutions 
The standard solutions were prepared by diluting the stock solution as shown in Table 4.2. 
 
Table 4.2 Preparation of analyte standard working solutions  
Solution type Volume of standard 
stock solution taken 
(mL) 
Volume of 
IS[1] stock 
solution 
taken (mL) 
Final 
volume 
(mL) 
Concentrations 
(mg/mL) 
a) Individual drug 
standard solutions 
0.40mL of each 
standard 
0.20mL of 
eicosane 
10.0mL 0.10mg/mL analyte 
and 0.02mg/mL 
internal standard 
b) Mixed standards 
solution 1 
0.40mL of each of 
standard (all standards 
mixed) 
0.20mL of 
eicosane 
10.0mL 0.10mg/mL analyte 
and 0.02mg/mL 
internal standard 
c) Mixed standards 
solution 2 
0.40mL of each of 
standard  all standards 
mixed) 
1.0mL of 
quinoline 
10.0mL 0.10mg/mL analyte 
and 0.1mg/mL 
internal standard 
[1]
 Internal standard
 
4.2.5 INVESTIGATION OF SAMPLE PREPARATION TECHNIQUES: DERIVATISATION 
 
The analysis of samples for this test was conducted with the GC-MS set up with method 1 
(section 4.2.7 Table 4.3). 
 
4.2.5.1 Derivatised standards  
Derivatisation of BZP, 4-TFMPP, 2-MeOPP, 4-MeOPP, amphetamine, cocaine, diazepam, 
EME and methamphetamine was carried out with PFPA: Ethyl acetate (2:1) solution. 
Individual and mixed standard solutions with quinoline as the internal standard were 
prepared as outlined in Table 4.2. A volume of 200µL of the analyte working standard 
solution was pipetted into a derivatisation tube and evaporated to dryness using a Mivac 
(40/50oC). PFPA solution (100µl) was then added. The solution was shaken to mix and 
placed in a heating block for 1hour 15 minutes at 70oC. The solution was evaporated to 
dryness using a Mivac (40/50oC). Ethyl acetate (200ul) was added to reconstitute and the 
solution was analysed by GC-MS (de Boer et al., 2001).  
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4.2.5.2 Un-derivatised standards 
Drug standard solutions were prepared as for the derivatised standards (section 4.2.5.1) 
omitting addition of the PFPA solution. 
 
4.2.6 SELECTION OF INTERNAL STANDARD  
 
The test was conducted with the GC-MS set up with method 3b (section 4.2.7 Table 4.3). 
Solution 1 was prepared by diluting the eicosane stock solution with methanol to a 
concentration of 0.02mg/mL. Solution 2 was prepared by diluting the quinoline stock 
solution with methanol to a concentration of 0.10mg/mL. Solution 3 was prepared by 
diluting the eicosane and quinoline stock solutions with methanol to give a mixed solution 
of concentration 0.02mg/mL eicosane and 0.10mg/mL quinoline. Solutions 2, 3 and 4 were 
analysed by GC-MS. 
 
4.2.7 INVESTIGATION OF COLUMN AND INSTRUMENTAL PARAMETERS 
 
The GC-MS was set up with the injector at 250oC and a split ratio of 20:1. The carrier gas 
was He (g) at a flow rate of 1mL/min. The MS transfer line was set at 280oC, source 
temperature 230oC, ionisation energy 70eV and scan range at m/z 40 - 500. The column 
and oven temperature were investigated by varying these parameters as shown in the Table 
4.3. A mixed standard solution (Table 4.2 solution 2) was used for the test.  
 
Table 4.3 Investigation of GC-MS column and instrumental parameters 
Parameter Method 1 Method 2a Method 2b Method 3a Method 3b 
Column  Zebron, ZB-1 Zebron, ZB-1 Zebron, ZB-1 Zebron, ZB-5 Supelco, Equity 5 
Initial 
Temperature 
50oC 50oC 90oC 60oC 60oC 
Hold 1 minute 1 minute 2 minute 1 minute 1 minute 
Ramp 1 15oC/min 10oC/min 10oC/min 10oC/min 10oC/min 
Temperature  300oC 150oC 150oC 150oC 150oC 
Hold 2 5 minutes 2 minutes 2 minutes 2 minutes 2 minutes 
Ramp 2 none 15oC/min 15oC/min 15oC/min 15oC/min 
Temperature  -  300oC 300oC 280oC 280oC 
Hold 3 -  5 minutes 5 minutes 2 minutes 2 minutes 
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In addition, a solution containing only piperazine standards was used to check if the method 
was capable of separation between isomers of FPP and TFMPP and other piperazines. 
Method 3b was applied. 
 
4.2.8 DATA ANALYSIS 
 
Relative retention time (RRT) and retention index (RI) were calculated according to 
equations 3.32 and 3.33 (Chapter 3 section 3.2.14) respectively. 
 
4.3 RESULTS AND DISCUSSION 
 
4.3.1 INVESTIGATION OF SAMPLE PREPARATION TECHNIQUES: DERIVATISATION 
 
The total ion chromatographic profiles (TIC) are shown in Figures 4.1 and 4.2. The 
chromatographic data derived (retention times, RT, relative retention times, RRT and 
retention indices, RI) is shown in Table 4.4. 
 
Table 4.4 Derivatisation versus un-derivatised chromatographic data  
Substance Un-derivatised PFPA derivatised 
 RT/mins RRT RI  RT/mins  RRT  RI  
(+)Amphetamine 6.76 0.88 1125 7.69 1.14 1217 
(+)Methamphetamine 7.32 0.95 1180 9.06 1.34 1351 
EME 9.96 1.29 1439 9.83 1.45 1427 
BZP 10.10 1.31 1453 12.69 1.88 1707 
4-TFMPP 10.8 1.40 1522 13.37 1.98 1774 
2-MeOPP 11.19 1.45 1560 13.88 2.05 1824 
4-MeOPP 12.09 1.57 1648 14.96 2.21 1930 
Cocaine 15.19 1.97 1953 17.68 2.62 2197 
Diazepam 16.55 12.14 2086 19.67 2.91 2392 
Quinoline 7.72 1.00 1219 6.76 1.00 1125 
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Figure 4.1 Total ion chromatogram of PFPA derivatised drugs. 
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Figure 4.2 Total ion chromatogram of un-derivatised drugs. 
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Figures 4.1 and 4.2 show that derivatisation improved peak sensitivity and peak profiles in 
comparison to the un-derivatised analytes (Figure 4.1 and 4.2; Table 4.4). Both the peak 
intensities and peak separation are greater in Figure 4.1 relative to 4.2 for all the analytes; 
for example amphetamine, methamphetamine and BZP. Furthermore, the retention indices 
(RIs) routinely used to identify a compound (Takahashi et al., 2009; Kaur, 2010) also give 
an indication of the degree of retention of analytes; the closer the RIs the closer the analytes 
in elution. The RIs of the derivatised peaks are higher and there is a greater difference in 
the RIs between adjacent peaks showing greater separation, e.g. EME and BZP have RIs of 
1439 and 1453 respectively compared to 1427 and 1707 derivatised (Table 4.4).This can be 
accounted for by the fact that derivatisation effectively increases the volatility of the drug 
(Chapter 2 section 2.6). Such results have commonly been found by other researchers such 
as de Boer et al. (2001) and Inoue et al. (2004). In these studies drugs of abuse including 
BZP and TFMPP were derivatised with silylation and acylation agents and sensitivity was 
improved. However, in the work of Inoue et al. (2004) it was indicated that derivatisation 
impaired peak separation between BZP and 3-TFMPP which had been not been observed in 
the un-derivatised samples. For a more comprehensive list of analytes and discussion, 
reference is made to Figure 4.14 and section 4.3.3. At the time of this investigation 3-
TFMPP was not yet available hence could not be compared, however BZP (12.69 minutes) 
and 4-TFMPP (13.37 minutes) were observed to be well resolved (Figure 4.1). In Figure 
4.2 column bleed and baseline drift were at higher retention times and temperatures (from 
16 minutes). This could be due to decomposition of the column at the higher temperatures 
used as the analysis progresses, however this did not impact on the results as all the 
analytes had already eluted. In addition, this became a factor in selection of a more stable 
column (section 4.7.3). 
 
The effect of derivatisation on the mass spectra fragmentation pattern is given for a 
representation of the drugs BZP and 4-TFMPP in Figures is 4.3 - 4.6.  
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Figure 4.3 Mass spectrum of PFPA derivatised BZP.  
 
 
Figure 4.4 Mass spectrum of un-derivatised BZP spectrum. 
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Figure 4.5 Mass spectrum of PFPA derivatised 4-TFMPP.  
 
 
Figure 4.6 Mass spectrum of un-derivatised 4-TFMPP.  
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The results indicated that derivatisation changes the mass spectra fragmentation pattern for 
most compounds. High intensities for the ions and in addition ions due to derivatising agent 
adducts were observed. Derivatisation appears to stabilise the compounds as less 
fragmentation is observed, this evidenced by the prevalence of the parent ions in the 
derivatised samples e.g. BZP and 4-TFMPP at m/z 323 (M+-PFPA and 176(M+) for BZP 
for the derivatised and un-derivatised respectively. For 4-TFMPP these were at m/z 377 
(M+-PFPA and 230(M+) for the derivatsed and un-derivatised respectively. For the 
piperazine compounds there is less fragmentation of the piperazine moiety as be seen by 
the higher prevalence of the molecular ion and fragments with the piperazine ring in the 
mass spectra (Figures 4.3 – 4.6). This is likely to be due to the presence of non-bonding 
electrons from the derivatising moiety, (-COC2F5) which can easily be delocalised. These 
are easier to remove than the covalent bond electrons resulting in a different fragmentation 
pattern to the un-derivatised form. A similar trend was observed by de Boer et al., (2001) 
with BSTFA and TFA as derivatising agents. In the chromatographic profile adducts 
(Figure 4.1) were observed (9.96, 18.40, 19.95 minutes) which could be the result of the 
reaction of the derivatisation agents with other materials in the sample matrix. de Boer et al. 
(2001), Takahashi et al. (2009), UNODC (2013c) in their work utilised both derivatisation 
and un-derivatised for the analysis of street samples. Both techniques gave good results 
with the un-derivatised mass spectra showing the expected fragmentation pattern and ions. 
Also fragmentation was not excessive; the parent ions were observed for example at 
m/z176 and m/z 230 for TFMPP drugs. Characteristic ions were identified for  BZP at m/z 
91 (100), 134, 56, 120, 176 (M+) and for TFMPP as was shown in Table 1.1 and were 
confirmed in this research in validation studies (Chapter 7). The un-derivatised samples 
gave chromatographic profiles and spectra that were satisfactory. All the characteristic ions 
were present. Therefore, the results are in agreement with those observed in other studies. 
The positive effects of derivatisation are counteracted by its limitations.  
 
The disadvantage of derivatisation is that the derivatising agents might react with the 
impurities in the drugs or other compounds in the sample matrix. This is undesirable in 
characterisation and profiling of drugs and is an imminent factor in this research. Since the 
method developed is to be employed in analysing street samples which according to Davies 
et al. (2010); Yuk (2010) contains a cocktail of unknown substances. Of importance is the 
fact that un-derivatised samples also showed acceptable results. This was also observed in 
the works of de Boer et al. (2010), Inoue et al. (2004) and Takahashi et al. (2009). It was 
 122 
 
observed that quinoline shows very low sensitivity on derivatisation hence would be a poor 
choice as an internal standard if derivatisation was to be applied. This is probably due to it 
not having a reactive H which is required for derivatisation reactions to occur as 
highlighted in Chapter 2 (section 2.6). Consequently, in such instances a deuterated 
standard of the drug is more effective as an internal standard. Furthermore, if the samples 
are derivatised, there is need to ensure all the analytes are 100% derivatised which might 
not always be feasible. Since the un-derivatised samples were successful it can therefore be 
suggested that not derivatising samples is an acceptable option for this study and as such 
was employed in all further studies. 
 
Since this section entailed to investigate whether derivatisation will be advantageous or not 
to this research, the discussion on mass spectra is limited. A further discussion on mass 
spectra (un-derivatised) is included in the section on application of the developed method 
(Chapter 7 section 7.7.4). 
 
4.3.2 SELECTION OF INTERNAL STANDARD 
 
A summary of the results is shown in Table 4.5 below. Figure 4.7 shows a comparative 
chromatographic profile (total ion chromatogram, TIC) for the analysis of eicosane and 
quinoline. The characteristic ions used for their identification and comparison were from de 
Boer et al. (2001), Moffat et al. (2011) and NIST (2014) e.g. m/z at 129 for quinoline and 
for eicosane 57 and 71. The chromatographic profiles for the analysis of samples with 
quinoline and eicosane as internal standards respectively are shown in Figures 4.7 - 4.10 for 
a representation of the samples to be analysed. 
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Table 4.5 Qualitative data for selection of internal standards 
Substance Retention 
time/mins 
Characteristic ions 
(m/z, intensity) 
Peak profile 
Quinoline 
C9H7N 
Mwt = 129 
9.74 129(100 and M+), 102, 
76, 63, 51 
Sharp symmetrical peaks. Resolution 
from adjacent peaks > 2, tailing <1.0. 
High sensitivity.  
Eicosane 
C9H7N 
Mwt = 282 
18.66 57(100), 71, 85, 99, 113, 
127, 141, 283(M+), 
Sharp symmetrical peaks. Resolution 
from adjacent peaks > 2, tailing = 1. 
High sensitivity. Peak area ratio with 
analytes 0.1 – 1.9. 
Synthetic 4-
FPP 
14.24 138(100), 180(M+), 122, 
56 
No co-elution for any peaks was 
observed with either internal standard. 
Synthetic 3-
TFMPP 
14.43 188(100), 230(M+), 145, 
56 
No co-elution for any peaks was 
observed with either internal standard. 
 
 
 
Figure 4.7 Selection of internal standard: Total ion chromatogram of mixed standards 
quinoline and eicosane.  
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Figure 4.8 Selection of internal standard: Total ion chromatogram of FPP standards with 
eicosane as the internal standard (IS).  
 
 
Figure 4.9 Selection of internal standard: Total ion chromatogram of TFMPP standards 
with eicosane as the internal standard.  
 
 
Figure 4.10 Selection of internal standard: Total ion chromatogram of 4-FPP with quinoline 
as the internal standard.  
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The total ion chromatograms (Figures 4.7 – 4.10) obtained with both internal standards 
were satisfactory. The peaks for both the internal standards were well defined, narrow, 
sharp, symmetrical peaks. Peak tailing was low (quinoline < 1 and eicosane = 1). 
Furthermore, they were well resolved from the analytes in the sample. Both internal 
standards had a resolution factor > 2 as such showed sufficient separation from other 
analytes (CDER, 2004). The peak area ratios for internal standard to analyte were also 
reasonable (0.2 - 2). It has been identified that such traits are indicative of good 
chromatographic properties in a compound (Horacio et al., 2008; IUPAC, 2014). Hence, 
they would generate accurate data. It has been identified that poor resolution and 
assymetric peaks reduce accuracy in quantitation of peak areas. In addition, they cause 
inconsistency in retention times (Andersson et al., 2007a; Khopkar, 2012). It therefore 
follows that both the internal standards can successfully be employed for both qualitative 
and quantitative analysis. Furthermore, they do not co-elute with any of the impurity peaks 
observed in the synthesised samples as shown Figure 4.10 for 4-FPP. This minimises 
interference during analysis and will be advantageous in characterisation of the drugs.  
 
The results obtained are comparable with the work of other researchers. Inoue et al. (2004) 
in their study on analysis of benzylpiperazine-like compounds successfully employed 
eicosane as an internal standard. Furthermore, the quinoline and eicosane show a wide gap 
in their retention times (9.75 - 18.66 minutes; Table 3.4). This has the advantage that both 
can be used simultaneously as internal standards and as such cover a wider range of 
analytes. In this study the drugs of focus 4-FPP and 3-TFMPP have been identified to exist 
in combination with a variety of other drug substances which are often unknown (Davies et 
al., 2010; Yuk, 2010; Arbo et al., 2012).  
 
It has been argued that drugs of abuse contain impurities (Andreasen et al., 2009; Bartos 
and Gorog, 2008; UN, 2001). Impurities are of unknown chemical properties and 
consequently there is need to limit or minimize potential reactions of other substances in 
the sample matrix with impurities. This method under development will also be utilised in 
characterisation and impurity profiling of 4-FPP and 3-TFMPP street samples. On this basis 
whilst both compounds are chemically stable, eicosane an n-alkane is chemically inert and 
as such was selected as the preferred internal standard in subsequent studies. 
Comparatively, quinoline a benzopyridine, is basic with a pKa of 4.9 (760mmHg, 20oC), 
(Jones, 1982) and potentially can undergo reactions of both the benzene ring and the 
 126 
 
pyridine ring. According to Jones (1982) quinoline can undergo electrophilic substitution in 
highly acidic conditions as shown below; 
N N
NO2
Quinoline Nitroquinoline
HNO3
H2SO4, 0
oC
 
Figure 4.11 Reaction of quinoline in acidic conditions. 
 
This has consequences if solvents, reagents, other drugs or chemicals in the sample are 
acidic. However, in this research the possibility was minimized through selection of a non-
reactive solvent and investigating stability studies (Chapter 5). In addition the 
chromatographic profiles (Figures 4.1 and 4.2) show that quinoline elutes earlier than most 
of the drugs under investigation whilst eicosane (Figure 4.14) is in line with the other 
analytes. Consequently, better precision and accuracy in results is achived with eicosane. 
These are probably the reasons why eicosane has found favour as an internal standard in 
characterisation and profiling work (Andersson et al., 2007a; Inoue et al., 2008; Santali et 
al., 2011), as such eicosane was selected as the internal standard of choice for this research. 
 
4.3.3 INVESTIGATION OF COLUMN AND INSTRUMENTAL PARAMETERS 
 
In order to establish preliminary parameters, different oven temperature programs and 
columns of different stationary phase polarities were investigated (Table 4.3). A non polar 
100%-dimethylpolysiloxane stationary phase column (Zebron ZB1) was used in methods 1 
and 2 and polar, 5%-phenyl-95%-dimethylpolysiloxane  stationary phase ( Zebron ZB5 and 
Supelco Equity-5) in method 3a and b. The total ion chromatograms (TIC) generated are 
presented in Figures 4.12 - 4.14.  In the results Figures 4.14a and b show more analytes 
than Figures 4.12 and 4.13 as some of the drug standards had not yet been procured (2-
TFMPP, 3-FPP, MBZP and CPP). Figure 4.14a also shows results for preliminary 
application of the method to piperazine drugs only. 
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Figure 4.12 Chromatographic profiles (TIC) of mixed standards obtained with Method 1 
and column Zebron ZB1 (Table 4.3). 
 
 
 
 Figure 4.13a Chromatographic profiles (TIC) of mixed standards obtained with Method 2a 
and column Zebron ZB1 (Table 4.3). 
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Figure 4.13b Chromatographic profiles (TIC) of mixed standards obtained with Method 2b 
and column Zebron ZB1 (Table 4.3) 
 
 
Figure 4.14a Chromatographic profiles (TIC) of mixed standards obtained with Method 3a 
and column Zebron ZB5 (Table 4.3).  
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Figure 4.14b Chromatographic profiles (TIC) of mixed standards obtained with Method 3b 
and column Supelco Equity 5 (Table 4.3).  
 
 
Figure 4.14c Method 3b TIC expanded view of the peaks in the range 12 - 16mins. 
 
The results showed that all the methods gave similar chromatographic peak profiles in 
terms of the order of elution of the peaks. The main difference in the methods was in the 
degree of resolution, tailing and general peak shape (Figures 4.12 - 4.14). With both 
methods 1 and 2 poor peak profiles were obtained. However, it is evident in total ion 
chromatograms that the results progressively show improvement from Figures 4.12, 4.13a 
to 4.13b. This is due to the variation in the oven temperature programming (Table 4.2) as 
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these methods used the same column, ZB1. Whislt improved the peak profiles were still not 
ideal. There is noticeably poor resolution for the peaks eluting in the range 12 – 16 minutes 
with method 2 as shown by 2-FPP, EME, BZP, 4-FPP, 3-TFMPP and MDMA (Figures 
4.13a and b). Hence a more polar stationary phase was applied (ZB5 column, method 3a in 
Table 4.2).  
 
The results showed a significant improvement in peak shape, as narrower more 
symmetrical peaks with higher intensities were observed.  In addition resolution and tailing 
were also better as evident for all the analytes in Figure 4.14a (method 3a). However, 
separation was poor between 3-TFMPP and MDMA due co-elution observed with both 
methods 2 and 3 (Figures 4.13b and 4.14a). A comparison could not be made with method 
1 as MDMA was not available at the time of analysis. To potentially improve and also 
confirm the results, a polar column from a different manufacturer was applied (Supelco 
Equity-5) whilst maintaining other conditions smilar to method 3b. The Equity-5 column 
gave slightly better resolution than the ZB5 as shown by the peaks 4-TFMPP, MBZP and 
MePP in Figures 4.14a (ZB5) and 4.14b (Equity-5). In addition both ZB5 and Equity-5 
columns gave less column bleed and relatively “cleaner” chromatograms (Figure 4.14 
relative to 4.12 and 4.13a; b) allowing for better accuracy in peak detection (Barwick, 
1999; McMaster, 2007).  
 
Since the columns’ physical properties were similar for all the columns the reason the ZB5 
and Equity 5 columns gave better results can be attributed to the chemical properties of the 
stationary phase in the column. In accordance with the Plate theory (Grob and Barry, 2004; 
McNair and Miller, 2009; Skoog et al., 2007) the resolution between peaks (equation 2.11) 
is dependent on the capacity factor and selectivity which are measures of retention of the 
substance in the column. An increase in the capacity factor and selectivity increases the 
resolution. These factors are in turn governed by the chemical properties of the analytes. 
Given that the drugs under consideration are polar it follows that the analytes have a higher 
affinity for the polar stationary phase. Consequently they show better separation and peak 
shape with the ZB5 and Equity 5 columns. The changes in oven temperature programming 
(initial hold temperature, time and ramping) from method 1 to 3b allows for longer 
equilibration time of the drug between the stationary phase and mobile phase. This results 
in an increase in the partition coefficient and consequently plate number, N. An increase in 
N increases resolution (section 2.2 equations 2.2, 2.8 – 2.11). 
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The results obtained are in accordance with the work of Andersson et al. (2007a), where it 
was found that ‘like separates like more efficiently’.  In addition, in their study the column 
was selected on the basis of inertness and resolution and minimal bleed. A study by 
Aalberg et al., (2004) shows the importance of selecting an appropriate column to achieve 
adequate selectivity. Optimisation was through varying stationary phase polarities so as to 
increase specificity towards regioisomeric MDMA substances. The authors reported that 
polar stationary phases allowed for higher temperature and were able to identify 10 
regioisomeric substances of MDMA. These results support the observed trend as the more 
polar column shows higher selectivity.  
 
It could be for these reasons that stationary phases of the type 5%-Phenyl-95%-
Dimethylpolysiloxane have been extensively used by other researchers in analysis of 
piperazines, amphetamines and other drugs of abuse (de Boer et al., 2001, Takahashi et al., 
2009, Kenyon et al., 2010; Lecompte et al., 2008,  UNODC, 2013c; Boumrah et al., 2014).  
In addition the Equity-5 column gave slightly better resolution than the ZB5 as shown by 
the peaks 4-TFMPP, MBZP and MePP in Figures 4.14a (ZB5) and 4.14b (Equity-5). 
Consequently, the Supelco Equity 5 column and method 3b was be applied in all 
subsequent studies. The preliminary chromatographic performance data is shown in Table 
4.6.  
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Table 4.6 Preliminary Method 3b performance characteristics 
Substance Mean values (n = 2) 
  N x 105 T/mins α R Rt/mins RRT 
Methamphetamine 3.831 5.872 1.422 5.603 8.880 0.480 
2-FPP 4.432 5.872 1.070 9.629 12.620 0.683 
3-FPP 13.636 3.174 1.040 12.607 14.515 0.785 
4-FPP 10.429 4.055 1.013 3.638 14.130 0.764 
3-TFMPP 13.740 ND[1] 1.003 1.058 14.320 0.774 
4-TFMPP 21.225 1.911 1.007 1.994 15.090 0.816 
BZP 6.244 6.677 1.021 4.615 13.840 0.749 
DBZP 58.723 1.023 1.019 11.683 19.950 1.079 
MBZP 10.672 4.473 1.013 3.711 15.190 0.822 
3-CPP 23.566 2.814 1.054 22.398 16.715 0.904 
4-MePP 15.870 3.672 1.086 28.646 15.390 0.832 
MDMA 15.922 ND[1] 1.010 2.937 14.370 0.777 
cocaine 61.013 0.986 1.074 45.053 20.335 1.100 
diazepam 66.788 2.178 ND[1] ND[1] 21.840 1.181 
caffeine 37.654 0.933 1.050 26.919 17.610 0.952 
eicosane (IS) 64.907 1.180 1.079 47.074 18.490 1.000 
[1]
 ND stands for not determined. This was due to coelution between 3-TFMPP and MDMA hence 
tailing could not be calculated for these two analytes. In addition, diazepam is the last peak hence 
there is no resolution to a subsequent peak after it. 
 
4.4 CONCLUSION 
 
The preliminary method developed (method 3b, Table 4.3) was able to detect and 
simultaneously analyse for 4-FPP and 3-TFMPP and all their congeners in street samples. 
In addition, separation of FPP and TFMPP positional isomers was achieved. These 
compounds are likely to be present as impurities in a street sample of these drugs. 
Therefore, the preliminary method development established usable parameters which were 
a foundation for further investigation. Of the methods investigated method 3b (section 
4.2.7) gave the best results in terms of general peak profile, resolution and tailing and 
therefore this method was selected for further development. The best column had a 
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stationary phase of the type 5%-Phenyl-95%-Dimethylpolysiloxane copolymer, hence this 
type of column was selected for use and Supelco Equity 5 is proposed as an ideal column in 
analysis of drugs of abuse. In the sample preparation stage, both derivatisation and non-
derivatisation were investigated and it was concluded that for the work to be conducted in 
this research there were no advantages to derivatising the samples. Not derivatising the 
samples gave good results as such other studies were carried out without derivatisation. 
 
 It has been reported by other researchers (Andersson et al., 2007a; Inoue et al., 2008; 
Hibbert, 2007; Maher et al., 2009) that optimisation attains optimum conditions and as such 
the best results possible with the method. It would be desirable to increase resolution and 
reduce tailing for the drugs eluting in the 12 -16 minutes range and as such method 3b was 
further developed, i.e., optimised (Chapter 6) so as to improve its performance. Prior to the 
optimisation method 3b was used in the study on solvents and stability studies (Chapter 5), 
so as to generate stability conditions  and select an appropriate solvent for use. 
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CHAPTER 5 
INVESTIGATION OF THE STABILITY OF DRUGS AND EFFECT 
OF SOLVENTS DURING ANALYSIS 
 
5.1 INTRODUCTION TO STABILTY  INVESTIGATIONS 
 
The conceptual framework for this was highlighted in Chapter 2 (section 2.7). Information 
derived from stability studies is used to set appropriate conditions, limits for analysis and 
storage during analytical investigations (FDA, 2008). Such information can be used to 
eliminate or minimise potential degradation and the resulting loss in stability during 
laboratory investigations.  
 
To ensure the stability of the drugs under investigation this study carried out various tests; 
 
a) The solubility of the analytes in different solvents (water, ethyl acetate, 
dichloromethane, methanol and 2-methylpropan-2-ol was investigated. This was to 
select a solvent capable of dissolving the analytes for further investigation,  
b) The chemical stability of the analytes during analysis in different solvents 
(methanol, dichloromethane and 2-methyl-propan-2-ol) under routine 
environmental conditions (ambient temperature and pressure) was tested,  
c) The stability of the analytes during analysis on the GC-MS auto-sampler during 
instrumental analysis was tested for the solvents methanol, dichloromethane and 2-
methyl-propan-2-ol,   
d) Data analysis and selection of the solvent in which the analytes were most stable,  
e) The stability during storage (at different temperatures and dark or light storage 
conditions was also conducted. Storage stability was commenced only after 
selection of solvent from the other tests (section 5.2.6 – 5.2.7).  
 
Unless stated, analysis was performed under routine ambient temperature and pressure. The 
drugs were handled according to their manufacturer’s instructions, to avoid unforeseen 
decomposition of the analytes. The drugs were stated by the manufacturers to be stable for 
one year from date of opening under routine dry, out of sunlight ambient conditions. 
Stability was established by determining whether concentration and retention times 
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remained constant with time (Yoshioka and Stella, 2000; ICH Q1A(R2), 2003). The 
significance of the results was statistically determined. This was achieved by application of 
the Chi (χ2) square test, Pearson’s correlation and ANOVA and variance (sections 3.2.7, 
3.2.4, 3.2.6 and 3.2.2).  
 
5.1.1 AIMS OF THIS STUDY 
 
The aim of this study was to investigate the effect of solvents on the analysis of drugs of 
abuse commonly found on the streets and to establish the stability of these drugs during 
routine laboratory analysis. Hence, define appropriate stability limits for their analysis 
under ambient environmental conditions, on the instrument during analysis and storage in 
the refrigerator (4oC) and freezer (-20oC). In addition also select an appropriate solvent for 
use in subsequent analytical work (Chapters 6, 7 and 8). 
 
5.2 MATERIALS AND METHODS 
 
In all the tests where 2-methyl-propan-2-ol was used as a solvent the temperature was 
maintained above its freezing point 20 - 25oC, during preparation of solutions. The storage 
test (5.2.8) was only carried out after the selection of a suitable solvent from the solubility, 
solvent selection and auto-sampler stability tests 
 
5.2.1 CHEMICALS/REAGENTS 
 
The drug standards used were as listed in Chapter 4 (section 4.2.1). The solvents ethyl 
acetate, methanol, 2-methyl-propan-2-ol, dicholoromethane and chloroform were from 
Fisher Chemicals.  
 
5.2.2 INSTRUMENTS 
 
A Perkin Elmer GC-MS Clarus Turbomass Gold 500MS fitted with a Supelco, Equity-5 
GC capillary column (30m x 0.25mm x 0.25um). The instrument was equipped with the 
NIST MS Search Version 2.0 library software.  The instrument was initially set up 
according to Table 4.3 Method 3b (Chapter 4, section 4.2.7), i.e., the injector was set at 
250oC with a split ratio of 20:1. The carrier gas was He (g) at a flow rate of 1mL/min. The 
 136 
 
initial oven temperature was set at 60 oC with a hold of 1min. The oven was ramped at 10 
oC /min to 150oC with a hold of 2min and at 10oC /min to 280oC, with a hold of 4min. The 
MS transfer line was set at 280oC, source temperature 230oC, ionisation energy 70eV and 
scan range at m/z 40 – 500. The total analysis run time was 23.67minutes. 
 
A Zanus Electrolux, Tutella system 3 temperature monitoring refrigerator (4oC) and a 
Scanfrost, Tutella system 6 temperature monitoring freezer (-20oC) were used for storage 
stability tests.  
 
5.2.3 STATISTICAL SOFTWARE  
Analysis of results was carried out using IBM SPSS Version 20 and MS Office Excel 2010. 
    
5.2.4 SOLUBILITY TEST 
 
Each analyte (1.0mg) was weighed into a test tube. Ethyl acetate (1.0mL) was added. The 
solution was shaken to dissolve or sonicated for 20 minutes if the analytes were observed to 
have a solid residue on shaking. If soluble, incremental amounts of solute were added up to 
10.0mg whilst observing to see whether higher amounts could be dissolved for the 
preparation of more concentrated solutions. The test was repeated for methanol, 2-methyl-
propan-2-ol, dichloromethane and water. 
  
5.2.5 PREPARATION OF STANDARD SOLUTIONS FOR THE STABILITY TESTS 
 
Standard solutions were prepared as outlined in preliminary method development (Chapter 
4, section 4.2.4.3) for individual drug standard solutions and mixed drug standards solution 
1 using methanol as a solvent. Standard solutions were similarly prepared using 
dichloromethane and 2-methyl-propan-2-ol as solvents. 
 
5.2.6 STABILITY OF THE DRUGS DURING ANALYSIS IN DIFFERENT SOLVENTS UNDER 
ROUTINE AMBIENT ENVIRONMENTAL CONDITIONS 
 
Standards solutions in methanol were used prepared as outlined in section 4.2.4.3 (Table 
4.2). The individual drug standard solution for each analyte was analysed 3 times on the 
GC-MS. The stability of the mixed drug standard solution was determined by analysing the 
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mixed drug standard solution 6 times on the GC-MS. The 6 replicates were used to 
determine repeatability so as to establish system suitability for quality control (section 
2.5.2). The test was similarly conducted using the solvents dichloromethane and 2-methyl-
propan-2-ol. The environmental conditions were ambient temperature and pressure. 
 
5.2.7 STABILITY OF THE DRUGS IN DIFFERENT SOLVENTS ON THE GC-MS  AUTO-
SAMPLER DURING INSTRUMENTAL ANALYSIS  
 
The standards listed inTable 4.1 (Chapter 4) were prepared in methanol as outlined in 
section 4.2.4.3. The final solution was split (50uL) into different vials (22) covering the 
stability period. The vials were all simultaneously placed on the auto-sampler programmed 
to inject hourly in sequence vial 1 to 22 for a 25 hours run cycle (time t0 – t25). The time of 
the first injection was recorded as t0. The test was repeated using the solvents 
dichloromethane and 2-methyl-propan-2-ol. 
 
The drugs were analysed as a) a mixed standard solution of all the piperazine based drugs 
and, b) a mixed drug standard solution of all the non-piperazines. For those analytes which 
did not show degradation the test was repeated and with an extended runtime of 36hours. 
Where a degradation product was observed in the mixed samples, the drugs were then 
individually analysed. 
 
5.2.8 STORAGE STABILITY 
 
Stock solutions of the mixed drug standards were prepared in 2-methylpropan-2-ol as 
outlined in section 4.2.4 (Chapter 4).The samples were placed in the refrigerator at 4oC. 
The time and day were recorded. Sampling and analysis was conducted daily for a period 
of one week. The study was similarly conducted for storage in a freezer (-20oC), except the 
samples were withdrawn every 3rd day for a period of a month or until degradation was 
observed in the analyte. 
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5.2.9 DATA ANALYSIS 
 
5.2.9.1 Checking for stability  
For all the stability tests (sections 5.2.6 - 5.2.8), the peak area ratios and retention times 
were determined. The peak area ratios were calculated according to equation 2.18 (Chapter 
3). The trend in peak area ratios and retention times over the period of investigation was 
then analysed for each analyte as a measure of stability. To measure the stability, stability 
graphs (peak area ratios or retention time versus time) were plotted. In addition statistical 
analysis was conducted using Chi (χ2) square and Mann-Kendall trend tests. The Chi square 
and Mann-Kendall analysis was conducted according to Chapter 3 sections 3.2.7 and 3.2.12 
respectively.  
 
Furthermore, the total ion chromatograms obtained in these tests were visual inspected for 
the presence of artefacts (secondary peaks). 
 
5.2.9.2 Solvent comparison  
Comparison of the solvents was conducted using the results from the stability of the drugs 
in different solvents during instrumental analysis test (section5.2.7). Pearson’s correlation 
and ANOVA (2-way) and variance were applied. These parameters were calculated 
according to Chapter 3 sections 3.2.4, 3.2.6 and 3.2.2 respectively. In the tests if a drug was 
insoluble in solvent it was assigned a value of zero. 
 
5.3 RESULTS AND DISCUSSION 
 
5.3.1 SOLUBILITY 
 
The solubility of the drugs in solvents commonly used during routine analysis of drugs of 
abuse is reported in Table 5.1 below. All 25 of the analytes tested dissolved in water, 
methanol and ethyl acetate. 23 were soluble in 2-methylpropan-2-ol. The least solubility 
was observed with dichloromethane with 21 analytes soluble. The insoluble analytes were 
detailed as; (+)-amphetamine and EME were found to be insoluble in both dichloromethane 
and 2-methylpropan-2-ol. In addition, CPP and nicotinamide were insoluble in 
dichloromethane. 
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Table 5.1 Solubility of drugs of abuse in different solvents.  
Substance H2O MeOH EtAc DCM MPOH 
1-(2-fluorophenyl)piperazine + + + + +[1] 
1-(3-fluorophenyl)piperazine + + + + + 
1-(4-fluorophenyl)piperazine + + + + + 
1-(2-trifluoromethylphenyl)piperazine + + + + + 
1-(3-trifluoromethylphenyl)piperazine + + + + + 
1-(4-trifluoromethylphenyl)piperazine + + + + + 
1-benzylpiperazine + + + + + 
1-(4-dibenzyl)piperazine + + + + + 
1-(4-Methylbenzyl)piperazine + + + + + 
1-(3-Chorophenyl)piperazine + + + − +[1] 
1-(4-Methylphenyl)piperazine + + + + + 
(±)3,4-Methylenedioxymethamphetamine HCl + + + + + 
(+)-Amphetamine SO4 + +[1] + − − 
(+)-Methamphetamine HCl + + + + + 
Caffeine + + + + + 
Cocaine HCl + + + + + 
Diazepam + + + + + 
Benzoylecgonine hydrate + + + + + 
Ecgonine methyl ester HCl hydrate + +[1] + − − 
Piperazine + + + + + 
Dapoxetine HCl + + + + + 
Nicotinamide + + + - + 
Dextromethorphan HBr + + + + + 
Eicosane (IS) + + + + + 
Quinoline (IS) + + + + + 
 
[1]
 Indicates that the analyte was soluble with shaking for 30mins or ultra-sonication for 10mins. Its 
solubility was ≤ 2mg/mL. All the other analytes were soluble up to 10mg/mL. MeOH denotes 
methanol, EtAc is ethyl acetate, DCM is dichloromethane, MPOH is 2-methylpropan-2-ol and IS 
denotes internal standard.  
 
The results indicated that all the solvents have good solvation properties (Table 5.1), as the 
majority of the drugs (≥ 84%) were soluble in all the solvents. Solubility was in the order 
water > ethyl acetate > methanol > 2-methylpropan-2-ol > dichloromethane. This is in 
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accordance with both the properties of the solvents (Gokel, 2004) and the polarity of the 
drugs. The solvents’ dipole and dielectric constants were reported in Table 2.1. A solvent’s 
dipole moments and dielectric constants affect its ability to solvate ions thereby to dissolve 
solutes. The analytes are polar and as such would dissolve more readily in the more polar 
solvent. Ethyl acetate and water have the highest dipole moment and as expected the 
highest solubility, whilst dichloromethane has the lowest. Methanol and 2-methylpropan-2-
ol have almost similar dipole moments, 1.68 and 1.67 respectively; consequently their 
solubilities are expected to be similar. However, a higher solubility is observed with 
methanol. This can be attributed to the effect of molecular structure; 2-methylpropan-2-ol is 
a tertiary alcohol (structure is shown in Table 2.3), hence it exhibits steric hindrance, with 
the methyl substituents adjacent to the functional group hindering solvation (Lawrence, 
2004). Consequently, based on solubility, ethyl acetate and methanol would be the solvents 
of choice as they dissolve a higher number of the drugs. Whilst there is no record of 
solubility studies of these drugs in the various solvents, methanol has been extensively, 
confirming the results of this study. Ethyl acetate has also been extensively applied for 
extraction and isolation of drugs and for general analysis especially when derivatised (de 
Boer et al., 2001; Inoue et al., 2008). Water has also been routinely used to dissolve street 
samples in the sample preparation stage, from which the analytes are then extracted by the 
organic solvent. In this study the street samples were to be dissolved in the organic solvent 
hence it was not investigated further.  
 
5.3.2 STABILITY OF THE DRUGS DURING ANALYSIS IN DIFFERENT SOLVENTS UNDER 
ROUTINE AMBIENT ENVIRONMENTAL CONDITIONS 
 
A typical total ion chromatogram (TIC) for the drugs obtained under routine conditions is 
shown in Figure 5.1. This was used as a comparator to the chromatograms generated under 
different stability conditions (sections 5.2.6 – 5.2.8). 
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Figure 5.1 Total ion chromatogram of the drugs under ambient conditions at time t0 (reference chromatogram). 
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No artefacts were observed in the freshly run samples under routine environmental 
conditions. It can therefore be deduced that the sample preparation step and the prevailing 
environmental conditions in the laboratory do not cause degradation. These results were 
used as a comparator for the rest of the stability studies. Very few studies were encountered 
on the stability of drugs of abuse; in addition these were mostly on stability during 
bioanalytical studies. However, the results obtained were as expected and in line with the 
previous findings by other researchers. Moody et al., (1999) investigated the long-term 
stability of drugs of abuse and chemotherapeutic agents at different storage conditions had 
comparatively similar results. They observed no degradation at ambient conditions prior to 
storage (at time t0). 
 
5.3.3 STABILITY OF  THE DRUGS IN DIFFERENT SOLVENTS ON THE GC-MS AUTO-
SAMPLER DURING INSTRUMENTAL ANALYSIS 
 
The stability of an analyte was determined by monitoring the change in concentration with 
time (Yoshioka and Stella, 2000) as peak area ratio. This was depicted graphically as 
stability profiles of the drugs. The stability profiles for each analyte for each of the solvents 
methanol, dichloromethane and 2-methylpropan-2-ol were determined and are exemplified 
by 2-FPP and DBZP in Figures 5.2 and 5.3 respectively. For the other drugs analysed 
reference is made to Appendix 1.   
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Figure 5.2 2-FPP stability profiles in different solvents over 25hours on the GC-MS autosampler. 
  
     
Figure 5.3 MBZP stability profiles in different solvents over 25hours on the GC-MS autosampler. 
 
Limits: acceptable limits of variation for stability (± 10% of Expected value). 
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It is evident in Figure 5.2 that for 2-FPP the peak area ratio is constant over the whole 
analysis time period. Consequently, the drug was deemed stable on the GC-MS auto-
sampler during instrumental analysis for all the solvents used. In comparison, for MBZP 
(Figure 5.3) in methanol and dichloromethane the peak area ratio is initial constant and then 
the trend decreased slightly after 18 hours. Hence, MBZP was deemed stable for 18 hours 
in methanol and 20 hours in dichloromethane. In addition, MBZP was stable for the whole 
analysis period (25 hours) in dichloromethane.  
 
A similar analysis was conducted for all the other drugs (stability graphs in Appendix 1). 
On average most of the drugs were stable in all the solvents on the GC-MS auto-sampler 
during instrumental analysis. It was found that the stability ranged from 14 – 25 hours and 
was in the order 2-methylpropan-2-ol > dichloromethane > methanol. For easier evaluation 
and comparison a summary of the results are depicted graphically in Figure 5.4 and 
tabulated in Appendix 2. In the graph the duration the drug was stable is shown in hours. 
Amphetamine and EME were insoluble in 2-methylpropan-2-ol whilst 3-CPP, 
amphetamine and EME were insoluble in dichloromethane. Hence, these drugs were not 
analysed for these two solvents, therefore their stability appears as zero in the graph. 
 
 
Figure 5.4 Graphical comparison of stability of drugs in different solvents on the auto-
sampler (n = 2). The solvents are represented as methanol (MeOH), dichloromethane 
(DCM) and 2-methylpropan-2-ol (MPOH). 
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The analytes were least stable in methanol, in which the drugs were stable for a period of 
14 – 25 hours. For the piperazines 4-FPP had the lowest stability period, 15hours, whilst 3-
TFMPP, 4-TFMPP, and DBZP were stable for 25hours. The non piperazines MDMA, 
caffeine, diazepam, and nicotinamide were stable in methanol for 25 hours, whilst cocaine 
and EME and BEH had the lowest stability (14hours).   
 
In comparison, the drugs when in dichloromethane show a higher stability period.  All the 
drugs were stable in dichloromethane for a period of 19 - 25 hours, with all the piperazines 
stable for 25 hours, except for 4-TFMPP (23 hours), BZP (22 hours) and MBZP (20 hours), 
whilst for the non piperazines, cocaine (23 hours), BEH (19 hours) and diazepam (22 
hours). All the non piperazines were stable in dichloromethane and all the drugs were stable 
in 2-methylpropan-2-ol in the range for 25 hours.  
 
It can therefore be deduced that the duration of stay of analytes on the instrument auto-
sampler has an impact on the stability of the drug. Extensively long periods exacerbate 
degradation. This is likely to be due to thermal effects as auto-samplers can warm up 
during analysis. Several studies have shown that solutions are more stable for a longer 
period if maintained at lower temperatures, such as in the refrigerator or freezer (Karinen et 
al., 2011; Moody et al., 1999; Nowatzke and Woolf, 2007). In the current study the auto-
sampler was found to be around ambient temperature (25 - 28oC). In addition, since the 
same drug analytes were analysed for each of the solvents, the observed results can also be 
attributed to the chemical properties of the solvent and its effect on the stability of the drug 
analytes (Yoshioka and Stella, 2000). No studies on stability of drugs of abuse during 
instrumental analysis were found, hence this limited comparative review of the results. To 
confirm the findings discussed above statistical analysis was conducted using Chi square 
and Mann-Kendal trend test, in accordance with Chapter 3 sections 3.2.7 and 3.2.12. 
 
5.3.4 STATISTICAL ANALYSIS OF STABILITY DATA 
 
5.3.4.1 Chi-square (χ2) and Standard deviations 
 
The results of the χ2 test on the stability data for each of the solvents methanol, 
dichloromethane and 2-methylpropan-2-ol were in the ranges shown in Table 5.2.  
 
 146 
 
Table 5.2 Statistical analysis:  Chi-square (χ2) and Standard deviations (n = 21) 
Test Dichloromethane Methanol 2-methylpropan-2-ol 
Chi-square χ2 =  P(χ20.05) = 0.975 - 
0.995  
P(χ20.05) = 0.975 - 0.995 P(χ20.05) = 0.975 – 0.995 
Std dev 0.05 – 0.16 0.01 – 0.78 0.02 – 0.07,  N = 3 
 
Statistical evaluation of the stability profile of each drug gave Chi square values that were 
less than the tabulated value (χ20.05,21 = 31.41) with probabilities above 97.5% (Table 5.2) 
and as such were significant. Consequently, this implies there is no difference between 
experimental and expected values, with any variations observed due to chance, and thus 
insignificant. This was also evidenced by the small values observed in the standard 
deviations (range 0.01 – 0.78). It can be said that generally analyte concentration did not 
vary greatly with time since the standard deviations were low. However, the results 
indicated that the analytes were most stable in 2-methylpropan-2-ol, σ = 0.02 – 0.07 with 
the highest standard deviation observed for DBZP very small (σ = 0.07). The retention 
times and retention indices analysed for selected drugs 2-FPP, 4-FPP, 3-TFMPP and 4-
TFMPP were stable over 25 hours (RSD < 1%). It can be argued that these solvents have 
found use with other researchers (Baker and Phillips, 1983; Dayright, 2001; Staack et al., 
2003; Inoue et al. 2004, Takahashi et al., 2009) due to the fact that they are stable enough 
for routine use (14 hours minimum from placement of fresh samples on the GC-MS auto-
sampler) and can be applied for longer periods with planning. It can also be argued based 
on the stability results, that 2-methylpropan-2-ol has potential for more application in 
analysis of drugs of abuse; currently its use is not common.  
 
5.3.4.2 Mann-Kendal trend analysis 
To confirm the statistical findings further analysis using the Mann-Kendal trend test 
(Chapter 3 section 3.2.12) was conducted. The results are shown in Tables 5.3 - 5.5. The 
Mann-Kendal test statistic (S), the corresponding cumulative normal distribution test 
statistic (Z), the probabilities, p corresponding to the Z values and the Trend size are given 
for the solvents methanol, dichloromethane and 2-methylpropan-2-ol.  
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Table 5.3 Summary of methanol Mann-Kendall statistical data for drug auto-
sampler/solvent stability (n = 21). 
Compound Test statistic 
S 
Z P (%) Trend  
Y/N 
Trend size 
(%) 
2-FPP +3 +0.0143 98.86 N -1.08 
3-FPP +6 +0.0356 97.16 N +7.81 
4-FPP -9 -0.0571 95.45 N -2.78 
2-TFMPP -3 -0.0143 98.86 N -5.94 
3-TFMPP -6 -0.0356 97.16 N -1.36 
4-TFMPP -13 -0.0857 93.17 N -0.52 
BZP -11 0.0071 99.43 N -3.96 
DBZP -7 -0.0427 96.59 N -0.18 
MBZP  +4 +0.0358 97.15 N -4.77 
3-CPP -4 -0.0214 98.29 N -3.59 
4-MePP -2 -0.0071 99.43 N -3.53 
MDMA -9 -0.0570 95.46 N +0.84 
Amphetamine 0 +0.0071 99.43 N -6.84 
Methamphetamine -5 -0.0285 97.72 N -4.00 
Caffeine -6 -0.0356 97.16 N +0.56 
Cocaine -18 -0.1211 90.36 N -4.48 
Diazepam -1 0 100.00 N +2.17 
Dapoxetine +12 +0.0784 93.75 N -0.71 
Nicotinamide 0 ±0.0077 99.94 N -0.26 
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Table 5.4 Summary of dichloromethane Mann-Kendall statistical data for drug auto-
sampler/solvent stability (n = 21). 
Compound Test statistic 
S 
Z P (%) Trend  
Y/N 
Trend size 
(%) 
2-FPP -4 -0.0214 98.30 N +1.56 
3-FPP -10 -0.0641 94.89 N -1.14 
4-FPP +7 +0.0427 96.59 N 0.00 
2-TFMPP -8 -0.0499 96.02 N +3.26 
3-TFMPP -8 -0.0498 96.03 N +0.22 
4-TFMPP -14 -0.0927 92.62 N -1.52 
BZP -4 -0.0214 98.30 N -3.30 
DBZP -8 -0.0499 96.02 N +0.04 
MBZP  -16 -0.1071 91.47 N -2.09 
3-CPP Insoluble   N  
4-MePP -4 -0.0214 98.30 N +1.67 
MDMA +4 +0.0214 98.30 N +2.41 
Amphetamine Insoluble      
Methamphetamine +9 +0.0571 95.45 N -0.80 
Caffeine +6 +0.0356 97.16 N -0.16 
Cocaine -8 -0.0500 96.01 N -4.34 
Diazepam +2 +0.0214 98.29 N +7.34 
Dapoxetine +5 +0.0285 97.73 N -2.56 
Nicotinamide Insoluble     
 
 
 
 
 
 
 
 
 
 
 
 149 
 
Table 5.5 Summary of 2-methylpropan-2-ol Mann-Kendall statistical data for drug auto-
sampler/solvent stability (n = 21). 
Compound Test statistic 
S 
Z P (%) Trend  
Y/N 
Trend size 
(%) 
2-FPP +10 +0.0640 94.90 N +1.10 
3-FPP -9 -0.0570 95.45 N +2.24 
4-FPP -3 -0.0142 98.86 N +0.90 
2-TFMPP -4 -0.0215 98.29 N +2.08 
3-TFMPP -12 -0.0784 93.75 N +0.09 
4-TFMPP +12 +0.0783 93.76 N +0.35 
BZP +3 +0.0143 98.86 N +0.32 
DBZP +4 +0.0214 98.30 N -0.32 
MBZP  -2 -0.0071 99.43 N +1.02 
3-CPP -3 -0.0142 98.86 N +1.70 
4-MePP -2 -0.0071 99.43 N +0.95 
MDMA -5 -0.0285 97.73 N -0.55 
Amphetamine Insoluble   N  
Methamphetamine -10 -0.0642 94.89 N +0.11 
Caffeine -4 -0.0214 98.30 N -1.80 
Cocaine -6 -0.0356 97.16 N -0.12 
Diazepam -8 -0.0498 96.03 N +0.10 
Dapoxetine +4 +0.0214 98.29 N -0.94 
Nicotinamide -4 -0.0215 98.29 N 0.00 
 
In the Mann-Kendal results Tables 5.3 - 5.5 the existence of signs indicates that potentially 
a trend exists, hence potentially there is loss of stability. In accordance with Onoz and 
Bayazit (2003) and Aalberg et al. (2005b) the trend in the degradation is increasing for the 
drugs with a positive sign and decreasing for those with a negative sign. However, 
evaluation of the Z values and probabilities so as to investigate the statistical significance 
of the results negates this deduction. The calculated Z values were all less than Z critical 
value (Zα/2 = 1.96). The ranges were -0.1211 to 0.0356 for methanol, with MBZP and 
cocaine showing the highest value (0.0356 and -0.1211 respectively). For dichloromethane 
0 to -0.0927 (4-TFMPP was highest) and for 2-methylpropan-2-ol 0 to -0.07836 (3-TFMPP 
was highest). This implied that no trend exists. Furthermore, the probability, p values are 
all greater than the significance level (α = 5%). This can be seen in the tables that for all the 
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solvents on average p > 90%. In the discussion of statistical concepts (Chapter 3) it was 
highlighted that if p > α, the null hypothesis for this test (Ho: no trend exists) is rejected. 
This implies that no statistically significant trend exists. As such the analytes can be 
considered stable for the time period investigated (25 hours on the auto-sampler). Any 
variations observed in the concentration are due to chance. Investigation of the trend size 
(Aalberg et al., 2005b) confirms the findings. These findings confirm the statistical 
observations made using Chi square analysis. The trend sizes are in range magnitude 0.26 – 
20.36 for methanol, 0 – 12.53 for dichloromethane and 0 – 2.24 for 2-methylpropane-2-ol, 
of which MBZP had the highest trend size values. This showed it had the highest potential 
for degradation. Similarly, cocaine also indicated degradation with a trend size of 11.21 for 
methanol relative to 5.54 for dichloromethane and 0.12 for 2-methylpropan-2-ol (Tables 
5.2 -5.4). However, it is suggested that whislt there is no statistically significant trend it is 
evident in the stability graphs for MBZP, cocaine (Appendix 1) that the stability of these 
compounds show potential degradation. The reason why this is not statistically could be 
that the time period when they went out of specification (i.e., start of degradation) is 
minimal compared to the overall stability period. In addition, the limits are narrow 10%. In 
other studies 15 – 20 % was used (Karinen et al., 2011; Nowatzke and Woolf, 2007). 
 
5.3.4.3 Statistical comparison of solvents 
Pearson’s correlation was used to determine if there were any differences on the effects of 
these solvents on the stability of the drugs. The results suggested that there was no 
correlation between the solvents methanol and dichloromethane (r = 0.37, n = 22, p = 0.05). 
There was no correlation between the solvents methanol and 2-methylpropan-2-ol (r = 
0.42, n = 22, p = 0.05). There was moderate correlation between the solvents 
dichloromethane and 2-methylpropan-2-ol (r = 0.66, n = 22, p = 0.05). 
 
Results from ANOVA analysis confirm these findings, F(21, 42) = 3.50, Fcrit = 1.81,  p = 2.68 
x 10-4. This implies statistically there is a significant difference in stability of the drugs in 
the solvents tested. As such, it can be concluded that the drugs show differences in stability 
depending on the solvent used. Therefore, it is imperative to select a solvent for use which 
minimises instability of the analytes under investigation.  
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5.3.5 DEGRADATION PRODUCTS 
 
The chromatographic profiles for the drugs that showed the presence of artefacts are 
exemplified by 1,4-dibenzylpiperazine in Figure 5.5. Appendix 3 shows the 
chromatographic profiles of the other drugs. 
 
 
Figure 5.5 Chromatographic profile (TIC) of DBZP stability study. 
 
A summary of the degradation products observed on the GC-MS auto-sampler for the drugs 
in the different solvents is given in Table 5.6.  
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Table 5.6 Degradation products observed during stability studies on the GC-MS auto-
sampler in different solvents. 
Reference Rt/mins Degradation compound observed Formula 
Solvent 1- methanol 
  
12.00  
Ecgonine  
Ecgonidine methyl ester. 
  
Solvent 2- dichloromethane 
4-FPP  
(not mixed) 
6.27 4-fluoroaniline C6H6NF 
 
DBZP 
(not mixed) 
6.27 
7.55 
Benzyl chloride 
Benzyl chloroformate 
C7H7Cl 
C8H7O2Cl 
MBZP 
(not mixed) 
15.03 Banzamide N-(3-amino-3-
hydroxyminopropyl)-N-methyl- 
     Or 
Piperazine,1-(2-trifluoromethylbenzyl)-4-
(3-methylbenzyl)- 
C11H15N3O2 
 
 
 
C20H23N2F3 
mixture-all 
piperazines 
6.29 
7.57 
15.03 
Benzyl chloride 
Benzyl chloroformate 
Not identified 
 
mixture-all 
nonpiperazines 
 No artefacts  
Solvent 3- 2-methylpropan-2-ol 
mixture-all 
piperazines 
6.27 
7.54 
4-fluoroaniline 
Benzoyl chloride - trace 
 
MBZP  No artefacts  
DBZP 
(not mixed) 
6.27 
7.54 
Benzyl chloride 
Benzyl chloroformate 
 
4-FPP 6.27 4-fluoroaniline  
 
For most of the drugs, degradation was not observed even though potentially from the 
chemistry of the drug and the solvents such reactions were expected (section 2.7). This 
could be due to the fact that conditions prevailing during analysis were not able to sustain 
such reactions. For example esterification was not observed with methanol as high 
temperatures maybe required.  
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Analysis of the chromatographic data revealed the presence of artefacts arising in some of 
the samples during the stability studies (Table 5.6; Figure 5.5 and Appendix 3). With the 
solvent methanol the piperazines showed the absence of degradation products. It has been 
reported that methanol undergoes oxidation to formaldehyde, formic acid, carbon dioxide 
and water (Tanabe and Matsuda, 1961). These products can react with piperazines where 
the nitrogen acts as a base, consequently with the piperazines esterification was expected 
with methanol/H+ (Figure 2.15). Its absence is likely to be due to the need for catalysis and 
higher temperature highlighted in section 2.7.3 for the reaction to occur. The non-
piperazines were also mostly stable, with only cocaine showing marked degradation. The 
presence of prominent amounts of degradation products as can be seen in its 
chromatographic profile (TIC) in Appendix 3. Ecgonine methyl ester and benzylecgonine 
were identified as the degradation products (Table 5.6) and in addition ecgonidine was 
present. This could be attributed to breakdown of cocaine through hydrolysis as shown in 
Figure 5.6. This is further confirmed by extrapolation of the results metabolic studies on 
cocaine were similar substances were identified as degradation products (Cole, 2003; 
Yoshioka and Stella, 2000). 
 
N
CH3 O
O
CH3
O
O
N
CH3 O
OH
O
O
N
CH3 O
O
CH3
OH
1. H2O
2. H+
3. OH-
+
  
Figure 5.6 Degradation of cocaine through hydrolysis.  
 
Even though hydrolysis was also expected for diazepam, no degradation was observed. 
This result is in accordance with literature; amides are less susceptible to hydrolysis than 
esters due to the C=O bond being less electrophilic and in addition the rate of degradation 
reactions are reported to be minimal (Yoshioka and Stella, 2000).  
 
The use of dichloromethane showed the presence of more degradation products than 
methanol or 2-methylpropan-2-ol (Table 5.6). 4-Fluoroaniline was also identified as being 
present, but this was attributed to it being residual precursor from the 4-FPP synthesis of 
the reference standard or breakdown of the 4-FPP. Stability of drugs in the solvent 
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dichloromethane results showed the presence of benzyl chloride and benzyl chloroformate, 
(Figure 5.6) for 1,4 dibenzylpiperazine (DBZP) and also in composite drug mixture. This 
correlates with its loss of stability after 25 hours. This can be attributed to DBZP on 
prolonged analysis (36 hours on the auto-sampler), being unstable in the solvent 
dichloromethane. Tanabe and Matsuda (1961) showed that dichloromethane undergoes 
hydrolysis, the reactions were shown in Figure 2.12 (section 2.7), the products of the 
hydrolysis; HCl, CH2CIOH in the presence of moisture facilitate degradation of DBZP (I) 
as shown in the reaction scheme below, Figure 5.7. The degradation results in the formation 
of benzyl chloride (II) and Benzyl chloroformate (IV). 
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N
H Cl
N
N+
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R
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NH
NH
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2
O+
H
H
OH
H
OH
H
OH
H
Cl
Cl OHH2O HCl
HCl
H2O
Cl -
-HCl
O
Cl
OH
H
H2O
HCl
O
O
Cl
I
II
III
IV
R = -CH3-Ph
+
+
+
+
 
 Figure 5.7 Proposed degradation pathway of benzylpiperazines, an exemplar of DBZP 
showing the formation the benzyl chloride and benzyl chloroformate.  
 
The absence or presence of this degradation pathway with the other piperazines can be 
attributed to electronic (inductive and resonance) and steric effects due to their molecular 
structure and the impact on basicity and consequently reactivity (Jones, 1982; Yoshioka 
and Stella, 2000). The presence of the methyl group attached to the nitrogen atom has a 
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positive inductive effect (+I) and a positive resonance effect (+R)  resulting in an increase 
in electron density about the nitrogen atom, which increases its basicity and consequently 
reactivity. It can therefore be suggested that the lack of such a methyl group in the non-
benzylpiperazines makes them less susceptible to degradation. DBZP is more likely to 
undergo this reaction than the other benzylpiperazines due to presence of two such methyl 
groups. This is supported by the results obtained, where benzylchloride and 
benzylchloroformate were absent in BZP and MBZP. This is in line with the basicity of 
amines (Lawrence, 2004).  
 
An un-identified peak was also observed at 15.03mins (Table 5.6 and Appendix 3) mixture 
arising from MBZP, tentatively identified as benzamide N-(3-amino-3-
hydroxyminopropyl)-N-methyl- or Piperazine,1-(2-trifluoromethylbenzyl)-4-(3-
methylbenzyl)-. The solvent 2-methylpropan-2-ol showed good results in both solvation 
and non-reactivity with analytes, as evidenced by the lack of degradation products on 
analysis using this solvent. This can be attributed to steric effects as it is a tertiary alcohol. 
This same property is somewhat of a hindrance as it has less solubility. However, stability 
of drugs in the solvent 2-methylpropan-2-ol results showed evidence of degradation on 
prolonged analysis in the solvent, artefacts were observed at 36 hours, trace amounts of 
benzyl chloride and benzyl chloroformate were observed. It was concluded that there was a 
strong possibility of esterification if ethyl acetate is used taking into consideration its 
chemical properties and those chemistry of the drugs to be analysed. This was confirmed by 
the presence of impurities due to esterification during synthesis (section 8.3.2), ethyl 
acetate was one of the solvent used as part of purification in one of the routes of synthesis 
routes. Furthermore, it was recorded that ethyl acetate was used extensively in 
derivatisation of samples whilst the other solvents were mainly applied to un-derivatised 
samples. Since in this research project the solvent was applied to characterisation of street 
samples expected to contain impurities, no derivatisation of samples was conducted and 
further use of ethyl acetate was considered unsatisfactory compared to the other solvents. 
However, it is highlighted that for work which does not involve impurity profiling of drugs 
ethyl acetate can be of use.  
 
It is evident from the discussions above, that of the solvents investigated the analytes were 
most stable in 2-methylpropan-2-ol, hence this solvent was deemed suitable for use in this 
 156 
 
research. Consequently, the stability of the analytes on storage in this solvent was 
investigated. 
 
It was discussed in chapter 2 (section 1.6) that currently no studies have been reported on 
the stability of drugs the auto-sampler during analysis and or the influence of solvents on 
that stability. Hence, no comparative analysis could be conducted. The data generated in 
this study can therefore be of use to other researchers.  
 
5.3.6 STABILITY OF DRUGS ON STORAGE IN THE REFRIGERATOR (4OC)  
 
The stability of all the analytes on storage in the fridge at 4oC in 2-methylpropan-2-ol is 
depicted in Figure 5.8. The graph shows the period the analytes were stable in days. 
 
 
Figure 5.8 Storage stability graph of all the drugs at 4oC (n = 2). 
 
5.3.7 STABILITY OF DRUGS ON STORAGE IN THE  FREEZER (-20OC) 
 
The stability of all the drugs on storage in the freezer (-20oC) in 2-methylpropan-2-ol is 
depicted in Figure 5.9.  The graph shows the period the analytes were stable in days. 
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Figure 5.9 Aggregate storage stability graph of all the drugs at (-)20oC (n = 2). 
 
The refrigerator (4oC) results indicated that the drugs are stable for 6 - 10 days whislt the 
freezer (-20oC) results indicated that drugs are stable up to a month (Figures 5.8 and 5.9). 
This therefore implies that with time even frozen drugs can undergo degradation. However, 
the degradation is much slower than that observed at higher temperatures. It was found on 
average to be about 24 hours on the auto-sampler and up to 8 days in the refrigerator. This 
is due to the very low temperatures which reduces the rate of degradation. The low 
temperature decreases the kinetic energy of the molecules and furthermore results in the 
molecules having inadequate energy to meet the activation energy required for any 
degradation reactions. However, the presence of moisture in the freezer can result in slow 
hydrolysis (Yoshioka and Stella, 2000) and is the likely reason for the observed 
degradation after a period of storage time. Few studies were encountered on stability of 
drugs during storage and these were mainly in biological studies, but some of the results 
could be extrapolated to this study. The work of Karinen et al., (2011) was found to be 
closely related to this study. They conducted a comparative stability of stock solutions of 
drugs of abuse stored in the refrigerator, freezer and at ambient conditions involving an 
extensive range of drugs. In their study the results of amphetamine, BEH, MDMA, 
methamphetamine, diazepam and cocaine were of interest as these drugs were also 
investigated in this study. It was observed that whilst both studies reported the presence of 
degradation, the results were rather divergent with respect to the period/duration the drug 
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was stable. In their study the drugs were stable for longer periods; the least stable was 
diazepam which showed degradation at 6 months (refrigerator). This could be due to tighter 
limits used in this study (±10%) compared to theirs (±20%). In addition, in this study the 
chromatographic profiles were also reviewed for any changes as confirmation. In other 
study studies Gunnar et al. (2004), Moody et al. (1999) and Nowatzke and Woolf (2007) 
indicated that for stability studies, an analyte was considered stable if its concentration 
remained within ±15 – 20% of the nominal value.  
 
5.4 CONCLUSION 
 
The solvents water, ethyl acetate, methanol, 2-methylpropan-2-ol and dichloromethane 
were investigated for their ability to dissolve the analytes. Good solubilities were observed 
for all the solvents, dissolving at least 84% of the 25 analytes investigated. As such any of 
the solvents could be applied in further analytical studies. The influence of the solvents 
methanol, 2-methylpropan-2-ol and dichloromethane on the stability of the analytes was 
investigated. All drugs analysed (22) were found stable in all the solvents at ambient 
temperature and pressure. It has been discussed that studies on the stability of drugs on the 
auto-sampler during routine laboratory investigations had not been encountered. 
Consequently, it was deemed imperative to study this aspect of stability, especially since 
analytes might spend a long duration on the auto-sampler awaiting analysis. In addition, 
auto-samplers can warm up with time hence this might have thermal effects on the stability 
(Yoshioka and Stella, 2000; ICH Q1A(R2), 2003; FDA, 2008).  The 22 drugs analysed 
showed the highest stability in 2-methylpropan-2-ol. All the analytes were stable in this 
solvent on the GC-MS auto-sampler for the period investigated (25 hours). Whilst in 
methanol, stability was in the range 14 – 25 hours and for dichloromethane 19 – 25 hours. 
Cocaine, BEH and EME were the drugs that were the least stable in the solvents. Artefacts 
were observed with dichloromethane (i.e., benzylchloride and benzylchloroformate). The 
formation of artefacts is undesirable (Aalberg et al., 2005b), since the solvent was also to 
be used in impurity profiling, 2-methylpropan-2-ol was the solvent selected for further use 
in all the studies. Further investigation of the stability of the analytes on storage in solution 
in 2-methylpropan-2-ol showed that the analytes were stable for 6 – 10 days in the 
refrigerator and 22 – 30 days in the freezer. This showed that the analytes can be retained 
for an adequate period during laboratory investigations. 
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It can be concluded that the following stability limits were established and can be set for 
piperazine drugs of abuse and their congeners; a) for routine ambient laboratory conditions 
(ambient temperature and pressure): stable  in the solvents methanol, dichloromethane and 
2-methylpropan-2-ol are stable, b) on the GC-MS auto-sampler: stable in methanol for 14 
hours, dichloromethane 19 hours and 2-methylpropan-2-ol 25 hours, c) for storage in the 
refrigerator at 4oC in 2-methylpropan-2ol: stable for 6 - 10 days, and d) storage in the 
freezer at (-)20oC in 2-methylpropan-2ol: stable for 22 - 30 days.  
 
 The results of this research provide novel information on the stability profile of piperazines 
and other drugs of abuse prevailing on the market, set stability limits for storage and 
analysis, i.e., provided data for other chapters of the research project. It was also identified 
that 2-methylpropan-2-ol has not been extensively used in the analysis of drugs of abuse; 
hence it is proposed as a solvent for use especially in profiling or impurity analysis, mainly 
due to its non-reactivity. 
 
It was highlighted that no record was found of a study on the stability of FPP, TFMPP and 
other piperazines or drugs of abuse during routine laboratory analysis, or as a research 
study in its own entirety. Information derived from stability studies can be used to eliminate 
or minimise potential degradation and the resulting loss in stability during laboratory 
investigations. Furthermore, in view of the increasing use of phenylpiperazines and other 
psychoactive substances (Kenyon et al., 2010; King and Kicman, 2011; Arbo et al., 2012; 
Philip et al., 2013;  EMCDDA, 2014) which will likely increase analytical investigations, 
the information derived from this study will therefore be of use in future investigations by 
other researchers. 
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CHAPTER 6 
OPTIMISATION OF THE METHOD 
 
6.1 INTRODUCTION TO THE OPTIMISATION STUDY  
 
In Chapter 4 it was discussed in that whilst the preliminary method of analysis developed 
(method 3b, Table 4.3) generated good chromatographic profiles for the drugs (Figure 4.16, 
and 4.17), it was desirable to improve resolution for those peaks between 14 to 15.5 
minutes. This was evidenced by the co-elution between 3-TFMPP and MDMA (14.22 and 
14.36 minutes respectively). The resolution was R = 1.06 whilst for all the other drugs R > 
2 and there was need to reduce the tailing. As such, there is need to investigate whether or 
not the variables in method 3b can be optimised to give better results. It was identified in 
the discussion on theoretical concepts (Chapter 2 sections 2.3 and 2.4) that method 
operational variables have a profound effect on the quality of the chromatographic result. 
Furthermore, these variables can be manipulated so as to enhance the method performance, 
i.e., optimised (Lavanya, 2013). In the investigation of instrumental parameters in Chapter 
4 the drugs identified as needing further work (resolution) elute in the temperature range 12 
- 16 minutes (temperature range 150 - 200oC). Consequently, in this study optimisation of 
column oven temperature focused on the mid ramp temperature of 150oC (section 6.2.2) as 
this was anticipated to have a higher effect on the results. However. it was also deemed 
desirable if all aspects of the chromatographic profile were improved as this would enhance 
accuracy. 
 
In this study, optimisation was conducted through investigation of the effect of injector port 
and oven temperatures, mobile phase flow rate, MS scan rate and ionisation energy on 
method 3b performance characteristics. Similar analysis successfully optimised methods in 
the works of Andersson et al. (2007a), Maher et al. (2009), Byrska et al. (2010) and Santali 
et al. (2011). The performance characteristics were measured in terms of plate number (N), 
resolution (Rs), tailing (T), capacity (retention) factor (k), selectivity (α) and retention time 
(Rt). The concepts behind these parameters were discussed in Chapter 2 (section 2.3).  
 
The data generated was then evaluated so as to select the injector temperature and oven 
temperature which gave optimum performance. Optimum variables were those that gave 
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the highest N, decreased T, increased k, increased selectivity, reduced mass spectral 
fragmentation, maintained or decreased analysis run time and generally resulted in sharp 
narrow peaks (Andersson et al., 2007a; Hibbert, 2007;  Inoue et al., 2008). To determine 
the validity of the results, statistical analysis was conducted using Correlation analysis, T-
test (paired), Friedman test and Wilcoxon signed-rank test (Chapter 3).  
 
This study was conducted as depicted in Figure 6.1. 
 
 
Figure 6.1 Structure of the experimental work for the method optimisation study. 
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6.1.1 AIMS 
 
The aims were to a) investigate the effect of variation of the method operational variables; 
injector port and oven temperatures, mobile phase flow rate, MS scan rate and ionisation 
energy on the on the quality of the chromatographic profile, i.e., plate number, resolution, 
tailing, capacity factor, selectivity and retention time, b) to select the optimum values of 
these parameters so as to improve method performance, and c) to generate an optimised 
method for validation and use in later studies (Chapter 7 and 8). 
 
6.2 MATERIALS AND METHODS 
 
All the tests (sections 6.2.6 – 6.2.11) were run in duplicate.  
 
6.2.1 CHEMICALS/REAGENTS 
The drug standards used were as listed in Chapter 4, section 4.2.1. 
 
6.2.2 INSTRUMENTS 
 
Optimisation was carried out using Perkin Elmer GC-MS, Clarus Turbomass Gold 500MS 
fitted with a Supelco, Equity-5 GC capillary column (30m x 0.25mm x 0.25µm). The 
instrument was equipped with a Perkin Elmer 4mm quartz split/splitless injector liner and 
with the NIST MS Search Version 2.0 library software.  The instrument was initially set up 
with the un-optimised method parameters (Method 3b Table 4.3 Chapter 4), i.e., the 
injector was set at 250oC with a split ratio of 20:1. The carrier gas was He (g) at a flow rate 
of 1mL/min. The initial oven temperature was set at 60 oC with a hold of 1min. The oven 
was ramped at 10 oC /min to 150oC with a hold of 2min and at 15oC /min to 280oC, with a 
hold of 4min. The MS transfer line was set at 280oC, source temperature 230oC, ionisation 
energy 70eV and scan range at m/z 40 – 500. The total analysis run time was 23.67minutes. 
  
6.2.3 STATISTICAL SOFTWARE   
 
Statistical analysis of results was carried out using IBM SPSS Statistics version 20 and MS 
Office Excel 2010. 
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6.2.4 PREPARATION OF STANDARD SOLUTIONS 
 
The drug standards listed in Table 4.1 (Chapter 4) were used to prepare standard solutions 
for use in the optimisation tests. Individual drug standard solutions and a mixed drug 
standard solution were prepared in 2-methylpropan-2-ol using the method outlined in 
Chapter 4 (section 4.2.4.3) with eicosane as the internal standard. 
 
6.2.5 CONTROL: UN-OPTIMISED METHOD ANALYSIS FOR COMPARISON 
 
The individual and mixed standard solutions were analysed by GC-MS. This test was 
carried out using the method specified in section 6.2.2 above without any variations.  
 
6.2.6 INVESTIGATING THE EFFECT OF INJECTOR PORT AND OVEN TEMPERATURES, 
MOBILE PHASE FLOW RATE, MS SCAN RATE AND MS IONISATION ENERGY 
 
Investigation of the method variables was carried out from phases 1 to 6 as shown in Table 
6.1. The parameter values were applied to the method in section 6.2.2 one at a time for each 
of the variables investigated. 
 
Table 6.1 Optimisation of method variables 
Analysis Variable investigated Parameter value[1] 
Phase 1 Injector port temperature 240, 250, 260, 270 oC 
Phase 2 Oven temperature (1st ramp) 140, 150, 160, 170, 180 oC 
Phase 3 Injector port, oven temperature Optimum values from phases 1 and 2 
Phase 4 Carrier gas flow rate 0.75, 1.0 mL/min 
Phase 5 MS scan rate: A = 1246Da/s 
     
                       B = 2277Da/s 
 
                       C = 4509Da/s 
scan time 0.349s; inter scan delay 0.02s; 
scan range m/z 40 – 500 
scan time 0.2s; inter scan delay 0.02s; 
scan range m/z 40 – 620 
scan time 0.1s; inter scan delay 0.02s; 
scan range m/z 40 – 500 
Phase 6 MS ionisation energy 60, 70eV 
[1]Values in bold are those in the original un-optimised method, these are the controls 
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6.2.7 DATA ANALYSIS 
 
Plate number, tailing, selectivity and resolution were calculated using the equations 
outlined in Chapter 2 (section 2.3). For plate number equation 2.8, tailing equation 2.12, 
selectivity equation 2.10 and resolution equation 2.11 were used. 
 
Statistical analysis of Phases 1 and 2 results was conducted using the Friedman test in 
accordance with section 3.2.8 (Chapter 3). 
 
Percentage gain or loss graphs were used to evaluate Phase 3 data. In addition statistical 
analysis was conducted using Correlation analysis, T-test (paired), Friedman test and 
Wilcoxon signed-rank test. The statistical calculations were done as outline in Chapter 3. 
For % Gain and loss graphs section 3.2.10, Correlation analysis section 3.2.4, T-test 
(paired) section 3.2.5, Friedman test section 3.2.8 and Wilcoxon signed-rank test section 
3.2.9. 
 
6.3 RESULTS AND DISCUSSION 
 
6.3.1 PHASE 1 INVESTIGATING THE EFFECT OF INJECTOR TEMPERATURE ON THE 
METHOD DEVELOPED  
 
The total ion chromatographic profile (TIC) is shown in Figure 6.2 for a representation of 
the injector temperatures investigated in comparison to the control. There was a slight 
change in the chromatographic profile for all the analytes, as can be seen in the total ion 
chromatogram (TIC), Figure 6.2. The peaks at one of the experimental injector port 
temperatures (260oC) compared to the control (250oC) showed less tailing. This was 
observed, for example, for methamphetamine, 2-TFMPP and 3-FPP and 4-TFMPP. 
However, the resolution between peaks and retention time were observed to be unaffected 
by changes in injector port temperature. 
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Figure 6.2 Phase 1 Chromatographic profiles (TIC) showing effect of injector temperature for selected temperatures (250 and 260oC). 
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To confirm the observations the chromatographic quality characteristics plate number N, 
tailing T, selectivity α, resolution Rs and retention time Rt were determined and analysed. 
The effect of injector temperature on N, T, α, Rs and Rt is shown below in Table 6.2 and 
graphically represented in Figures 6.3 - 6.6.  
 
Table 6.2 Phase 1 optimisation: Effect of injector port temperature.  
Temp/oC Mean values (n = 2)  Temp/oC Mean values (n = 2) 
 N x 
105 
T α Rs Rt/min   N x 105 T α Rs 
Meth       MBZP     
240 4.015 4.224 1.422 5.938 8.880  240 11.629 4.211 1.013 3.768 
250 3.831 4.000 1.422 5.603 8.880  250 10.672 4.211 1.013 3.711 
260 3.613 3.038 1.422 5.476 8.880  260 13.545 4.188 1.014 4.086 
270 3.798 3.353 1.422 5.938 8.880  270 11.629 4.048 1.013 3.740 
280 3.785 3.394 1.422 6.318 8.860  280 12.024 3.810 1.014 3.897 
2-FPP       CPP     
240 5.265 3.947 1.070 9.660 12.620  240 22.813 3.000 1.054 21.248 
250 4.432 3.750 1.070 9.629 12.620  250 23.566 2.875 1.054 22.398 
260 4.265 3.491 1.070 9.354 12.620  260 23.551 2.875 1.054 22.398 
270 5.478 3.182 1.070 9.745 12.620  270 23.551 2.875 1.054 22.849 
280 6.914 3.210 1.070 11.439 12.605  280 23.551 2.764 1.054 22.273 
3-FPP       MePP     
240 13.627 3.001 1.040 12.270 14.510  240 15.330 3.142 1.086 28.282 
250 13.636 2.513 1.040 12.607 14.515  250 15.870 2.960 1.086 28.646 
260 14.107 2.500 1.040 12.835 14.510  260 15.860 2.788 1.086 28.646 
270 13.627 2.466 1.040 12.716 14.510  270 14.846 2.700 1.086 28.037 
280 14.087 2.611 1.040 13.202 14.500  280 15.310 2.850 1.087 28.496 
4-FPP       MDMA     
240 12.107 3.401 1.013 3.951 14.130  240 15.341 ND[1] 1.010 2.911 
250 10.429 3.250 1.013 3.638 14.130  250 15.922 ND[1] 1.010 2.937 
260 12.107 2.953 1.013 3.819 14.130  260 14.813 ND[1] 1.010 3.015 
270 10.426 3.275 1.013 3.727 14.130  270 14.307 ND[1] 1.010 2.861 
280 12.904 3.300 1.013 3.883 14.120  280 17.826 ND[1] 1.011 3.260 
2-TFMPP       caffeine     
240 5.724 4.000 1.070 13.560 12.620  240 34.968 1.045 1.050 26.346 
250 4.432 5.875 1.070 13.140 12.620  250 37.654 1.000 1.050 26.919 
260 4.264 3.240 1.070 13.544 12.620  260 37.654 1.019 1.050 25.277 
270 5.022 3.583 1.071 13.889 12.620  270 37.654 1.000 1.050 27.883 
280 4.620 3.989 1.070 13.440 12.620  280 37.611 1.000 1.051 27.225 
3-TFMPP       cocaine     
240 16.389 ND 1.003 1.096 14.320  240 57.872 1.000 1.081 43.899 
250 13.740 ND 1.003 1.058 14.320  250 61.013 1.000 1.074 45.053 
260 14.208 ND 1.003 1.049 14.320  260 57.872 1.000 1.081 43.218 
270 15.234 ND 1.003 1.058 14.320  270 57.872 1.000 1.081 43.381 
280 14.188 ND 1.003 0.863 14.310  280 57.872 1.000 1.081 43.349 
4-TFMPP       diazepam     
240 18.199 1.842 1.007 1.977 15.090  240 45.127 1.273 ND[1] ND[1] 
250 21.225 1.803 1.007 1.994 15.090  250 66.788 1.193 ND[1] ND[1] 
260 21.211 1.745 1.007 1.910 15.085  260 43.277 1.150 ND[1] ND[1] 
270 21.225 1.715 1.007 2.044 15.090  270 43.277 1.110 ND[1] ND[1] 
 167 
 
280 21.197 1.625 1.006 2.010 15.080  280 43.238 1.036 ND[1] ND[1] 
BZP       eicosane     
240 5.511 5.880 1.021 4.602 13.840  240 64.907 1.000 1.079 47.924 
250 6.244 5.557 1.021 4.615 13.840  250 64.907 1.000 1.079 47.074 
260 6.501 4.950 1.021 4.911 13.835  260 56.236 1.000 1.079 44.882 
270 5.511 5.068 1.021 4.427 13.840  270 64.907 1.000 1.079 47.074 
280 7.541 5.278 1.022 5.284 13.820  280 64.907 1.000 1.079 46.117 
DBZP            
240 55.729 1.100 1.019 11.233 19.955       
250 58.723 1.023 1.019 11.683 19.950       
260 55.729 1.013 1.019 11.233 19.950       
270 55.729 1.034 1.019 11.233 19.950       
280 55.673 1.011 1.020 11.528 19.940       
[1]
 ND stands for not determined.  
 
In Table 6.2 and all subsequent tables and graphs the analytes were not determined (ND) is 
indicated. This was due to the co-elution between 3-TFMPP and MDMA hence tailing 
could not be calculated for these two analytes. In addition diazepam is the last peak hence 
there is no resolution to a subsequent peak after it.  
 
 
Figure 6.3 Phase 1 Effect of injector temperatures on plate number (N x 105). 
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Figure 6.4 Phase 1 Effect of injector temperatures on tailing. 
 
 
Figure 6.5 Phase 1 Effect of injector temperatures on selectivity. 
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Figure 6.6 Phase 1 Effect of injector temperatures on resolution. 
 
The following general trends were observed on the effect of injector port temperatures on 
plate number, tailing, selectivity, resolution and retention time. The changes observed can 
be attributed to the influence of injector port temperature on volatilisation of the sample 
during injection (Barwick, 1999; Grob, 1994; Kaur, 2010). In Figure 6.3 plate number, N 
increased with increase in temperature. According to equation 2.8, plate number increases 
with increase in retention time and decreases with with increase in peak width. If the 
sample is not flash volatilised on injection band broadening can occur, thereby reducing 
plate number. For DBZP, cocaine and diazepam plate number, N increased from 240oC to 
250oC, theafter it decreased to 260oC and remained constant (260 – 280oC).  Figure 6.3 
shows that the degree of change increased from DBZP to diazepam and is significantly 
large for diazepam. This can be attributed to the boiling points of the compounds which 
influence their chromatographic properties. The elution order of the analytes (Figure 6.2) 
followed the trend in their boiling points with compounds with higher boiling points having 
higher retention times, e.g. the last 5 are caffeine, eicosane, DBZP, cocaine and diazepam, 
with diazepam which has the highest boiling point eluting last. With increase in injector 
port temperature volatilisation of the sample increases until it reaches optimum after which 
it can remain constant, e.g. for caffeine, N is constant. Thereafter with further increase in 
temperature loss of sample from the injector port can occur due to vapourisation if the 
temperature is too high. Barwick (1999) reported that as much as a 30% loss can occur.  
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In Figure 6.4 tailing decreased with increase in temperature. Selectivity (Figure 6.5) and 
retention time (Table 6.2) were marginally affected by injector port temperature and 
remained relatively constant. In confirmation the variance in these parameters was zero for 
methamphetamine, 2-TFMP and 3-FPP.  Resolution was observed to be very high for all 
the drugs except the co-eluting substances (3-TFMPP and MDMA), with R for most drugs 
> 3 (Table 6.2). It has been stated that a resolution of R > 2 implies good separation 
between peaks (IUPAC, 2014; CDER, 2004; Horacio et al., 2008). However, whilst there is 
adequate resolution generally it was observed to be constant and only marginally varied 
with injector temperature (Figure 6.6).  However, for a few of the analytes the trend in 
resolution was not consistent as can be seen for 2-TFMPP and cocaine (Table 6.2; Figure 
6.6).  
 
According to Hibbert (2007) the purpose of optimisation is to select those variables which 
improve the chromatographic peak profile and consequently the results generated by the 
method. As such the graphs (Figures 6.3 – 6.6) were reviewed so as to evaluate which of 
the injector temperatures investigated resulted in optimum plate number, tailing, selectivity, 
resolution and retention time (the criteria for acceptability was discussed in Chapter 2 
section 2.4). Inoue et al. (2008) and Maher et al. (2009) used similar approaches in 
optimising their methods. It was found that overall the injector temperature at 260oC gave 
the best results in terms of highest values of plate number, selectivity and resolution and 
lowest values for tailing and retention times. 
 
The influence of injector temperatures can be attributed to the fact that to achieve the best 
result flash vapourisation of the compound is required on injection. This reduces leading 
peaks and band broadening (Barwick, 1999; Kronstrand and Jones, 2000; Andersson, 
2007a) and as such sharper, narrower peaks, decreased tailing, improved peak separations 
are obtained. 
 
 Further evaluation was conducted by statistical analysis so as to confirm the above 
findings and also determine the actual trends and their significance. Thus determine the 
injector temperature which gave optimum results.  
 
6.3.1.1 Statistical analysis of Phase 1 investigating the effect of injector temperature 
The statistical results are shown in Table 6.3. 
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Table 6.3 Statistical analysis of effect of injector results (Phase 1): Friedman Test. 
 Plate number Tailing Selectivity Resolution 
Temp oC Median 
rank 
Upper 
quartile 
(75%)   
Mean 
rank 
Median 
rank 
Lower 
quartile 
(25%)   
Upper 
quartile 
(75%)   
Mean 
rank 
Median 
rank 
Upper 
quartile 
(75%)   
Mean 
rank 
Median 
rank 
Upper 
quartile 
(75%)   
Mean 
rank 
240 3.00 3.75 2.88 5.00 4.50 5.00 4.63 3.00 3.00 2.81 2.50 4.00 2.91 
250 3.50 5.00 3.47 4.00 3.00 4.00 3.50 2.75 3.00 2.66 3.00 3.875 2.88 
260 3.00 3.75 2.85 3.00 1.00 3.00 2.33 3.00 3.00 2.97 2.50 4.00 2.56 
270 2.50 3.75 2.74 2.00 2.00 3.00 2.20 3.00 3.00 2.97 3.25 4.75 3.09 
280 3.00 5.00 3.06 3.00 1.00 3.00 2.33 3.00 5.00 3.59 4.00 5.00 3.56 
Test 
statistic 
Fr = 2.530, N = 17, df = 4, p = 
0.639 
Fr = 31.88, N = 15, df = 4, p = 0.000 Fr = 10.947, N = 16, df = 4, p = 
0.027 
Fr = 3.563, N = 16, df = 4, p = 
0.468 
 
In the table Fr is the Friedman test statistic. 
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A Friedman test was conducted to determine whether the analytes had a differential rank 
response on being subjected to different injector port temperatures. With the objective of 
choosing the optimum value for further analytical investigation. The response was 
measured in terms of plate number, tailing, selectivity and resolution. The criterion for the 
Friedman test is; if p > 0.05 the results are insignificant, if Fr < Fr (critical) reject Ho 
(Sprent and Smeeton, 2007, Corder and Foreman, 2009, Best et al., 2009). The injector 
results (Table 6.3) indicate that injector temperature has a statistically insignificant effect 
on plate number (Fr = 2.530, N = 17, df = 4, p = 0.639) and resolution (Fr = 3.563, N = 16, 
df = 4, p = 0.468). As evidenced by both values for p being greater than the limit 0.05. In 
addition, the Fr observed was lower than Fr(critical) = 9.49 (Corder and Foreman, 2009; 
Best et al., 2009; Martin et al., 1993) consequently Ho was retained. This means any 
variations in plate number and resolution are statistically found to be unaffected by changes 
in injector temperature. Any variations observed are therefore due to chance. 
 
This statistical outcome is consistent with the discussion graphical analysis Figures 6.3 – 
6.6 conducted above where it was highlighted changes were observed for example, even 
small variations such as for 4-FPP plate number, N is virtually constant. Considering that 
for all the analytes the N values are large (x105), the changes observed are minimal. In 
contrast, the results show that there are significant differences in tailing (Fr = 31.88, N = 
15, df = 4, p = 0.000) and selectivity (Fr = 10.947, N = 16, df = 4, p = 0.027) at various 
injector and as such Ho is rejected. This implies that both these parameters were statistically 
found to be variable with temperature. A further review of the statistical results was 
conducted so as to ascertain the magnitude of the changes and hence select the optimum 
temperature which gave the highest changes. 
 
In the review of the descriptive data in Table 6.3 the criteria is that the upper quartile range 
(75% + range) encompasses the highest tailing. As such, for the injector at 240 and 250oC 
should be avoided as these temperatures fall in this range. The lower quartile range 
encompasses the lowest tailing results. It can be seen that the lowest median (= 1) is 
observed with temperatures 260 and 280oC. For selectivity, resolution and plate number an 
increase is desirable unlike tailing. Hence, for the criteria for these parameters the upper 
quartile implies good effect whilst the lower quartile implies bad effect. A similar analysis 
for selectivity gives the highest median at 240, 260, 270 and 280oC; however the highest 
upper quartile range is observed with 280oC. It is therefore proposed that an injector 
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temperature of 260oC maximises the chromatographic profile to a higher degree than the 
other temperatures investigated, hence was investigated in further optimisation (Phase 3). 
This view confirms the observations made on review of the quality of the chromatographic 
profile for 260oC (TIC) (Figure 6.1) where it was observed that this temperature gave better 
peak profiles than the control (250oC). Since both the 250oC and 280oC gave good results, 
further use of 280oC was not recommended since a higher temperature causes evaporation 
of some of the sample from the needle during injection (Grob, 1994). Barwick (1999) 
reported that for very high boiling point components losses of up to 80% can occur. In 
addition a higher temperature would shorten the life span of the septum in the injector.  
 
6.3.2 PHASE 2 INVESTIGATING THE EFFECT OF OVEN TEMPERATURE ON THE METHOD 
DEVELOPED  
 
The chromatographic profiles (TIC) resulting from variation of oven temperatures are 
shown in Figure 6.7 for a representation of the oven temperatures investigated. The Figure 
shows the result for the oven at 160oC, 180oC and the control (150oC) for comparison. 
There were a marked changes in the chromatographic profile for all the analytes, as can be 
seen in the total ion chromatogram (TIC), Figure 6.7 for oven at 160oC and 180oC in 
comparison to the control (150oC). It can be observed in Figure 6.7 that the TIC with the 
injector temperature at 180oC shows has a more marked effect. Peak separation was 
observed to increase with temperature from 150 to 180oC. This was more apparent for the 
peaks eluting in the range 12 - 16 minutes. The peak shapes are narrower, less broad at the 
base and tail less. This indicates a reduction in band broadening, hence the reduced tailing. 
Furthermore, the retention time decreased with increase in oven temperature for the peaks 
eluting in the said range, whilst it had the opposite effect for those eluting thereafter. In this 
chapter it was previously discussed (section 6.1) that the optimisation of oven temperature 
was to focus on the mid-ramp temperature so as to try and improve resolution between the 
analytes in the range 12 - 16 minutes. It was further highlighted that due their boiling points 
optimising the mid ramp temperature within 150 - 200oC would have more impact on their 
chromatographic behaviour. As such, it can be suggested that the optimisation of oven 
temperature gave the desired outcome i.e improved the method perfomance.  
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Figure 6.7 Phase 2 chromatographic profiles (TIC) showing effect of the selected oven temperatures, 160oC and 180oC in comparison to 
the control (up-optimised method at 150oC).
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The plate number (N), tailing (T), selectivity (α), resolution (Rs) and retention time (Rt) 
were determined so as to further evaluate the changes in the chromatographic peak profile 
of the analytes, with oven temeperature and confirm the observations made earlier on 
Figure 6.7. The parameters were evaluated for all the oven temperatures investigated 140 - 
200oC) and the data is given in Appendix 4 and depicted in Figures 6.8 - 6.11 for easier 
evaluation.  
 
 
Figure 6.8 Phase 2 Effect of oven temperatures on plate number (N x 105) comparative 
to control 150oC. 
 
 
Figure 6.9 Phase 2 Effect of oven temperatures on tailing comparative to control 150oC. 
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Figure 6.10 Phase 2 Effect of oven temperatures on selectivity comparative to control 
150oC. 
 
 
Figure 6.11 Phase 2 Effect of oven temperatures on resolution comparative to control 
150oC. 
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selectivity changed minimally, it followed a similar trend as evidenced for example by CPP 
(Appendix 4); with increase in temperature, selectivity increased from 1.051 to 1.092. In 
line with this, resolution simultaneously increased from 21.027 to 26.903. In addition, 
selectivity changes whilst small were more than those observed with the injector. This was 
evidenced by the changes in Figure 6.10 (oven) in comparison to Figure 6.5 (injector) for 
the selectivity of 3-FPP, 2-TFMPP, CPP and MePP. However, statistical analysis was 
required to confirm the significance of these observations. Furthermore, this would also 
enable selection of the oven temperature that gives the best results in plate number, tailing, 
selectivity, resolution and retention time. 
 
The greater impact of oven temperature is due to the fact that the oven temperature has a 
direct impact on the partitioning processes inside the column. Mainly oven temperature 
influences the vapour pressure inside the column and consequently the partition coefficient. 
An increase in oven temperature results in an increase in vapour pressure thereby 
equilibration of the analyte between the stationary phase and mobile phase is achieved 
faster. This reduces the partition coefficient, which in turn reduces the retention factor and 
consequently increases plate number. This is in accordance with the chromatographic 
concepts and their influence on optimisation described in sections 2.3 and 2.4(Chapter 2). 
An increase in oven temperature increases the kinetic energy of the analyte molecules, 
thereby reducing resistance to mass transfer (C term in the van Deemeter r equation) in 
accordance with the Rate theory (section 2.4 equations 2.13 - 2.16). This increases the 
elution rate hence the decrease in retention time. Furthermore, the increased migration of 
the molecules reduces longitudinal diffusion (B-term), (Moody, 1982; Kaur, 2010; 
Khopkar, 2012; IUPAC, 2014) as such this reduces the height of a theoretical plate 
(HETP). This term is inversely proportional to plate number hence reduction of HETP 
increases plate number. Changes in column plate number impact on resolution. This affects 
separation between substances (equation 2.11) as was discussed in section 2.3 for 
resolution. Therefore, the increase in plate number resulted in the improved resolution 
observed in the results. This equation also explains the similarity in behaviour of selectivity 
and plate number. The fact that selectivity only changed marginal is due to selectivity being 
dependent on capacity factor (retention factor) hence is more subject to changes in the type 
of stationary phase.  
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With the oven at 180oC resolution was observed to be lower for those drugs with lower 
retention times eluting before 16 minutes and more improved for the drugs eluting after 
16mins (Figure 6.7, 6.11 and Appendix 4). In contrast, 160oC gave better resolution for the 
early eluting drugs.  It was discussed in section 6.1 that drugs eluting within this range 
would be influenced more by investigation of the oven temperatures under consideration 
(1st oven ramp temperature) as their boiling points fall within this temperature range. As 
such these eluted faster at higher temperatures hence the observed reduction in their in 
resolution at 180oC.  
 
6.3.2.1 Statistical analysis of Phase 2 investigating the effect of oven temperature. 
The Friedman test results for statistical analysis of the oven data are summarised in Table 
6.4.   
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Table 6.4 Statistical analysis of effect of oven temperature results (Phase 2): Friedman Test. 
 Plate number Tailing Selectivity Resolution 
Temp oC Median 
rank 
Upper 
quartile 
(75%)  
Mean 
rank 
Median 
rank 
Lower 
quartile 
(25%)   
Upper 
quartile 
(75%)   
Mean 
rank 
Median 
rank 
Upper 
quartile 
(75%)   
Mean 
rank 
Median 
rank 
Upper 
quartile 
(75%)   
Mean 
rank 
140 6.00 7.00 5.76 6.00 6.00 7.00 5.93 1.50 2.375 2.13 3.00 4.00 2.88 
150 4.00 5.00 4.06 6.00 5.00 7.00 5.87 2.75 4.25 3.09 2.00 2.75 2.44 
160 3.00 4.50 3.47 5.00 4.00 5.00 4.57 4.50 5.75 4.41 4.45 7.00 4.50 
170 2.00 4.50 2.82 4.00 3.00 4.00 3.83 5.00 6.75 4.81 4.00 5.95 4.00 
180 3.00 5.00 3.50 2.50 1.00 3.00 2.57 5.00 6.00 4.81 5.00 6.65 4.75 
190 4.00 6.00 4.29 2.00 1.00 2.00 2.23 4.50 6.00 4.47 5.00 6.00 4.63 
200 5.00 6.50 4.09 2.00 1.50 4.00 3.00 3.75 7.00 4.28 6.00 6.00 4.81 
Test 
statistic 
Fr = 18.714, N = 17, df = 6, p = 
0.005 
Fr = 48.016, N = 15, df = 6, p = 0.000 Fr = 22.710, N = 16, df = 6, p = 
0.001 
Fr = 19.098, N = 16, df = 6, p = 
0.004 
 
In the table Fr is Friedman test statistic.
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The Friedman test results for variation of oven temperature (Table 6.4) show that all the 
parameters plate number (Fr = 18.714, N = 17, df = 6, p = 0.005), tailing (Fr = 48.016, N = 
15, df = 6, p = 0.000), selectivity (Fr = 22.710, N = 16, df = 6, p = 0.001) and resolution 
(Fr = 19.098, N = 16, df = 6, p = 0.004) are significant. This is in agreement to the 
discussion above where it was highlighted that the oven has a greaterr effect on the 
parameters than injector temperature. An analysis of the descriptive data indicated the 
highest two temperatures (in order) were; for plate number 140>200oC, tailing 140>150oC 
(lowest at 190 and 180oC), selectivity 170>180oC, resolution 200>180>160oC. As such it is 
proposed that an oven temperature of 180oC maximises the chromatographic profile to a 
higher degree than the other temperatures investigated and that 160oC also be investigated 
in further optimisation (Phase 3). 
 
6.3.3 PHASE 3 INVESTIGATING THE EFFECT OF SIMULTANEOUSLY APPLYING THE OVEN 
AND INJECTOR TEMPERATURES SELECTED AS OPTIMUM IN PHASES 1 AND 2  
 
The temperatures investigated were those chosen as giving optimum results in Phase 1 
(injector port temperature 260oC) and Phase 2 (oven 160 and 180oC). The purpose was to 
determine which of the oven temperatures gave the best result when applied together with 
the optimum injector temperature from Phase 1. The chromatographic profiles (TIC) 
observed are shown in Figures 6.12 and 6.13 below.  
 
Figure 6.12 Phase 3 Effect of simultaneously implementing the temperatures oven at 160oC 
and injector at 260oC selected in Phases 1 and 2 on the chromatographic profile. 
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Figure 6.13 Phase 3 Effect of simultaneously implementing the temperatures oven at 
180oC and injector at 260oC selected in Phases 1 and 2 on the chromatographic profile. 
 
The results of simultaneously implementing the selected injector and oven temperature 
from Phases 1 and 2 of the studies show a general improvement in the chromatographic 
peak profile, Figures 6.12 (oven 160/injector 260oC) and 6.13 (oven 180/injector 260oC) 
comparative to the TICs for the individual variables, Figure 6.7 (oven 160oC and 180oC) 
and Figure 6.2 (injector 260oC). In both cases the simultaneous use of injector and oven 
temperatures resulted in improved peak shapes; the peaks are narrower and tailing appears 
reduced. However, the TICs for the simultaneous implementation appear similar. Hence, it 
cannot be accurately confirmed which is the better profile by visual inspection of the TICs. 
To enable an evaluation of the optimisation on the chromatographic profile of the analytes 
the performance parameters plate number, tailing, selectivity and resolution were 
determined from the TICs and the arising values are shown in Table 6.5.  
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Table 6.5 Phase 3 Investigating the effect of simultaneously applying the injector and oven temperatures selected as optimum in phases 1 and 2 on 
column plate number N, resolution Rs, tailing T, selectivity α and retention time Rt ( For Mean, n = 2). 
Temp/oC   Mean values        
  
Temp/oC   Mean values       
  N x 105 T α Rs Rt/min     N x 105 T α Rs Rt/min 
Methamphetamine 
            
MBZP 
       
150    4.554        2.518        1.423       64.935        8.870    150   17.791        3.570        1.014        4.414       15.190  
160    6.198        2.330        1.380       60.706        8.870    160   11.786        2.685        1.015        4.148       15.150  
180    5.345        2.116        1.367       62.829        8.870    180    7.922        3.989        1.021        4.568       14.605  
2-FPP 
            
3-CPP 
          
150   10.710        3.618        1.025        6.121       13.500    150   23.580        2.301        1.053       22.273       16.720  
160    6.564        3.562        1.030        6.081       13.210    160   23.342        2.645        1.058       23.849       16.830  
180   11.309        2.909        1.023        5.510       12.830    180   15.390        2.331        1.070       24.558       16.790  
3-FPP 
            
4-MePP 
          
150   16.245        2.638        1.040       13.371       14.515    150   17.014        3.302        1.086       29.170       15.395  
160   12.360        2.150        1.045       13.827       14.395    160   12.570        1.709        1.094       29.284       15.380  
180   10.422        2.052        1.049       12.706       13.795    180    7.789        3.493        1.126       30.956       14.905  
4-FPP 
            
MDMA 
       
150   12.922        4.022        1.013        4.056       14.130    150   14.353  ND[1]       1.010        3.096       14.370  
160    9.958        3.346        1.015        4.236       13.955    160   10.383  ND[1]       1.012        3.246       14.220  
180   11.402        2.682        1.013        3.854       13.400    180    9.824  ND[1]       1.013        3.116       13.625  
2-TFMPP 
            
Caffeine 
          
150    6.465        4.025        1.070       15.287       12.620    150   37.654        1.149        1.051       27.225       17.610  
160    5.524        3.998        1.079       14.785       12.240    160   36.627        0.833        1.053       28.082       17.800  
180    7.775        3.324        1.058       13.644       12.125    180   30.592        1.258        1.065       30.286       17.960  
3-TFMPP 
            
Cocaine 
          
150   17.028  ND[1]       1.004        1.088       14.320    150   63.816        1.015        1.081       44.723       20.340  
160   15.563  ND[1]       1.004        1.005       14.170    160   62.059        1.136        1.084       44.486       20.640  
180   16.349  ND[1]       1.004        1.025       13.575    180   66.434        1.197        1.081       45.158       21.180  
4-TFMPP 
        
Diazepam 
          
150   22.133        1.672        1.007        2.320       15.090    150   44.910        1.316  ND[1] ND[1]      21.990  
160   21.085        1.353        1.007        2.259       15.040    160   46.354        1.275  ND[1] ND[1]      22.300  
180   12.335        1.616        1.010        2.291       14.470    180   44.860        1.125  ND[1] ND[1]      22.900  
BZP           
  
Eicosane(IS) 
          
150    9.373        8.403        1.021        5.516       13.853    150   65.012        0.940        1.079       47.483       18.505  
160    6.824        7.606        1.025        5.645       13.610    160   60.909        1.205        1.080       48.441       18.750  
180    8.502        6.073        1.021        5.224       13.120    180   46.496        1.028        1.085       46.488       19.120  
DBZP 
                        
150   61.453        0.838        1.019       11.790       19.960                
160   66.150        1.001        1.019       12.058       20.250                
180   57.538        1.038        1.021       12.736       20.750         
[1]
 ND stands for not determined. This was due to co-elution between 3-TFMPP and MDMA hence tailing could not be calculated for these two analytes. In addition diazepam 
is the last peak hence there is no resolution to a subsequent peak after it. This applies to all other Tables and Figures where this notation is used 
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The data is comprehensive as such graphical analysis was conducted for easier evaluation of 
trends in the data. A graphical representation of the data for plate number and tailing is 
shown in Figures 6.14 and 6.15 respectively and the other parameters in Appendix 5. 
 
 
Figure 6.14 Phase 3 Effect of simultaneously applying selected optimum temperatures 
(injector port 260oC; oven 160oC and 180oC; control 150oC) on plate number, N (values 
of N x 105). 
 
 
Figure 6.15 Phase 3 Effect of simultaneously applying selected optimum temperatures 
(injector port 260oC; oven 160oC and 180oC; control 150oC) on tailing, T. 
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A review the data for plate number, tailing, selectivity and resolution (Table 6.5) and the 
graphical analysis (Figures 6.14; 6.15 and Appendix 5) showed that there is a general 
decrease in plate number, decrease in tailing, increase in selectivity and a mixed response for 
resolution for both temperatures comparative to the control (150oC). However, it is not easy 
to elucidate magnitude of the response from the data or determine which temperature 
achieved the best results. To overcome this limitation and for effective comparison of the 
results of the two oven temperatures investigated; 160oC and 180oC (with optimum injector 
port temperature 260oC) gain and loss graphs (Chapter 3 section 3.3.10) were employed. 
These simplify data by showing the percentage change in the response (Bersimis and Parakis, 
2007; Cheung et al., 2012).  
 
The results of analysis of the data in Table 6.5 (Phase 3 data) using Gain or Loss graphs to 
show the percentage change in plate number, N and tailing, T are shown in Figures 6.16 and 
6.17 respectively. The other parameters are given in Appendix 6. 
 
  
Figure 6.16 Phase 3 Gain or Loss graph for effect of selected injector and oven 
temperatures on plate number, N. 
 
From the graphs a gain in plate number was desirable. As such it can be argued that generally 
both the selected oven temperatures (160oC and 180oC ) do not achieve the desired outcome, 
as Figure 6.16 shows that for most (>76%) of the analytes plate number, N has decreased. 
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The magnitude of the change in plate number for the drugs was very variable ranging from 0 
to the highest 54 % observed in 4-MePP with the oven at 180oC. For those drugs that had a 
gain in plate number (methamphetamine, 2-FPP, 2-TFMPP, cocaine DBZP and diazepam) 
the oven at 180oC had a higher number of the drugs gaining in plate number than at 160oC (4 
compared to 3). However, the plate number after Phase 1 optimisation was sufficiently high. 
This is evidenced by the good peaks observed in Figures 6.12 and 6.13, consequently the 
emphasis was on reducing tailing so as to get narrower, more symmetrical peaks and 
improving resolution. It has been shown that symmetrical peaks with less tailing increase 
separation between analytes. In accordance with the Plate theory of chromatography (Chapter 
2, section 2.3) equations 2.8 (plate number) and 2.11 (resolution), reduced tailing results in a 
reduction in peak widths and hence increases the value of N and subsequently increases 
resolution.  
 
The effect (gain or loss) on tailing is shown in Figure 6.17. A loss in tailing, T was deemed 
desirable as it implies a lower tailing factor. 
 
  
Figure 6.17 Phase 3 Gain or Loss graph for effect of selected injector and oven temperatures 
on tailing, T. 
 
From the graph (Figure 6.17) it is evident there is generally a loss in tailing for the analytes as 
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(160oC and 180oC) were remarkably effective as most of the drugs (67% ) had a loss in 
tailing and 33% were unchanged. The oven at 180oC gave better results than at 160oC, with a 
greater number of drugs (60%) showing a higher degree of loss than the160oC. Gain and loss 
graphs for the other parameters (Appendix 6) show that there was a gain in selectivity for 
75% of the analytes with the oven at 160oC compared to 56% with the oven at 180oC.  For 
resolution 56% of the analytes gained with the oven at 160oC, whilst the oven at 180oC 
showed a decrease (44 % gain). It should be noted that the degree of gain in selectivity 
(highest 3%) and resolution (highest 11%) were smaller than for plate number and tailing. 
However, resolution was remarkably high for all the drugs (Table 6.5) in the range, R = 3 - 
45, except the coe-luting substances, 3-TFMPP and MDMA in comparison the acceptable 
criteria for resolution, R > 2 (ICH, 2005; Horacio et al., 2008). It has also been reported that a 
resolution of R > 1.25 is acceptable for GC-MS (Bowers et al., 2002). Of concern is the fact 
that baseline separation is unlikely to be achieved with such a low resolution factor. 
Consequently, for plate number and tailing the oven temperature 180oC is best, whilst for 
selectivity and resolution 160oC is the better option. 
 
Retention times were longer at 160oC than at 180oC except for drugs eluting later in the run 
(after 16minutes), caffeine, eicosane, cocaine, DBZP and diazepam. This could be due to the 
fact that these drugs have higher boiling points above the temperatures under investigation 
and as such are not appreciably affected by them. This is also evidenced by the smaller 
impact these temperatures have on the peak profile parameters for these drugs comparative to 
the others (Appendix 5) especially for the lower temperature. 
 
6.3.3.1 Statistical analysis of Phase 3 results 
 
The results for statistical analysis of Table 6.5 Phase 3 data are shown below. For the T-test 
Table 6.6, Wilcoxon Signed rank test in Table 6.7 and Friedman test in Table 6.8.  
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Table 6.6 Statistical analysis of Phase 3 data: T-test (paired, α = 0.05), pair variables 160oC 
and 180oC. 
T-test (paired) Plate number Tailing Selectivity Resolution 
Pair differences      
Mean 2.587 -0.00960 -0.00169 -0.1757 
Std. deviation 5.253 0.261 0.01168 1.163 
Std. error  mean 1.274 0.0673 0.00292 0.2908 
Test statistic t = 2.030, N = 17, df 
= 16, p = 0.059 
t = -0.143, N = 15, 
df = 14, p = 0.889  
t = -0.578, N = 16, 
df = 15, p = 0.572 
t = -0.604, N = 16, 
df = 15, p = 0.555 
Pearson’s 
correlation 
coefficient 
r = 0.9713 r = 0.9753 r = 0.9916 r = 0.9983 
 
The T-test (paired) was conducted in order to ascertain the influence of the two selected oven 
temperatures (160 and 180oC) on chromatographic performance. The hypothesis postulated, 
Ho: there is no difference in the effect of the two temperatures. The level of significance was 
95%. The criteria were if p < 0.05 and if t(calculated) > t(critical), Ho was rejected 
(Laurencelle and Frangois, 2002; Corder and Foreman, 2009). The results (Table 6.6) showed 
that there is no statistically significant difference between two variables in their effect on all 
the parameters, i.e., for plate number (t(16) = 2.030,  p = 0.059), tailing (t(14) = 0.143, p = 
0.889, selectivity (t(15) = 0.578, p = 0.572 and resolution (t(15) = -0.604, p = 0.555. As 
evidenced by both values for p being greater than the limit 0.05. Consequently Ho was 
retained. This means statistically the two temperatures exert similar effects, with any 
differences due to chance. Hence, either 160oC or 180oC can be used with the same result. 
This supports the observation made on discussion of the total ion chromatograms (TICs) 
obtained with the two temperatures (Figures 6.12 and 6.13) that visually it was difficult to 
distinguish between the TICs. 
 
Statistical analysis by Pearson’s correlation coefficient shows that the results for plate 
number are marginal whilst those for the other parameters show high correlation in the effects 
of the two temperatures as evidenced by the high Pearson’s correlation coefficients (Table 
6.6) which are in the range 0.9713 – 0.9983.  
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Table 6.7 Statistical analysis of Phase 3 data: Wilcoxon Signed rank (paired, α = 0.05), pair variables 160oC and 180oC. 
 Plate number Tailing Selectivity Resolution 
 N Mean  Sum ranks N Mean  Sum ranks  N Mean  Sum ranks N Mean  Sum ranks 
(-) ranks 11 10.18 112.00 6 5.00 30.00  6 8.42 50.50 7 8.14 57.00 
(+) ranks 6 6.83 41.00 4 6.25 25.00  9 7.72 69.50 9 8.78 79.00 
Ties 0   5    1   0   
Total 17   15    16   16   
Test 
statistic 
Z = -1.681*, p = 0.093 (2-tailed) 
*Based on (+) ranks 
Z = -2.55*, p = 0.799 (2-tailed) 
*Based on (+) ranks 
Z = -0.540*, p = 0.589 (2-tailed) 
*Based on (-) ranks 
Z = -0.569*, p = 0.569 (2-tailed) 
*Based on (-) ranks 
 
 
Table 6.8 Statistical analysis of Phase 3 data: Friedman Test: comparison of 160, 180 and the control 150oC. 
 Plate number Tailing Selectivity Resolution 
Temp oC Median 
rank 
Upper 
quartile 
(75%)  
Mean 
rank 
Median 
rank 
Lower 
quartile 
(25%)   
Upper 
quartile 
(75%)   
Mean 
rank 
Median 
rank 
Upper 
quartile 
(75%)   
Mean 
rank 
Median 
rank 
Upper 
quartile 
(75%)   
Mean 
rank 
150 17.0280 41.282 2.59 2.510 1.000 3.200 2.73 1.50 2.375 2.13 3.00 4.00 2.88 
160 2.570 41.491 1.82 1.908 1.000 2.750 1.70 2.75 4.25 3.09 2.00 2.75 2.44 
180 11.402 37.726 1.59 2.052 1.000 2.588 1.57 4.50 5.75 4.41 4.45 7.00 4.50 
Test 
statistic 
Fr = 9.294, N = 3, df = 2, p = 0.010 Fr = 48.016, N = 15, df = 6, p = 0.000 Fr = 22.710, N = 16, df = 6, p = 
0.001 
Fr = 19.098, N = 16, df = 6, p = 
0.004 
 
Fr is the Friedman test statistic and p is the asymptotic significance at 95%level of significance. 
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Further statistical analysis was done to confirm that there were no differences in the 
distribution of data using Wilcoxon signed rank test (Table 6.7). It has been discussed in 
chapter 3 that Wilcoxon tests ranks the data and that consequently it gives a better analysis 
than the t-test. The advantages derived from ranking were discussed in Chapter 3 (section 
3.4.8) for the Friedman test which also makes use of ranking and was applied for Phase 1 
data (section 6.3.1.1). However, the results of the Wilcoxon signed rank test followed a 
similar pattern as for the t-test, there is no statistical significance for all the parameters; for 
plate number (Z = -1.681, p = 0.093), tailing (Z = -2.55, p = 0.799), selectivity (Z = -0.540, p 
= 0.589) and resolution (Z = -0.569, p = 0.569). Examining the ranks shows that on average 
plate number decreased (negative ranks), which is in agreement with the gain and loss 
analysis. Compared to the 160oC, plate number and Tailing were lower for 180oC selectivity 
and whilst the resolutions were higher. 
 
The Wilcoxon signed rank test showed that the effect is the same between the 160 and 180oC 
but did not divulge whether the two temperatures resulted in any increase or decrease 
chromatographic performance. As such, further statistical analysis was conducted. Since the 
Wilcoxon signed rank test can only compare 2 subjects the Friedman test was applied on the 
two temperatures and the control temperature (150oC). This was to elucidate whether there 
was any statstistically significant change in the results of each of the two oven temperatures 
in comparison to the control temperature. The results of the Friedman test (Table 6.8) indicate 
that for all the parameters there are significant differences in their distribution when subjected 
to a change in temperature from 150oC. For plate number (Fr = 9.294, N = 3, df = 2, p = 
0.010), tailing (Fr = 48.016, N = 15, df = 6, p = 0.000), selectivity (Fr = 22.710, N = 16, df = 
6, p = 0.001), and resolution (Fr = 19.098, N = 16, df = 6, p = 0.004). Investigation of the 
descriptive statistics (Table 6.8) to elucidate the degree of the effect revealed that there are 
marked changes; plate number decreases on increase of temperature the median rank is 
lowest at 180oC hence 180oC results in the lowest plate number. Tailing follows a similar 
trend, however the median rank is lowest at 160oC, hence it results in the lowest tailing. 
Selectivity increases with temperature and is highest for 180oC, resolution decreases at 160oC 
whilst it is enhanced at 180oC. It can be seen that a compromise has to be reached as no one 
temperature has an optimum effect on all the parameters. Consequently, basing on plate 
number and tailing the oven at 160oC is the better of the two whilst basing on selectivity and 
resolution 180oC is best. On average 170oC was proposed to be the statistically correct 
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optimum temperature. It offers a compromise in performance such an approach was applied 
by Maher et al. (2009).  
 
In evaluation of the results there was no similar study on developing and optimising a method 
for the drugs under investigation. Nor was there a method for simultaneous analysis of such a 
number of mixed drugs together. There was no data such as tailing, resolution available for a 
more subjective analysis of the results. As such, a reference was made of research work 
which had a bearing on the objectives of this study, and could be extrapolated for the benefit 
of this work or to provide insight into this study.  
 
Santali et al. (2011) in their study on developing a method for mephedrone and Inoue et al. 
(2008) in a study on developing a method for profiling methamphetamine by GC-MS also 
observed that both plate number and tailing were temperature dependent. Furthermore, in 
optimising their methods variation of both injector and column temperatures similarly 
improved plate number and tailing 
 
Andersson et al. (2007a), Inoue et al. (2008) developed and optimised methods for profiling 
of amphetamine and methamphetamine. They applied similar concepts as in this study and 
also reported improved chromatographic results. This proves that the method is dependent on 
operational variables as theorised in the Plate theory. The work of Maher at al. (2009) was 
found to be highly significant to this study, as it was on the differentiation of regioisomers of 
TFMPP, which is one of the drugs of focus for the overall research project. The results were 
comparable since they also resolved all three (2, 3, 4) TFMPP isomers. It was observed that 
the order of elution of the substances was similar to this study 2-TFMPP>3-TFMPP>4-
TFMPP. The analytical methodology similarly to this study was carried out without 
derivatisation, using a capillary column. However, in contrast to this study the column was 
non-polar (Rtx-1). Preliminary method studies (Chapter 4) evaluated a non-polar column and 
found that whilst it resolves the TFMPP isomers, resolution of these compounds to other 
drugs was poor; in addition a more polar column gave better peak profiles.  
 
Optimisation as with other researchers (Andersson et al., 2007a; Inoue et al., 2008; Maher et 
al., 2009; Byrska et al., 2010; Santali et al., 2011) used the approach of evaluating different 
columns and several temperature programs. A compromise was reached between resolution 
and analysis time. The performance characteristics such as resolution or tailing were not 
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stated for comparison. However, interestingly the chromatographic profile was said to have 
excellent resolution and on observation the total ion chromatogram supported this. It is 
important to note that this study was on TFMPP and its isomers only. In drugs of abuse this 
substance is found in a sample matrix in combination with other drug substances (Baron et 
al., 2011; Davies et al., 2010; Yuk, 2010; King and Kicman, 2011; Arbo et al., 2012) and as 
such depending on the intended use, the method might have limitations. The method under 
development in this research is therefore advantageous as it overcomes these limitations. 
Congeners and impurities expected to be present have been evaluated. In addition, complete 
resolution of the FPP and TFMPP isomers was achieved. Furthermore, it simultaneously 
analyses for all the substances investigated. Therefore, it can be applied for the analysis of 
any of these drugs individual or in combination in street samples. This imparts it with 
versatility. It has been identified that drugs of abuse exist in a variety of combinations and 
dosages in street samples (Yeap et al., 2010; Kelleher et al., 2011). 
 
Byrska et al. (2010) studied 6 piperazines MePP, BZP, TFMPP, MBZP, MeOPP and 3-CPP. 
Except for MeOPP these are part of the drugs under investigation. The column stationary 
phases are similar (5-MS) as were the column physical properties. Resolution and tailing 
were not specified. However, it was observed that the peaks were not baseline resolved; in 
addition MeOPP and 3-CPP showed considerable tailing. This could be the reason why in 
their study GC-MS was used only for qualitative analysis and HPLC for quantitative analysis. 
Whilst this study provided an important insight into optimisation there is need to ensure it is 
capable of simultaneously meeting both qualitative and quantitative aspects, if it is to have 
more diverse application e.g. characterisation of street samples. 
 
6.3.4 PHASE 4 EFFECT OF CARRIER GAS FLOW-RATE  
 
The chromatographic profiles resulting from variation of flow rate are represented by Figure 
6.18.  
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Figure 6.18 Phase 4 Effect of flow rate. Showing the total ion chromatomatographic profiles observed at different flow rates (0.75 and 
1.0ml/min) for comparison.  
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The retention times increased at lower flow rates as evident in Figure 6.18 at a flow rate of 
0.75mL/min longer retention times were observed. However, the effect on resolution was 
marginal and not as pronounced and the peaks appeared slightly broader at 0.75mL/min in 
comparison to flow rates of 1mL/min (control) and 1.25mL/min. At 1.25mL/min the peaks 
started to show tailing. It has been discussed that retention time and peak shape increased 
with reduced flow rate, which is in line with the observed results. In fact, they advocated that 
slow is best. Andersson et al. (2007a) also made a similar observation. This is in partial 
agreement with this study where flow rate at 0.75mL/min was found to slightly improve 
resolution; however the benefits were counteracted by tailing. This was deemed 
counterproductive to the objective of optimisation and as such the flow rate of 1.0mL/min 
was proposed as giving optimum results. The increase in retention time with flow rate can be 
attributed to the fact that flow rate is a measure of mobile phase velocity, µ. A decrease in 
flow rate results in the analyte being retained longer in the column hence its lower retention 
time. Longitudinal diffusion (B term) was identified as one of the causes of band broadening. 
It is evident from the equation for B (equation 2.15 Chapter 2) that a decrease in velocity 
increases B hence band broadening. This results in the observed tailing at lower flow rates. 
 
6.3.5 PHASE 5 EFFECT OF MS SCAN RATE  
The total ion chromatogram obtained is shown in Figure 6.19. 
 
 
Figure 6.19 Phase 5 Effect of MS scan rate, showing the impact on peak shape.  
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The results for optimisation of the detector MS scan rate (Figure 6.19) showed that higher 
scan rates give an improved peak shape in terms of symmetry at the apex of the peak. This 
can be attributed to faster sampling giving more data points, hence the peak shape is 
smoother. This is important as peak shape is critical in peak processing, e.g. poor peak shape 
reduces accuracy in quantitation of the area under the peak (Barwick, 1999; Kaur, 2010). 
Studies on optimisation of detectors focus mainly on selection of detector systems as such 
these results show that a chosen detector system can be enhanced to achieve optimum results 
is especially important in reducing instrument errors.  
 
6.3.6 PHASE 6 EFFECT OF MS IONISATION ENERGY 
 
The effect of ionisation energy (EI) on the mass spectra of a compound was investigated 
using 3-TFMPP and BZP as representatives of the analytes. The effect of EI on their mass 
spectra is shown in Figures 6.20 and 6.21. The figure shows the mass spectra observed at 50, 
60, 70 and 80eV. 
 
The ideal ionisation energy gives optimum abundances for all the ions and a mass spectrum 
with adequate fragmentation for easy interpretation and structural derivation. A visual 
insepection of Figures 6.20 and 6.21 indicated that all the ionisation energies investigated 
show a similar fragmentation pattern. The relative intensities appeared slightly different as 
evident in Figure 6.20 for the ions at m/z 145, 172 and the parent ion 230(M+). This implies 
that ionisation affected the abundancies of the ions. Further evaluation of the mass spectral 
data (ions and their abundance) was conducted. The results are given in Table 6.9 (3-TFMPP) 
and Table 6.10 (BZP) corresponding to the spectra in Figures 6.20 and 6.21.  
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Figure 6.20 Phase 6 Effect of ionisation energy (EI) on the mass spectra of 3-TFMPP showing the mass spectra at different EI (50, 60, 70 
and 80eV) for comparison. 
(M+) 
(M+) 
(M+) 
(M+) 
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Figure 6.21 Phase 6 Effect of ionisation energy (EI) on the mass spectra of BZP showing the mass spectra at different EI (50, 60, 70 and 
80eV) for comparison. 
(M+) (M+) 
(M+) (M+) 
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Table 6.9 Phase 6 Mass spectra data for effect of ionisation energy on 3-TFMPP. 
 Intensity (%TIC) 
Ionisation 
Energy (eV) 
Fragment Ion (m/z) 
 230(M+) 188 172 159 145 127 109 95 75 42 
50 8.38 39.08 5.68 1.77 5.78 0.91 0.46 1.12 0.54 1.6 
60 7.67 36.46 5.43 1.29 6.02 1.24 0.51 0.94 0.86 1.9 
70 7.23 35.7 6.28 1.43 6.46 0.91 0.54 1.43 1.37 1.89 
80 6.92 36.13 6.73 1.4 5.84 0.99 0.46 1.38 1.6 1.68 
 
Table 6.10 Phase 6 Mass spectra data for effect of ionisation energy on BZP. 
 Intensity (%TIC) 
Ionisation 
Energy (eV) 
Fragment Ion (m/z) 
 176 (M+) 134 120 119 118 91 85 77 65 56 
50 5.16 17.03 2.24 0.68 1.38 30.24 2.95 0.64 3.63 6.06 
60 5.58 16.98 1.92 0.65 1.38 28.67 2.75 0.54 4.06 6.82 
70 4.16 18.67 1.54 0.79 1.80 28.28 3.54 0.52 4.63 8.37 
80 3.71 16.64 1.95 0.55 1.52 28.57 3.05 0.63 3.78 7.93 
 
It was observed that at lower ionisation energies (50eV) there is a higher abundance of the 
ions with larger masses. Such as the molecular ion as evidenced by 3-TFMPP in Table 6.9 
and BZP in Table 6.10. For 3-TFMPP the intensity of the molecular ion at m/z 230 decreased 
from 8.38 to 6.92 %TIC with increase in ionisation energy from 50 to 80eV. The principal 
ion at m/z 188 showed a similar trend. At higher ionisation energies more fragmentation of 
the molecular ion occurs as a result of higher energies and velocities of the bombarding 
electrons resulting in a higher abundance of the low molecular mass ions. Ionisation energy at 
70eV gave the most optimum results as it shows the highest intensity values for the majority 
of the lower molecular ions e.g. 5.29, 4.00 and 1.53% at m/z 42, 95 and 109 for 3TFMPP. 
Furthermore, adequately high abundances for the high molecular mass compounds in addition 
the molecular ion was also observed making identification of compounds easier. The 
differences lie in the intensities of the observed ions. A similar trend was observed by Vekey 
(1996) in a study on internal energy effects on mass spectrometry. The study highlighted that 
very low ionisation energies (20eV and lower) have a more profound impact on the mass 
spectra due to very little fragmentation occurring, whereas higher ionisation energies result in 
similar fragmentation patterns. Furthermore, it has been discussed (Vekey, 1996) that 
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ionisation energy at 70eVgives optimum intensity values and is typically used in mass spectra 
libraries such as NIST. This could be the reason why it has found favour in most research 
studies (Takahashi et al 2009; de Boer et al, 2001; Inoue et al., 2004; Staack, 2007). As such 
in further investigations for this research 70eV will be used. 
 
6.3.7 OPTIMISED METHOD 
 
The chromatographic profile (TIC) of the final method after optimisation is shown in Figure 
6.22 and the method parameters in the conclusion (section 6.4). 
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Figure 6.22 Chromatographic profile (TIC) of the optimised method. The mass of the principal ion for each analyte is shown below the 
retention time.
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The optimised method’s total ion chromatogram (Figure 2.22) showed improved peak 
profiles. The peaks in the range 12 - 16 minutes were more resolved. This range of peaks 
was discussed in section 6.1 as requiring improvement in resolution and tailing. The tailing 
was also less for the all the peaks from methamphetamine to CPP. This is in agreement 
with observations made in the discussions on optimisation and the related statistical 
analysis. 
 
6.4 CONCLUSION 
  
Optimisation of the method operational variables; injector port temperature, oven 
temperature, carrier flow-rate, MS scan rate, and MS ionisation was investigated with the 
aim of improving performance of the method in terms of the quality of chromatographic 
peak profiles generated. The injector and oven temperatures improved the quality 
characteristics of the chromatograms generated, i.e., plate number, tailing, selectivity and 
resolution. The method improved to give good peak shapes, high resolution, R > 2 and 
reduced tailing. 
 
Variation of oven temperature was found to change the parameters to a greater degree than 
the injector port temperatue. This is due to the direct impact of changes in oven temperature 
on the stationary phase. Variation of flow rate showed that fast flow rates reduced the 
resolution. Optimising the MS scan rate showed that peak shape was dependent on scan 
rate. Too slow scan rates broadened the peaks. Investigating MS ionisation energies 
indicated that ionisation energy (EI) affects the ion abundances. Use of EIs which were too 
high decreased the intensity of the peaks and also showed slightly more fragmentation. This 
has the potential to make the mass spectra complex and its evaluation less easy e.g. the 
parent ion can disappear. It was found that 70eV gave the best results. This confirmed the 
works of de Boer et al. (2001), Maurer (2004) and UNODC (2013c), and in addition 
generally most spectral libraries (e.g. NIST) apply EI 70eV.  
 
It was found that the co-eluting peaks could not be completely resolved upon optimisation. 
This was not a limitation as for these analytes (3-TFMPP and MDMA, DBZP and 
dextromethorphan) extracted ions would be applied in the analysis of samples containing 
both the analytes (Takahashi et al., 2009; de Boer et al., 2001). Furthermore, the peaks were 
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sufficiently distinct for identification using retention times (3-TFMPP 13.78minutes and 
MDMA 13.83 minutes).  
 
Consequently, it can be concluded that optimisation was successful and resulted in the 
following optimised method; the initial oven temperature was set at 60oC with a hold for 
1min and ramped at 10oC /min to 170oC with a hold for 2min. The oven was further 
ramped at 15oC /min to 280oC, with a hold for 4min. The MS transfer line was set at 280oC, 
source temperature 230oC, ionisation energy 70eV and scan range at m/z 40 - 500. The 
carrier gas was He (g) at a flow rate of 1mL/min. The injector was set at 260oC with a split 
ratio of 20:1. The instrument was equipped with a Supelco, Equity-5 (30m x 2.5mm x 
2.5µm) capillary column. The total analysis run time was 25.33 minutes. 
 
There was a rather limited amount of previous research on method development and or 
optimisation for similar drugs, especially involving FPP, one of the two main drugs of 
focus for the overall research. This is probably due to the drugs being relatively new on the 
market and this was a limitation in this study for comparative purposes. In depth data on 
optimisation of the drugs was found to be mainly on amphetamines. In addition, the few 
studies found reported optimisation mostly on qualitative methods on a limited number of 
drugs. Therefore, this study will provide relevant data on optimisation of a method for the 
analysis and profiling of phenylpiperazines, benzylpiperazines and other drugs of abuse in 
street samples. According to Eurachem (1998) a method requires validation before its 
application so as to establish its reliability. The need for validation was established in 
section 2.5 (Chapter 2) and therefore, the method optimised will undergo validation in a 
later study (Chapter 7) of this research.  
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CHAPTER 7 
VALIDATION OF THE OPTIMISED METHOD 
 
7.1 INTRODUCTION TO THE VALIDATION STUDY 
 
The previous chapters saw the development and optimisation of a method for the analysis, 
chemical characterisation and profiling of piperazine drugs of abuse. The need for 
validation was established in Chapter 1 (section 1.9) and the theoretical considerations and 
definitions underpinning method validation were discussed in Chapter 2 (section 2.5). In 
this study validation was conducted as per ICH (2005) and Eurachem (1998) guidelines. 
The tests conducted (outlined in Appendix 8) were linearity, limit of detection (LOD), limit 
of quantitation (LOQ), accuracy and precision. The test for accuracy was determined 
through the method of %recovery of unknown. Precision of the method was determined as 
a) repeatability and b) intermediate precision.  
 
The need for quality control (QC) was established in Chapter 2 (section 2.5.2). As such, 
throughout the life of the research project quality control was assured through monitoring 
instrument and column performance so as to establish there suitability for use. This was 
achieved by monitoring the detector response, precision and variation in retention time and 
peak shape. The analytes used for QC were n-alkanes (carbon number C8 to C24) and 1-(4-
methylphenyl)piperazine 4-MePP and Shewhart quality control charts were used as a 
monitoring tool. Corrective action was taken when a parameter was found to be out of 
limits. For example, if the peak shape deteriorated, inconsistent results or high column 
bleed were obtained, these were indications of an aging column and as such the column 
was changed. The MePP was monitored every 3 months; this period was used due to the 
instrument being robust, i.e., giving consistent results. The general background in a 
chromatogram might show the presence of distinct peaks or an abundance of small peaks 
due to column bleed. In this study, contaminant mass ions due to column bleed (section 
2.5.2) were monitored using the ion at m/z = 207. This ion was selected for monitoring as it 
is characteristic of polysiloxane based columns (McMaster, 2007). 
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7.1.1 AIMS OF THIS CHAPTER 
 
The aims of this study were to investigate and establish linearity (linearity range and 
working range), limit of detection, limit of quantitation, accuracy and, precision. Thereby 
confirm suitability of the GC-MS method developed for its use in qualitative and 
quantitative analysis. This will therefore validate its use for the chemical characterisation 
and impurity profiling of 4-FPP and 3-TFMPP street drugs. 
 
7.2 MATERIALS AND METHODS 
 
All the work in this study was conducted at 25oC (above the freezing point of the solvent, 
22oC) 
 
7.2.1 CHEMICALS/REAGENTS 
 
The drug standards used were as listed in Chapter 4, section 4.2.1. 
 
7.2.2 INSTRUMENTS 
 
Validation was conducted using Perkin Elmer GC-MS, Clarus Turbomass Gold 500MS 
fitted with a Supelco, Equity-5 GC capillary column (30m x 0.25mm x 0.25µm). The 
instrument was equipped with a Perkin Elmer 4mm quartz split/splitless injector liner  and 
with the NIST MS Search Version 2.0 library software and was set up with the method to 
be validated. The injector was set at 260oC with a split ratio of 20:1. The carrier gas was He 
(g) at a flow rate of 1mL/min. The initial oven temperature was set at 60oC with a hold of 
1min. The oven was ramped was at 10oC /min to 170oC with a hold of 2min and at 15oC 
/min to 280oC with a hold of 4min. The MS transfer line was set at 280oC, source 
temperature 230oC, ionisation energy 70eV and scan range at m/z 40 - 500. The total 
analysis run time was 25.33minutess. A Shimadzu GC-MS and a Phenomenox, Zebron ZB-
5 GC capillary column (30m x 0.25mm x 0.25um), serial number 164043) were used in the 
test for robustness.  
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7.2.3 STATISTICAL SOFTWARE  
 
Analysis of results was carried out using IBM SPSS Version 20 and MS Office Excel 2010. 
 
7.2.4 PREPARATION OF STANDARD SOLUTIONS 
 
The drug standards listed in Chapter 4 (Table 4.1) and ephedrine were used to prepare 
standard solutions for use in validation. Stock solutions of each analyte were prepared at a 
concentration of 1mg/mL free base in 2-methyl-propan-2-ol as outlined in Chapter 4 
(section 4.2.4). For studies of retention time, precision and accuracy standards at 0.1mg/mL 
containing eicosane (0.02mg/mL) as the internal standard were used.  
 
7.2.5 LINEARITY AND METHOD DETECTION LIMITS TEST 
 
For linearity studies the stock solutions (section 7.2.4) were diluted to give 6 to 10 
calibration standards for each analyte in the concentration range 0.01 – 1.0mg/mL free base 
(equivalent to 0.5 – 50.0µg/mL on column) containing 0.02 mg/mL of the internal standard 
eicosane. This was used to generate calibration, limit of detection (LOD) and limit of 
quantitation (LOQ) data. 
 
7.2.6  ACCURACY TEST 
 
A standard solution to be used for determing the %recovery was prepared for each analyte. 
The standard was weighed (7.00 - 10.0mg) to a 10.0mL volumetric flask. The procedure 
followed was as outlined in Chapter 3 section 4.2.4.3 for individual drug standard solutions. 
The recovery solution was prepared in triplicate. 
 
Samples were also created to simulate real street samples by adding standards of the 
analytes to powdered tablets and extracting the analytes in the same manner as for street 
samples (section 8.2.4.2.2.2). Control samples were also analysed without standards added. 
The samples were analysed by GC-MS and the amount recovered was calculated by 
determination of the difference between the samples with standards added and the control. 
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7.2.7 PRECISION 
 
The test was carried out concurrently with linearity tests (section 7.2.5). The test was 
carried as a) repeatability: The mixed standard solution was analysed six times by GC-MS, 
b) intermediate precision: The test was carried out using a total of 7 - 9 standard solutions 
at different concentrations. The calibration solutions specified in section 7.2.5 above were 
used. Each solution was analysed 3 times by GC-MS. 
 
7.2.8 METHOD ROBUSTNESS 
 
The test was conducted by using two different analysts and instruments; a) different analyst 
conducted linearity tests on a selected number of drugs (3-TFMPP and caffeine) and b) The 
mixed standard solution (0.10mg/mL) was analysed 6 times using a Shimadzu GC-MS. 
 
7.2.9 QUALITY CONTROL  
 
The n-alkanes (octane, decane, dodecane, tetradecane, hexadecane, octadecane, eicosane, 
docosane and tetracosane were individually weighed (10.0mg) and dissolved in pentane to 
give stock solutions of 1mg/mL. The solutions were diluted to give a mixed QC solution 
containing 0.1mg/mL each analyte. The n-alkanes solution was analysed by GC-MS prior 
to any analysis of analytes and also analysed at the end of each run sequence.  
 
 A solution of 4-MePP standard (0.1mg/mL) was prepared as outlined in Chapter 4, section 
4.2.4.3 for individual standards. The solution was injected into the GC-MS six times every 
3 months. However, for any quantitative determination where the mixed standard solution 
was used, the mixed standard solution was analysed 3 times and 4-MePP was monitored 
from this solution. As a measure of precision, the standard deviation and %RSD were 
monitored.  
 
Column bleed was monitored by generating a background scan. A blank solution, i.e., only 
the solvent with no analytes was analysed by GC-MS. The chromatogram generated was 
observed for peak abundance and the presence of the peaks at m/z 207 and 281.  
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System suitability was determined prior to any quantitative work by injecting a standard 
solution of the analyte 6 times and determining the standard deviation and % RSD. 
 
7.2.10 DATA ANALYSIS 
 
7.2.10.1 Linearity and method detection limits 
Calibration graphs were plotted for each analyte for both the total ion chromatogram (TIC) 
data and extracted ion (m/z) data. In the graphs peak area ratio versus concentration (µg 
base on column) were plotted. The confidence interval was also depicted for each data 
point using error bars. The peak area ratio was calculated according to equation 2.18 
(Chapter 2), confidence interval equation 3.5 and concentration equations 3.35 - 3.40 
(Chapter 3).  
 
The linearity (lack of fit) was tested by the following methods; a) visual inspection of the 
calibration line plots, b) regression analysis and determination of correlation coefficients, c) 
use of residual plots (Thompson et al. 2002, ICH, 2005; Thompson, 2005). Regression 
analysis and correlation coefficients were determined according to section 3.12 (Chapter 3) 
and residual analysis according to Chapter 2 section 2.5.1.1.2. The randomness of the 
residuals was evaluated according to the Runs test section 3.2.13 (Chapter 3). The linearity 
range was also determined as per section 2.5.1.2. 
 
Method detection limits were calculated as per equations 2.19 and 2.20 Chapter 2 (section 
3.0) 
 
7.2.10.2 Accuracy  
The recovery (%) of the known standard was determined. The criteria for accuracy was that 
recovery = 100 ± 5%. The standard deviation and relative standard deviations were also 
calculated. The recovery was calculated according to 2.22 (Chapter 2) 
 
7.2.10.3 Precision 
The standard deviation and relative standard deviations were evaluated (ICH, 2005). These 
were calculated according to Chapter 3 section 3.2.2. 
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7.2.10.4 Robustness 
Statistical comparative analysis of the results was conducted through Pearson’s correlation 
coefficient, T-test (paired) and ANOVA (2-way). These parameters were calculated 
according to Chapter 2 sections 3.2.4, 3.2.5 and 3.2.6.  
 
7.2.10.5 Extracted ion data 
Linearity, range, limit of detection, limit of quantitation, accuracy and precision were 
determined using extracted ions for the drugs and compared to those derived from total ion 
chromatograms. For the comparison ANOVA (2-way) was applied. The ions used were 3-
TFMPP (m/z 188), MDMA (m/z 135), DBZP (m/z 91 or 266) and dextromethorphan (m/z 
271).These ions were selected from the mass spectra and were distinct to the compound 
(Table 7.9 and Appendix 10). 
 
7.2.10.6 Quality control 
The variation in detector response (peak height), retention times and precision through the 
course of the research projected were calculated and monitored. To determine precision, 
peak height ratios (analyte to internal standard) were calculated for each of the repeated 
injections. The standard deviation and %RSD were then determined. QC charts were 
plotted. 
 
7.2.10.7 Method application GC-MS confirmation of drug identity data parameters 
Qualitative data for each drug was derived as retention time, relative retention time, 
retention index and mass spectra. Relative retention time and retention index were 
calculated according to equations 3.33 and 3.34 (Chapter 3). 
 
7.3 RESULTS AND DISCUSSION 
 
7.3.1 LINEARITY AND METHOD DETECTION LIMITS 
 
7.3.1.1 Linearity: Calibration graphs 
A typical calibration graph is shown in Figure 7.1 for 3-TFMPP as an exemplar. The 
calibration graphs for all the analytes are shown in Appendix 9. In the graphs the error bars 
represent the confidence interval (95% CL) for each peak area ratio value. In the graphs the 
concentration is for the free base on column. 
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Figure 7.1 Calibration graph for 3-TFMPP. 
 
A visual inspection of the calibration graphs (Appendix 9) indicated a linear trend for all 
the drugs. According to ICH (2005) and Thompson et al. (2002) linearity should be tested. 
The need and how to establish linearity was discussed in Chapter 2. Consequently, analysis 
of regression coefficients and residuals was conducted (section 7.6.2.8) to verify whether 
linearity was achieved. 
 
7.3.1.2 Testing for linearity 
7.3.1.2.1 Analysis of regression coefficients  
The regression coefficients (R2) are shown in Table 7.1 and were used to determine the 
linearity of the calibration graphs (Appendix 9).  
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Table 7.1 Testing for linearity: regression coefficients, R2. 
Analyte R2 n[1] 
2-FPP 0.9992 8 
3-FPP 0.9989 7 
4-FPP 0.9998 8 
2-TFMPP 0.9991 8 
3-TFMPP 0.9991 7 
4-TFMPP 0.9989 7 
BZP 0.9999 7 
DBZP 0.9996 8 
MBZP  0.9990 7 
3-CPP 0.9986 8 
4-MePP 0.9990 6 
MDMA 0.9995 7 
Methamphetamine 0.9990 8 
Caffeine 0.9975 7 
Cocaine 0.9968 7 
Diazepam 0.9946 6 
Dapoxetine 0.9970 7 
Dextromethorphan 0.9997 6 
Nicotinamide 0.9998 8 
Ephedrine 0.9991 5 
[1]n is the sample size: number of calibration standards analysed 
 
According to Chan et al., (2010) an R2 > 0.99 implies linearity is achieved. This was 
evidenced by the correlation coefficients which were R2 > 0.995 for all the analytes. This 
implied a highly linear trend. It was discussed in Chapter 2 section 2.5.1.1.2) that use of 
correlation coefficients on their own to test for linearity is inadequate and might give 
misleading results (Thompson et al., 2002; Rambla-Alegre et al., 2012). As such, the 
analysis of residuals reported below was conducted to further test for linearity. 
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7.3.1.2.2 Analysis of residuals 
An exemplar of the residual plots is given in Figures 7.2 and 7.3 for 2-FPP and 
nicotinamide.    
 
 
Figure 7.2 Residual analysis to test for linearity of the 2-FPP calibration plot. 
 
  
Figure 7.3 Residual analysis to test for linearity of the nicotinamide calibration plot. 
 
A visual analysis of the plots of the residuals was conducted and the distribution patterns 
were observed to have no particular trend for all the analytes as evidenced by Figures 7.2 
and 7.3. It was discussed in Chapter 2 that if the distribution pattern of the residuals is 
random it indicates a linear trend. Furthermore, the deviations from linearity are not 
statistically significant if the sum of the residuals has a mean of zero (Thompson, 2005; 
Van Loco et al., 2002). The mean of the residuals was calculated and is given in Table 7.2. 
The mean values of all the analytes were in the range of -0.0017 to +0.0014 (Table 7.2), 
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these can therefore be approximated as zero. Therefore, both the distribution patterns 
observed and the mean are in agreement with the criteria for linearity. As such, the 
residuals are random indicating the calibration plots are linear. This confirms the 
observations made using correlation coefficients. To further statistically confirm the 
randomness of the residuals the Runs test was conducted. The results are also given in 
Table 7.2.  
 
Table 7.2 Testing for linearity: Residuals randomness. 
 Mean[1] RUNS TEST 
  n(-) n(+) N 
No.  
of Runs Z 
p Asymp.  
(2-tailed) 
p Exact   
(2-tailed) 
2-FPP 0.0013 3 5 8 5 0.00 1.00 1.00 
3-FPP -0.0014 3 4 7 5 0.06 0.95 0.66 
4-FPP 0.0000 4 4 8 6 0.38 0.70 0.74 
2-TFMPP 0.0000 3 5 8 5 0.00 1.00 1.00 
3-TFMPP 0.0000 4 3 7 4 0.00 1.00 1.00 
4-TFMPP 0.0000 4 3 7 4 0.00 1.00 1.00 
BZP 0.0000 3 4 7 6 0.91 0.36 0.26 
DBZP 0.0000 5 3 8 6 0.62 0.54 0.43 
MBZP 0.0014 4 3 7 4 0.00 1.00 1.00 
CPP 0.0000 5 3 8 4 -0.21 0.84 0.71 
MePP 0.0000 3 3 6 4 0.00 1.00 1.00 
MDMA -0.0014 3 4 7 6 0.91 0.36 0.26 
Methamphetamine 0.0000 4 4 8 4 -0.38 0.70 0.74 
Caffeine 0.0014 5 2 7 4 0.00 1.00 1.00 
Cocaine 0.0000 3 4 7 4 0.00 1.00 1.00 
Diazepam 0.0000 2 4 6 3 -0.18 0.86 0.60 
Dapoxetine 0.0000 4 3 7 4 0.00 1.00 1.00 
Dexetromethorphan -0.0017 3 3 6 5 0.46 0.65 0.60 
Nicotinamide 0.0000 3 5 8 7 1.44 0.15 0.11 
[1]Test value = mean, n(-) is observations < Test value and n(+) is observations ≥ Test value, N is 
the total number of observation (number of residuals). 
 
The total number of runs observed R, relative to the sample sizes N, for all the analytes 
indicates randomness (section 3.2.13). This is also evidenced by the probability (p > 0.05). 
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According to Sprent and Smeeton (2007) and (Chatterjee and Simonoff, 2012) too few or 
too many runs imply a departure from randomness and if randomness is not achieved, the 
probability is less than the significance level, i.e., p < 0.05 (significance level α/2 = 0.05). 
Hence, the residuals are random. This confirms the observations made using the mean and 
visual inspection.  
 
The application of residual analysis to test for linearity is commonly used in research and 
Byrska et al. (2010), Rambla-Alegre et al. (2012), Van Loco et al. (2002) and Vorce et al. 
(2008) successfully applied residual analysis in addition to correlation coefficients to verify 
linearity in their studies. It can therefore be said this test is complimentary to use of 
correlation coefficients. It can therefore be concluded that the calibration plots are linear 
and any departures from linearity are insignificant and due to random chance. 
 
 
7.3.1.3 Linearity ranges and method detection limits 
The linearity data (linearity range and working range), limit of detection (LOD) and limit of 
quantitation (LOQ) corresponding to the calibration graphs (Appendix 9) were determined 
and are shown in Table 7.3. In addition, the concentration range in which linearity was 
achieved is also given in terms of the linearity and working range (ICH, 2005; Rambla-
Alegre et al., 2012). The detection limits indicated that the method has good sensitivity (ng 
range) for all the drugs, with detection limits in the range 0.26 - 1.95 x 10-3µg/mL free base 
on column. The quantitation limits for all the drugs were in the range 0.77 - 5.90µg/mL free 
base on column. As such, the drugs can be reliably detected and analysed qualitatively and 
quantitatively in various concentration ranges, even for samples containing very low 
concentrations.  
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Table 7.3 Calibration results: linearity range and method detection limits. 
Analyte Linearity range 
(µg/mL free base on column) 
Method detection limits 
(free base on column) 
 Linearity 
range 
Working 
range 
LOD (x 10-3µg/mL) LOQ (µg/mL) 
2-FPP 2.6 – 42.1 3.9 – 31.6 0.82 ± 0.037 2.48 ± 0.113 
3-FPP 4.6 – 49.5 6.2 – 37.1 0.93 ± 0.049 2.79 ± 0.150 
4-FPP 1.3 – 41.7 3.9 – 41.7 0.36 ± 0.022 1.09 ± 0.065 
2-TFMPP 2.5 – 40.0 3.8 – 40.0 0.97 ± 0.044 2.93 ± 0.133 
3-TFMPP 3.3 – 39.1 4.9 – 39.1 0.85 ± 0.040 2.58 ± 0.120 
4-TFMPP 3.8 – 40.8 7.7 – 30.6 1.16 ± 0.10 3.50 ± 0.317 
BZP 3.8 – 40.7 4.0 – 40.0 0.28 ± 0.014 0.86± 0.043 
1.4DBZP 1.0 – 32.0 4.0 – 32.0 0.45 ± 0.005 1.36 ± 0.015 
MBZP  3.1 – 33.4 4.2 – 33.4 0.83± 0.046 2.54 ± 0.140 
4CPP 2.9 – 47.1 5.9 – 47.1 1.18 ± 0.059 3.58 ± 0.179 
4-MePP 3.8 – 40.0 6.0 – 40.0 1.01 ± 0.008 3.06 ± 0.023 
MDMA 1.0 – 16.2 2.0 – 16.2 0.26 ± 0.015 0.77 ± 0.069 
Methamphetamine 1.0 – 33.3 4.2 – 33.3 0.69 ± 0.040 2.10 ± 0.122 
Caffeine 3.8 – 30.0 5.0 – 30.0 1.10 ± 0.13 3.35 ± 0.40 
Cocaine 3.7 – 39.3 6.0 – 29.5 1.74 ± 0.11 5.26 ± 0.340 
Diazepam 5.0 – 30.0 7.5 – 30.0 1.95 ± 0.035 5.90 ± 0.105 
Dapoxetine 2.3 – 37.5 7.0 – 28.1 1.62 ± 0.062 4.90 ± 0.189 
Dextromethorphan 2.0 – 31.4 2.5 – 30.0 0.52 ± 0.003 1.5 ± 0.010 
Nicotinamide 2.1 – 33.4 5.0 – 33.4 0.32 ± 0.016 0.98 ± 0.048 
Ephedrine 2.5 – 20.2 3.0 – 20.0 0.56 ± 0.030 1.71 ± 0.09 
 
It was found that on average the common working range was 5 - 35.0µg/mL free base on 
column. It was shown that street samples containing piperazine drugs have relatively high 
drug content for example 50 - 200 mg BZP, 90 110mg 3-CPP (Kenyon et al., 2010). Hence, 
the observed detection, quantitation limits and working range are ideal as since they are 
sensitive enough (µg range) to be applicable to analysis of street samples. Furthermore, the 
wide working range is advantageous since the method is to be used for analysis of street 
samples as these drugs are expected to be found in various combinations and dosages with 
3-TFMPP and 4-FPP (Yeap et al., 2010, Vorce et al., 2008). In addition, the wide range 
implies they can be simultaneously analysed since it encompasses the individual working 
ranges of the drugs. 
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7.3.2 ACCURACY AND PRECISION 
 
The simulated street samples and the standards gave similar results with a correlation of 
100 ± 1.5%. Hence any differences were deemed statistically insignificant and as such 
either could be applied in this study. The results for accuracy and precision determined 
using the standards are tabulated (Table 7.4). In accordance with section 7.2.10 (Data 
analysis) the recovery (%) is given as a measure of accuracy and the standard deviation 
(SD) and relative standard deviations (%RSD) as a measure of precision. In addition the SD 
is also given show the error in the accuracy determinations.  
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Table 7.4 Accuracy and Precision. 
 Accuracy Precision 
 %Recovery (n = 3) Repeatability (intra-day), n = 6 Intermediate (inter-day), n = 9 
 
 SD %RSD SD %RSD 
2-FPP 98.7% ± 0.03 0.023 1.40 0.10 1.72 
3-FPP 100.7% ± 0.04 0.017 1.23 0.31 1.41 
4-FPP 100.4% ± 0.03 0.024 1.15 0.10 1.46 
2-TFMPP 100.1% ± 0.02 0.016 1.15 0.06 1.45 
3-TFMPP 99.23% ± 0.24   0.090 1.38 0.34 1.50 
4-TFMPP 98.8% ± 0.02 0.020 0.83 0.14 1.25 
BZP 100.02% ± 0.01 0.090 1.10 0.09 1.10 
1.4DBZP 100.3% ± 0.04 0.012 1.47 0.14 1.25 
MBZP  99.6% ± 0.03 0.010 1.43 0.07 1.24 
3-CPP 101.7% ± 0.02 0.037 1.90 0.23 1.73 
4-MePP 99.1% ± 0.02 0.003 0.62 0.50 1.41 
MDMA 100.2% ± 0.02 0.040 1.31 0.04 1.17 
Methamphetamine 101.3% ± 0.02 0.009 1.86 0.63 1.44 
Caffeine 98.2% ± 0.03 0.160 1.70 0.23 1.69 
Cocaine 100.0% ± 0.01 0.010 1.31 0.66 1.40 
Diazepam 99.4% ± 0.01 0.130 1.32 0.32 1.53 
Dapoxetine 99.4% ± 0.02 0.018 1.88 0.22 1.73 
Dextromethorphan 99.8% ± 0.09 0.020 1.48 0.08 1.28 
Nicotinamide 100.9% ± 0.03 0.014 1.13 0.06 1.18 
Ephedrine 99.3% ± 0.01 0.006 1.04 0.94 1.39 
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The results (Table 7.4) show that accuracy on average was 99.8% (range 98.5 - 102. 9%). 
Precision for all the drugs was less than 2%, with RSD in the range of 0.83 - 1.90% for 
repeatability as a measure of intra-day precision. The range was 1.10 -1.73% for 
intermediate precision also known as inter-day precision (ICH, 2005). 4-TFMPP (RSD = 
0.83%) and 3-CPP (RSD = 1.90%) showed the lowest and highest deviations respectively. 
The criterion for achieving acceptable accuracy was reported as 98 - 102% for an analyte 
ratio of 0.1 (Gonzalez and Herrador, 2007). For precision, the critera was stated as RSD < 
2.0% (Eurachem, 1998; Gonzalez and Herrador, 2007). Therefore, it is evident from the 
results that good method accuracy and precision were achieved for all the analytes. 
 
Comparison of the validation results with the work of other researchers was rather limited 
as only a few research studies has been conducted on these drugs, especially for 4-FPP. 
However, Byrska et al. (2010) in a study on determination of piperazines developed and 
validated a GC-MS method for qualitative analysis. The study investigated BZP, 3-CPP, 
MBZP, MePP and 3-TFMPP. The LODs obtained were in the range 2.5 - 5.0µg/mL (this 
was also stated as mg/mL), hence the sensitivity of their method is lower than that observed 
with the method in this research (LODs were 0.26 – 1.95 x 10-3µg/mL. Whilst their 
methods and the one for this study can be applied for qualitative investigation, the analysis 
of street samples this would not be a limitation due to relatively high drug content 
(mg/tablet) but the method might face a challenge in analysis of samples with very low 
concentrations, e.g. if the method is extrapolated to toxicological investigations. Vorce et 
al. (2008) obtained comparable linearity data for BZP and 3-TFMPP; R2 = 0.9991 and 
0.9990 respectively. Their accuracy data (97.8% for BZP and 101.4% for 3-TFMPP) was 
comparable to those in this study 100.2% and 99.23%.  However, their method was less 
sensitive with detection limits in the range of 0.1mg/L for both BZP and 3-TFMPP. It 
should be taken into account that the method was for analysis of drugs of abuse in a 
biological matrix, urine and not street samples, or the combination of analytes used in this 
study. Boumrah et al. (2014) developed a method for piperazines (BZP, TFMPP, CPP, 
MeOPP, MDBP) and amphetamines (MDMA, MDA, MDEA, MBDB) in seized drugs. 
They reported LODs in the range 71.5 - 116µg/mL for the piperazines. Whilst like this 
study the method was for street samples as for this study, the LODs were lower. However, 
they would still be applicable to street samples as these contain high dosages of drugs 
(section 1.2.2, Table 1.3). The limitation is the range/number of drugs investigated was less 
including the congeners in street samples. Also the common diluents were not investigated, 
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e.g., caffeine nor were isomers of TFMPP. In addition, the authors recommended 
derivatisation to improve resolution. Furthermore other validation parameters were not 
reported unlike this study which reports more holistic data (Kuleya et al., 2014). 
 
7.3.3 COMPARISON OF TOTAL ION CHROMATOGRAM (TIC) AND EXTRACTED ION DATA 
(M/Z DATA) 
 
A comparison of linearity data derived using TIC with that from extracted ion data was 
conducted, so as to verify if the results are comparable. This is especially important if there 
are substances which co-elute in the sample, for example in this study, 3-TFMPP and 
MDMA, DBZP and dextromethorphan. In addition, new additives and sample 
combinations are increasingly appearing on the street market. Consequently, there is a 
possibility of co-elution of such substances on analysis. This limitation is overcome by use 
of extracted ions characteristic to the drug only (de Boer et al., 2001; Takahashi et al., 
2009). The linearity results using extracted ion data are shown in Tables 7.5 and 7.6.  
 
The data derived from total ion chromatograms (TICs) of the analytes (Tables 7.1 - 7.4) in 
comparison to the extracted ion (Tables 7.5 and 7.6) show similar linearity, LOD, LOQ, 
accuracy and precision trends. For example, for 3-TFMPP, LOD = 0.85 x 10-3µg/mL free 
base on column, LOQ = 2.58µg/mL free base on column for TIC data, whilst for extracted 
ion data, LOD = 0.72 x 10-3µg/mL free base on column, LOQ = 2.18µg/mL free base on 
column. In addition, the regression coefficients were comparable. This suggested that either 
method could be used without any significant differences in the results. 
 
Statistical analysis by ANOVA (2-way without replication) was conducted to determine 
whether the results from TIC data were statistically significantly different to those from the 
extracted ion data. The statistical results on LOD and accuracy data show that there was no 
significance difference; F(1) = 0.79, p = 0.39, Fcrit = 4.45 for LOD and F(1) = 3.39, p = 
0.08, Fcrit = 4.45 at 5% significance level. The p < 0.05 the significance level and The F 
value observed is less than the critical value. This implies statistically the TIC and m/z 
show similar results and any deviations are due to chance.  
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Table 7.5 Calibration results using extracted ion (mz) data.  
Substance Ion used (m/z) R2 n Linearity (µg/mL free base on 
column) 
Method detection limits (free base on column) 
    Linearity range Working 
range 
LOD (x 10-3µg/mL)   LOQ (µg/mL)   
2-FPP 138 0.9991 8 2.6 – 42.1 3.9 – 31.6 0.82 ± 0.016 2.5 ±0.049 
3-FPP 138 0.9988 7 4.6 – 49.5 6.2 – 37.1 0.96 ± 0.017 2.92 ± 0.050 
4-FPP 138 0.9998 8 1.3 – 41.7 3.9 – 41.7 0.36 ± 0.008 1.08 ± 0.023 
2-TFMPP 188 0.9985 8 2.5 – 40.0 3.8 – 40.0 1.04 ± 0.017 3.15 ± 0.220 
3-TFMPP 188 0.9993 7 3.3 – 52.1 4.9 – 39.1 0.72 ± 0.009 2.18 ± 0.027 
4-TFMPP 188 0.9985 7 3.8 – 40.8 7.7 – 30.6 1.22 ± 0.036 5.40 ± 0.108 
BZP 91 0.9999 7 3.8 – 40.7 4.0 – 40.0 0.29 ± 0.003 0.87 ± 0.010 
DBZP 91 and 266 0.9996 8 1.0 – 32.0 4.0 -32.0 0.44 ± 0.019 1.33 ± 0.0573 
MBZP  105 0.9989 7 3.1 – 33.4 4.2 – 33.4 0.86 ± 0.003 2.62 ± 0.003 
3-CPP 154 0.9987 8 2.9 – 47.1 5.9 – 47.1 1.15 ± 0.011 3.48 ± 0.050 
4-MePP 134 0.9989 6 7.5 – 40.0 12.5 – 40.0 1.04 ± 0.03 3.18 ± 0.100 
MDMA 135 0.9996 7 1.0 – 16.2 2.0 – 16.2 0.24 ± 0.001 0.73 ± 0.004 
Methamphetamine 91 0.9962 8 1.0 – 33.3 4.2 – 33.3 0.67 ± 0.004 2.04 ± 0.013 
Caffeine 194 0.9938 7 3.8 – 30.0 5.0 – 30.0 1.74 ± 0.057 5.26 ± 0.176 
Cocaine 82 0.9959 7 3.7 – 39.3 6.0 – 29.5 1.97 ± 0.019 5.98 ± 0.056 
Diazepam 256 0.9963 6 5.0 – 30.0 7.5 – 30.0 1.62 ± 0.025 4.90 ± 0.078 
Dapoxetine 134 0.9967 7 2.3 – 37.5 7.0 – 28.1 1.69 ± 0.074 5.11 ± 0.223 
Dextromethorphan 271 0.9995 6 2.0 – 31.4 2.5 – 30.0 0.58 ± 0.003 1.74 ± 0.010 
Nicotinamide 122 0.9998 8 2.1 – 33.4 5.0 – 33.4 0.33 ± 0.003 1.00 ± 0.009 
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Table 7.6 Accuracy and Precision –determined from extracted ion data. 
Substance Accuracy 
 %Recovery (Mean, n = 3) SD %RSD 
 
   
2-FPP 99.8 ± 0.034 0.014 1.37 
3-FPP 100.3 ± 0.038 0.014 1.44 
4-FPP 99.8 ± 0.027 0.011 1.08 
2-TFMPP 99.5 ±5 0.035 0.014 1.40 
3-TFMPP 100.1 ± 0.020 0.008 0.79 
4-TFMPP 99.1 ± 0.021 0.008 0.85 
BZP 100.9 ± 0.020 0.007 0.74 
DBZP 99.6 ± 0.021 0.011 1.14 
MBZP  100.2 ± 0.026 0.011 1.06 
3-CPP 102.8 ± 0.021 0.008 0.81 
4-MePP 98.5 ± 0.015 0.006 0.62 
MDMA 100.0 ± 0.029 0.012 1.18 
Methamphetamine 101.0 ± 0.032 0.013 1.25 
Caffeine 102.9 ± 0.042 0.017 1.62 
Cocaine 102.8 ± 0.025 0.020 1.92 
Diazepam 100.5 ± 0.048 0.002 1.91 
Dapoxetine 100.7 ± 0.010 0.004 0.39 
Dextromethorphan 100.9 ± 0.005 0.009 0.88 
Nicotinamide 100.4 ± 0.028 0.011 1.11 
 
It has been discussed that co-elution was observed between MDMA and 3-TFMPP; DBZP 
and dextromethorphan, making selective determination of these analytes difficult if they 
co-exist in the same sample. Furthermore, it was proposed that this could be overcome 
through use of extracted ions as their mass spectra are sufficiently different to discriminate 
between them (Chapter 4). As such, it can be confirmed that either TIC or extracted ion 
data can be used in the method. Therefore, the extracted ions for 3-TFMPP (m/z 188), 
MDMA (m/z135), DBZP (m/z 91 or 266) and dextromethorphan (m/z 271) can be 
employed in analysis of these substances. Since drugs often exist as combinations in street 
samples (Yeap et al., 2010) this will be advantageous. 
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7.3.4 METHOD ROBUSTNESS 
7.3.4.1 Robustness using different analysts 
The chromatographic profiles obtained by two different analysts working independently are 
shown in Figures 4 and 5.  
 
 
Figure 7.4 Total ion chromatogram of mixed drug standard: Analyst 2. 
 
 
Figure 7.5 Total ion chromatogram of mixed drug standard: Analyst 1. 
 
The chromatographic profiles generated by different analysts (Figures 7.4 and 7.5) were 
similar in terms of the order of elution of the analytes and peak shapes. This was confirmed 
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by the qualitative data; retention times, relative retention times and retention indices. The 
data for 2 is presented in Table 7.7 (derived from Figure 7.4) together with that for analyst 
1 (extracted from Table 7.8) for comparison.  
 
Table 7.7 Method robustness: Comparison of GC-MS data generated by different analysts. 
 Analyst 2 Analyst 1 
Compound Rt/mins RRT RI  
(±0.37%) 
Rt/mins RRT RI 
Methamphetamine 9.07 0.470 1199 8.84 0.466 1201 
Nicotinamide 11.92 0.618 1392 11.88 0.627 1412 
2-TFMPP 12.36 0.641 1421 12.12 0.639 1427 
2-FPP 13.18 0.684 1477 12.88 0.679 1479 
BZP 13.56 0.703 1503 13.24 0.698 1505 
4-FPP 13.92 0.722 1527 13.56 0.715 1527 
3-TFMPP 14.19 0.736 1545 13.78 0.727 1542 
MDMA         14.25 0.739 1549 13.83 0.729 1545 
3-FPP 14.44 0.749 1562 14.05 0.741 1548 
4-TFMPP 15.17 0.787 1611 14.82 0.782 1614 
MBZP 15.29 0.793 1619 14.98 0.790 1624 
4-MePP      15.54 0.806 1636 15.23 0.803 1642 
3-CPP 17.12 0.888 1743 16.85 0.889 1754 
Caffeine 18.14 0.941 1822 17.90 0.944 1867 
Dextromethorphan 20.74 1.076 2210 20.50 1.081 2208 
DBZP 20.78 1.078 2216 20.53 1.083 2212 
Cocaine 21.17 1.098 2275 20.95 1.105 2268 
Diazepam 22.93 1.189 2537 22.68 1.196 2494 
Dapoxetine 23.32 1.210 2596 23.01 1.214 2179 
Eicosane ( IS) 19.28 1.000 1993 18.96[1] 1.000 2006[1] 
[1]To verify the accuracy of the calculations, the accuracy of Retention index (RI) calculations was 
determined. The expected retention index of eicosane is 2000, the actual value obtained was 1993 
hence error in experimental RI values = 0.35%. Consequently the calculations were deemed highly 
accurate. 
 
A comparative analysis of analyst 1 and analyst 2 results (Table 7.7) by ANOVA (2 factor 
without replication) indicated that there were no significant differences in the results 
 222 
 
obtained by the 2 analysts. F(1, 24) = 2.20, p = 0.16, Fcrit = 4.41, for relative retention time 
F(19,20) = 3697, p < 0.001, Fcrit = 2.14 and for retention indices F(1,18) = 0.81, p < 0.38, 
Fcrit = 4.41. Consequently, any variations observed were due to chance. Therefore, the 
method can be deemed robust as it is able to consistently give similar results independent of 
changes in the analyst. 
 
7.3.4.2 Robustness using different instruments 
To further test for robustness analysis was conducted on a different CG-MS instrument 
(Shimadzu GC-MS). The total ion chromatogram generated is given in Figure 7.6. The 
peak profile in terms of order of elution, peak shape, retention time and resolution were 
observed to be similar with those from the Perkin Elmer instrument routinely used for this 
research (Figure 7.5 and Table 7.8). The relative retention times of the 17 analytes shown 
in Appendix 11 were statistically evaluated by ANOVA (single factor) and t-test which 
indicated that there were no significant differences in the results obtained by the 2 
instruments. F(1, 17) = 0.38, p = 0.54, Fcrit = 4.15. For the t-test (2-tailed) t(16) = -14.25, p 
= 1.7 x 10-10, tcrit = 2.12. Consequently, it was concluded that the method is unaffected by 
the type of GC-MS used and is robust and therefore capable of transferring the method to 
different instruments and analysts. This is very useful as it means the method can be used 
under different laboratory conditions. 
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Figure 7.6 Test for robustness: Total ion chromatogram generated on a different GC-MS instrument (Shimadzu GC-MS). 
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7.3.5 METHOD APPLICATION: CONFIRMATION OF DRUG IDENTITY PARAMETERS  
 
7.3.5.1 GC-MS analytical profile of drugs 
The chromatographic peak profile of the mixed drugs using the validated method is shown 
in Figure 7.5.The qualitative data for confirmation of drug identity is shown in Table 7.8. In 
the table RRT is relative retention time and RI is relative retention index. 
 
Table 7.8 Qualitative data for confirmation of drug identity. 
Compound Retention time/mins RRT RI 
Methamphetamine 8.84 0.465 1201 
Nicotinamide 11.88 0.626 1412 
2-TFMPP 12.12 0.638 1427 
2-FPP 12.88 0.678 1479 
BZP 13.24 0.698 1505 
4-FPP 13.56 0.714 1527 
3-TFMPP 13.78 0.726 1542 
MDMA 13.83 0.729 1545 
3-FPP 14.05 0.731 1548 
4-TFMPP 14.82 0.781 1614 
MBZP 14.98 0.789 1624 
MePP 15.23 0.802 1642 
CPP 16.85 0.888 1754 
Caffeine 17.90 0.943 1867 
Dextromethorphan 20.50 1.080 2208 
DBZP 20.53 1.081 2212 
Cocaine 20.95 1.104 2268 
Diazepam 22.68 1.195 2494 
Dapoxetine 23.01 1.212 2179 
Eicosane (IS) 18.96 1.00 2006[1] 
[1]
 Verification of Retention index (RI) calculations: The expected retention index of eicosane is 
2000, the value obtained wass 2006, hence error in experimental RI values = 0.30%). 
 
The chromatographic profile (TIC, Figure 7.5), retention times, relative retention times and 
retention indices (Table 7.8) for each analyte indicated that it is possible to isolate and 
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selectively analyse these substances by the method developed CDER (2004). According to 
USP (2011) system suitability tests were 5 – 6 consecutive injections are made should show 
an RSD < 2 if the variability between the measurements is acceptable. As such, the results 
indicated that the instrument and method was consistent and had good repeatability.  
 
Inoue et al., (2008) discussed that if good selectivity is not achieved, then resolution 
between peaks is reduced and this in turn reduces accuracy in the results. It is evident that 
good specificity was achieved by the method, since the resolution between analytes was R 
> 2 for all the analytes except the co-eluting substances (Chapter 7). Hence, the method is 
confirmed to have achieved validation. As such these GC-MS chromatographic parameters 
were used to identify substances in later investigations (analysis of street samples, Chapter 
8). In addition, the chromatographic profile shows that the method is able to simultaneously 
analyse for all the drugs investigated. It has been reported that confirmation of 
identification of a compound is also conducted through evaluation of mass spectra (de Boer 
et al., 2001; Kaur, 2010) and the ionisation energy which achieved the best spectral data 
was determined during optimisation (Chapter 6). Therefore, consideration will be given to 
the mass spectra that can be applied to the identification of the drugs under investigation as 
an identification tool. 
 
7.3.5.2 Mass spectral data of (2, 3, 4) FPP and TFMPP isomers 
A representation of mass spectra results is shown for (2, 3, 4) isomers of FPP and TFMPP 
in Figures 7.7 and 7.8 respectively. The mass spectra of all the drugs investigated are 
shown in Appendix 10. In addition the mass spectra ions are given in Table 7.9.  
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Figure 7.7 Mass spectra of (2, 3, 4) FPP positional isomers. 
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Figure 7.8 Mass spectra of (2, 3, 4) TFMPP positional isomers. 
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Table 7.9 Mass spectra data for the analytes  
Substance Mass/ Da Observed Principal ions, m/z(%intensity) 
2-FPP 180.2 138(100), 180(M+, 25.69), 122(21.11), 123(14.62), 56(14.44), 
95(11.26), 75 (7.63), 109(6.99), 77(4.30), 83(2.57), 91(1.58), 
69(1.60), 150(0.61) 
3-FPP 180.2 138(100), 180(M+, 25.75), 122(17.45), 123(13.63), 56(13.16), 
95(16.88), 75 (8.97), 109(6.41), 77(1.11), 83(1.84), 91(0.69), 
69(1.59), 150(0.96) 
4-FPP 180.2 138(100), 180(M+, 24.81), 122(25.56), 123(16.37), 56(13.93), 
95(18.98), 75 (8.93), 109(6.08), 77(1.06), 83(2.32), 91(0.85), 
69(1.56), 150(1.15) 
2-TFMPP 230.2 188(100), 230(M+, 18.94), 56(19.48), 145(15.87), 172(19.33), 
173(9.49), 174(1.42), 175(0.33), 189(13.82), 127(8.44), 
95(3.74), 75(4.03), 109(1.15), 154(2.77), 159(4.60), 88(0.26) 
3-TFMPP 230.2 188(100), 230(M+, 20.26), 56(16.69), 145(18.10), 172(17.58), 
173(8.81), 174(3.60), 175(1.13), 189(10.49), 127(2.55), 
95(4.00), 75(3.85), 109(1.53), 154(1.34), 159(3.99), 88(0)  
4-TFMPP 230.2 188(100), 230(M+, 20.38), 56(15.01), 145(17.20), 172(16.70), 
173(8.35), 174(3.29), 175(1.41), 189(9.16), 127(2.87), 
95(4.59), 75(3.07), 109(1.42), 154(2.23), 159(4.79), 88(0.20) 
BZP 176.3 91(100), 134(66.03), 56(29.59), 65(16.36), 176(M+, 14.71), 
120(5.45), 118(6.38), 119(2.80), 77(1.84), 85(12.51) 
1.4DBZP 266.4 91(100), 120(22.96), 65(10.11), 135(1.51), 105(2.15), 
106(2.04), 51(1.71), 77(1.38), 89(2.20), 63(1.39), 41(2.54), 
175(20.24) 
MBZP  190.3 105(100), 56(26.25), 148(29.45), 42(7.89), 77(13.86), 
103(9.20), 85(15.11), 190(M+, 2.63), 79(8.98), 134(8.95), 
106(8.69), 118(4.54), 160(2.46), 65(2.35), 119(0.70), 120(0.25) 
3-CPP 196.7 154(100), 156(32.26), 196(M+, 28.15), 138(13.57), 111(12.56), 
56(17.19), 75(11.17), 77(6.14),113(5.28), 119(4.30), 125(3.83), 
63(2.56), 89(2.00), 117(1.56), 98(1.52), 104(1.49), 85(1.40), 
91(1.21), 166(1.05) 
4-MePP) 176.3 134(100), 176(M+, 31.05), 91(21.05), 118(12.84), 135(9.96), 
56(10.17), 65(8.80), 120(6.10), 77(3.65), 89(3.20), 119(14.46), 
105(3.64), 146(0.84) 
MDMA 193.2 58(100), 135(5.78), 77(6.13), 51(5.66), 55(0.41), 136(2.69), 
105(1.87), 63(1.83) 
193(M+,0.31 ), 178(0.28), 56(6.12), 120(0.32), 148(0.27)   
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(+)Methamphetamine 149.2 58(100), 91(10.07), 65(5.89), 56(8.07), 42(5.77), 59(4.05), 
51(2.42), 63(2.06), 77(1.94), 89(1.54), 134(1.73), 115(1.36), 
92(0.79, 119(0.85), 148((M-H)+, 0.26) 
Caffeine 194.2 194(M+, 100),  109(54.26), 55(37.07), 67(46.38), 82(30.96), 
195(8.22), 42(17.22), 110(7.53) 
Cocaine HCl 
 
303.4 
(base) 
82(100), 182(68.51), 94(37.19), 77(37.69), 105(31.04), 
42(23.56), 198(8.00), 303(M+, 10.03), 122(9.19), 272(4.40), 
51(10.89), 68(5.46), 59(4.83), 152(4.79), 166(2.98), 140(0.40)     
Diazepam 284.7 256(100), 283(80.88), 284(M+,61.43), 285(37.28), 257(46.66), 
255(40.52), 258(33.90), 286(21.03)  
Dextromethorphan HBr 271.4 
(base) 
59(100), 271(M+, 49.77), 150(52.35), 270(27.98), 214 (27.88), 
42(21.36), 171(0.83)  
Nicotinamide 122.1 122(100, M+), 78(98.51), 106(73.08), 51(52.01), 50(29.34), 
52(26.38), 44(21.47), 123((M+H)+, 6.40)  
Dapoxetine 305.4 134(100), 115(11.57), 91(8.67), 58(9.53), 117(7.17), 127(5.23), 
84(3.23), 77(3.00), 162(2.22), 160(1.98), 183(0.33), 177(0.30), 
306((M+H)+, 0.91,  
Ephedrine 165.2 58(100), 77, 42, 105, 146, 117, 91 
 
The results (Appendix 10 and Table 7.9) show that typical mass spectra, characteristic of 
the analytes were obtained for all the drugs (Moffat et al., 2011; NIST, 2014; de Boer et al., 
2001; Takahashi et al., 2009). For all the analytes except DBZP and MDMA the molecular 
ion (M)+ was observed which further aids in identification. This also confirms that the 
ionisation energy selected under optimisation (EI 70eV) is suitable. The absence of the 
molecular ion can be attributed to its fragmentation. For example, for DBZP the molecular 
ion is expected at m/z 266, however, cleavage of the benzyl groups results mainly in 
formation of the ion at m/z 91 (benzyl group) as evidenced by its principal abundance in 
the mass spectra of DBZP. The route of fragmentation for the cleavage is similar to that of 
BZP presented in Figure 7.29 (route d).  
 
It has been reported the fragmentation pattern is characteristic of a compound and can be 
utilised in its identification (Kaur, 2010; Khopkar, 2012). Hence, the mass spectra and ions 
observed listed in Table 7.9 typically identify these compounds and can be utilised in future 
identification of unknowns. de Boer et al. (2001) in one of the earliest studies on 
piperazines and of recent UNODC (2013c) gives a limited data on the mass spectra of 
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piperazines and other drugs. UNODC gives the top 5 principal ions only, de Boer et al., on 
the other hand gives more extensive data but only for BZP, TFMPP and MeOPP. This 
study brings in additional spectral data and study gives more comprehensive mass spectra 
by identifying ion m/z values for the piperazines and also all the congeners. Furthermore, 
the route of fragmentation and the corresponding fragment structures for benzylpiperazines 
and phenylpiperazines represented by BZP and 3-TFMPP respectively were reported 
(Figures 7.10 – 7.11). This aids in understanding the processes involved.  
 
It is evident that the isomers of FPP and TFMPP, Figures 7.7 and 7.8 respectively have 
similar mass spectra. The fragmentation pattern and ions observed were similar. The ions at 
mz 180(100), 230 (M+), 122, 56 and 95 were observed for FPP. The ions 188(100), 
230(M+), 56, 145, 172 were observed for TFMPP. A review of the mass spectral ions in 
Table 7.9 confirmed this observation as the intensities of the ions were not sufficiently 
different enough to be used for identification. This is typical of isomers. It was established 
that positional isomers show similar chemical properties, hence they cannot be 
differentiated on the basis of mass spectra only (Maher et al., 2009; Takahashi et al., 2009). 
It was earlier discussed that the total ion chromatogram (Figure 7.5) and qualitative data 
(Table 7.9) showed that the isomers were well resolved from each other with resolution, R 
> 2.0. Consequently, even though on the basis mass spectra the FPP and TFMPP cannot be 
identified indiscriminately, with this method the isomers can be distinguished according to 
their retention time, relative retention times and mass indices.  
 
The structures for the ion fragments given in Table 7.9 are proposed for phenylpiperazines 
and benzylpiperazines. Also proposed are the corresponding routes of fragmentation (de 
Boer et al., 2001, Inoue et al, 2004). BZP (Figures 7.9 and 7.10) and 4-TFMM (Figures 
7.11 and 7.12) are used as exemplars respectively.  
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Figure 7.9 Proposed routes of fragmentation of un-derivatised BZP. 
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Figure 7.10 Structures of GC-Mass spectra ion fragments for un-derivatised BZP (EI, 70eV).  
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Figure 7.11 Proposed routes of fragmentation of un-derivatised 4-TFMPP (Similarly for 2 and 3-TFMPP). 
 
m/z 230(M+)     188      174                 
N+NF3C
(I)   
CH3
N+
H
F3C
 (II)   
CH2
N+
H
F3C
(III)         
 
173         172       145 
+CH2
NF3C
 (IV)         
CH
N+F3C
(V)    
C+
F3C (VI)   (VIII) m/z/56-as for BZP 
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Figures 7.9 – 7.10 showed that some of the ions are common such as at m/z56. These ions 
were generated by both routes of fragmentation for benzylpiperazines and 
phenylpiperazines. The more specific ions can then be applied for more selective 
distinction as routinely practiced in most studies (Khopkar, 2012). It is therefore suggested 
that the proposed routes of fragmentation and the fragment structures aid in understanding 
the process behind the mass spectra obtained. Studies showing routes of fragmentation and 
fragments ion structures are very limited, more for piperazine drugs (de Boer et al., 2001, 
UNODC, 2013c, Inoue et al., 2004; Takahashi et al., 2009). For both 3-TFMPP and BZP, 
limited information on fragmentation ions and structures have been reported for selected 
ions only (de Boer et al., 2001; Inoue et al., 2004; Elie et al., 2013). de Boer et al. in his 
study gave structures for BZP, TFMPP and MeOPP. But the routes of fragmentation were 
not reported.  Such data is reported in this study (Table 7.9, Figures 7.8 – 7.11). 
 
There were a limited number of studies on validation of similar drugs of abuse by other 
researchers for comparative purposes. However, Inoue et al. (2004) in their study on 
piperazine like compounds investigated BZP, 3-TFMPP, 3-CPP, 4-FPP. No detection limits 
were specified; however the study did a comprehensive qualitative analysis and generated 
comparable mass spectra in terms of the ions observed. In addition, the retention indices 
observed are also similar to those obtained in this study. However, a limitation to their 
methods was inability to separate the FPP isomers. The challenge posed by isomers was 
also encountered in other studies (Takahashi et al., 2009; Elliot and Smith, 2008). In 
addition the range of drug substances was rather limited as adulterants, such as caffeine 
have been commonly observed in most legal highs (Davies et al, 2010). These 
shortcomings were overcome with this method, as the isomers were not only resolved, but a 
wider range of drugs was investigated. This encompassed 4-FPP, 3-TFMPP and their 
congeners in street samples in which the drugs exist as combinations (Kelleher et al., 2011). 
In addition, this method gives holistic data (retention times, relative retention times, 
retention indices, mass spectra, linearity, LOD, LOQ, accuracy, precision and selectivity) 
for 19 drug substances for use in both qualitative and quantitative analysis. 
 
A study by UNODC (2013) developed methods (three) for the analysis of materials 
containing piperazine drugs (BZP, MeOPP, FPP, TFMPP). The method gives similar 
results in terms of the trend in elution. In addition, the methodology is basically similar. 
These methods can successfully be employed for qualitative analysis. Differences lie in the 
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solvent used, diversity of the drugs analysed and practical applicability. This investigation 
has a more practical approach, as it not only gives a method which can be used for both 
analysis of drug standards, but also for actual street samples. It has been said street samples 
of piperazine drugs contain a mixture of other drugs and or adulterants and diluents (Davies 
et al, 2010; Yuk, 2010, Yeap et al., 2010, Kenyon et al., 2010). This method was developed 
with this information in mind and has been able to overcome the complexity of a street 
sample matrix. The drugs studied were those expected to be found in a street sample with 
FPP, TFMPP or other piperazines. In addition, it investigated potential residual precursors 
and by-products of synthesis and therefore, can be applied to a street sample which might 
contain these impurities. Furthermore, it can analyse for these impurities thereby fulfilling 
one of its objectives; characterisation and profiling. The method has successfully been 
applied in the analysis of street samples (Chapter 8). Consequently, the methods by 
UNODC may face limitations when applied to actual street samples.  
 
In the UNODC (2013c) method the solvent was methanol unlike this study where 2-
methylpropan-2-ol was used, though similar columns were used in both cases. The use of 
methanol can affect the stability of the analytes if they are left on the auto-sampler for 
prolonged periods. It was established in Chapter 5 (Stability studies) that some analytes 
show degradation in methanol if left on the auto-sampler for a prolonged duration. For 
example, the minimum stability period was 15 hours for cocaine. For the GC-MS method 
the authors did not report linearity, limits of detection, accuracy and precision. This 
information is critical for a new method as it gives the performance characteristics of the 
method, consequently such data from this study Tables 7.1 – 7.6 will be of use to other 
researchers.  
 
7.3.6 QUALITY CONTROL 
 
The results of monitoring the variability in detector response and method performance 
(retention time) for the QC standard (alkane mix and QC sample 4-MePP, section 7.2.9) are 
graphically represented in Figures 7.13 and 7.14. The limits on the chart define the 
boundaries within which the results are acceptable. When the results exceed the limit or are 
lower than the lower limit then corrective action such as servicing the instrument is taken, 
so as to bring the variable back to acceptable standards.   
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Figure 7.13 Quality control chart for variation in detector response using peak height. 
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Figure 7.14 Quality control chart: variation in retention time (n-alkanes C8 – C24, section 7.2.9). 
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The QC data for n-alkanes was within the limits indicated on the quality control chart 
(Figure 7.13), indicating consistency of the detector response throughout the life of the 
project.  However, the detector response was observed to give low values below the limit 
(Figure 7.14 end of February value). This resulted in corrective action, i.e., instrument 
service maintenance was conducted and the performance improved. The retention times of 
n-alkanes were monitored as well as the ion at m/z 207 for column bleed (sections 7.2.9 
and 2.4.2). This was to verify the stability of the column since aging can result in retention 
times lengthening and the column increasingly bleeds. The retention times were found to be 
consistent as shown by their lack of significant variation on QC chart, i.e., for the period 
investigated they were within the limits depicted on the chart (Figure 7.14). In addition, it 
also gave an indication of instrument repeatability. Column bleed was monitored through 
checking for ion m/z 207 in analyte mass spectra. It was identified in the discussion in 
chapter 2 (section 2.5.2), that an aging column can cause inconsistent results (Hibbert et al., 
2007; McNair and Miller, 2009). As such the column was changed when excessive column 
bleed was observed. McNair and Miller highlighted that column bleed can cause too high a 
background in chromatography, which can interfere with the peaks of interest by enhancing 
the peaks. In their study in developing a GC method for profiling amphetamines Andersson 
et al. (2007b) similarly monitored column bleed as part of quality control.  
 
The precision of the instrument was monitored using 4-MePP, one of the drugs under 
investigation, as an additional method of maintaining variability of the instrument’s 
response. 4-MePP was used, as it elutes mid-way through the chromatographic profile of 
the analytes (Figure 7.5). In addition, it is also relatively stable, as it has been successful 
analysed and optimised in previous studies (Chapter 6).The data is shown in Table 7.10. 
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Table 7.10 QC trend in 4-MePP retention times and instrument precision (detector 
response) on repeated injections. 
 Date RT  RRT  Precision (N =6) 
   SD %RSD 
15/04/2011 15.477 0.813 0.100 1.35 
21/05/2011 15.463 0.836 0.011 1.10 
29/05/2011 15.400 0.832 0.023 1.43 
04/06/2011 15.410 0.833 0.010 1.12 
08/09/2011 15.220 0.803 0.015 1.24 
04/02/2013 15.540 0.806 0.006 1.31 
05/03/2013 15.547 0.806 0.006 0.80 
 
According to Gonzalez and Herrador (2007); Eurachem (1998) and ICH (2005) precision is 
normally expressed as standard deviation or relative standard deviation (%RSD) and RSD 
≤ 2% to be acceptable. The precision was below the limit throughout the period 
investigated. Hence, it can be concluded that the instrument performance was consistent. 
This is also evidenced by the low standard deviation and %RSD values in Table 7.10. 
Furthermore, system suitability results gave %RSD of 6 injections in the range 0.8 – 1.94 
for all the drugs investigated prior to any quantitative investigations. According to Horacio 
et al. (2008) system suitability tests (were 5 – 6 consecutive injections are made) should 
show an RSD < 2 for the variability between the measurements to be acceptable. As such, 
the results further confirmed that the instrument was consistent and had good repeatability.  
 
The QC results helped to highlight systematic errors resulting in their minimisation during 
the course of the research. Consequently, neither the instrument nor the column contributed 
adversely to the analytical work. This established reliability in the investigations conducted 
and aided in generating accurate data.   
 
7.4 CONCLUSION 
 
It was established that the method developed is suitable for its intended use, i.e., analysis 
and profiling of piperazine based street drugs. Method accuracy was reported on average as 
99.8% and precision was RSD < 2%. Detection limits were in the range 0.5 – 1.95 x 10-
3µg/mL free base on column. On average, the common working range was 5 – 35.0µg/mL 
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free base on column.  This was ideal for the analysis of street samples, as they have high 
dosages of drugs (mg range) (Kelleher et al., 2011). Furthermore, it can also be applied to 
very low concentrations. This could prove useful if the method is extrapolated to 
toxicological studies. In such studies drug concentrations in the biological samples are 
usually low (Stack and Maurer, 2005). In addition it was found that the method developed 
was able to simultaneously analyse for 22 drugs which can be found in different 
combinations with the target analytes 4-FPP and 3-TFMPP in street samples. In addition, 
the method was able to completely resolve (baseline resolution) the (2, 3, 4) isomers of 
both FPP and TFMPP thereby being the first method available able to simultaneously 
analyse these isomers and congeners in street samples. The isomers 2-FPP, 3-FPP and 4-
FPP were separated with R > 2 and retention times of 12.88 min (2-FPP), 14.05 min (3-
FPP) and13.56 min (4-FPP) respectively  
 
It was observed that there is co-elution between 3TFMPP/MDMA and also 
DBZP/dextromethorphan. However, whilst the ideal situation is complete resolution, it was 
established that there is statistically no significant difference between using total ion 
chromatographic data and extracted ion data. Hence, this limitation was overcome through 
use of extracted ions for these particular drugs (3-TFMPP m/z 188), MDMA m/z135, 
DBZP m/z 91 or 266 and dextromethorphan m/z 271). Consequently, the method 
developed was found to work satisfactorily and will be employed in the characterisation 
and impurity profiling aspect of the research, in profiling of 3-TFMPP and 4-FPP.  
 
Currently, there was no record of the drugs having been chemically profiled. However, in 
this study comprehensive data for all the 22 drugs investigated was reported (retention 
times, relative retention times, retention indices, and mass spectra) for all the 3-FPP and 2-
TFMPP isomers and the other drugs investigated. Furthermore, this study brings in 
additional spectral data in terms of more comprehensive mass spectra and identifying ion 
m/z values for the piperazines and also all the congeners. In addition, the routes of 
fragmentation and fragment structures for benzylpiperazines and phenylpiperazines were 
identified. It is suggested this data will aid further investigation of these drugs and can be 
used by other researchers, law enforcement agencies and in toxicity studies.  
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CHAPTER 8 
ANALYSIS, CHARACTERISATION AND SYNTHESIS OF STREET 
SAMPLES 
 
8.1 INTRODUCTION TO THIS STUDY 
 
It has been identified that characterisation can provide a chemical picture of the make up or 
composition of a drug (Bartos and Gorog, 2008; UN, 2001). This entails physical and 
chemical analysis, and identification of potential routes of synthesis. The need for 
characterisation and profiling of piperazine drugs was identified in Chapter 1. 
 
In this study, the morphology, dimensions, colour, logos and any other physical traits of 
street samples were analysed (Milliet et al., 2009). Identification and quantitative 
determination of the components of street samples was conducted through presumptive 
testing and GC-MS analysis. In addition, the identity of impurities present in the street 
samples was investigated. Presumptive testing employed the Marquis and Simon’s tests, 
these methods were identified in section 1.8 (Chapter 1) as appropriate to the drugs under 
investigation. These tests were conducted according to the methods by UNODC (2006) and 
Takahashi et al. (2009). Identification by GC-MS was on the basis of retention times, 
relative retention times, retention indices and mass spectra, applying the parameter values 
identified in the method developed as a reference (section 7.3.5). 
 
The synthesis of 4-FPP and 3-TFMPP was conducted as a representative of the synthesis of 
phenylpiperazines. The drugs were synthesised according to the methods by Liu and 
Robichaud (2005) and Kiritsy et al. (1978). These routes were identified as potential routes 
of clandestine synthesis from literature (section 1.7 Chapter 1). Analysis of the samples 
synthesised was conducted by UV-Vis, FTIR and GC-MS so as to ascertain their identity. 
These techniques had been identified in Chapter 1 (section 1.8) as the appropriate 
techniques for this research. In addition, the impurity profile was investigated (Aalberg et 
al., 2005a; Bartos and Gorog, 2008). This was achieved through identification of 
precursors, isomers and by-products of synthesis. Furthermore, the impact of reaction time 
on yield was conducted. Residual precursors were identified (Chapter 1) as potential 
impurities that can be present in the sample after synthesis and as such there is need to test 
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whether when in street samples they would not react or degrade. Hence, the test for stability 
was conducted on the precursors. 
 
A comparison of the total ion chromatographic profiles of the street samples and the 
synthesised samples was conducted. This involved the comparison of not only the drug 
components but their impurity profiles especially those arising from the synthesis routes as 
this would indicate any links to the synthesis routes (UN, 2001; Aalberg et al., 2005a. This 
study mainly focused on characterisation consequently, impurity profiling was only 
partially covered.  
 
The street samples were provided courtesy of Cambridgeshire Constabulary. The samples 
were illicit drug seizures by the police. Each sample consisted of three tablets with the 
exception of two which had one tablet. The GC-MS method (Kuleya et al., 2014) of 
analysis developed, optimised and validated in previous chapters was applied in this study. 
 
8.1.1 AIMS 
 
The aims of this study were to carry out the physical and chemical characterisation of street 
samples thought to contain the piperazines 3-TFMPP and 4-FPP. To achieve this, the 
following objectives were implemented; to a) identify potential viable routes of clandestine 
synthesis of phenylpiperazines (4-FPP and 3-TFMPP), b) synthesise and analyse 4-FPP and 
3-TFMPP and their chemical impurities arising from the synthesis (by-products, positional 
isomers, residual solvents and precursors and c) compare street samples and the laboratory 
synthesised samples. 
 
8.2 MATERIALS AND METHODS 
 
8.2.1 CHEMICALS/REAGENTS 
 
The drug standards and solvent, 2-methylpropan-2-ol used were as outlined in Chapter 4 
(section 4.2.1). In addition anhydrous piperazine, 4-fluoroaniline, 3-trifluoromethylaniline, 
bis(2-chloroethyl)amine hydrochloride, diethylene glycol monomethyl ether, 3-bromo-l-
(trifluoromethy1)benzene and anhydrous methanol were all purchased from Sigma. Sodium 
carbonate, diethyl ether, ethyl acetate, sodium hydroxide, benzene, anhydrous magnesium 
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sulphate, anhydrous sodium sulphate, anhydrous methanol, acetaldehyde, sodium 
nitroprusside, sulphuric acid, Whatman ashless 542 filter paper, and petroleum ether were 
all purchased from Fischer Chemicals.  
 
8.2.2 INSTRUMENTS 
 
The GC-MS instrument and set up were as per the optimised and validated method outlined 
in Chapter 7 (section 7.2.2). In addition an Agilent Cary 300 UV-Vis spectrophotometer 
and a Perkin Elmer Spectrum One FTIR Spectrometer equipped with a Perkin Elmer 
Universal ATR sampling accessory were utilised for additional identification of synthesised 
samples. A Nikon D90 digital SLR camera was used to take photographs of the street 
samples. An Eppendorf 5810 centrifuge was used for clarification of solutions of samples. 
 
8.2.3 STATISTICAL SOFTWARE  
 
Analysis of results was carried out using IBM SPSS Version 20 and MS Office Excel 2010. 
 
8.2.4 METHODS: STREET SAMPLES 
 
8.2.4.1 Physical characteristics 
A physical description and photograph of the street samples were recorded. The 
characteristics analysed were colour, logos, shape, diameter, thickness, mass and any other 
markings observed such as damage.  
 
8.2.4.2 Chemical characteristics 
  
8.2.4.2.1 Presumptive tests 
8.2.4.2.1.1 Marquis test 
The Marquis reagent was prepared by mixing 40% formaldehyde (5.0mL) with 
concentrated sulphuric acid (100.0mL) (UNODC, 2006; Takahashi et al., 2009). The test 
was carried out by addition of a small amount (≈3.0mg) of the drug standard onto a reaction 
plate. The control was an empty well on the reaction plate. One drop of the Marquis reagent 
was added to the sample and the control. The colour changes were observed and noted. The 
test was repeated using the street samples A1 - A11. 
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8.2.4.2.1.2 Simon’s test 
The following solutions were prepared; a) Solution 1: 20% aqueous sodium carbonate, b) 
Solution 2: 50% ethanolic acetaldehyde and, c) Solution 3: 1% aqueous sodium 
nitroprusside (UNODC, 2006; Takahashi et al., 2009). The test was carried out as for the 
Marquis test, sequentially adding a drop of each of the solutions 1 - 3. 
 
8.2.4.2.2 Qualitative and quantitative analysis of street samples 
8.2.4.2.2.1 Standard solutions 
Individual drug standard and mixed drug standard solutions were prepared as outlined in 
Development of the method (Chapter 4, section 4.2.4.3) using 2-methyl-propan-2ol as a 
solvent. 
 
8.2.4.2.2.2 Sample preparation  
The sample was crushed to a fine powder and homogenised using the “cone and quarter” 
method. A sample of the powder (30.0mg) was dissolved in 7.0 mL 2-methyl-propan-2-ol 
in a volumetric flask; the sample was placed in an ultrasonic bath for 30 minutes and then 
diluted to volume. After thorough mixing the solution was centrifuged at 3000 rpm for 3 
minutes to remove the solid material. A sample of the supernatant (1mL) was diluted 
tenfold and analysed by GC-MS. The samples were prepared in triplicate. 
 
8.2.5 METHODS: SYNTHESIS 
 
The substances 4-FPP and 3-TFMP were synthesised individually using methods identified 
in literature as possible routes of synthesis in clandestine laboratories (Liu and Robichaud, 
2005, Kiritsy et al., 1978). 
 
8.2.5.1 Synthesis Route 1: Synthesis of 4-FPP and 3-TFMPP 
4-FPP and 3-TFMPP were synthesized from fluoroanilines (Chapter 1, Figures 1.17a and 
1.17b) according to previously published procedures (Liu and Robichaud, 2005). 4-
Fluoroaniline 0.3334g (3.0 mmol), bis(2-chloroethyl)amine hydrochloride 0.5355g (3.0 
mmol), and diethylene glycol monomethyl ether (0.75mL) were weighed into a reaction 
vessel and mixed under dry N2(g). The mixture was heated at 150oC for 7.5 hours, (6 - 12 
hours recommended) and then cooled to room temperature. Methanol (0.4mL) was added 
to dissolve substance and followed by addition of diethyl ether (Et2O) (150.0mL). The 
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precipitate was filtered and washed with the ether to provide hydrochloride salt. Sodium 
carbonate solution (10%) was added until alkaline to litmus paper, so as to convert the salt 
to the free amine. This was extracted with ethyl acetate (10.0mL) twice. The organic layers 
were collected dried over anhydrous sodium sulphate (2.00g). This was followed by 
filtration using Whatman ashless 542 filter paper. The filtrate was concentrated in using 
rotary evaporator.  
 
The same procedure was used for the synthesis of 3-TFMPP except 3-
trifluoromethylaniline was used instead of 4-fluoroaniline. To ascertain the impact of the 
length of reaction time on product yield, the drugs were synthesised under varying reaction 
times; 6, 8, 12hours. The method stated 6 - 12 hours (Liu and Robichaud, 2005) 
 
8.2.5.2 Synthesis Route 2 (Kiritsy et al., 1978) Method A: Synthesis of 3-TFMPP 
3-bromo-l-(trifluoromethy1)benzene 22.50g (0.10 mol) and 43.1g (0.50 mol) of anhydrous 
piperazine were weighed to a reaction vessel. The mixture was refluxed at 100 oC for 45 
hours. The hot melt was poured into a 250.0mL of 10% NaOH solution to give 18.70g 
(0.08 mol). The product was extracted with petroleum ether and the solvent was removed 
with a rotary evaporator.  
 
8.2.5.3 Synthesis Route 2 (Kiritsy et al., 1978) Method B: Synthesis of 4-FPP 
39.60g (0.22 mol) bis(2-chloroethy1)amine hydrochloride, 47.00g (0.44 mol) of Na2CO3, 
and 30.00g (0.22 mol) of 4-fluoroaniline were weighed into a reaction vessel. To this 
ethanol (150.00 mL) was added. The mixture was refluxed at 100oC for 46 hours. The 
solvent was concentrated and the residue re-dissolved in water. The aqueous solution was 
extracted with benzene. The extracts were dried over MgS04 and the solvent was removed 
under reduced pressure using a rotary evaporator. 
 
8.2.5.4 Identification of synthesised samples by UV-Vis analysis  
Reference standard solutions were individually prepared for each FPP drug isomer (2-FPP, 
3-FPP and 4-FPP). The standard was weighed (10.0mg) and dissolved in methanol and in 
2-methylpropan-2-ol (10.0mL). The solution was shaken to dissolve and diluted to a 
concentration of 0.02mg/mL. A solution of the synthesised FPP sample was similarly 
prepared. The UV-Vis spectra of the solutions were determined with the solvent as a blank. 
The scan range was set to 200 - 800nm wavelength. 
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The test was similarly conducted for the synthesised TFMPP samples using standards of 
TFMPP isomers as the reference solutions. 
 
8.2.5.5 Identification of synthesised samples by FTIR-Attenuated Total Reflectance 
(ATR) 
The synthesised FPP sample was sampled using the ATR technique and its FTIR spectrum 
determined. The scan range was set at 650 - 4000cm-1 wave numbers.  For each sample 5 
scans were taken at a resolution of 4 cm-1. The spectra of the standards (2-FPP, 3-FPP and 
4-FPP) were similarly determined. The sample and standards spectra were comparatively 
analysed.  
 
The test was similarly conducted for the synthesised TFMPP samples 
 
8.2.5.6 Identification of synthesised samples by GC-MS analysis  
The samples were prepared according to the procedure outlined in Chapter 4 (section 
4.2.4.3) for individual drug standard solutions and mixed drug standard solution1 using 2-
methyl-propan-2-ol as a solvent. The following set of samples were prepared a) 2-FPP, 3-
FPP, 4-FPP reference standards and the synthesised FPP and b) 2-TFMPP, 3-TFMPP, 4-
TFMPP reference standards and the synthesised TFMPP. All the samples were analysed by 
GC-MS. 
 
8.2.5.7 Analysis of precursors from synthesis 
8.2.5.7.1 Identification of precursors 
Solutions of the precursors, 4-fluoroaniline, 3-trifluoromethyl aniline, 2-
Bischloroethylamine hydrochloride, diethylene glycol monomethyl ether and piperazine 
were individually prepared. The solutions were prepared as per the procedure outlined in 
Chapter 4 (section 4.2.4.3) for individual drug standard solutions and mixed drug standard 
solution1 using 2-methyl-propan-2-ol as a solvent and the precursor as the analyte.  
 
8.2.5.7.2 Test for precursor reactivity- stability of precursors  
Stability testing of the precursors to the synthesis (routes 1 and 2) was done as per the 
method outlined in Chapter 5 (section 5.2.7) on GC-MS auto-sampler stability. The 
following were prepared a) individual solutions of each precursor and b) mixed 
combinations of precursors as tabulated below in Table 8.1.  
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Table 8.1 Precursor combinations for stability/reactivity testing. 
Combinations (synthesis route 1 precursors) 
 4-FPP precursors  3-TFMPP precursors 
2-bischloroethylamine   
4-fluoroaniline 
2-bischloroethylamine   
3-trifluoromethyl aniline 
diethyl glycol monomethyl ether  
4-fluoroaniline 
diethylene glycol monomethyl ether   
3-trifluoromethyl aniline 
2-bischloroethylamine   
diethyl glycol monomethyl ether  
4-fluoroaniline 
2-bischloroethylamine  
diethyl glycol monomethyl ether  
3-trifluoromethyl aniline  
diethyl glycol monomethyl ether and 2-bischloroethylamine 
 
8.2.6 DATA ANALYSIS METHODS  
 
8.2.6.1 Qualitative analysis and identification of street samples 
Identification of illicit drugs in the street samples was achieved by comparison to the drug 
reference standards using the confirmation of identity parameters established during 
validation (Chapter 7, section 7.3.5). 
 
In addition, the street samples were checked for impurities. The total ion chromatograms 
were checked for the presence of precursors, isomers of FPP and TFMPP and any other 
artefacts. Identification of sample components was achieved by comparison to reference 
standards. Where these were unavailable the NIST library software was applied.  
 
8.2.6.2 Quantitative analysis of street samples 
Quantification of the identified analytes was determined according to section 3.35 
equations 3.35 - 3.40 (Chapter 3).  
 
8.2.6.3 Synthesis 
Identification of the synthesised sample was by comparison of the FPP isomers to the 
synthesised FPP sample and comparison to TFMPP isomers for the synthesised TFMPP 
sample. In addition, the synthesised sample was checked for impurities. The total ion 
chromatograms were checked for the presence of precursors, isomer and by-products. 
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Identification of sample components was achieved by comparison to reference standards. 
Where these were unavailable the NIST library was applied.  
 
To statistically confirm the identity of the synthesised samples comparative analysis by 
Pearson’s correlation (Chapter 3 section 3.2.4) was conducted between the isomers and the 
synthesised samples. The test was applied on the UV-Vis and FTIR results. The statistical 
data was analysed to determine the isomer that showed the strongest correlation to the 
synthesised sample.  
 
8.2.6.3.1  Determination of yield for the synthesis 
The yield was calculated according to equation 3.41 (Chapter 3). Comparison was made to 
the expected yields. According to the authors the expected yield for route 1 was 67% 3-
TFMPP and 87% 4-FPP (Liu and Robuchaud; 2005). The expected yield for route 2 was 
81.2% 3-TFMPP and 30% 4-FPP (Kiritsy et al.; 1978). 
 
8.2.6.4 Precursor reactivity- stability of precursors 
The total ion chromatograms both for the individual precursor and for the combinations 
were checked for the presence of secondary peaks (artefacts). 
 
8.2.6.5 Comparison of street samples and synthesised samples 
The total ion chromatograms of the street samples and the synthesised samples were 
compared for any similarity in the peaks observed. Furthermore, they were checked for the 
presence of synthesis precursors so as to identify the route of synthesis used in manufacture 
of the street sample and also similarities in other impurities observed. 
 
8.3 RESULTS AND DISCUSSION 
 
8.3.1 STREET SAMPLES 
 
8.3.1.1 Physical characteristics 
The physical characteristics of the street samples investigated are shown in Table 8.2. The 
11 street samples received for investigation were all tablets. These showed a variety of 
physical traits. As shown in Table 8.1 this was mainly in the colour and logos inscribed on 
the Tablets. The sizes of the tablets were in the range 7.5mm diameter x 3.0mm width to 
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10.0mm diameter x 2.5mm width with 8mm diameter x 4mm width being the most 
common (36% of the samples). The tablet mass ranged from 229.9 – 354.5mg with a mean 
mass of 286 ± 31.9mg. The relative standard deviations showed that for each of the samples 
the tablets were reasonably consistent in mass (RSD 2.02 – 15.3%). It was established in 
Chapter 2 (section 2.8.1) that physical characteristics such as the shape, logo, colour, 
dimensions or any other markings can provide links between different samples of tablets 
(Milliet et al., 2009; Cheng et al., 2003; Makino et al., 2003).  In studies on profiling of 
MDMA, Makino et al, (2003) and Zingg (2005) investigated the physical characteristic of 
tablets and similarly concluded that physical characteristics can be characteristic of 
manufacturers for example logos. In addition, defects on the tablets can be characteristic of 
the metal dies used during manufacture. Consequently, the samples were inspected for any 
common similarities in physical traits.  
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Table 8.2 Physical characteristics of the street samples analysed tablets (Tablets courtesy of Cambridgeshire Constabulary).  
Name Tablet (mg) Size (mm)  
diameter x thickness 
Description  Image 
A1 333.2 
 
N= 3, RSD = 5.4% 
8.0mm x 5.5mm Round, cream coloured tablets with a clown face 
inscribed on one side. 
 
A2 303.3 
 
N = 3, RSD = 4.7% 
7.5mm x 4.0mm Round, pale blue cream coloured tablets. With a single 
score line on one side and a smiley face inscribed on 
the other side. 
 
A3 309.7 
 
N = 3, RSD = 9.8% 
8.5mm x 4.0mm Round, green coloured tablets with the Mercedes car 
logo inscribed on one side.  
 
A4 306.5 
 
N = 2, RSD = 12.8%,  
8.5mm x 3.0mm Round, off-white coloured tablets with slight blue and 
brown flecks. A bull’s head was inscribed on one side.  
 
A5 223.9 
 
N = 3, RSD = 4.1%, 
8.5mm x 4.0mm Round beige coloured tablets with an in-twined 3D 
design on one side. 
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A6 298.3 
 
N = 1, RSD = N/A 
8.0mm x 3.0mm Round, pink coloured tablets with a single score line 
on one side. The tablets were slightly discoloured. 
 
A7 265.5  
 
N = 3, RSD = 2.1% 
8.0mm x 4.0mm Round, yellow coloured tablets with a single score line 
and copyright sign on one side. A star was inscribed on 
the other side. 
 
A8 203.5  
 
N = 3, RSD = 12.1% 
7.5mm x 3.0mm Flat, round, pale yellow coloured tablets. A kangaroo 
was inscribed on one side. The texture was not smooth 
and the colour intensity inconsistent. 
 
A9 229.9 
 
N = 1, RSD = N/A 
8.0mm x 4.0mm Round, pink coloured tablets.  The colour intensity 
was inconsistent. A dolphin was inscribed on one side. 
 
A10 354.5 
 
N = 2, RSD = 15.3% 
8.5mm x 4.5mm Round, pink coloured tablets with a single score line 
one side and a fairy inscribed on the other side. 
 
A11 290.8 
 
N = 3, RSD = 2.1% 
10.0mm x 2.5mm Round, bevel edged, speckled, orange coloured tablets 
with a star inscribed on one side. 
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The samples were found to have similarity in size, but no similarity in colour and logos. In 
addition defects were observed on samples A2, A3, A9 and A10. These tablets were 
chipped. The patterns of the damage on the tablets were not similar. It is therefore 
suggested that the damage arose out of poor tablet quality and not die defects. This view 
was taken as a result of observing that the tablets were of poor quality, i.e., samples A9 and 
A8 were observed to be easily friable with A8 also having a rough texture. This implies 
poor methods of manufacture and skill. It is likely not enough binders were used. This also 
confirms that tablets were made in a non-professional laboratory such as a clandestine 
manufacture and hence are a potential health risk. 
 
8.3.1.2 Chemical characteristics 
 
8.3.1.2.1 Presumptive tests 
The results of presumptive testing with Marquis and Simon’s reagent are shown in Table 
8.3 and 8.4 for the drug standards and street samples respectively.  
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Table 8.3 Presumptive tests results of the drug standards. 
Substance Marquis reagent Simon’s reagent 
2-FPP No change, turned pale yellow with time Pale violet 
3-FPP No change, turned pale yellow with time Brown  
4-FPP No change, turned pale yellow with time Pale violet 
2-TFMPP No change Pale blue-green 
3-TFMPP No change Pale pink 
4-TFMPP No change No change 
BZP No change Blue  
DBZP No change No change 
MBZP  Pink  Violet  
3-CPP No change No change 
4-MePP No change, turned pale yellow-green 
with time 
Violet  
MDMA.HCl Black Dark blue 
(+)Amphetamine SO4 Orange  No change 
(+)Methamphetamine HCl Orange  Dark blue 
Caffeine No change No change 
Cocaine HCl No change Pale pink 
Diazepam Pale yellow  No change 
Dapoxetine HCl Black  No change 
Dextromethorphan HBr Black  Pale pink 
Nicotinamide No change brown 
Control  No change No change 
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Table 8.4 Presumptive tests results of the street samples. 
Sample Marquis reagent Simon’s reagent 
A1 No change No change 
A2 No change Pale pink 
A3 Black  Dark blue 
A4 Black  Dark blue 
A5 No change Slightly Pale violet 
A6 No change No change 
A7 Black  Dark blue 
A8 No change No change 
A9 Black  Dark blue 
A10 No change Pale pink 
A11 Black  Dark blue 
Control No change No change 
 
The results for presumptive tests (Table 8.3) on the reference standards were similar to 
those prescribed in UNODC guides for National Drug Testing Laboratories (UNODC, 
2006; 2013c; Kovar and Laudsazun, 1989; Cole, 2003). This can be seen for amphetamine, 
methamphetamine, MDMA, dapoxetine and dextromethorphan giving a positive result to 
the Marquis reagent. This is due to the reaction of aromatic compounds with the Marquis 
reagent. The mechanism was shown in the theoretical concepts (Chapter 2, Figure 2.16). 
The formation of the carbenium ion (VII) is responsible for the colour observed with 
aromatic compounds. The reaction and final colour also depend on the substituents present. 
It is suggested that the reason piperazines do not react with the Marquis reagent is due to 
the fact that the substituent, R in the reaction in Figure 2.16 is a piperazine ring. This has 
electron donating properties which reduces the charge on the first carbenium ion (IV) 
thereby decreasing the reaction from occuring. According to the UNODC, (2013a) and 
Inoue et al., (2004) piperazines do not give a positive reaction to Marquis reagent. This can 
be seen for the benzyl and phenyl piperazine based drugs, BZP, FPP, and TFMPP which 
showed no reaction (Table 8.4).  
 
The response to the Simon’s reagent was also in line with that observed by other 
researchers. Simon’s reagents tests for secondary amine, consequently as can be seen in 
Table 8.4 the compounds which are secondary amines such as methamphetamine, MDMA, 
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BZP,  FPP, TFMPP produced a colour change with Simon’s reagent. The blue colour is due 
to the formation of the ion (VII) shown in the reaction in Figure 2.17 (Chapter 2). However, 
most of the piperazines showed poor sensitivity. The piperazines which contain a secondary 
nitrogen atom (all except DBZP) are heterocyclic amines. Hence, the lone pair of electrons 
on the nitrogen is delocalised in the ring making them less available for bonding and as 
such this reduces reactivity. This is probably the reason they produce no reaction or a faint 
colour change. Comparatively, the aliphatic secondary amines (amphetamines) show better 
reactivity and produce the standard dark blue colour. 
 
Inoue et al. (2004) conducted presumptive tests on a number of piperazine drugs and 
obtained similar results with the piperazines giving less sensitivity to Simon’s reagent. 
Similarly UNODC (2013c) investigated BZP, 4MePP, 3CPP, (2, 3, 4) FPP and TFMPP, 
methamphetamine and MDMA and obtained similar results with both reagents. 
 
Street samples A3, A4, A5, A7, A9 and A11 (Table 8.4) showed a positive reaction to both 
the Marquis reagent and Simon’s reagent. This clearly suggests the presence of an 
amphetamine derivative which is also a secondary amine. This was potentially MDMA 
since it is one of the most commonly found drugs of abuse on the street (Yeap et al., 2010; 
Davies et al., 2010). The other street samples (A1, A2, A5, A6, A8 and A10) showed no 
reaction to the Marquis reagent. Also, the observed absence of the standard blue colour to 
Simon’s reagent suggested the absence of amphetamines. It was discussed (section 2.8.2) 
that according to the UNODC (2013c) piperazines were less sensitive than secondary 
amines, as such these samples may contain piperazines. On comparison to the standards 
(Table 8.3) these samples showed similar reactions to piperazines, e.g. the piperazines 
generally gave no reaction with both the Marquis and Simon’s reagent except for 3-TFMPP 
which gave a pale pink colour with Simon’s reagent. This was also observed for the 
samples A2 and A10 further suggesting the samples to contain piperazine substances.  
 
8.3.1.2.2 Qualitative and quantitative analysis of street samples  
The total ion chromatograms (TICs) arising from analysis of the street samples are shown 
below in Figures 8.1 - 8.11. A typical mixed standard TIC used for comparison and 
identification of the samples components is given in Figure 8.12. 
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Figure 8.1 Total ion chromatogram of street sample A1.  
 
 
Figure 8.2 Total ion chromatogram of street sample A2. 
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Figure 8.3 Total ion chromatogram of street sample A3. 
 
 
Figure 8.4 Total ion chromatogram of street sample A4. 
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Figure 8.5 Total ion chromatogram of street sample A5. 
 
 
Figure 8.6 Total ion chromatogram of street sample A6. 
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Figure 8.7 Total ion chromatogram of street sample A7. 
 
 
Figure 8.8 Total ion chromatogram of street sample A8. 
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Figure 8.9 Total ion chromatogram of street sample A9. 
 
 
Figure 8.10 Total ion chromatogram of street sample A10 
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Figure 8.11 Total ion chromatogram of street sample A11. 
 
 
Figure 8.12 Total ion chromatogram of the standards. 
 
The total ion chromatograms (Figures 8.1 - 8.11) show that one or more substances exist in 
the street samples. Identification of these substances was done on the basis of retention time 
(RT), relative retention time (RRT), retention index (RI) and mass spectra comparative to 
the reference standards (Figure 8.12).  The data is shown in Table 8.5 below and the mass 
spectra in Appendix 12. In addition, the components were quantified and the data is also 
given in Table 8.5. 
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Table 8.5 Chemical characteristics of the street samples analysed tablets.  
Name Substances observed in sample 
 RT 
(mins) 
RRT Principal ions observed in mass 
spectra (GC-MS, EI, 70eV),  m/z 
Identity Content per 
tablet in mg  
(%mass) 
A1 13.61 
14.22 
20.79 
18.97 
20.46 
0.705 
0.737 
1.077 
0.983 
1.060 
91(100), 134, 56, 65, 176(M+) 
188(100), 230(M+), 56, 145, 172 
91(100), 120, 65, 135, 106, 266(M+) 
BZP 
3-TFMPP 
DBZP 
Impurity A 
Impurity B 
56 (17%) 
106 (32%) 
8 (2%) 
 
A2 11.81 
14.21 
18.14 
18.96 
20.46 
0.612 
0.218 
0.940 
0.983 
1.061 
58(100), 77, 105, 117, 146, 165(M+)                
188(100), 230(M+), 56, 145, 172 
194(M+, 100),  109, 55, 67, 82 
Ephedrine 
3-TFMPP 
Caffeine 
Impurity A 
Impurity B 
55 (18%) 
70 (23%) 
92 (30%) 
A3 14.28 
18.13 
0.741 
0.940 
58(100), 135, 77, 51, 55, 193(M+) 
194(M+, 100),  109, 55, 67, 82 
MDMA 
Caffeine 
50 (16%) 
0.3 (0.1%) 
A4 14.26 0.739 58(100), 135, 77, 51, 55, 193(M+) MDMA 55(18%) 
A5 13.55 
14.28 
20.75 
18.11 
18.93 
20.42 
14.87 
0.704 
0.741 
1.077 
0.940 
0.983 
1.060 
0.772 
91(100), 134, 56, 65, 176(M+) 
188(100), 230(M+), 56, 145, 172 
91(100), 120, 65, 135, (266, M+) 
194(M+, 100),  109, 55, 67, 82 
BZP 
3-TFMPP 
DBZP 
Caffeine 
Impurity A 
Impurity B 
Impurity C 
17 (8%) 
21 (9%) 
1 (0.5% 
Trace 
A6 18.96 
20.45 
12.92 
15.54 
15.93 
0.983 
1.060 
0.670 
0.806 
0.826 
No psychoactive substance was 
detected. 
Impurity A 
Impurity B 
Impurity D 
Impurity E 
Impurity F 
 
A7 14.26 0.739 58(100), 135, 77, 51, 55, 193(M+) MDMA 100 (38%) 
A8 No analytes were detected. 
A9 14.26 0.739 58(100), 135, 77, 51, 55, 193(M+) 
194(M+, 100),  109, 55, 67, 82 
MDMA 
Caffeine 
50 (22%) 
0.1 (0.04%) 
A10 11.81 
14.21 
0.612 
0.737 
58(100), 77, 105, 117, 146, 165(M+)                
188(100), 230(M+), 56, 145, 172 
Ephedrine 
3-TFMPP 
6 (2%) 
36 (10%) 
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18.14 
5.65 
0.940 
0.293 
194(M+, 100),  109, 55, 67, 82 Caffeine 
Impurity A 
101 (28%) 
A11 14.26 0.739 58(100), 135, 77, 51, 55, 193(M+) MDMA 69 (24%) 
 
Table 8.6 Qualitative GC-MS data for the standards for confirmation of unknown identities. 
Compound Retention time/mins Relative retention 
time 
Retention 
index 
Methamphetamine           9.08 0.471 1198.31 
Nicotinamide 11.92 0.618 1390.61 
2-TFMPP 12.37 0.641 1421.01 
2-FPP 13.18 0.683 1475.74 
BZP 13.57 0.703 1502.09 
4-FPP 13.93 0.722 1526.42 
3-TFMPP 14.20 0.736 1544.66 
MDMA         14.26 0.739 1548.72 
3-FPP 14.44 0.749 1560.88 
4-TFMPP 15.18 0.787 1610.88 
MBZP 15.30 0.793 1618.99 
4-MePP      15.55 0.806 1635.88 
3-CPP 17.13 0.888 1742.64 
Caffeine 18.15 0.941 1865.00 
Dextromethorphan 20.75 1.076 2190.00 
DBZP 20.78 1.077 2193.75 
Cocaine 21.17 1.097 2242.50 
Diazepam 22.94 1.189 2463.75 
Dapoxetine 23.32 1.209 2511.25 
Eicosane ( IS) 19.29 1.000 2007.50 
 
The retention times, relative retention times and retention indices of the substances found in 
the street samples identified the peak at 13.61 minutes as BZP, 14.22 minutes as TFMPP, 
20.79 minutes as DBZP, 11.81 minutes as ephedrine, 18.14 minutes as caffeine and 14.28 
minutes as MDMA (Figures 8.1 -  8.10 and 8.10). This was due to the analytes having 
similar characteristics to those of the reference standards for these drugs (Table 8.6 
comparative to Table 8.5). This was further confirmed by the similarity in the mass spectra 
(Table 8.5 and Appendix 12). For example, for sample A it is evident that the peak at 
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13.61minutes with a relative retention time of 0.705 and principal mass spectral ions at mz/ 
91(100), 176(M+), 134, 56 and 65 corresponds to the BZP reference standard (Table 8.6 
and Appendix 12). The standard has similar retention and mass spectra data.  
 
However, for the (2, 3, 4) TFMPP isomers the mass spectra was similar and could not be 
distinguished. This was a limiting factor in specifically identifying the peak at 14.22 
minutes using mass spectra. This challenge was also observed in other studies involving 
positional isomers (Takahashi et al., 2009, Inoue et al., 2004; Elliot and Smith 2008). In 
this study the isomers showed complete peak separation (Figure 8.12), hence this limitation 
was overcome by investigating the retention times, relative retention times and retention 
indices of the unknown substances comparative to the drug standards (Tables 8.5 and 8.6). 
Consequently, the composition of the samples was confirmed as containing a combination 
of the following a) BZP, 3-TFMPP, DBZP for samples A1 and A5 in addition sample A5 
contained trace amounts of caffeine. This could be due to contamination during 
manufacture since the amount was very low (trace level) compared to the caffeine content 
in other samples b) a combination of ephedrine, 3-TFMPP and caffeine for samples A2 and 
A10, c) MDMA for samples A3, A4, A7, A9 and A11 and d) no psychoactive substances 
for samples A6 and A8. In addition impurities were observed in most of the drugs with the 
exception of MDMA samples which had no impurities (samples A8, A9 and A11). The 
results obtained are in-line with the presumptive tests above and as such this confirms 
presumptive tests are an important aid in drug identification.  The concentration was 
observed to be in the range 17 – 56mg BZP, 21 – 106mg 3-TFMPP, 1 – 8mg DBZP, 6 – 
55mg ephedrine, 0.1 – 101mg caffeine and 50 – 100mg MDMA (Table 8.5). The total mass 
contributions ranged from 0% (samples A6 and A8) to 71% (sample A6). The solubility of 
the analytes in the solvent used was confirmed in sections 5.2.4 and 5.3.1. Consequently, 
the concentrations obtained can be attributed to the manufacturers adding low amounts of 
the drugs and or adulterants and making up with other non psychoactive bulking agents 
such as starch. This is most likely to increase profits, e.g. samples A6 and A8 had no 
psychoactive substances at all. 
 
Yeap et al. (2010) in a review on ‘legal highs’ reported the prevalence of BZP and TFMPP 
combination in designer drugs with a variety of dosages such as 75mg BZP and 5mg 
TFMPP in Jet tablets. The authors reported the dosage range for BZP was 50 – 200mg and 
for TFMPP 5 – 25mg. They further stated that the drug seizures were tablets and capsules 
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of various colours and composition containing such drugs as cocaine, dextromethorphan, 
caffeine, steroids, ephedrine and vitamins among others. Caffeine was found to be the most 
common adulterant (9 9%). DEA (2009a) reported doses of BZP 50 - 200mg, CPP 90 - 
110mg. The findings are similar to those obtained in this study in terms of the variety in the 
drugs. In this study it was found that TFMPP is the most common piperazine appearing in 
all the samples not containing MDMA (excluding those without psychoactive drugs), i.e., 4 
out of 11 samples (36.4%) contained 3-TFMPP and 2 contained BZP (18.2%). However, 
the concentration of 3-TFMPP varied with caffeine. When 3-TFMPP was lower (A2, A10) 
it was observed that the caffeine content was higher and furthermore was also mixed with 
ephedrine. 
 
Europol and EMCDDA (2007) reported that twenty six capsules and tablets were analysed 
by a team from St Georges University of London. BZP and TFMPP was also found to be 
the most common piperazine combination with a mean BZP content of 65mg and 22mg for 
3-TFMPP. However the actual range reported varied widely 28 – 138mg BZP and 4 - 72mg 
TFMPP. As can be seen in Table 8.5 both BZP and TFMPP were found to be in 
combination, however these were also mixed with other adulterants. The concentration 
ranges also fall within those generally found by other researchers (de Boer et al, 2001; 
Kelleher et al., 2011, Takahashi et al., 2009). Takahashi et al (2009) investigated 205 
different psychoactive drugs so as to create a library of psychoactive designer drugs. Whilst 
the study was purely qualitative the drugs identified in the study were also found to be 
present in the street samples investigated in this study. It is interesting to note that such 
diversity in drug concentration exists; hence the user is unaware of what they are getting.  
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Table 8.7 Qualitative analysis of impurities in sample. 
Sample Impurity   Substances observed in sample  
  RT 
(mins) 
RRT Principal ions observed in mass spectra (GC-MS, EI, 
70eV),  m/z 
Preliminary identity 
A1 Impurity A 
Impurity B 
18.97 
20.46 
0.983 
1.060 
57(100), 55, 43, 60, 73, 69, 129, 87, 83, 282, 96 
41(100), 60, 73, 43, 69, 57, 71, 129, 83, 97, 171 
N-hexanedecanoic acid 
Octanedecanoic acid 
A2 Impurity A 
Impurity B 
18.96 
20.46 
0.983 
1.061 
41(100), 43, 73, 60, 69, 55, 71, 83,129, 171, 282 
57(100), 55, 43, 41, 73, 60, 69, 83, 87, 96, 129 
N-hexanedecanoic acid 
Octanedecanoic acid 
A5 Impurity A 
Impurity B 
Impurity C 
18.93 
20.42 
14.87 
0.983 
1.060 
0.772 
43(100), 73, 60, 57, 69, 83, 115, 129, 186, 157, 141 
60(100), 55, 43, 69, 129, 97, 79, 209, 115, 191, 283 
120(100), 44, 65, 92, 165, 137, 96, 106, 84, 84, 141 
N-hexanedecanoic acid 
Octanedecanoic acid 
Ethyl P-acetamoobenzoate or benzocaine 
A6 Impurity A 
Impurity B 
Impurity D 
Impurity E 
Impurity F 
Impurity G 
Impurity H 
18.96 
20.45 
13.10 
15.54 
15.93 
18.28 
12.96 
0.983 
1.060 
0.679 
0.806 
0.826 
0.947 
0.672 
43(100), 41, 73, 55, 60, 57, 69, 71, 83, 129,61 
43(100), 55, 57, 41, 60, 73, 69, 97, 129, 83,185 
129(100), 77, 117, 56, 45, 132, 61, 156, 103, 65, 87 
117(100), 75, 44, 133, 56,  50, 159, 89, 234, 98, 149 
75(100), 129, 117, 133, 203, 103, 143, 175, 149, 159, 185 
73(100), 74, 43, 103, 61, 55, 85, 133, 117 
44(100), 103, 86, 73, 61, 57, 117, 133, 146 
N-hexanedecanoic acid 
Octanedecanoic acid 
 
 
 
Sorbitol  
1,4-anhydro-glucitol  
A10 Impurity A 5.65 0.293 105(100), 77, 50, 41, 56, 78, 191, 59, 67, 88, 145, 171  
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The analysis shows the presence of some impurities In the total ion chromatograms 
(Figures) showed, the peak sizes for the impurities varied from trace to visually visible 
peaks and is an indication of the amount of the impurity present. In all the samples were 
impurities were observed (A1, A2, A5, A6, A10) impurities at retention times 18.96 
minutes; relative retention time (RRT) at 0.983) and 20.46 minutes (relative retention times 
(1.061) were the most abundant giving small prominent peaks in the total ion 
chromatograms (Figures 8.1, 8.2, 8.5 and 8.6) above. The other impurities were at trace 
level. The mass spectra of the impurities is given in Appendix 12 (Figures 3, 4, 8, 9 and 11 
- 19) and also for the other observed substances. A typical representation of the mass 
spectra is shown below for the common impurities (Impurities A and B).  
 
Figure 8.13 Mass spectrum of sample A1 peak at 18.97mins (RRT = 0.983) identified as N-
hexanedecanoic acid (impurity A). 
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Figure 8.14 Mass spectrum of sample A5 peak at 18.93mins (RRT = 0.983) identified as N-
hexanedecanoic acid (impurity A). 
 
Figure 8.15 Mass spectrum of sample A1 peak at 20.46mins (RRT = 1.060) identified as 
octanedecanoic acid (impurity B). 
 
The impurities were preliminary identified using the NIST spectral library. The most 
common impurities were identified as N-hexanedecanoic acid (impurity A) and 
octanedecanoic acid (impurity B). These are palmitic acid and stearic acid respectively; 
common fatty acids which are routinely used as lubricants in manufacture of 
pharmaceuticals such as tablets (King, 2009; Simth and Webb, 2007). These have also been 
identified in investigation of street drugs (Kelleher et al., 2011). In addition sorbitol and 
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1,4-anhydro-glucitol (sample A6 impurity G and H) were present in the sample with no 
psychoactive substances (sample A6). These are sugars also commonly found in tablets, 
capsules and other pharmaceutical preparations where they act as sweeteners (Smith and 
Webb, 2007). Consequently, it is suggested that the samples with no psychoactive 
substances are likely for the purpose of misleading the user into thinking they contain the 
real drugs. Baron et al. (2011), Davies et al. (2010) and Kelleher et al. (2011) had similar 
findings in their studies in addition they also reported the presence of tablets with no 
pyschoactive substances.  
 
Some of the impurities observed in the different samples show similar chemical properties 
in terms of retention times, hexanedecanoic acid and octanedecanoic acid (impurities A and 
B) in samples A1, A2, A5 and A6 as shown by their similar retention times  (Table 8.7). It 
is therefore possible that samples A1, A2, A5 and A6 similar reagents were used in the 
manufacture of these samples or they were potentially manufactured from the same source. 
This is also confirmed by the similarity in the composition of drugs highlighted in the 
discussion of Table 8.5 above. A1 was identified as having similar composition to A5 and 
A2 to A10, however the dosages were different. The MDMA samples were observed not to 
have any impurities. However, similarities in dosage were observed between samples A3 
and A9. Both samples contained the adulterant caffeine. In addition, it was identified above 
that the tablet quality was poor for these samples. Potentially, they could also be from the 
same source.  
 
8.3.2 SYNTHESIS 
 
8.3.2.1 Synthesis Route 1 and 2 product description and yields 
The synthesised 4-FPP was a dark brown viscous liquid. The synthesised 3-TFMPP was 
observed to be a dark brown liquid. The amounts of reagents used and the yields generated 
on synthesis are shown in the tables below. For the synthesis conducted by route 1 (Liu and 
Robichaud, 2005) the results are in Tables 8.8 and 8.9 and for route 2 (Kiritsy et al., 1978) 
Table 8.10. Also given in tables is the variation of yield with reaction time. 
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Table 8.8 4-FPP synthesis yields: Route 1. 
Reference Amount/Run 
Synthesis 4-FPP 1 (trial) 2 3 4 5 6 
4-fluoroaniline (g) 0.6737 0.3340 0.3334 0.6105 0.6658 0.6702 
Bis(2-chloroethyl)amine HCl (g) 1.072 0.5355 0.5355 0.4906 0.5347 1.0761 
Product amount (g) 0.7431 0.3495 0.3479 0.8100 0.8770 0.8950 
Expected stoichiometric amount(g) 1.0823 0.5407 0.5407 1.0814 1.0814 1.0865 
Product yield (%) 68.66 64.64 64.34 74.90 81.10 82.37 
Reaction time (hours) 7.5 7.0 7.5 8.0 10.0 12.0 
 
Table 8.9 3-TFMPP synthesis yields: Route 1. 
Reference  Amount/ Run  
Synthesis 3-TFMPP 1(trial) 2 3 4 5 
3-Trifluoromethylaniline (g) 0.4834 0.9670 0.4836 0.9675 0.9677 
Bis(2-chloroethyl)amine hydrochloride (g) 0.5357 1.0720 0.5358 1.0740 1.0730 
Product amount (g) - [1] 0.7538 0.4018 0.8785 0.8569 
Expected stoichiometric amount (g) 0.6907 1.3817 0.6910 1.3824 1.3826 
Product yield (%) N/A 54.56 58.15 63.55 61.98 
Reaction time (hours) 7.0 7.5 8.0 10.0 12.0 
[1]
 Trial sample not determined due to leakage of during extraction. 
 
The yields generated using route 2 synthesis (Kiritsy et al., 1978) results are shown in 
Table 8.10 below.  
 
Table 8.10 3-TFMPP synthesis yields: Route 2. 
Reference Amount/ Run 
Synthesis 3-TFMPP 1 2 
Anhydrous piperazine/g 4.3535 4.3535 
3-bromo-l-(trifluoromethy1)benzene/g 2.2727 2.7400 
Product amount (g) 1.4272 1.4568 
Expected stoichiometric amount (g) 1.8511 1.8511 
Product yield (%) 77.1% 78.7% 
 
The product yields obtained were comparable but slightly lower than the expected yields 
(Tables 8.8 – 8.10), e.g. 82.37% 4-FPP compared to the expected 87%. In their studies the 
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authors reported yields of 87% 4-FPP and 67% 3-TFMPP (Liu and Robichaud, 2005).  
According to Kiritsy et al. (1978) synthesis by their procedure (route 2) should give 
expected of 30% 4-FPP and 81% 3-TFMPP. For the synthesis of 4-FPP route 1 (Liu and 
Robichaud, 2005) gave relatively high yields, comparatively the results showed a much 
higher disparity to that of synthesis route 2 (Kiritsy et al., 1978), 87 % versus 30%. 
However, for 3-TFMPP the method by Kiritsy et al. (1978 as expected gave higher yields 
for 3-TFMPP, 81 % versus 67% respectively. The disparities could be due to the presence 
of competitive side reactions, consequently reducing the product yield. In the reaction 
(Chapter 1; Figures 1.18a,b) of anilines (I) with bis(2-chloroethylamine) (II), a competitive 
side reaction of the product of the reaction (III) and reactant (II) occurs resulting in low 
yields of the product. This is possible if the reaction is carried out in the presence of a base. 
In synthesis route 1, diethylene glycol monomethyl ether is used so as to minimise the 
competitive side reaction. Consequently, the use of sodium carbonate as part of the 
reactants in Kiritsy et al. (1978), (Chapter 1; Figure 1.16b) is likely to have resulted in low 
yields by driving the side reaction shown in Figure 1.15. Assuming that the side reaction 
occurs, the following products (II and III) could be produced as impurities (Figure 8.16); 
 
NHNR
R'
I
II
I: R = F, R' = H for pFPP
   R = H, R' = CF3 for mTFMPP
III
NN
F3C
N
Cl
Cl
NN N
Cl
Cl
F
NH
Cl Cl
base/Na2CO3
N,N-bis(2-chloroethyl)-4-[3-(trifluoromethyl)phenyl]piperazin-1-amine
N,N-bis(2-chloroethyl)-4-(4-fluorophenyl)piperazin-1-amine
 
Figure 8.16 Reaction for potential impurities arising from Route 1 synthesis (section 1.7). 
 
Both methods were found easy to use with the synthesis route 2, being much simpler as it 
involved fewer steps in the procedure but its reflux period was about 3 times longer (12 
hours versus 45 - 46hours). In addition, synthesis route 1 method for is more amenable to 
the synthesis of a wider range of 1-arylpiperazine, in the study by Liu and Robichaud 
(2005) a total of 11 1-arlypiperazines were synthesised both psychoactive and non-
psychoactive. It can therefore be concluded that both the routes of synthesis are viable and 
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have potential for the synthesis of 4-FPP and 3-TFMPP drug illicitly. Furthermore, they 
have potential for application to other phenylpiperazine drugs of abuse.   
 
The impact of reaction time on yield is shown by the variation in product yield with 
reaction time (Tables 8.8 and 8.9). The yield increased with increase in reaction time. In the 
tables it can be seen that with lower reaction times lower yields are obtained, at 7 hours 
64.6% 4-FPP was obtained comparative to 74.9% at 8 hours and 82.4% at 12 hours. Liu 
and Robichaud (2005) in their study reported the reaction time as 6-12hours and expected 
yields of 87% 4-FPP. Consequently, it is evident that this was achieved at the longest 
reaction time stated (12 hours). 3-TFMPP followed a similar trend (54.56 to 61.98%). As 
such it was concluded advantageous to use the longest reaction time so as to obtain better 
yields. This may impact on the procedure followed by other researchers in future studies. 
 
8.3.2.2 Identification of synthesised samples by UV-Vis analysis 
Results for the confirmation of identity of synthesised samples by UV-Vis are shown in 
Tables 8.11 for the FPP sample and 8.12 for the TFMPP. The UV-Vis spectra are given in 
Figures 8.17 and 8.18. 
 
Table 8.11 UV-Vis analysis of synthetic 4-FPP. 
Name Wavelength, λmax (nm) 
2-FPP standard 241.0           - 
3-FPP standard 250.0           279.9 
4-FPP standard 241.0           290.0 
Synthesised FPP sample 241.0           293.0 
 
Table 8.12 UV-Vis analysis of synthetic 3-TFMPP. 
Name Wavelength, λmax (nm) 
2-TFMPP standard 254.0             - 
3-TFMPP standard 263.0             - 
4-TFMPP standard 254.0             297.0 
Synthesised 4-FPP sample 254.9            298.0 
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Figure 8.17 UV-Vis spectra of the synthesised FPP relative to (2, 3, 4) FPP standards. 
 
 
Figure 8.18 UV-Vis spectra of the synthesised TFMPP relative to (2, 3, 4) TFMPP standards. 
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The synthesised samples had similar UV-Vis spectral profiles to 4-FPP and 3-TFMPP 
standards (Tables 8.11 and 8.12; Figures 8.17 and 8.18). This is evidenced by their similar 
spectra and wavelengths, e.g. the synthesised FPP sample and 4-FPP standard both show 
λmax 241nm and 290nm which are absent in the other isomers. As such the UV-Vis results 
suggest that the synthesised samples are 4-FPP and 3-TFMPP. 
 
8.3.2.3 Identification of synthesised samples by FTIR-ATR analysis 
Results for confirmation of identity of synthesised FPP sample (route 1) by FTIR are 
shown in Tables 8.13, 8.14 and Figure 8.19. The 4-FPP reference spectrum is given in 
Figure 8.20 for comparison. Statistical analysis by Pearson’s correlation was determined on 
the entire spectrum. This gave an indication of the significance of the relationship 
(similarity) between the sample and reference spectra. This was of use in determining the 
identity of the sample relative to the isomers.  
 
Table 8.13 Identification of synthesised 4-FPP by FTIR: correlation of spectrum.  
Compound Correlation coefficient 
Synthesised FPP sample to 2-FPP standard 0.32 
Synthesised FPP sample  to 3-FPP standard 0.14 
Synthesised FPP sample  to 4-FPP standard 0.95 
 
Table 8.14 FTIR peak table for 4-FPP showing characteristic peaks for identification of 
sample. 
Name 
 
 
 
Characteristic peaks 
(wavenumber cm-1)  
(UNODC, 2013c) 
Observed peaks 
(wavenumber cm-1) 
2-FPP standard 764, 1149, 1209, 1252, 1500 [1] 748, 1139, 1207, 1233, 1498 
3-FPP standard Not given 759, 1165, 1177, 1250, 1494 
4-FPP standard 845, 1165, 1228, 1423, 1512 [2] 812, 1161, 1228, 1416, 1505 
Synthesised TFMPP sample 816, 1121, 1224, 1414, 1508 816, 1121, 1224,  -        1508 
[1] 2-FPP.HCl; [2] 4-FPP.2HCl: UNODC data was given for the salt form. 
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 Figure 8.19 FTIR spectra of synthesised FPP comparative to 4-FPP standard. 
  
 
Figure 8.20 Literature reference FTIR spectra for identification of the synthesised 4-FPP 
(NIST, 2014). 
 
 275 
 
Results for confirmation of identity of synthesised TFMPP sample (route 1) by FTIR are 
shown in Tables 8.15, 8.16 and Figure 8.21. The reference spectrum is given in Figure 8.22 
for comparison. The correlation coefficients were determined on the entire spectrum. 
 
Table 8.15 Identification of synthesised 3-TFMPP by FTIR: correlation of spectrum. 
Compound Correlation coefficient 
Synthesised TFMPP sample  to 2-TFMPP standard 0.28 
Synthesised TFMPP sample  to 3-TFMPP standard 0.93 
Synthesised TFMPP sample  to 4-TFMPP standard 0.32 
 
Table 8.16 FTIR peak table for 3-TFMPP showing characteristic peaks for identification of 
sample. 
Name Characteristic peaks 
(wavenumber cm-1)  
(UNODC, 2013c) 
Observed peaks 
(wavenumber cm-1) 
2-TFMPP standard 1036, 1109, 1136, 1315, 1454 1034, 1105, 1131, 1310, 1454 
3-TFMPP standard 1120, 1163, 1319, 1354, 1450 1114, 1160, 1318, 1351, 1448 
4-TFMPP standard 1068, 1109, 1244, 1325, 1614 1069, -         1242, 1321, 1614 
Synthesised TFMPP sample - 1113, 1158, 1318, 1343, 1450 
 
 
Figure 8.21 FTIR spectra of synthesised TFMPP comparative to 3-TFMPP standard. 
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Figure 8.22 Literature reference FTIR spectra for identification of the synthesised 
TFMPP (NIST, 2014).  
 
The FTIR spectra of the isomers of both FPP and 3-TFMPP were sufficiently different to 
allow distinction of 4-FPP and 3-TFMPP from its isomers (Tables 8.13 – 8.16 and Figures 
8.19 - 8.22). The synthesised FPP samples showed the highest correlation to the 4-FPP 
standard with a correlation coefficient, r of 0.95. The correlation to the other isomers was 
significantly lower, r = 0.14 relative to 3-FPP and r =0.32 relative to 2-FPP (Table 8.13).  
For the TFMPP synthesised sample, the correlation was 0.28 relative to 2-TFMPP, 0.32 to 
4-TFMPP and 0.93 to 3-TFMPP (Table 8.15). However, the FTIR spectra of the 2-TFMPP 
and 4-TFMPP isomers were relatively similar as can be seen from their close correlation 
coefficients (Table 8.15). It was discussed in Chapter 2 (section 3.3.4) that the higher the 
correlation coefficient the greater the similarity. A correlation coefficient of 1.0 implies that 
the substances being compared are the same. This was also confirmed by the characteristics 
peaks observed in the sample (Tables 8.14 and 8.16). It can therefore be suggested that the 
synthesised samples are 4-FPP and 3-TFMPP. The results also confirm the study by 
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UNODC (2013c) were it was reported that 4FPP and 3-TFMPP could be distinctly 
identified by FTIR. 
 
8.3.2.4 Identification of synthesised samples by GC-MS analysis 
 
To further confirm the identity of the synthesised samples, analysis by GC-MS was 
conducted. The data is given in Table 8.17 and the masss spectra are given in Figures 8.25 
(FPP sample) and 8.26 (TFMPP sample).  
 
Table 8.17 GC-MS confirmation data for the identification of the synthesised substances.  
Compound Retention 
time/mins 
Relative 
retention time 
Retention 
indices 
2-FPP standard 13.50 0.730 1511.69 
3-FPP standard 14.51 0.785 1591.85 
4-FPP standard 14.13 0.764 1561.69 
Synthesised 4-FPP sample 14.12 0.764 1560.90 
2-TFMPP standard 12.61 0.682 1441.06 
3-TFMPP standard 14.32 0.774 1576.77 
4-TFMPP standard 15.09 0.816 1637.88 
Synthesised 3-TFMPP sample 14.33 0.775 1577.56 
Eicosane  18.49 1.000 2010.53[1] 
[1]Accuracy 99.5% (expected eicosane retention indices = 2000) 
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Figure 8.23 Mass spectra of peak at 14.25mins in the synthesised samples (Figure 8.25). 
 
 
Figure 8.24 Mass spectra of the peaks 14.33mins in the synthesised samples (Figure 
8.26). 
 
Comparison of the synthesised sample mass spectra to those of the standards for FPP and 
TFMPP isomers (section 7.3.5.2 and Appendix 7.5) showed that in the samples ions 
characteristic to FPP and TFMPP (de Boer et al., 2001; Maurer, 2004; Takahashi et al., 
2009) were observed. These were at m/z 138(100), 180(M+), 122 and 56 for the FPP 
sample in Figure 8.23. The characteristic ions observed for the TFMPP sample were at m/z 
188(100), 230(M+), 145 and 56 (Figure 8.24). Consequently, this confirmed the samples as 
containing FPP and TFMPP. However, on the basis of mass spectra alone it could not be 
distinguished which isomer had been synthesised. However, further identification on the 
basis of retention times and retention indices (Table 8.17) identified the synthesised 
substances as 4-FPP and 3-TFMPP.  It is evident from the table that the retention times and 
retention indices of the synthesised samples are similar to the 4-FPP and 3-TFMPP 
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isomers. It can be seen, that for example the same relative retention times were observed 
for the synthesized sample and 4-FPP standard (0.764). In addition, their retention indices 
were similar (1562 and 1561 respectively). Thereby, confirming the samples as 4-FPP and 
3-TFMPP.  
 
Baker and Phillips (1983) in their review of analysis of drugs of abuse identified FTIR and 
UV-Vis spectrometry as techniques which can successfully be applied for identification. 
This is also evidenced by the work of Inoue et al. (2004) in their study on an analysis of 
seized BZP like compounds and Takahashi et al. (2009). The GC-MS results confirmed the 
results by UV-Vis and FTIR. Hence, it was concluded that the routes of synthesis 
investigated synthesised 4-FPP and 3-TFMPP. This is in agreement with the works of Liu 
and Robichaud (2005) and Kiritsy et al. (1978) where these substances were synthesised. 
Consequently, it was concluded that the routes of synthesis are viable and could be of use 
in clandestine synthesis of these substances. 
 
Several impurities were observed in the synthetic samples as is evident in the 
chromatographic profiles of the synthesised samples, Figures 8.25 and 8.26.  
 
 
Figure 8.25 GC-MS Total Ion Chromatogram for identification of synthesised FPP (route 
1) showing the peak identified as 4-FPP and the main impurity peak. 
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Figure 8.26 GC-MS Total Ion Chromatogram for identification of the synthesised TFMPP (route 1) showing the peak identified as 3-
TFMPP and the major impurities (some of the impurities were preliminary identified from NIST mass spectra library). 
.
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Preliminary identification using GC-MS mass spectral search (NIST library) identified the 
impurities (Appendices 13 and 14). These impurities were grouped into precursors, isomers 
of 4-FPP, 3-TFMPP and other by-products; the main impurities were preliminary identified 
by GC-MS as 1-(4-fluorophenyl)-4-piperidone and 3-trifluoromethylbenzoic acid, 3-
methylbutyl ester for 4-FPP and 3-TFMPP samples respectively. Further testing using 
reference standards confirmed the presence of;  
 
a) 3-Trifluoromethylaniline and dimethyl glycol monoethyl ether, precursors to the 
synthesis routes. This is likely to be due to incomplete reaction, since stoichiometric 
amounts of reagents were used. This view was supported by the lack of precursors as 
impurities in the synthesis done with longer reaction time. It can therefore be argued 
that reaction time not only affects yield as was discussed in section 8.3.2.1 but also 
quality of the drug (Lawrence, 2004).  
b) Trace amounts of isomers of 4-FPP and 3-TFMPP. This can be due to resonance effects 
that were discussed and shown in Figure 2.21 (Chapter 2 section 2.8.3).  
c) By-products of synthesis such as 1-(4-fluorophenyl)-4-piperidone (4-FPP synthesis), 
morpholine,4-(2-chloethyl)- and 3-trifluoromethylbenzoic acid,3-methylbutyl ester (3-
TFMPP synthesis). It was noted that the number and amount of impurities varied 
depending on duration of synthesis. Some of the impurities are still to be confirmed and 
therefore this was suggested for future research work. 
 
Precursors used in the synthesis of 4-FPP and 3-TFMPP were also analysed individually 
and in different combinations. The results indicated (Appendix 13) that if present in the 
street sample, precursors can selectively be analysed as they are sufficiently resolved from 
each other and from the target substances, their isomers and the other impurities observed. 
The precursors do not show any secondary peaks when mixed, hence no side reactions 
occurred (Figures 8.25 and 8.26); this could be because the syntheses require an elevated 
temperature. These findings are ideal as it implies that no interference from any residual 
precursors can occur during analysis of samples. 
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8.3.3 COMPARISON OF STREET SAMPLES AND IN-HOUSE SYNTHESISED 4-FPP AND 3-
TFMPP DRUGS 
 
The total ion chromatograms of the street samples (Figures 8.1 - 8.12) were compared to 
that of synthesized sample (Figures 8.26 and 8.27). In addition, the mass spectra of the 
street sample components (Appendix 12) were compared to the mass spectra of the 
synthesis impurities (Appendix 14). It was observed that the main impurities were not 
similar. In the street samples the main impurities were those arising from tableting or 
adulteration (adulterants, binders, sugars). The major impurities that had been observed in 
the synthesized were absent. However, traces of 3-trifluoroaniline were found in some of 
the street samples containing 3-TFMPP when analysed at very high concentration (above 
0.1mg/mL used in the study, at 0.5mg/mL). This was evidenced by the presence of a peak 
with similar retention time to the 3-trifluoroaniline standard (Appendix 12). Furthermore, 
some of the mass spectral ions (m/z 161, 142, 114, 111, 65, 81, 91, 120 and 133) 
characteristic of 3-trifluoromethylaniline were observed in samples A1 and A2. The ions at 
m/z161, 114, 111, 65 and 81 were evident in the mass spectra for sample A1 (Appendix 16 
Figure 4). Due to the very low concentration of the impurity observed (trace) interference 
from the background was evident in the spectrum. This compound is a precursor in route 1 
synthesis. This implies that the 3-TFMPP in the street samples (A1 and A2) was mostly 
likely synthesized by this route.  However, it is suggested that the 3-TFMPP was 
commercially synthesized using this route and not in a clandestine manner since the profile 
of impurities obtained with the in-house synthesized 3-TFMPP sample was not similar to 
the street samples. The street samples contained less of the synthesis impurities. The 
observed impurities were mainly those due to tableting such as binders, sugars and starch. 
 
8.4 CONCLUSION 
 
Street samples were successfully characterised by the method developed, optimised and 
validated in previous studies of this research (Kuleya et al., 2014). The method selectively 
analysed for the different piperazine, their congeners, adulterants and also other impurities 
which were present in the street samples. The 11 street samples investigated were all tablets 
of various colours and logos. The sizes of the tablets ranged from 7.5mm diameter x 3.0mm 
width to 10.0mm diameter x 2.5mm width with a mean mass of 286 ± 31.9mg. 
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On analysis the samples were found to be MDMA (45.5%), piperazines (36.4%) and 
samples containing no psychoactive substance (18.2%). The piperazine samples were found 
to contain more than one psychoactive substances, i.e., BZP, DBZP, 3-TFMPP, caffeine 
and ephedrine. 3-TFMPP was found to be the most common piperazine in street samples. 
Street samples containing MDMA did not contain any other psychoactive substances. 
Caffeine was found to be the most common adulterant, present in 45.5% of the samples. 
Drug concentrations were found to be diverse. The dosages were in the range 17 - 56mg 
BZP, 21 - 106mg 3-TFMPP, 1 - 8mg DBZP, 6 - 55mg ephedrine, 0.1 - 101mg caffeine and 
50 - 100mg MDMA.  Impurities were also found to be present in most of the street samples 
(72.7%) with the tablet binders N-hexanedecanoic acid and octanedecanoic acid being the 
most common. 
 
4-FPP and 3-TFMPP were successfully synthesised. The percentage yields were 64.34% 4-
FPP and 58.15% 3-TFMPP. The identity of the synthesised samples was confirmed by 
several techniques; FTIR and UV-Vis and GC-MS. Several impurities were observed in the 
synthesised drugs with the number of impurities dependent on the extent of the purification 
of the product. The main impurities were preliminary identified as 1-(4-fluorophenyl)-4-
piperidone and 3-trifluoromethylbenzoic acid, 3-methylbutyl ester for 4-FPP and 3-TFMPP 
samples respectively. Both methods of synthesis investigated have the potential to be used 
on the street, single drug manufactures of 3-TFMPP are  likely to use synthesis route 2 for 
its high yield, were as those who manufacture a variety are more likely to use synthesis 
route 1 as it is amenable to a wider spectrum of drugs. This is the more likely situation as 
the drugs are found in combination with other substances. It can be argued that viable 
routes of synthesis exist which can be used be used or adapted for clandestine synthesis 
these substances, giving good product yields. Especially in view of the reported continued 
rise in prevalence of these drugs (UNODC, 2014) and also increasing legislative controls 
(King and Kicman, 2011) might drive suppliers to clandestine synthesis.  
 
Traces of 3-trifluoroaniline were found in some of the street samples when analysed at very 
high concentration (1mg/mL). This compound is a precursor to one of the routes of 
synthesis investigated (route 1). This suggests a link between the route of synthesis 
investigated and the route used in the manufacture of the street sample. As such, this further 
confirms that it is a viable route of synthesis. However, it is proposed that the 3-TFMPP 
was most likely commercially synthesized using this route and not in a clandestine manner 
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since the profile of impurities obtained with the in-house synthesized 3-TFMPP sample was 
not similar to the street samples. The street samples contained less of the synthesis 
impurities. The observed impurities were mainly those due to tableting such as binders and 
cutting agents such as sugars, starch and also common adulterants such as caffeine and 
ephedrine. 
 
It is proposed that even though the methods highlighted in this study were for 4-FPP and 3-
TFMPP these methods can be applied for illicit synthesis of other phenylpiperazine drugs. 
Furthermore, the routes of syntheses identification in this study and the method of analysis 
developed prove will be a useful tool in profiling clandestine drugs found on the market by 
other researchers. 
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CHAPTER 9 
CONCLUSION AND FUTURE RECOMMENDATIONS 
 
9.1 GENERAL CONCLUSIONS 
 
9.1.1 INTRODUCTION 
 
Phenylpiperazines are prevalent as drugs of abuse (UNODC, 2013b). It was discussed in 
Chapter 1 that these drugs exist in combination with other drugs. These were found to be 
other piperazine drugs of abuse and also other psychoactive drugs such as (+) 
methamphetamine and dextromethorphan. In addition adulterants such as caffeine and 
cutting agents are commonly present (Kelleher et al, 2011; UN, 2001). Studies by Baron et 
al. (2011) and Kelleher et al. (2011) highlighted that the labelling on the street compounds 
is often misleading with drugs labelled as herbal highs, vitamin supplements etc. when in 
actual fact they contain a psychoactive drugs such as piperazines. In some cases those 
stated as piperazine street samples are sold as ecstasy. A case in study was a report by DEA 
(2010) where a drug labelled as ecstasy was actually on analysis found to be 4-FPP.  In 
addition, the dosages of the drugs are often not labelled on the street samples. Furthermore, 
these have been found to be variable. LTG (2006) and Kenyon et al. (2010) reported ranges 
of 50 - 200mg for BZP and 5 - 75mg for TFMPP. However, dosages for 4-FPP or any of 
the other drugs have not yet been reported. This study had similar findings; the dosages of 
the street samples analysed were variable. Also, it has been highlighted that impurities 
arising from the synthesis during manufacture of the drug are likely to be present. These 
were identified as precursors and by-products of synthesis and were determined by several 
complexities such as duration of synthesis, skill/technique of the manufacturer. It is 
therefore evident that the purity of most of the illicit drugs on the streets inclusive of 4-FPP 
and 3-TFMPP is unknown. In addition analytical information on piperazines is still limited. 
It was therefore found imperative to investigate and characterise piperazines and generate 
data to potentially overcome these limitations. 
 
It has been established that characterisation of piperazines has not yet been done (Chapter 
1, section 1.8.3). In order to characterise and profile the drugs requires the development of 
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methods of analysis. It was discussed in Chapter 1 (section 1.8) that there are limitation to 
currently existing methods (de Boer et al., 2001; Staack et al., 2003; Inoue et al., 2004; 
LTG, 2006; Vorce et al., 2008; Takahashi et al, 2009; Maher et al., 2009; Kelleher et al., 
2011; UNODC, 2013c). In these studies whilst the methods are useful for qualitative 
analysis and to a limited extent to quantitative analysis it was found that they were limited 
as they had not been applied to actual profiling of street samples. In addition, they did not 
take into account all the congeners identified in this study in street drugs containing 4-FPP 
and 3TFMPP. Furthermore, the presence of positional isomers of FPP and TFMPP posed a 
challenge iterated by the authors.  
 
 Consequently, this research project developed, optimised and validated a GC-MS method 
of analysis. It investigated the stability of drugs during analysis, clandestine routes of 
synthesis and carried out analysis, characterisation and profiling of 4-FPP and 3-TFMPP 
drugs of abuse.  The results of this research provides novel information and, a) address the 
aforementioned gaps in research, b) provide methods for analysis which can be used in 
future investigation of illicit drugs in identification and quantification, c) provide insight 
into the profile of psychoactive phenylpiperazines prevailing on the market- the impurities 
present and their potential route for clandestine synthesis, d) identified precursors and 
chemicals which can potentially be controlled as a means to limit availability of these 
drugs, hence may impact on future analytical, pharmaceutical and forensic studies and 
regulations.  
 
It is also worth noting the socioeconomic impact that drugs of abuse have on communities. 
With increases in the abuse of so called ‘safe drugs’ such as 4-FPP and 3-TFMPP, 
unknown purity and the limited research currently available on their toxicity, these may 
have unknown detrimental health effects. 
 
9.1.2 KEY FINDINGS  
 
9.1.2.1 Investigation of the stability of drugs and use of 2-methylpropan-2-ol as a 
solvent 
Twenty two drugs were investigated for stability in the solvents methanol, dichloromethane 
and 2-methylpropan-2-ol. In addition under different environmental conditions; ambient 
temperature, on the GC-MS auto-sampler during analysis, storage at 4oC in the refrigerator 
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and storage at (-20oC) in the freezer. It was found that whilst on the GC-MS auto-sampler 
the least stability was observed in methanol. In methanol the drugs were stable for a period 
of 14 – 25 hours. In dichloromethane the drugs were stable for a period of 19 – 25 hours 
and in 2-methylpropan-2-ol for 25 hours. Cocaine, BEH and EME showed the lowest 
stability (14 hours in methanol). The formation of artefacts due to a solvent is undesirable, 
especially since in this research where the solvent will also be used in impurity profiling. 
Artefacts were observed with dichloromethane and methanol (mainly benzyl chloride, 
benzychloroformate, ecgonine methyl ester and benzylecgonine hydrate). Consequently the 
2-methylpropan-2-ol was the solvent selected for further use in all the studies. 
 
Storage stability of drug analytes in 2-methylpropan-2-ol in the fridge and refrigerator 
indicated that the drugs were stable for 6 - 10 days in the refrigerator and for 22 - 30 days 
in the freezer.  
 
9.1.2.2 GC-MS method development, optimisation and validation 
 
The operational variables injector and oven temperatures, carrier gas flow rate, MS scan 
rate and MS optimisation energy were investigated so as to improve performance of the 
preliminary method developed. The results confirmed findings by Santali et al, (2011), 
Maher et al., (2009), Andersson et al, (2007a) and Byrska et al., (2010) where it was found 
that variation of similar operational variables resulted in better quality chromatographic 
profiles.  It was observed that optimisation of the preliminary method developed improved 
its performance in terms of the quality of chromatographic peak profiles generated.  The 
method improved to give better peak shapes, high resolution, R > 2 and reduced tailing.  
 
The need for method validation was established in section 2.5 (Chapter 2). On validation 
(Chapter 7) it was established that the method developed is suitable for its intended use, 
i.e., analysis and profiling of piperazine based street drugs. Method accuracy was reported 
on average as 99.8% and precision was RSD < 2%. Detection limits were in the range 0.5 - 
1.95 x 10-3µg/mL free base on column. On average, the common working range was 
equivalent to 5 - 35.0µg/mL free base on column.  This was ideal for the analysis of street 
samples were concentratios are high (mg range) (Kelleher et al., 2011). Furthermore, it can 
also be applied to very low concentration. This could prove useful if the method is 
extrapolated to toxicological studies. In such studies concentrations in the biological 
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samples are usually low (Stack and Maurer, 2005). In addition, it was found that the 
method developed was able to simultaneously analyse for 20 drugs which can be found in 
different combinations with the target analytes 4-FPP and 3-TFMPP in street samples. 
Also, the method was able to completely resolve (baseline resolution) the (2, 3, 4) isomers 
of both FPP and TFMPP thereby being the first method available able to simultaneously 
analyse these isomers and congeners in street samples. Hence, the method developed was 
found to work satisfactorily and will be employed in the characterisation and impurity 
profiling aspect of the research, in profiling of 3TFMPP and 4-FPP.  
 
However, it was observed that there is co-elution between 3-TFMPP/MDMA and also 
DBZP/dapoxetine. Whilst it would be ideal to achieve baseline resolution, it was 
established that there is statistically no significant difference between using total ion 
chromatographic data and extracted ion data. Hence, this limitation was overcome through 
use of extracted ions for these particular drugs.  
 
9.1.2.3 Analysis, characterisation and synthesis of street samples 
9.1.2.3.1 Street samples 
Street samples (11) were successfully analysed and of these 5 were found to contain 1 or 
more piperazines in addition to other substances. 4 were found to contain MDMA as the 
only psychoactive substance and 2 were found to contain no psychoactive substance at all. 
The street samples which contained piperazines were found to contain one or more of BZP, 
3-TFMPP, ephedrine and caffeine. 3-TFMPP was found to the most common piperazine in 
street samples and caffeine as the most common adulterant. The street samples containing 
MDMA did not contain any other psychoactive substances. Drug concentrations were 
found to be diverse. The concentrations were in the range 17 – 56mg BZP, 21 – 106mg 3-
TFMPP, 1 – 8mg DBZP, 6 – 55mg ephedrine, 0.1 – 101mg caffeine and 50 – 100mg 
MDMA.  Impurities were also found to be present in street samples. 
 
9.1.2.3.2 Synthesis 
4-FPP and 3-TFMPP were successfully synthesised. It can therefore be suggested that 
viable routes of synthesis exist for potential clandestine synthesis of these substances. The 
percentage yields were 64.34% 4-FPP and 58.15% 3-TFMPP. The identity of the 
synthesised samples was confirmed by several techniques; FTIR-ATR, UV-Vis and GC-
MS. Several impurities were observed in the synthesised samples. The main impurities 
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were preliminary identified as 1-(4-fluorophenyl)-4-piperidone and 3-
trifluoromethylbenzoic acid, 3-methylbutyl ester for 4-FPP and 3-TFMPP samples 
respectively. The number of impurities depends on how far purification is carried out.  
Both methods of synthesis investigated have the potential to be used on the street, single 
drug manufactures of 3-TFMPP are  likely to use synthesis route 2 for its high yield, where 
as those who manufacture a variety are more likely to use synthesis route 1 as it is 
amenable to a wider spectrum of drugs. This is the more likely situation as the drugs are 
found in combination with other substances. It can be argued that the routes of synthesis in 
literature can be used or adapted for clandestine synthesis, giving good product yields. The 
methods highlighted in this study were for 4-FPP and 3-TFMPP these methods can be 
applied for illicit synthesis of other phenylpiperazine drugs. Furthermore, the identification 
of routes of syntheses and development of methods of analysis prove will be a useful tool 
in profiling clandestine drugs found on the market by other researchers 
 
On comparison of street samples and in-house synthesized samples it was observed that the 
impurity profiles were not similar. However, traces of 3-trifluoromethylaniline were found 
in some of the street samples containing 3-TFMPP when analysed at very high 
concentration. 3-Trifluoromethylaniline is a precursor in route 1 synthesis. As such, this 
confirms route 1as a viable route of synthesis. However, it is most likely the 3-TFMPP was 
commercially synthesized using this route and not in a clandestine manner and then used in 
the manufacture of the illicit drugs. This deduction was made on the basis that the profile of 
impurities obtained with the in-house synthesized 3-TFMPP sample was not similar to the 
street samples.  
 
9.1.2.4 The method developed 
The final optimised and validated method was as follows; the initial oven temperature was 
set at 60oC with a hold for 1min and ramped at 10oC /min to 170oC with a hold for 2min. 
The oven was further ramped at 15oC /min to 280oC, with a hold for 4min. The MS transfer 
line was set at 280oC, source temperature 230oC, ionisation energy 70eV and scan range 
m/z 40 – 500. The carrier gas was He (g) at a flow rate of 1ml/min. The injector was set at 
260oC with a split ratio of 20:1. The instrument was equipped with a Supelco, Equity-5 
(30m x 2.5mm x 2.5um) capillary column. The total analysis run time was 25.33 minutes.   
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9.1.3 CONCLUSION 
 
The results of this research provided novel information in the stability profile of 
psychoactive phenylpiperazines and other drugs of abuse prevailing on the market. It was 
also noted that 2-methylpropan-2-ol has not been extensively used in literature hence it is 
proposed as a solvent for use to other researchers, especially in profiling or impurity 
analysis mainly due to its non-reactivity. 
 
There was a limited amount of previous research on method development and or 
optimisation for similar drugs, especially involving FPP, one of the two main drugs of 
focus for the overall research. This was probably due to the drugs being relatively new on 
the market and this was a limitation in this study for comparative purposes. In depth data on 
optimisation of the drugs was found to be mainly on amphetamines. In addition, the few 
studies found mostly reported optimisation on qualitative methods and on a limited number 
of drugs. Therefore, this study provides relevant data on optimisation and validation of a 
method for the analysis and profiling of phenylpiperazines, benzylpiperazines and other 
drugs of abuse in street samples.  
 
The data for all the 22 drugs investigated was also reported. Currently, there was no record 
of the drugs having been chemically profiled. Furthermore, the drugs can be reliably 
detected and analysed qualitatively and quantitatively in a wide concentration range. 
Hence, this will prove useful in application to both samples containing very low 
concentrations and high doses with good accuracy precision. Also, the GC-MS analytical 
data (retention times, relative retention times, retention indices, and mass spectra) for all 
the FPP and TFMPP isomers and the other drugs investigated was generated for the first 
time. This study brings in additional spectral data in terms of more comprehensive mass 
spectra and identifying ion m/z values for the piperzines and also all the congeners. In 
addition, the routes of fragmentation and fragment structures for benzylpiperazines and 
phenylpiperazines. It is suggested this data will aid further investigation of these drugs and 
can be used by other researchers, law enforcement agencies and in toxicity studies. 
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9.2 FUTURE WORK 
 
In the review on methods of analysis (Chapter 1, section 1.8) it was found that researchers 
highlighted the need for HPLC for the separation of isomers of FPP and TFMPP (Elliott 
and Smith, 2008; Vorce et al., 2008; Takahashi et al., 2009). Consequently, it is suggested 
that such techniques as LC-MS will have the potential to distinguish between the analytes. 
Investigation of the use of HPLC, both in characterisation of piperazines is therefore 
proposed for future work. It is hoped that an attempt will be made to develop an 
HPLC/DAD or HPLC/MS method for the separation of the isomers and also for 
characterisation. Schurenkamp (2010) successfully developed a chiral HPLC/DAD method 
for analysis of CPP isomers in seized tablets. 
 
Preliminary analysis for impurities of the in-house synthesised 4-FPP and 3-TFMPP 
indicated that phenylpiperazines street drugs potentially contain several impurities 
dependent not only on the route but also technique.  Therefore, it is suggested that a more 
in depth investigation of impurities including extraction of trace components be conducted. 
However, application of this method to the analysis of trace impurities might require 
carrying out an additional test, i.e., extraction of trace impurities by liquid-liquid extraction 
and or solid-phase extraction (discussed in section 1.8.3). This study can therefore be a 
foundation for further investigations, such as to develop methods for other drugs and to 
carry out impurity profiling using radio labelled precursors. This will assist law 
enforcement agents in establishing links between samples, thereby identifying the origin of 
the drugs. Furthermore, investigation of the piperazine drugs which are fluoro compounds 
using stable isotopes of fluorine, nitrogen or chlorine for (CPP and related substances) 
could be investigated as this study identified some the compounds and was not exhaustive. 
It is also suggested that analysis and impurity profiling of street samples containing other 
piperazine drugs be conducted using the method developed. The method was found to 
selectively analyse for 20 drug substances and as such it has the potential to be applied for 
the profiling of not just the drugs investigated. Furthermore, future investigation of other 
routes of synthesis or the same routes on other drugs would be useful. It is likely that with 
increasing control on piperazines clandestine manufacture may arise. In addition, it has 
been identified that profiling of piperazines has not been done. Hence, such a study will 
generate useful data which can be utilised by law enforcement agencies and other 
researchers. 
 292 
 
REFERENCES 
Aalberg, L., Andersson, K., Bertler, C., Borén, H., Cole, M.D., Dahlén, J., Finnon, Y., Huizer, 
H., Jalava, K., Kaa, E., Lock, E., Lopes, A., Poortman-van der Meer, A. and Sippola, E., 
2005a. Development of a harmonised method for the profiling of amphetamines: I. 
Synthesis of standards and compilation of analytical data. Forensic science international, 
149 (2–3), pp.219-229.  
Aalberg, L., Andersson, K., Bertler, C., Cole, M.D., Finnon, Y., Huizer, H., Jalava, K., Kaa, E., 
Lock, E., Lopes, A., Meer, A.P.d., Sippola, E. and Dahlén, J., 2005b. Development of a 
harmonised method for the profiling of amphetamines: II. Stability of impurities in organic 
solvents. Forensic science international, 149 (2–3), pp.231-241.  
Aalberg, L., DeRuiter, J., Noggle, F.T., Sippola, E. and Clark, C.R., 2000. Chromatographic and 
Mass Spectral Methods of Identification for the Side-Chain and Ring Regioisomers of 
Methylenedioxymethamphetamine. Journal of chromatographic science, 38 (8), pp.329-
336.  
Advisory Council on the Misuse of Drugs (ACMD), 2011. Consideration of the Novel 
Psychoactive Substances (‘Legal Highs’).Advisory Council on the Misuse of Drugs. Home 
office, UK. [pdf]. Available at: 
<https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119139/ac
mdnps2011.pdf> [Accessed 10 September 2014]. 
Advisory Council on the Misuse of Drugs (ACMD, 2008). Control of 1-benzylpiperazine (BZP) 
and related compounds. Home Office, London, UK. [pdf]. Available at: 
<https://www.gov.uk/government/publications/acmd-1-benzylpiperazine-bzp-report-2008> 
[Accessed on 30 January 2013]. 
Analytical Methods Committee (AMC), 2001. Robust Statistics: A method of coping with 
outliers. Technical Brief No. 6.Royal Society of Chemistry. [Online]. Available at: 
http://www.rsc.org/amc  [Accessed 10 on August 2011]. 
Andersson, K., Jalava, K., Lock, E., Finnon, Y., Huizer, H., Kaa, E., Lopes, A., Poortman-van 
der Meer, A., Cole, M.D., Dahlén, J. and Sippola, E., 2007a. Development of a harmonised 
method for the profiling of amphetamines: III. Development of the gas chromatographic 
method. Forensic science international, 169 (1), pp.50-63.  
Andersson, K., Jalava, K., Lock, E., Huizer, H., Kaa, E., Lopes, A., Poortman-van der Meer, A., 
Cole, M.D., Dahlén, J. and Sippola, E., 2007b. Development of a harmonised method for 
the profiling of amphetamines: IV. Optimisation of sample preparation. Forensic science 
international, 169 (1), pp.64-76.  
Andreasen, M.F., Lindholst, C. and Kaa, E., 2009. Adulterants and Diluents in Heroin, 
Amphetamine, and Cocaine Found on the Illicit Drug Market in Aarhus, Denmark. The 
Open Forensic Science Journal, 2, pp.16-20 . 
Arbo, M.D., Bastos, M.L. and Carmo, H.F., 2012. Piperazine compounds as drugs of abuse. 
Drug and Alcohol Dependence, 122 (3) 174– 185.   
Baker, P.B. and Phillips, G.F., 1983. The forensic analysis of drugs of abuse. A review. Analyst, 
108 (1288), pp.777-807.  
 293 
 
Baltzly, R., Buck J.S., Lorz E., Schön W., 1944. The preparation of n-mono-substituted and 
unsymmetrically disubstituted piperazines. Journal of American Chemical Society. 66 (2), 
pp 263–266. 
Barceloux, D.G., 2012. Medical Toxicology of Drug Abuse: Synthesized Chemicals and 
Psychoactive Plants. Hoboken, New Jersey:  John Wiley & Sons Inc.  
Baron, M., Elie, M. and Elie, L., 2011. An analysis of legal highs?do they contain what it says 
on the tin? Drug Testing and Analysis, 3(9), pp.576-581.  
Bartos, D. and Gorog, S., 2008. Recent Advances in the Impurity Profiling of Drugs. Current 
Pharmaceutical Analysis. 4(4), 215-230.  
Barwick, V.J., 1999. Sources of uncertainty in gas chromatography and high-performance liquid 
chromatography. Journal of Chromatography A, 849, pp.13-33.  
Bersimis, S., Psarakis, S. and Panaretos, J., 2007. Multivariate statistical process control charts: 
an overview. Quality and Reliability Engineering International, 23 (5), pp.517-543.  
Best, D.J., Rayner, J.C.W. and Thas, O., 2009. Nonparametric Tests for Randomized Block 
Data with Ties and Ordered Alternatives Newcastle: Applied Statistics Education and 
Research Collaboration (ASEARC).  
Boumrah, Y., Rosset, M., Lecompte, Y., Bouanani, S., Khimeche, K. and Dahmani, A., 2014. 
Development of a targeted GC/MS screening method and validation of an HPLC/DAD 
quantification method for piperazines–amphetamines mixtures in seized material. Egyptian 
Journal of Forensic Sciences, [e-journal] 4(3), pp.90-99. Available through: ScienceDirect, 
<http://www.sciencedirect.com/science/article/pii/S2090536X14000185>.  
Bowers, L.D., Armbruster, D.A., Cairns, T., Cody, J.T., Fitzgerald, R., Goldberger, B.A. and 
Lewis, David Shaw, Leslie M., 2002. Gas Chromatography/Mass Spectrometry (GC/MS) 
Confirmation of Drugs; Approved Guideline. Volume 22 Number 22. NCCLS document 
C43-A. USA: Clinical and laboratory standards institute formerly NCCLS.  
Brick, J. and Erickson, C.K., 2013. Drugs, the Brain, and Behavior: The Pharmacology of Drug 
Use Disorders. 2nd ed. New York: Routledge.  
Byrska, B.,  Zuba, D., Stanaszek, R., 2010. Determination of piperazine derivatives in “legal 
highs”.  Problems of Forensic Sciences, 81(LXXX1), pp. 101-113.  
 Center for Drug Evaluation and Research (CDER, 2004. Reviewer Guidance: Validation of 
Chromatographic Methods. [Online]. Available at: 
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM134409.pdf> [Accessed on 20 December 2012]. 
Chan, C.C., Herman, L. and  Zhang, X.M., eds., 2010. Practical Approaches to method 
validation and essential instrument performance verification. Hoboken, New Jersey: 
Wiley.  
Chatterjee, S. and Simonoff, J.e.S., 2012. Handbook of Regression Analysis. Hoboken, New 
Jersey: John Wiley and Sons Inc.  
 294 
 
Cheng, W.C., Poon, N.L. and Chan, M.F., 2003. Chemical profiling of 3,4-
methylenedioxymethamphetamine (MDMA) tablets seized in Hong Kong : Journal of 
Forensic Science,48 (6) pp.1 May 2014-1249-56.  
Cheung, Y.Y., Jung, B., Sohn, J.H. and Ogrinc, G., 2012. Quality Initiatives: Statistical Control 
Charts: Simplifying the Analysis of Data for Quality Improvement. Radiographics, 32 (7), 
pp.2113-2126.  
Cole, C., Jones, L., McVeigh, J., Kicman, A., Syed, Q. and Bellis, M., 2011. Adulterants in 
illicit drugs: a review of empirical evidence. Drug Test Analysis, 3(2), pp.89–96.  
Cole, M.D., 2003. Analysis of Controlled Substances. Chichester. Wiley. 
Corder, G.W, and Foreman, D.I., 2009. Nonparametric Statistics for Non-Statisticians: A Step-
by-Step Approach. Hoboken, New Jersey: John Wiley & Sons Inc. 
Coulson, C. and Caulkins, J.P., 2012. Scheduling of newly emerging drugs: a critical review of 
decisions over 40 years. Addiction, 102, pp.766-763.  
Cymerman, J.C. and Young, R.J., 1962. 1-Benzylpiperazine. Organic Syntheses, Coll. 5, pp.88-
91.  
Dargan, P. and Wood, D., 2013. Novel Psychoactive Substances: Classification, Pharmacology 
and Toxicology. Burlington: Elsevier Science.  
 Davies, S., Lee, T., Ramsey, J., Dargan, P.I., Wood, D.M., 2012. Risk of caffeine toxicity 
associated with the use of “legal highs” (novel psychoactive substances). European 
Journal of Clinical Pharmacology, 68(4), pp. 435-439.  
Davies, S., Wood, D.M., Smith, G., Button, J., Ramsey, J., and Archer, R., 2010, Purchasing 
‘legal highs’ on the Internet—is there consistency in what you get? Oxford Journal of 
Medicine, 103(7), pp. 489–493.  
 Dayrit, F.M., Dumlao, M.C., 2004. Impurity profiling of methamphetamine hydrochloride 
drugs seized in the Philippines. Forensic Science International, 144(1) pp. 29-36 
de Boer, D., Bosman, I.J., Hidvegi, E, Manzoni C, Benko, A.A., dos Reys, L.J. and Maes, R.A.,  
2001. Piperazine-like compounds: a new group of designer drugs-of-abuse on the 
European market. Forensic Science International. 121(1-2), pp.47-56.  
de Souza, S.V.C. and Junqueira, R.G., 2005. A procedure to assess linearity by ordinary least 
squares method. Analytica Chimica Acta, 552 (1–2), pp.25-35.  
Dijkstra, A., Massart, D.L., Kaufman, L., 1996. Evaluation and Optimization of Laboratory 
Methods and Analytical Procedures. Amsterdam: Elsevier Science Publishing Inc.  
Drug Enforcement Administration (DEA), 2009a. Microgram Bulletin 42(8). Washington: U.S. 
Department of Justice [Online]. Available at: 
<http://www.justice.gov/dea/pr/micrograms/2009/mg0809.pdf>  [Accessed 5 September 
2014]. 
Drug Enforcement Administration (DEA), 2009b. Microgram Bulletin 42(12). December 2009. 
Washington: U.S. Department of Justice [Online]. Available at: 
 295 
 
<http://www.justice.gov/dea/pr/micrograms/2009/mg1209.pdf> [Accessed 5 September 
2014]. 
Drug Enforcement Administration (DEA), 2011. Drugs of Abuse 2011 Edition: A DEA 
Resource Guide. Washington: U.S. Department of Justice. Available at: 
<http://www.justice.gov/dea/docs/drugs_of_abuse_2011.pdf>  [Accessed 5 March 2014]. 
Elie, M.P., Elie, L.E. and Baron, M.G., 2013. Keeping pace with NPS releases: fast GC-MS 
screening of legal high products. Drug Testing and Analysis, 5 (5), pp.281-290.  
Elliott, S. and Smith, C., 2008. Investigation of the first deaths in the United Kingdom involving 
the detection and quantitation of the piperazines BZP and 3-TFMPP. Journal of Analytical 
Toxicology. 32(2), pp.172-177.  
Elliott, S., 2011.  Current awareness of piperazines: pharmacology and toxicology. Drug Testing 
and Analysis, 3(7-8), pp. 430–438. doi: 10.1002/dta.307.   
Eurachem, 1998. The Fitness for Purpose of Analytical Methods: A Laboratory Guide to 
Method Validationand Related Topics. UK: EURACHEM Working Group.[Online]. 
Available at: https://www.eurachem.org/images/stories/Guides/pdf/valid.pdf; [Acessed 1 
July 2011] 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2013b. Amphetamine 
drug profile. [Online]. Available at: <http://www.emcdda.europa.eu/publications/drug-
profiles/amphetamine> [Accessed on 30 September 2013]. 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2014. European Drug 
Report 2014. Trends and developments United Kingdom: Department of Health (DH), 
United Kingdom Focal Point on Drugs. [Online]. Available at:  
<http://www.emcdda.europa.eu/publications/edr/trends-developments/2014> [Accessed on 
20 July 2014]. 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2013a. European 
Drug Report 2013: Trends and developments. EMCDDA, Lisbon, May 2013. [Online] 
Available at: 
<http://www.emcdda.europa.eu/attachements.cfm/att_213154_EN_TDAT13001ENN1.pdf
> [Accessed on 30 October 2013]. 
European Monitoring Centre for Drugs and Drug addiction (EMCDDA), 2011. The state of the 
drugs problem in Europe. EMCDDA Annual report 2011. [Online]. Available at: 
<http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_E
N.pdf> [Accessed on 2 Jan 2012]. 
European Monitoring Centre for Drugs and Drug addiction (EMCDDA), 2009. BZP and other 
Piperazines, [Online]. Available at: <http://www.emcdda.europa.eu/publications/drug-
profiles/bzp> [Accessed on 25 March 2010].  
European Monitoring Centre for Drugs and Drug Addiction and Europol (EMCDDA-Europol), 
2013. EU drug markets report: a strategic analysis. Luxembourg: Publications Office of 
the European Union. [Online].Available at: 
<http://www.emcdda.europa.eu/publications/joint-publications/drug-markets> [Accessed 
on 30 September 2013]. 
 296 
 
European Monitoring Centre for Drugs and Drug Addiction and Europol Europol (EMCDDA-
Europol), 2012. EMCDDA–Europol 2011 Annual Report on the implementation of Council 
Decision 2005/387/JHA. Lisbon: EMCDDA/Europol, Lisbon, April 2012. 
[Online]Available at: <http://www.emcdda.europa.eu/publications/implementation-
reports/2011> [Accessed on 30 September 2013]. 
European Monitoring Centre for Drugs and Drug Addiction and Europol Europol (EMCDDA-
Europol), 2007.    
Europol–EMCDDA Joint Report on a new psychoactive substance: 1-benzylpiperazine 
(BZP). Lisbon: EMCDDA. [pdf]. Available at: 
<http://www.emcdda.europa.eu/attachements.cfm/att_132205_EN_2007_BZP_Joint%20re
port.pdf>  [1 March 2013]. 
Expert Committee on Drug Dependence (ECDD), 2012. 1-(3-trifluoromethylphenyl) piperazine 
(TFMPP). Pre-Review Report Expert Committee on Drug Dependence Thirty-fifth 
Meeting. Hammamet, Tunisia. Available at: 
<www.who.int/medicines/areas/quality_safety/5.3bTFMPPpre-review.pdf> [Accessed on 
30 September 2013]. 
Filler, R. and Saha, R., 2009. Fluorine in medicinal chemistry: a century of progress and a 60 
year retrospective of selected highlights. Future medical chemistry, 1 (5), pp.777-791.  
Food and Drug Administration, FDA., 2008. Guidance for Industry: Drug Stability Guidelines. 
Rockville:U.S. Department of Health and Human Services. [pdf]. Available at: 
<http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/Gui
danceforIndustry/ucm051556.pdf > [Accessed 1 May 2014]. 
Friedman, M., 1937. The Use of Ranks to Avoid the Assumption of Normality Implicit in the 
Analysis of Variance. Journal of the American Statistical Association, 32 (200), pp.675-
701.  
Gee, P. and Schep, L., 2013. Chapter 8 - 1-Benzylpiperazine and other Piperazine-based 
Derivatives. [e-book] Paul I. Dargan and David M. Wood, eds. 2013. Novel Psychoactive 
Substances, pp.179-209. Boston:Academic Press.  
Gee, P., Richardson, S., Woltersdorf, W. and Moore, G., 2005. Toxic effects of BZP-based 
herbal party pills in humans: a prospective study in Christchurch, New Zealand. The New 
Zealand Medical Journal, 118(1227), pp.U1784.  
Gibbons, R.D. and Coleman, D.E., 2001. Statistical Methods for Detection and Quantification 
of Environmental Contamination. New York: John Wiley & Sons.  
Gokel, G.W., 2004. Dean's handbook of organic chemistry. New York: McGraw-Hill. 2nd ed. 
New York: McGraw-Hill.  
González, A.G., Herrador, A.M., 2007. A practical guide to analytical method validation, 
including measurement uncertainty and accuracy profiles. Trends in Analytical Chemistry, 
26(3), pp.227-238.  
Gopal, K.K.,  2006. 100 Statistical Tests. 3rd ed. London, UK: Sage Publications Ltd.   
Grob, K., 1994. Injection techniques in capillary GC. Analytical Chemistry, 66 (20), pp.1009A-
1019A.  
 297 
 
Grob, R.L. and Barry, E.F., 2004. Morden practice of gas chromatography. New Jersey: John 
Wiley and Sons, Inc.  
Gunnar, T., Mykkänen, S., Ariniemi, K. and Lillsunde, P., 2004. Validated semiquantitative/ 
quantitative screening of 51 drugs in whole blood as silylated derivatives by gas 
chromatography–selected ion monitoring mass spectrometry and gas chromatography 
electron capture detection. Journal of Chromatography B, 806, pp.205–219. 
Gustavo González, A. and Ángeles Herrador, M., 2007. A practical guide to analytical method 
validation, including measurement uncertainty and accuracy profiles. TrAC Trends in 
Analytical Chemistry 26 (3), pp.227-238.  
Haroz, R. and Greenberg, M., 2006. New drugs of Abuse in North America. Clinical 
Laboratory Medicine. 26, pp.147-164.  
Hibbert, D.B., 2007. Quality Assurance in the Analytical Chemistry Laboratory. New York, 
USA:  Oxford University Press.  
Horacio N. Pappa, H.N., DeStefano, A.J., 2008. Revised USP System Suitability Parameters. 
United States Pharmacopoeia(USP),USA. 
 Huber, P.J., 1996. Robust Statistical Procedures. 2nd ed. CBMS-NSF Regional conference 
series in applied mathematics. I-xi., Society for Industrial and Applied Mathematics.  
Huizer, H., 1987. Analytical studies on illicit heroin. , 9(4), 203-211. Pharmacy World & 
Science, 9 (4), pp.203-211.  
Inoue H., Iwata Y.T, Kanamori T., Miyaguchi H., Tsujikawa K., Kuwayama K., Tsutsumi H., 
Katagi M., Tsuchihashi H. and Kishi T., 2004. Analysis of Benzylpiperazine-like 
compounds. Japanese Journal of Science and Technology for Identification. 9(2), pp.165-
184  
Inoue, T., Yuko, T.I. and Kuwayama, K., 2008. Characterisation and profiling of 
methamphetamine seizures. Journal of Helath Science, 54(6), pp. 615-222. [Online].  
International Conference on Harmonisation (ICH) Q1A(R2), 2003. ICH harmonised tripartite 
guideline: Stability testing of new drug substances and products Q1A(R2). Geneva: ICH. 
[pdf]. Available at: <http://www.ich.org/products/guidelines/quality/article/quality-
guidelines.html> [Accessed 1 March 2014]. 
 International Conference on Harmonisation (ICH), 2005. ICH Harmonised Tripartite 
Guideline: Validation of Analytical Procedures: Text And Methodology, Q2(R1). [Online]. 
Available at: <http://www.ich.org/products/guidelines/quality/article/quality-
guidelines.html.> [Accessed on 10 August 2011]. 
International Union of Pure and Applied Chemistry (IUPAC), 2 February 2014.  
Compendium of Chemical Terminology. Version 2.3.3 : Gold Book. [Online]. Available at: 
< http://goldbook.iupac.org/PDF/goldbook.pdf> [Accessed 1 September 2014].  
Jones, G., 1982. The Chemistry of Heterocyclic Compounds, Quinolines, Part 2, Hoboken, New 
Jersey: John Wiley & Sons, Inc.  
 298 
 
Kang, C.W. and Kvam, P.H., 2007. Nonparametric Statistics with Applications to Science and 
Engineering, Hoboken, New Jersey: John Wiley & Sons, Inc.  
Karch, S.B. ed, 2007. Drug Abuse Handbook, Second Edition. New York:  CRC Press, Taylor 
and Franscis Group LLC.  
Karinen, R., Øiestad, E.L., Andresen, W., Smith-Kielland, A. and Christophersen, A., 2011. 
Comparison of the stability of stock solutions of drugs of abuse and other drugs stored in a 
freezer, refrigerator, and at ambient temperature for up to one year. Journal of Analytical 
Toxicology, 35(8), pp. 583 - 90.  
Kaur, H., 2010. Instrumental Methods of Chemical Analysis. Meerut, IND: Global Media.  
Kelleher, C., Christie, R., Lalor, K., Fox, J., Bowden, M. and O'Donnell, C., 2011. An Overview 
of New Psychoactive Substances and the Outlets Supplying Them. Dublin,Ireland: National 
Advisory Committee on Drugs, Centre for Social and Educational Research, Dublin 
Institute of Technology.  
Kenyon, S., Button, J., Ramsey J. and David W.H., 2010. ‘Legal highs’ - Analysis of tablets and 
capsules containing piperazines. [Not published]. Online. Available at: 
<http://www.iatdmct.org/images/File/Yung%20scientists/PiperazineTabletsCapsules_LTG
_2006_SKenyon_Final.pdf> [Accessed on 15 October 2010]. 
Khopkar, S.M., 2012. Basic Concepts of Analytical Chemistry. 3rd ed. Kent, GBR: New 
Academic Science.  
King, L., 2009. Forensic chemistry of substances of misuse: a guide to drug control. Cambridge: 
Royal society of chemistry.  
King, L.A. and Kicman, A.T., 2011. A brief history of ‘new psychoactive substances’. Drug 
Testing and Analysis, 3 (7-8), pp. 401–403. DOI 10.1002/dta.319. [Online]. 
King, L.A., 1997. Drug content of powders and other illicit preparations in the UK. Forensic 
science international, [e-journal] 85 (2), pp.135-147.  
Kiritsy, J.A., Yung, D.K. and Mahony, D.,E., 1978. Synthesis and quantitative structure-activity 
relationships of some antibacterial 3-formylrifamycin SV N-(4-substituted 
phenyl)piperazinoacethydrazones. Journal of Medicinal Chemistry, 21 (12), pp.1301-1307.  
Knapp, D., 1979. Handbook of analytical derivatization reactions. New York: John Wiley and 
Sons Inc.  
Kovar, K.L.andLaudszun, M., 1989. Chemistry and Reaction Mechanisms of Rapid Tests for 
Drugs of Abuse and Precursors Chemicals. Scientific and technical notes. SCITEC/6. 
United Nations.  
Kronstrand, R., Jones, A.W., 2000. Drugs of abuse:  Analysis. Encyclopedia of Forensic 
sciences, pp. 598-610, Elsevier, Oxford.   
Kuleya, C., Hall, S., Gautam, L. and Cole, M.D., 2014. An optimised gas chromatographic-
mass spectrometric method for the chemical characterisation of benzylpiperazine and 1-
arylpiperazine based drugs. Analytical Methods, 6 (1), pp.156-163. 
 299 
 
Kvam, P.H. and Vidakovic, B., 2007. Nonparametric Statistics with Applications to Science and 
Engineering. Hoboken, New Jersey: John Wiley and Sons Inc.  
Laurencelle, L. and Frangois, D.A., 2002. Statistical Tables : Explained and Applied.  
Lavanya G., Sunil M., Eswarudu, M.M., Eswaraiah, M.C., Harisudha, K. and Spandana B.N., 
2013. Analytical Method Validation: An Updated Review. International Journal of 
Pharmaceutical Sciences and Research, 4(4), pp.1280-1286. 
Lawrence, S.A., 2004. Amines: Synthesis, Properties and Applications. Cambridge: Cambridge 
University Press.  
Lecompte, Y., Roussel, O. & Perrin, M., 2008. 1-benzylpiperazine (BZP) and 1-(3-
trifluoromethylphenyl)piperazine (TFMPP): emergence of two agents which lead to 
misuse. Annales Pharmaceutiques Francaises. 66(2), pp.85-91.  
Liu, K.G. and Robichaud, A.J., 2005. A general and convenient synthesis of N-aryl piperazines. 
Tetrahedron letters, 46 (46), pp.7921-7922.,  
Lock, E., Aalberg, L., Andersson, K., Dahlén, J., Cole, M.D., Finnon, Y., Huizer, H., Jalava, K., 
Kaa, E., Lopes, A., Poortman-van der Meer, A. and Sippola, E., 2007. Development of a 
harmonised method for the profiling of amphetamines V: Determination of the variability 
of the optimised method. Forensic science international, 169(1,) pp. 77-85. 
London Toxicology Group (LTG), 2006. Analytical profiles of the piperazines : London 
Toxicology Group Monographs.London, UK: London Toxicology Group, St Georges, 
University of London.  
Maher, H.M., Awad, T. and Clark, C.R., 2009. Differentiation of the regioisomeric 2-, 3-, and 
4-trifluoromethylphenylpiperazines (TFMPP) by GC–IRD and GC–MS. Forensic Science 
International, 188 (1), pp. 31–39.  
Makino, K., Kurobane, S., Miyasaka, K. and Nagano, K., 2003. Profiling of Ecstasy Tablets 
Seized in Japan. Microgram Journal, 1 (3-4), pp.169-176.   
Martin, L., Leblanc, R. and Toan, N.K., 1993. Tables for the Friedman Rank Test. The 
Canadian Journal of Statistics / La Revue Canadienne de Statistique, 21(1), pp. 39-43. 
Maurer, H.H., 2004. Mass Spectra of Select Benzyl- and Phenyl- Piperazine Designer 
Drugs.Technical Note. Microgram Journal, 2 (1-4) pp.22-26.   
Maurer, H.H., 2010. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. 
Therapeutic Drug Monitoring, 32(5), pp. 544 - 9.  
McMaster, M.C., 2007. Sources of GC/MS background contamination. GC/MS: A Practical 
User's Guide. 2ed. Hoboken, New Jersey: Wiley and Sons Inc Wiley online libray. 
Chapter: Appendix C. Available at: 
<ahttp://onlinelibrary.wiley.com/doi/10.1002/9780470228357.index/summary> 
McNair, H.M. and Miller, J.M., 2009. Basic Gas Chromatography. 2nd ed. Hoboken, New 
Jersey: John Wiley & Sons, Inc.  
 300 
 
Miller, J.M., 2005. Chromatography: Concepts and Contrasts. Hoboken, New Jersey: Wiley 
and Sons Inc.  
Miller, J.N., 1991. Basic statistical methods for Analytical Chemistry. Part 2. Calibration and 
regression methods. Analyst, 1 (116), pp.3-14.  
Milliet, Q., Weyermann, C. and Esseiva, P., 2009. The profiling of MDMA tablets: A study of 
the combination of physical characteristics and organic impurities as sources of 
information. Forensic science international, [e-journal] 187 (1–3), pp.58-65.  
Mishani, E., Dence, C.S., McCarthy, T.J. & Welch, M.J., 1996. Formation of phenylpiperazines 
by a novel alumina supported bis-alkylation. Tetrahedron Letters. 37(3), pp.319-322. 
Moffat, A.C., Osselton, M.D., Widdop, B. and Watts, J. eds., 2011. Clarke's Analysis of Drugs 
and Poisons. 4th ed. London, UK: Pharmaceutical Press.  
Moody, D.E., Monti, K.M. and Spanbauer, A.C., 1999. Long-term stability of abused drugs and 
antiabuse chemotherapeutical agents stored at -20 degrees C. Journal of Analytical 
Toxicology, 23(6), pp. 535 – 540.   
Moody, H.W., 1982. The evaluation of the parameters in the van Deemter equation. Journal of 
Chemical Education, 59(4), pp. 290. DOI: 10.1021/ed059p290.  
Nikolova, I., Danchev, N., 2008. Piperazine Based Substances of Abuse: A New Party Pills on 
Bulgarian Drug Market, Biotechnology & Biotechnological Equipment, 22(2), pp. 652-655.  
NIST, 2014. NIST Standard Reference Database 1A, Nist web book, [Online]. Available at: 
http://webbook.nist.gov/chemistry/gc-ri  [Accessed on 14 August 2014] 
Nowatzke, W. and Woolf, E., 2007.  Best practices during bioanalytical method validation for 
the characterization of assay reagents and the evaluation of analyte stability in assay 
standards, quality controls, and study samples. The American Association of 
Pharmaceutical Scientists Journal, 9(2), pp. E117–E122 
O’O’Neal, C.L., Crouch, D.J. and Fatah, A.A., 2000. Validation of twelve chemical spot tests 
for the detection of drugs of abuse. Forensic science international, 109 (3), pp.189-201.  
Onoz, B. and Bayazit, M., 2003. The Power of Statistical Tests for Trend Detection. Turkish 
Journal of Engineering and Environmental Sciences, 27, pp.247-251.  
Park, B.K., Kitteringham, N.R. and O'Neill, P.,M., 2001. Metabolism of fluorine-containing 
drugs. Annual Review of Pharmacology and Toxicology, 41 (1), pp.443-470.  
Philp, M., Shimmon, R., Stojanovska, N., Tahtouhb, M. and Fu, S., 2013. Development and 
validation of a presumptive colour spot test method for the detection of piperazine 
analogues in seized illicit materials. Analytical Methods, 5 (5402), pp.5353-5358.  
Pollard, C.B., Wicker, T.H, Jr., (1954). Derivatives of Piperazine. XXIV. Synthesis of 1-
Arylpiperazines and Amino Alcohol Derivatives. Journal of the American Chemical 
Society, 76(7), pp.1853-1855. 
 301 
 
Quirke, J.M.E., Adams, C.L. and Van Berkel, G.J., 1994. Chemical derivatization for 
electrospray ionization mass spectrometry. 1. Alkyl Halides, Alcohols, Phenols, Thiols, 
and Amines. Analytical Chemistry, 66 (8), pp.1302-1315.  
Rambla-Alegre, M., Esteve-Romero, J. and Carda-Broch, S., 2012. Is it really necessary to 
validate an analytical method or not? That is the question. Journal of Chromatography A, 
[e-journal] 1232 (0), pp.101-109.  
Santali, E.Y., Cadogan, A., Daeid, N.N., Savage, K.A. and Sutcliffe, O.B., 2011. Synthesis, full 
chemical characterisation and development of validated methods for the quantification of 
(±)-4′-methylmethcathinone (mephedrone): A new “legal high”. Journal of pharmaceutical 
and biomedical analysis, 56 (2), pp.246-255.  
Schifano, F., Orsolini, L., Duccio Papanti, G. and Corkery, J.M., 2015. Novel psychoactive 
substances of interest for psychiatry. World Psychiatry, 14 (1), pp.15-26.  
Schurenkamp, J., Beike, J., Pfeiffer, H. & Kohler, H., 2010. Separation of positional CPP 
isomers by chiral HPLC-DAD of seized tablets. International journal of legal medicine, 
125(1), pp.95-9 
Sedefov, R., 2011. Early-warning system: new drugs and emergingdrug trends in Europe 
(promises and pitfalls). Department of Health (DH), United Kingdom.  
Seymour, R.B. and 'Smith, D.E., 2011. Guide to Psychoactive Drugs: An up-to-the-minute 
reference to mind-altering substances. London, England: Routledge Routledge Taylor & 
Francis Group Taylor & Francis Group.  
Shaman Australis, 2003. Piperazines. Shaman Australis Botanics. [Online] Available at: 
<www.shaman-australis.com.au/Website/law/Piperazine/index.htm> [Accessed on 25 
March 2010].  
Shulgin, A. and Shulgin, A., 1991. PiHKAL: A Chemical Love Story. Berkeley, California: 
Transform Press.  
Skoog, D.A., 2007. Principles of instrumental analysis. [e-book] 6th ed.. ed. Belmont, Calif.: 
Belmont, Calif.: Thomson Brooks/Cole. Available through: Primo.  
Skoog, D.A., 2007. Principles of instrumental analysis. 6th ed. Belmont, Calif.: Belmont, Calif: 
Thomson Brooks/Cole.  
Smith, R.J. and Webb, M.L. eds., Handley, A.J. and Chalmers, J.M., 2007. Analysis of drug 
impurities. Oxford, UK: Blackwell Publishing Ltd.  
Sprent, P. and Smeeton, N.C., 2007. Applied Nonparametric Statistical Methods, Fourth 
Edition. USA: CRC Press, Taylor Francis Group.  
Staack, R.F. and Maurer, H.H., 2005. Metabolism of designer drugs of abuse. Current Drug 
Metabolism 6(3), pp.259-274. 
Staack, R.F., 2007. Piperazine designer drugs of abuse. The Lancet, 369(9571), pp.1411-1413. 
Staack, R.F.; Fritschi, G. and Maurer, H.H., 2003. New designer drug 1-(3-
trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and 
 302 
 
liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on 
its toxicological detection in rat urine. Journal of Mass Spectrometry 38(9), pp.971-981. 
Takahashi, M., Nagashima, M., Suzuki, J., Seto, T., Yasuda, I., and Yoshida., 2009. Creation 
and application of psychoactive designer drugs data library using liquid chromatography 
with photodiode array spectrophotometry detector and gas chromatography-mass 
spectrometry. Talanta. 77(4), pp.1245-1272.  
Tanabe, K. and Matsuda, M., 1961. The mechanism of the hydrolysis of methylene chloride 
Journal of the Research Institute for Catalysis, 9 (239), pp.246-255.  
Taverniers, I., De Loose, M. and Van Bockstaele, E., 2004. Trends in quality in the analytical 
laboratory. II. Analytical method validation and quality assurance. TrAC Trends in 
Analytical Chemistry, 23 (8), pp.535-552.  
Telepchak, M.J., August, T.F. and Glynn Chaney, G., 2004. Chemical Derivatization. Forensic 
Science and Medicine: Forensic and Clinical Applications of Solid Phase Extraction, pp 
297-309. 
Telepchak, M.J., August, T.F. and Glynn Chaney, G., 2004. Chemical Derivatization. Forensic 
Science and Medicine: Forensic and Clinical Applications of Solid Phase Extraction, pp 
297-309.  
Thompson, M., 2005. Is my calibration linear? Technical Brief No. 3. Analytical Methods 
Committee (AMC). Royal Society of Chemistry. [Online]. Available at: 
<http://www.rsc.org/amc> [Accessed on 10 August 2011]. 
Thompson, M., Ellison, S., L.R. and Wood, R., 2002. Harmonized guidelines for single-
laboratory validation of methods of analysis (IUPAC Technical Report): Pure and Applied 
Chemistry. http://dx.doi.org/10.1351/pac200274050835 ed. International Union of Pure 
And Applied Chemistry (IUPAC).74 (5) pp.835-855.  
Toutenburg, H., 2002. Statistical analysis of designed experiments. [e-book] 2nd ed.. ed. New 
York: New York : Springer. Available through: Primo.  
Trachsel, D., 2012. Fluorine in psychedelic phenethylamines. Drug Testing and Analysis, [e-
journal] 4 (7-8), pp.577-590.  
UK Acts of Parliament. The Misuse of Drugs Act 1971 (Amendment) Order 2009 (2009). 
HMSO. [Online]. Available at: 
<http://www.opsi.gov.uk/si/si2009/draft/pdf/ukdsi_9780111486610_en.pdf>  [Accessed on 
20 June 2011]. 
UK Focal Point, 2013. United Kingdom drug situation: Annual report to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2012. Department of 
Health. London. UK. [Online]. Avalailable at: http://www.cph.org.uk/wp-
content/uploads/2013/03/23779-FOCAL-POINT-REPORT-2012-B5.pdf. [Accessed 22 
November 2013]  
United Kingdom Focal Point On Drugs, 2010. Annual report to the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) 2010. Department of Health (DH), 
United Kingdom drug situation. [Online]. Available at: 
http://www.cph.org.uk/showPublication.aspx?pubid=707 [Accessed 10 June 2011]. 
 303 
 
United Kingdom Focal Point, 2012. United Kingdom drug situation: Annual report to the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2012. London. 
UK: Department of Health. [pdf]. Available at: <http://www.nta.nhs.uk/uploads/2012.pdf> 
[1 August 2014]. 
United Kingdom Focal Point, 2013. United Kingdom drug situation: Annual report to the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2013. 
Department of Health. London. UK. London. UK: Department of Health. [pdf]. Available 
at: <http://www.nta.nhs.uk/uploads/24780focalpointreport2013.pdf> [Accessed 1 May 
2014]. 
United Nations International Drug Control Programme (UN), 2001. Drug 
Characterization/Impurity Profiling. Background and Concepts. Manual for Use by 
National Law Enforcement Authorities and Drug Testing Laboratories. Vienna 2001. 
ST/NAR/32/Rev.1. [Online]. Available at: <http://www.unodc.org/pdf/publications/st-nar-
32-rev1.pdf > [Accessed on 21 December 2013]. 
United Nations Office on Drugs and Crime (UNODC), 1994. Rapid Testing methods of drugs of 
abuse. A manual for use by national law enforcement and narcotics laboratory personnel. 
ST/NAR/13/REV.1.  New York: United Nations. [pdf]. Available at: 
<http://www.unodc.org/unodc/en/scientists/rapid-testing-methods-of-drugs-of-abuse.html; 
[Accessed 15 Januery 2014]. 
United Nations Office on Drugs and Crime (UNODC), 2006. Recommended methods for the 
identification and analysis of amphetamine, methamphetamine and their ring-substituted 
analogues in seized materials: Manual for use by national drug testing laboratories. New 
York: United Nations Office on Drugs and Crime. [pdf]. Available at: 
<https://www.unodc.org/pdf/scientific/stnar34.pdf> [29 May 2013].  
United Nations Office on Drugs and Crime (UNODC), 2012. Global smart update global smart 
update 2012, Vol 8. [pdf] Available at: 
<http://www.unodc.org/documents/scientific/Global_SMART_Update_8_E_web.pdf> 
[Accessed on 21 December 2013]. 
United Nations Office on Drugs and Crime (UNODC), 2013a. World Drug Report 2013 . 
Vienna, Austria. United Nations Publication. [pdf]. Available at: 
<http://www.unodc.org/unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf> 
[Accessed on 21 December 2013]. 
United Nations Office on Drugs and Crime (UNODC), 2013b. The challenge of new 
psychoactive substances. Global SMART programme. Vienna, Austria. United Nations 
Publication. [pdf]. Available at: <www.unodc.org/documents/scientific/NPS_Report.pdf> 
[Accessed on 21 April 2013]. 
United Nations Office on Drugs and Crime (UNODC), 2013c. Recommended methods for the 
Identification and Analysis of Piperazines in Seized Materials. New York: UNITED 
NATIONS. [pdf]Available at: 
<www.unodc.org/documents/scientific/Methods_for_the_identification_and_analysis_of_p
iperazines_in_seized_materials.pdf> [Accessed on 21 December 2013].  
United Nations Office on Drugs and Crime (UNODC), 2014.  
World Drug Report New York: United Nations. [pdf]. Available at: 
http://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf [1 
September 2014]. 
 304 
 
van Iterson R.A, (ND). Theoretical considerations: Kovats index, Standardbase [Online, 
unpublished]. Available at: <http://www.standardbase.com/tech/GCKovats.pdf> [Accessed 
4 March 2011]. 
Van Loco, J., Elskens, M., Croux, C. and Beernaert, H., 2002. Linearity of calibration curves: 
use and misuse of the correlation coefficient. Accreditation and Quality Assurance, 7 (7), 
pp.281-285.  
Vékey, K., 1996. Internal Energy Effects in Mass Spectrometry. Journal of Mass Spectrometry, 
31 (5), pp.445-463.  
Verweij, A.M.A., 1992. Impurities in illicit drug preparations: 3,4-
MethylenedioxyAmphetamine and 3,4-MethylenedioxyMethylamphetamine. .Forensic 
Science Review, 4, pp.137-146.  
Vorce, S.P., Holler, J.M., Levine, B., Past, M.R., 2008. Detection of 1-benzylpiperazine and 1-
(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-
ESI-MS. Journal of Analytical Toxicology. 32(6), pp.444-450. 
Wilcoxon, F., 1945. Individual Comparisons by Ranking Methods 
: Biometrics Bulletin, 1(6) pp.80-83.  
Winstock, A. and Wilkins, C., 2011. ‘Legal highs’. The challenge of new psychoactive 
substances. Series on Legislative Reform of Drug Policies Number 16. Transnational 
Institute, International Drug Policy Consortium (IDPC). [Online]. Available at: 
<www.tni.org/sites/www.tni.org/files/download/dlr16.pdf>  [Accessed on 17 April 2013] 
Winstock, A.R. and Ramsey, J.D., 2010. Legal highs and the challenges for policy makers. 
Addiction, 105 (10), pp.1685–1687. doi: 10.1111/j.1360-0443.2010.02934.x.  
Yeap, C.W., Bianb, C.K. and Abdullaha, A.F.L., 2010. A Review on Benzylpiperazine and 
Trifluoromethylphenypiperazine: Origins, Effects, Prevalence and Legal Status. Health 
and the Environment Journal. 1(2) pp. 38-50.  
Yoshioka, S. and Stella, V.J., 2000. Stability of Drugs and Dosage Forms. Hingham, MA, USA: 
Kluwer Academic Publishers.  
Yuk, S., 2010. Combating illegal foods and drugs containing unauthorized substances. 4th 
Seminar of European Customs Chemists. Finland. [Online]. Available at: 
http://www.tulli.fi/en/secc/material/2ndJune2010/02.06.10_OpeningPlenary_04_Yuk.pdf . 
[accessed on15 October 2010].  
Zingg, C., 2005. The Analysis of Ecstasy Tablets in a Forensic Drug Intelligence Perspective, 
PhD. University of Lausanne, Institute of Police Science. 
 
 
  
 Chipo Kuleya    SID No. 9766990 
PhD student:     Faculty of Science & Technology 
 
305
APPENDIX 1 Auto-sampler stability graphs in different solvents (Limits are ± 10% of expected value). 
 
   
 Figure 1 2-FPP stability profiles in different solvents over 25 hours on the GC-MS autosampler. 
 
     
Figure 2 3-FPP stability profiles in different solvents over 25 hours on the GC-MS autosampler. 
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Figure 3 4-FPP stability profiles in different solvents over 25hours on the GC-MS autosampler. 
 
     
Figure 4 2-TFMPP stability profiles in different solvents over 25 hours on the GC-MS autosampler. 
 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 1 2 4 5 6 7 8 10 11 13 14 16 17 18 19 20 22 23 24 25
T
I
C
 
p
e
a
k
 
a
r
e
a
 
r
a
t
i
o
time/hrs
Methanol
experimental 4FPP expected trendline Limts
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 1 2 4 5 6 7 8 10 11 13 14 16 17 18 19 20 22 23 24 25
T
I
C
 
p
e
a
k
 
a
r
e
a
 
r
a
t
i
o
time/hrs
Dichoromethane
experimental 4FPP Expected trendline Limits
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 1 2 4 5 6 7 8 10 11 13 14 1617 18 19 20 22 23 24 25
T
I
C
 
p
e
a
k
 
a
r
e
a
 
r
a
t
i
o
time/hrs
2-methylpropan-2-ol
experimental 4FPP Expected trendline Limits
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0 1 2 4 5 6 7 8 10 11 13 14 16 17 18 19 20 22 23 24
T
I
C
 
p
e
a
k
 
a
r
e
a
 
r
a
t
i
o
time/hrs
Methanol
experimental 2TFMPP expected trendline
Limits
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0 1 2 4 5 6 7 8 10 11 13 14 16 17 18 19 20 22 23 24 25
T
I
C
 
p
e
a
k
 
a
r
e
a
 
r
a
t
i
o
time/hrs
Dichloromethane
experimental 2TFMPP expected trendline
Limits
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0 1 2 4 5 6 7 8 10 11 13 14 16 17 18 19 20 22 23 24 25
T
I
C
 
p
e
a
k
 
a
r
e
a
 
r
a
t
i
o
time/hrs
2-methylpropan-2-ol
experimental 2TFMPP expected trendline
Limits
 Chipo Kuleya    SID No. 9766990 
PhD student:     Faculty of Science & Technology 
 
307
     
Figure 5 3-TFMPP stability profiles in different solvents over 25 hours on the GC-MS autosampler. 
 
     
Figure 6 4-TFMPP stability profiles in different solvents over 25hours on the GC-MS autosampler. 
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Figure 7 BZP stability profiles in different solvents over 25hours on the GC-MS autosampler. 
 
     
Figure 8 DBZP stability profiles in different solvents over 25hours on the GC-MS autosampler. 
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Figure 9 MBZP stability profiles in different solvents over 25hours on the GC-MS autosampler. 
 
   insoluble in DCM                                              
Figure 10 CPP stability profiles in different solvents over 25 hours on the GC-MS autosampler. 
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Figure 11 MePP stability profiles in different solvents over 25 hours on the GC-MS autosampler. 
 
   insoluble in DCM and MPOH 
Figure 12 Amphetamine stability profiles in different solvents over 25 hours on the GC-MS autosampler  
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Figure 13 Methamphetamine stability profiles in different solvents over 25 hours on the GC-MS autosampler 
 
     
Figure 14 MDMA stability profiles in different solvents over 25 hours on the GC-MS autosampler 
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Figure 15 Caffeine stability profiles in different solvents over 25 hours on the GC-MS autosampler 
 
     
Figure 16 Cocaine stability profiles in different solvents over 25 hours on the GC-MS autosampler  
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Figure 17 Dapoxetine stability profiles in different solvents over 25 hours on the GC-MS autosampler 
 
     
Figure 18 Diazepam stability profiles in different solvents over 25 hours on the GC-MS autosampler 
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Figure 19 Nicotinamide stability profiles in different solvents over 25 hours on the GC-MS autosampler 
 
Limits: acceptable limits of variation for stability (± 10% of Expected value) 
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APPENDIX 2 Stability of drugs in different solvents on the GC-MS auto-sampler 
In the Table MeOH is methanol, DCM is dichloromethane and MPOH is 2-
methyldichoromethane. 
 
Table 1 Stability data for solvents/auto-sampler analysis 
  
 Time stable/hours  
Substance MeOH DCM MPOH Expected 
2-FPP 20 25 25 25 
3-FPP 20 25 25 25 
4-FPP 25 25 25 25 
2-TFMPP 19 25 25 25 
3-TFMPP 25 25 25 25 
4-TFMPP 25 25 25 25 
BZP 19 22 25 25 
DBZP 25 25 25 25 
MBZP  18 20 25 25 
3-CPP 18 0 25 25 
4-MePP 19 25 25 25 
Amphetamine 17 0 0 25 
Methamphetamine 19 25 25 25 
Caffeine 25 25 25 25 
Cocaine 14 23 25 25 
MDMA 25 25 25 25 
Diazepam 25 22 25 25 
Dapoxetine 25 25 25 25 
Nicotinamide 25 0 25 25 
BEH 14 19 25 25 
EME 14 0 0 25 
Piperazine 25 25 25 25 
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APPENDIX 3 Degradation products observed on investigation of stability of the 
drugs in different solvents on the auto-sampler 
 
 
Figure 1 MBZP in 2-methylpropan-2-ol 
 
 
Figure 2 MBZP in dichloromethane 
 
 
Figure 3 Mass spectra of degradant peak at 15.03 mins in MBZP (Figure 2) 
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Figure 4 DBZP in dichloromethane  
 
 
Figure 5 Mass spectra and preliminary identification of degradant peak at 6.27mins in 
DBZP (Figure 4) 
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Figure 6 Mass spectra and preliminary identification of degradant peak at 7.5mins in 
DBZP (Figure 5) 
 
The chromatographic profiles of 4-fluoroaniline, benzyl chloride and benzyl 
chloroformate standards for the identification of degradants are shown below.  
 
 
Figure 7 Chromatographic profile of 4-fluoroaniline stability study  
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Figure 8 Mass spectra of 4-fluoroaniline stability  
 
 
Figure 9 Chromatographic profile of benzyl chloride stability study  
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Figure 10 Mass spectra of benzyl chloride stability study  
 
Figure 11 Chromatographic profile of dichloromethane solvent 
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APPENDIX 4 Phase 2 Investigating the effect of oven temperature on the method developed.  
The table below shows the effect of oven temperature on column efficiency N, resolution R, tailing T, selectivity α and retention time Rt. 
 
Table 1 Phase 1 Effect of oven temperature  
Temp/oC  Mean values (n = 2)  Temp/oC Mean values 
 N x105 T α R Rt/mins   N x105 T α R Rt/mins 
Methamphetamine      MBZP      
140           4.596          3.475          1.448        69.464          8.870   140 14.574 4.268 1.013 4.060 15.115 
150           3.124          4.001          1.422        55.546          8.870   150 12.365 4.637 1.014 3.927 15.180 
160           4.219          2.333          1.378        58.565          8.865   160 10.930 4.447 1.015 4.254 15.135 
170           4.002          2.228          1.366        59.341          8.865   170 9.965 4.081 1.018 4.454 14.960 
180           4.002          3.273          1.366        59.435          8.865   180 8.218 3.784 1.020 4.512 14.590 
190           4.325          2.393          1.365        60.009          8.870   190 10.578 3.409 1.017 4.355 14.400 
200           5.339          2.245          0.365        63.738          8.865   200 11.344 3.600 1.015 4.225 14.390 
2-FPP       CPP      
140           7.006          3.713          1.022          5.609        13.600   140 24.654 2.750 1.051 21.027 16.530 
150           8.429          3.428          1.024          5.344        13.500   150 23.552 2.700 1.054 22.398 16.710 
160           6.484          3.125          1.030          6.377        13.195   160 25.629 2.427 1.057 24.374 16.820 
170           7.926          2.896          1.027          5.473        12.875   170 19.735 2.425 1.063 23.470 16.850 
180         11.215          2.579          1.023          5.653        12.820   180 17.842 2.190 1.070 25.295 16.775 
190         10.352          2.778          1.023          5.447        12.820   190 12.195 2.381 1.081 25.772 16.550 
200         12.068          4.409          1.023          5.743        12.815   200 13.777 2.647 1.092 26.903 16.185 
3-FPP       MePP      
140         18.226          3.202          1.035        13.106        14.510   140 18.061 2.892 1.080 27.923 15.305 
150         13.631          3.213          1.040        12.608        14.510   150 15.320 3.125 1.086 28.389 15.385 
160         10.938          3.000          1.045        13.461        14.375   160 15.064 3.000 1.095 30.877 15.365 
170           8.247          2.527          1.055        13.393        14.065   170 10.681 3.000 1.107 30.367 15.225 
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180         10.026          2.332          1.049        12.683        13.780   180 9.575 2.971 1.127 33.783 14.885 
190         13.873          2.053          1.041        13.033        13.740   190 11.701 2.500 1.131 33.458 14.640 
200         13.339          2.121          1.040        12.398        13.735   200 15.083 2.972 1.108 30.732 14.605 
4-FPP       MDMA      
140         13.937          3.529          1.012          3.802        14.160   140 18.423 ND 1.010 3.123 14.370 
150         12.913          3.297          1.013          3.953        14.125   150 13.827 ND 1.010 2.938 14.365 
160           9.594          3.228          1.016          3.971        13.930   160 12.105 ND 1.011 2.991 14.215 
170           8.193          3.327          1.017          3.834        13.565   170 8.547 ND 1.015 3.443 13.855 
180         10.889          2.642          1.013          3.535        13.385   180 12.126 ND 1.013 3.251 13.610 
190         14.276          3.088          1.012          3.645        13.380   190 13.571 ND 1.011 3.212 15.590 
200         13.145          2.625          1.012          3.607        13.375   200 16.025 ND 1.011 3.312 15.585 
2-TFMPP       Caffeine      
140           6.896          4.750          1.059        13.715        12.840   140 34.038 1.080 1.048 25.152 17.370 
150           5.068          5.750          1.071        13.680        12.610   150 20.688 1.056 1.051 27.225 17.605 
160           6.499          4.250          1.079        15.354        12.225   160 33.883 1.018 1.040 20.564 17.785 
170           8.340          4.094          1.064        13.873        12.105   170 28.767 1.009 1.058 28.019 17.951 
180           8.347          3.850          1.059        13.964        12.110   180 26.605 1.000 1.064 28.861 17.950 
190           8.052          2.833          1.059        13.593        12.110   190 26.497 1.000 1.072 31.467 17.890 
200           8.340          3.820          1.059        14.229        12.105   200 16.421 1.000 1.083 30.261 17.670 
3TFMPP       Cocaine      
140         17.063   ND          1.002          0.821        14.335   140 58.358 1.131 1.082 42.887 20.015 
150         13.370   ND          1.003          0.900        13.320   150 57.929 1.036 1.081 43.009 20.340 
160         11.388   ND          1.004          1.143        14.155   160 57.267 1.023 1.081 42.523 20.630 
170           8.479   ND          1.004          1.000        13.379   170 53.734 1.021 1.080 41.871 20.915 
180         13.001   ND          1.004          1.029        13.560   180 58.507 1.000 1.081 42.851 21.170 
190         15.919   ND          1.004          1.115        13.540   190 63.425 1.042 1.082 45.749 21.390 
200         16.648   ND          1.004          1.177        13.535   200 53.326 1.000 1.085 45.659 21.555 
4-TFMPP       Diazepam     
140         28.870          2.053          1.006          2.110        15.025   140 40.576 1.280 ND ND 21.650 
 Chipo Kuleya    SID No. 9766990 
PhD student:     Faculty of Science & Technology 
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150         21.210          2.111          1.006          1.974        15.085   150 41.707 1.081 ND ND 21.995 
160         21.009          1.806          1.007          2.212        15.025   160 39.529 1.113 ND ND 22.290 
170         12.569          1.750          1.008          2.214        14.835   170 42.282 1.121 ND ND 22.595 
180         12.700          1.753          1.009          2.261        14.455   180 41.479 1.074 ND ND 22.885 
190         21.286          1.500          1.007          2.099        14.300   190 46.573 1.034 ND ND 23.150 
200         19.353          1.500          1.042          2.203        14.285   200 48.558 1.037 ND ND 23.385 
BZP       Eicosane      
140           9.186          5.559          1.019          4.900        13.900   140 62.956 1.000 1.079 46.127 18.210 
150           7.369          5.556          1.021          5.158        13.830   150 64.942 1.000 1.079 46.594 18.495 
160           9.096          5.074          1.025          6.413        15.590   160 61.081 1.000 1.080 45.937 18.745 
170           5.719          5.000          1.026          5.231        13.225   170 55.149 1.000 1.068 38.709 18.955 
180           9.075          4.306          1.021          5.168        13.110   180 45.203 1.000 1.085 46.702 19.105 
190           8.877          4.500          1.021          5.353        13.110   190 36.843 1.000 1.091 46.183 19.180 
200           8.767          6.250          1.021          5.256        13.105   200 33.350 1.000 1.048 23.426 19.140 
DBZP             
140         56.220          1.150          1.019        11.156        19.645         
150         55.785          1.030          1.019        11.233        19.960         
160         55.095          1.012          1.020        11.446        20.235         
170         56.576          1.011          1.020        11.598        20.505         
180         56.099          1.000          1.021        12.401        20.735         
190         54.820          1.000          1.022        13.183        20.930         
200         50.905          1.000          1.024        13.248        21.060         
ND = not determined due to 1) 3TFMPP and MDMA co-elute and 2) diazepam is the last peak hence there is no resolution to a subsequent peak after it. 
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APPENDIX 5 Phase 3 Investigating the effect of simultaneously applying the injector 
and oven temperatures selected as optimum in phase 1  
 
Note:  
The temperatures investigated were those chosen as giving optimum results in Phase 1 (injector 
port temperature 260oC) and Phase 2 (oven temperatures 160 and 180oC). The purpose was to 
determing which of the oven temperatures gave the best result when applied together with the 
optimum injector temperature from Phase 1.  The effect on plate number, tailing, selectivity 
resolution and retention time are in Figures 1 – 5. For plate number N = N x105. For 3-TFMPP 
and MDMA tailing not determined peaks highly co-eluting. IS = internal standard (eicosane). 
 
 
Figure 1 Effect of simultaneous applying selected injector and oven temperatures on number, N 
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Figure 2 Effect of simultaneous applying selected injector and oven temperatures on tailing 
factor, T 
 
 
Figure 3 Simultaneous effect of injector and oven temperatures on Selectivity, α 
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Figure 4 Simultaneous effect of injector and oven temperatures on Resolution, R 
 
 
Figure 5 Simultaneous effect of injector and oven temperatures on Retention time, Rt 
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APPENDIX 6 Phase 3 Investigating the effect of simultaneously applying the oven and 
injector temperatures selected as optimum in phases 1 and 2 
 
Figures 1 - 4 show the % gain or loss graphs for the effect of simultaneously applying injector 
and oven temperature vasriations on plate number, tailing, selectivity and resolution. 
 
 
Figure 1 %Gain or loss for effect of injector and oven temperatures on plate number, N  
 
 
Figure 2 %Gain or loss for effect of injector and oven temperatures on tailing, T 
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Figure 3 %Gain or loss for effect of injector and oven temperatures on selectivity, α 
 
 
Figure 4 % Gain or loss for effect of injector and oven temperatures on resolution, Rs  
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APPENDIX 7 Phase Investigating the ffect of optimisation of ionisation energy on mass spectra of BZP 
 
  
 
  
 
Figure 1 Phase 6 Effect of ionisation energy (EI) on the mass spectra of 3-TFMPP showing the mass spectra at different EI (50, 60, 70 and 
80eV) for comparison. 
(M+) (M+) 
(M+) (M+) 
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APPENDIX 8 Method validation characteristics investigated in the study (Horacio 
et al, 2008; ICH, 2005; Thompson, 2002; Eurachem, 1998) 
 
Validation characteristics Analytical procedure 
 Identification 
(including impurities) 
Quantitative tests 
Specificity x x 
Linearity  x 
Quantitation limit  x 
Detection limit x x 
Range :       linearity range  
                   working range 
 x 
Accuracy x x 
Precision- repeatability 
               - intermediate precision 
x x 
Robustness x x 
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APPENDIX 9 Calibration graphs  
 
 
Figure 1 Calibration graph for 3-TFMPP. 
 
               
Figure 2 Calibration graph for for 2-FPP. 
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Figure 3 Calibration graph for 3-FPP. 
  
 
Figure 4 Calibration graph for 4-FPP. 
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Figure 5 Calibration graph for 2-TFMPP. 
                       
  
Figure 6 Calibration graph for 4-TFMPP. 
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Figure 7 Calibration graph for BZP. 
 
  
Figure 8 Calibration graph for DBZP. 
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Figure 9 Calibration graph for MBZP. 
 
  
Figure 10 Calibration graph for 3-CPP. 
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Figure 11 Calibration graph for 4-MePP. 
 
  
Figure 12 Calibration graph for MDMA.                         
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Figure 13 Calibration graph for methamphetamine.                        
 
  
Figure 14 Calibration graph for caffeine. 
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Figure 15 Calibration graph for cocaine. 
 
  
Figure 16 Calibration graph for diazepam. 
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Figure 17 Calibration graph for dapoxetine. 
 
  
Figure 18 Calibration graph for dextromethorphan. 
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Figure 19 Calibration graph for nicotinamide. 
 
 
Figure 20 Calibration graph for ephedrine. 
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APPENDIX 10 GC-MS mass spectra of analyte drug standards (GC-MS/EI 70eV) 
 
 
Figure 1 Mass spectrum of 2-FPP 
 
 
Figure 2 Mass spectrum of 3-FPP 
 
 
Figure 3 Mass spectrum of 4-FPP 
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Figure 4 Mass spectrum of 2-TFMPP 
 
 
Figure 5 Mass spectrum of 3-TFMPP 
 
 
Figure 6 Mass spectrum of 4-TFMPP 
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Figure 7 Mass spectrum of BZP 
 
 
Figure 8 Mass spectrum of DBZP 
 
 
Figure 9 Mass spectrum of MBZP 
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Figure 10 Mass spectrum of 4-MePP 
 
 
Figure 11 Mass spectrum of 3-CPP 
 
 
Figure 12 Mass spectrum of MDMA 
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Figure 13 Mass spectrum of (+) Methamphetamine 
 
 
Figure 14 Mass spectrum of Caffeine 
 
 
Figure 15 Mass spectrum of Cocaine 
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Figure 16 Mass spectrum of Dextromethorphan 
 
 
Figure 17 Mass spectrum of Diazepam 
 
 
Figure 18 Mass spectrum of Dapoxetine 
  347
 
Figure 19 Mass spectrum of Nicotinamide 
  
 
 
Figure 20 Mass spectrum of Ephedrine 
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APPENDIX 11 Test for Robustness using different GC-MS instruments 
 
 Shimadzu Perkin Elmer 
Compound RT/mins 6̅ = ±0.005 RRT RI RT/mins RRT RI 
Methamphetamine          7.979 0.431 1173.86 8.84 0.465 1201 
Nicotinamide 10.287 0.555 1337.53 11.88 0.626 1412 
2-TFMPP 11.084 0.598 1394.07 12.12 0.638 1427 
2-FPP 11.715 0.632 1438.81 12.88 0.678 1479 
BZP 12.072 0.651 1464.16 13.24 0.698 1505 
4-FPP 12.260 0.662 1477.5 13.56 0.714 1527 
3-TFMPP 12.499 0.674 1494.47 13.78 0.726 1542 
MDMA         12.643 0.682 1504.68 13.83 0.729 1545 
4-TFMPP 13.315 0.718 1552.3 14.82 0.781 1614 
MBZP 13.587 0.733 1571.57 14.98 0.789 1624 
4-MePP      13.838 0.747 1589.4 15.23 0.802 1642 
3-CPP 15.59 0.841 1713.63 16.85 0.888 1754 
Caffeine 16.507 0.891 1778.71 17.9 0.943 1867 
DBZP 19.66 1.061 2171.37 20.53 1.081 2212 
Cocaine 19.983 1.078 2216.86 20.95 1.104 2268 
Diazepam 21.478 1.159 2427.45 22.68 1.195 2494 
Dapoxetine 21.89 1.181 2485.48 23.01 1.212 2179 
Eicosane ( IS) 18.532 1.000 2013 18.96 1.000 2006 
RT is retention time, RRT is relative retention time and RI is relative retention index 
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APPENDIX 12 Mass spectra of the components in street samples (GC-MS/EI 
70eV) 
 
 
Figure 1 Mass spectrum of sample A1 peak at 13.61mins 
 
 
Figure 2 Mass spectrum of sample A1 peak at 14.22mins 
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Figure 3 Mass spectrum of sample A1 peak at 18.97mins 
 
 
Figure 4 Mass spectrum of sample A1 peak at 20.46mins 
 
 
Figure 5 Mass spectrum of sample A1 peak at 20.79mins 
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Figure 6 Mass spectrum of sample A2 peak at 11.81mins 
 
 
Figure 7 Mass spectrum of sample A2 peak at 18.14mins 
 
Figure 8 Mass spectrum of sample A2 peak at 18.96mins 
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Figure 9 Mass spectrum of sample A2 peak at 20.46mins 
 
 
Figure 10 Mass spectrum of sample A2 peak at 20.28mins (similar for A4, A7, A9, 
A11) 
 
Figure 11 Mass spectrum of sample A5 peak at 14.87mins 
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Figure 12 Mass spectrum of sample A5 peak at 18.93mins 
 
 
Figure 13 Mass spectrum of sample A5 peak at 20.42mins 
 
 
Figure 14 Mass spectrum of sample A6 peak at 13.10mins 
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Figure 15 Mass spectrum of sample A6 peak at 15.54mins 
 
 
Figure 16 Mass spectrum of sample A6 peak at 15.93mins 
 
 
Figure 17 Mass spectrum of sample A6 peak at 18.96mins 
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Figure 18 Mass spectrum of sample A6 peak at 20.45mins 
 
 
Figure 19 Mass spectrum of sample A10 peak at 5.65mins 
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APPENDIX 13 Qualitative data for analysis of precursors 
 
The precursors for the synthesis of 4-FPP were diethylene glycol monomethyl ether 
(DGME; I), 2-bischloroethylamine HCl (2-Bis; II) and 4-fluoroaniline (4Fa, III). For 
analysis of 3-TFMPP 3-trifluoromethyl aniline (3TFa, IV) was used instead of 4-
fluoroaniline. 
 
OH
O
O
O
O
CH3
(I)  
NH
Cl Cl
.HCl
 (II) 
        
F
NH2
 (III)      NH2
CF3
  (IV) 
         
Figure 1 Structures of synthesis precursors (Route 1) 
 
Table 1 Qualitative data for analysis of precursors (Quantifier ion highlighted in red) 
Substance Retention time/mins Characteristic ions (m/z) 
DGME  (Mwt = 208) 4.99 45(100),75, 90, 207(M+) 
3-Bis (Mwt = 141) (base) 6.78 92(100), 105, 119, 141(M+) 
4Fa (Mwt = 111) 6.03 84(100), 91, 111(100)(M+) 
3TFa (Mwt = 161) 6.74 114, 142, 161(100)(M+) 
Combinations  Comments 
2Bis + DGME  4.99- DGME 
6.77- 2bis 
7.45 
These precursors are common for 
both 4-FPP and 3-TFMPP 
For 4-FPP   
2Bis + 4Fa 6.03- 4Fa 
6.77- 2bis 
7.45 
No co-elution, impurity at 
7.45mins 
D + 4Fa 4.99- DGME 
6.04- 4Fa 
7.45 
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2Bis + DGME + 4Fa 4.98- DGME 
6.03- 4Fa 
6.77- 2Bis 
 
For TFMPP   
2Bis + 3TFa 6.74- 3TFa 
6.77- 2bis 
7.45 
Co-elution 
D + 3TFa 4.99- DGME 
6.74- 3TFa 
7.45 
 
2Bis + DGME + 3TFa 4.98- DGME 
6.74- 3TFa 
6.77- 2Bis 
7.45 
Co-elution between 2Bis and 3TFa 
Synthetic 4-FPP 14.28 138(100), 180(M+), 122, 56 
Synthetic mTFMPP 14.43 188(100), 230(M+), 145, 56 
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APPENDIX 14 Analysis of impurities in synthesised samples 
 
Table1: Confirmation data         
Compound   FORMULA Mwt Characteristic Rt/mins Rt of IS/min RRT RI 
Preliminary Identification of Impurities     ions m/z         
in synthetic FPP      quantifier in red         
trans 1,4 di-tert butyl cyclohexane(nd) C14H28 196 57(100), 94, 121, 278 7.15 18.64 0.384 1064.09 
1-p(fluorophenyl)-4-piperidone C11H12ONF 193 95, 123(100), 194 13.99 18.64 0.751 1520.09 
1-m(fluorophenyl)piperazine (isomer) C10H13N2F 180 95, 123, 138(100), 180(M+) 14.30 18.64 0.767 1540.75 
                 
Preliminary Identification of Impurities               
in synthetic FPP                
Benzenamine, N-ethyl  C8H11N 121 77, 106(100),121(M+) 6.37 18.58 0.343 1012.35 
3-trifluoromethyl aniline (precursor)   161 114, 142, 161(100)(M+) 6.74 19.58 0.344 1036.75 
1.3.5-triazine,2-methyl-4.6- C16H29O3N7 367 100(100), 200, 207, 243 7.38 18.58 0.397 1079.42 
bis(2-4 morpoline)ethylamino (nd)               
Dodecane-1-fluoro  C12H2SF 188 57(100), 71, 88 7.45 18.58 0.401 1084.09 
Piperazine, (1-3) trifluoro methyl C11H13F3 230 56, 145, 175, 188(100), 189 7.91 18.58 0.426 1114.75 
(= isomer-2-TFMPP)                
2 or 3- trifluoromethyl benzoic acid- C13H15O2F3 260 71, 145, 173, 244(100) 14.05 18.58 0.756 1524.09 
3 methyl butyl ester                
         18.64 18.64 1.000 2021.11 
eicosane (internal standard, IS)               
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APPENDIX 15 Reference spectra for the identification of impurities in street samples 
 
The spectra was generated from analysis of standards were these were not available 
literature spectra are given (NIST, 2014) identification. The mass spectrum of 3-
Trifluoromethylaniline is shown in Appendix 16. 
 
 
Figure 1 Identification of impurity at 18.96 mins (Relative retention time 0.983) present in samples 
A1, A2, A5, A6. 
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Figure 2 Identification of impurity at 20.46mins (Relative retention time 1.060) present in samples 
A1, A2, A5, A6 
 
 
Figure 3: Identification of impurity at 18.28mins (Relative retention time 0.947) present in sample 
A6 
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Figure 4 Identification of impurity at 12.96 mins (Relative retention time 0.672) present in sample 
A6 
 
 
Figure 5 Identification of impurity at 14.90 mins (Relative retention time 0.772) present in sample 
A5 
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APPENDIX 16 Comparison of street samples and in-house synthesised samples 
impurity profile 
 
 
Figure 1 Total ion chromatogram of 3-Trifluoromethylanilie (a synthesis precursor) 
 
 
Figure 2 Mass spectra of 3-Trifluoromethylanilie 
 
  363
 
Figure 3 Total ion chromatogram of street sample A1 on trace analysis for impurities (3-
trifluoromethylanilie) 
 
A similar chromatogram was obtained with sample A2. 
 
 
Figure 4 Mass spectra of street sample A1 showing traces of 3-Trifluoromethylanilie at 
6.95 mins 
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Figure 5 Mass spectra of street sample A2 showing traces of 3-Trifluoromethylanilie at 
6.95 mins 
 
 
Figure 6 Mass spectra of street sample A10- checking for traces of 3-Trifluoromethylanilie 
at 6.95 mins. 
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